<SEC-DOCUMENT>0000950170-25-102382.txt : 20250805
<SEC-HEADER>0000950170-25-102382.hdr.sgml : 20250805
<ACCEPTANCE-DATETIME>20250805070049
ACCESSION NUMBER:		0000950170-25-102382
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250805
DATE AS OF CHANGE:		20250805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pediatrix Medical Group, Inc.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		251182729

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDNAX, INC.
		DATE OF NAME CHANGE:	20090102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>md-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-04T16:52:13.3291+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:md="http://www.mednax.com/20250630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_2452faa5-c63e-41b1-9ecb-64f47d6b6a21" name="dei:EntityCentralIndexKey" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b">0000893949</ix:nonNumeric><ix:nonNumeric id="F_cc16b5cc-e75e-4826-85a3-edee8f36a28d" name="dei:CurrentFiscalYearEndDate" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b">--12-31</ix:nonNumeric><ix:nonNumeric id="F_f19b10c0-6976-4e93-9ac6-d04367410af8" name="dei:AmendmentFlag" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b">false</ix:nonNumeric><ix:nonNumeric id="F_acf8be9b-3b49-4232-8a48-f6b9be1c692e" name="dei:DocumentFiscalPeriodFocus" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b">Q2</ix:nonNumeric><ix:nonFraction id="F_3875a626-bb1e-4615-91b4-f05288577949" name="us-gaap:CommitmentsAndContingencies" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c39704f4-3c98-4511-894d-c36f242d9d7a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cf86f0f4-bac9-4424-900d-398a72ffa700" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" unitRef="U_USDollarShare" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_41f9c648-83e8-464a-88ca-8ef3d8d63694" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_df98536b-e39d-432d-8681-2c87691c7474" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" unitRef="U_USDollarShare" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction><ix:nonFraction id="F_4970b6ac-9f7d-44b0-99a6-3cbfbe49de9b" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20250630.xsd"/></ix:references><ix:resources><xbrli:context id="C_849c5446-6175-47f3-9857-a3245904bf88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85ae1910-2e7f-4c51-938e-e043272c5d66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87d0e1c2-aa54-424d-8b9f-e5b52e218d71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d9af789-c635-4423-848f-c01e14b9c5be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e53119c-ac1b-4329-8f58-b7176456bb51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eb88e83-6d3f-4f77-ab85-5922b2e851d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_990f8274-6879-4e07-9304-6c955d3df201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99df4261-c382-44e0-b2a9-ed7013c4e41e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a921698-6494-4872-95ea-71129e633bb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c88a547-180e-4424-b50b-a5932a2d00ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0b59a66-3754-4522-ac83-cb30014bf52e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0c2cfa6-1c3d-4c86-9c0c-7cee140ba3f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a20cd2e0-875c-4771-bf90-0ccec5055b0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2d739c0-705d-43b1-a3d2-dabd70774246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4e56d63-8e80-4097-be11-b3c834580fc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6a93686-1eb5-408b-b60f-73f0299eb788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a732c152-f078-48ed-9981-fe2813bfd8a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9baaa9e-b082-47b3-80b0-110bd4e5da9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab9de21c-3708-4752-bea2-ef95a1215496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adc93a05-2575-42d8-b329-4f35de71ac68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afa0579d-26f5-4238-9a84-dde4391f4adf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b236758c-5257-4c6e-9757-301028de1d7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b46b7d38-353d-4da0-915e-fea75ff40a63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b627c7d1-b301-4b96-8344-f2a1a41efccb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b93ac8f1-2c07-4a19-9bb3-1a7e4f60d143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc9a9da7-0be2-410f-9e41-d1f7b709a28b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd51850b-1d63-4d74-a72e-b7306dc264a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be5ebf4b-3722-4087-8a25-4b48fa85c81e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be92627c-332d-4ae8-91f7-a264f6271741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c1710474-b351-446a-ac79-006d3ecf6183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4b9e66b-5f53-4567-b3c0-f31b5bcc6403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4e1c5ae-2d10-47df-935e-85a1a3d8a79a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5c51110-c65e-4f11-aa51-b3928ddfb6df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8cb11ad-5131-4dcd-b1e9-3b140f8c2c78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb9f2cce-17c5-4e8f-8e06-23440c974965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1c3550d-a30d-470c-81b8-b361b7723645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d41e6181-d9d5-4854-bb79-fc2110b6a1b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5dd1698-9ade-461a-94c5-4ad7011a957b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d63eb551-12c7-4a81-96be-660b39fca8d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1195bd8-3f70-421d-a6ef-34e21a43644f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2c40e04-69e3-4727-909e-2d58b4ab1248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2fb96e5-6737-49f7-bfc9-5420746a9a50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e76ed61f-3566-4b74-9cb3-da9368513ff8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8f5ba84-ac17-483d-b73f-e6039ec42af4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8fa676e-89e5-4c48-82b7-8f14961e5d15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea584bda-977e-42b7-b574-9d656ac33e6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea8772ff-e4ea-40c9-bb6b-4db26a751f8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb7d37cd-390f-4b5f-aeef-a6cc4db6d17b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edc12ded-37cf-49fc-92de-c7343544ab45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f08258f9-06ee-42bc-be52-ac38a7e86703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f341ef8f-6752-4a72-9c1d-980e03786ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f52719a9-de3b-449c-92cd-aff10e01b14e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f586607b-347a-4864-85e3-de49880ea621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6087d4e-66e6-45e6-ae80-7267213024b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f769378b-1c4e-4a71-b4e3-23dc8047aca4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda73ce3-e67d-432f-a66a-80057b60473d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdaffee8-484a-4258-af49-fe479aa12caf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fff7438c-96ca-489b-9cad-339fddf8c81f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02338ba1-62e1-425d-a755-642941b0622b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0236986c-5db2-4fdd-b4fa-b8140c8d6f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02bea4f4-754b-413e-9d98-79f2fe330f07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03af3506-de9e-4102-99ce-56bb360a66d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04755f25-aca6-47b4-a390-81102d0c243b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_070261c9-34d5-4928-b2a8-489b2db71abd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_083e4a33-a175-4d28-b0bd-2e88cf498028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08f4d25d-4559-4691-80b0-687c52c265b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a519f8a-d93b-4b46-a7c9-3139cb8a19ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b40aab0-d10e-4136-8e7e-ca8504900115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bcc6ee1-f926-4fb2-8414-61d8916092c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c404152-671c-423e-89ad-d5d765b11984"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d526502-108f-4746-acb3-bb517ba52829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dec167a-ac7c-418a-ae69-3cbcc4fb92b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f263814-412a-40d2-829d-21ded60e6d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_116f6c49-cd97-47f6-a585-d9c09874db22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1362b435-1b65-4eb1-a216-edd421fea37f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15a46667-2e0c-46ce-9da6-40aaeece1d0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15ed1157-0265-4dfa-865e-1e42fe186550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16252d43-9504-4f57-9f9e-531fbb28977d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17f99e9d-a60a-4fc9-ac76-147b8ed76885"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">md:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19fe297e-98f1-459f-8107-8508db33674a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b31d254-d902-4fef-9793-39c5c0901157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c6b672e-7b2c-4c32-b75a-2b3216ee662e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cb160af-9159-4c8c-acca-d4f2300fc206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23133a2a-3883-4163-a76d-7a02c6deddb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f6f6e25-d54c-4b0a-a12d-048947969ac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f91671e-71e9-4083-b736-fa78c83a4f94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30cac922-a319-4eb7-99f1-fe21f2139c14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32069b17-a7c4-4765-a651-4f7755dcf1a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_398bed08-bdb8-41f7-9f6c-82ad320a2a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d0d3861-fcff-4c38-a557-3d670d1a3de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d9eb462-edff-4b9a-8d90-654154da97b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e05a392-a376-4596-8bcf-ca0fdc5e9ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4801f813-81b6-4595-8272-9e5826e33caf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ba683c9-c1d0-4296-8d60-6b927301e2bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4de6435d-c283-42d7-909b-380362f9a807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f66fd46-91e2-44aa-ad85-e4197757b4e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_536d7005-510c-4f6d-8437-48a7087b29e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63924c28-bea0-4566-b7e1-f16b7fb50afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6767043a-8ca4-4e7b-8a97-d9178cf9f8df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b743dc4-e2d9-4c22-8237-82828c532fdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c67057d-5918-42a2-94a9-d2f590fd5ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ddf4aea-8896-44ae-a2ff-471183878dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70926ddf-afe5-4399-bd86-e068c0af16d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70cd78d0-0823-4309-b089-3800b415f013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c443208-51e1-40be-8cfa-d297ad11e687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d2132bf-03a8-4280-9a81-ef0cfcfa8452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f02ccee-734a-4e9c-aed7-0eab8a75869b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>md:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f063dc1c-161a-426e-8d75-85c2bad97413" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2d369ec-7d22-44ee-989a-d38f9657db11" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b01dd25-8c1e-45fe-822c-c61b63019569" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afcd409c-6a6b-4383-9705-35c1078c40a9" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span></p><p style="text-indent:-4.895%;padding-left:4.667%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55ca7aea-1e14-4a42-b2e9-0c41d32e6dff" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from ______ to ______</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1e9e4c5-2970-45d8-b8b1-aa4a953f6d3d" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-12111</span></ix:nonNumeric></span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img261193434_0.jpg" alt="img261193434_0.jpg" style="width:134px;height:84px;"/></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:14.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0ea1859-e61c-43d9-b8ec-cb85281f8d0b" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:47.71%;box-sizing:content-box;"/>
     <td style="width:3.821%;box-sizing:content-box;"/>
     <td style="width:48.47%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5673bb80-1ea5-40e0-86c6-1f3f68a84bb0" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_d8a3d145-ac50-4383-83de-9c1cc8a871df" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">26-3667538</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporation or organization)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;text-indent:48.95pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:9.067%;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_2754f939-e47a-402b-b7f0-61cef48d5691" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1301 Concord Terrace</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_64e2095d-2fbf-413f-89ec-cc5543ceffbe" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sunrise</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;"><ix:nonNumeric id="F_d4839d92-db3d-41f0-87f4-96fc302ec5d2" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Florida</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_6e5afba2-e074-474f-8494-15ab44a5832f" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33323</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01108a81-f545-409d-ae3c-d8657bacc032" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">954</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de96af33-c902-45af-afbf-ef82658aed10" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">384-0175</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former name, former address and former fiscal year, if changed since last report)</span></p><p style="margin-left:26.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:26.667%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39.76%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:18.08%;box-sizing:content-box;"/>
     <td style="width:1.06%;box-sizing:content-box;"/>
     <td style="width:40.1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;text-indent:31.5pt;padding-left:0.06in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:31.5pt;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol</span></p></td>
     <td style="padding-top:0in;text-indent:31.5pt;padding-left:0.06in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.06in;"><p style="text-indent:-6.188%;padding-left:5.84%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.06in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7db6b274-ff3e-4f4b-b835-8ddda6ccd03c" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $.01 per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="margin-left:0.84%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="margin-left:0.84%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_091a6894-536b-4e71-8f0d-c4b07725f30b" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MD</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;text-indent:4.5pt;padding-left:0.06in;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="margin-left:0.84%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0.06in;vertical-align:top;padding-bottom:0in;padding-right:0.06in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e20eb2eb-5798-4f1e-bff8-206b517d8c47" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">New York Stock Exchange</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4cd852e-d36b-4567-9f4c-4d89967269c4" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   &#9745;  No   &#9744;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7554ab12-6c57-4884-9039-c527307f7ebe" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   &#9745;  No   &#9744;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:18.455%;box-sizing:content-box;"/>
     <td style="width:1.946%;box-sizing:content-box;"/>
     <td style="width:55.527%;box-sizing:content-box;"/>
     <td style="width:22.066%;box-sizing:content-box;"/>
     <td style="width:2.006%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8671a6b7-7661-4808-87f1-a1f242610312" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9745;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_e032612f-e29a-4ddb-b762-396ed6ea0fbf" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_7354ba2f-9a35-4441-8067-12b2b9b37d11" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.63in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No   </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b2e386a-4d32-4b97-a43c-122eb250a863" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9745;</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 1, 2025, the registrant had outstanding </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6a4ba8e-11fa-4ba3-8d5d-c076eb7b3a81" contextRef="C_e2c40e04-69e3-4727-909e-2d58b4ab1248" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">87,084,187</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, par value $.01 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.74%;box-sizing:content-box;"/>
     <td style="width:84%;box-sizing:content-box;"/>
     <td style="width:5.26%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I - FINANCIAL INFORMATION</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for the Three and Six Months</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></h2><p style="text-indent:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ended</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"> </span><a href="#statements_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">June 30, 2025 and 2024 (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Equity for the Three and Six Months Ended</span></a></p><p style="text-indent:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">June 30, 2025 and 2024 (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Six Months Ended</span></a></p><p style="text-indent:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">June 30, 2025 and 2024 (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements (Unaudited)</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 2.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 3.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 4.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II - OTHER INFORMATION</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 1A.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 2.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 5.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Item 6.</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibit_index"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><h2 style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></h2></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Balance Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.287%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ASSETS</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcb0cf69-dfd8-4566-8db7-a30fd2374dfa" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,732</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6847212c-d92f-465d-85eb-b29819e1c75d" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,940</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a948edb9-36a0-4ff0-8c1e-397fe2f75072" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,594</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37147dfb-5fe4-4e9a-bca4-568c75d9714d" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,566</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61fdb5df-5518-4f37-8977-89af3d55addd" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,992</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94d53a0e-f513-435f-ac8d-6b4bd71ed994" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,990</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98f06a91-0bc9-4d6e-8bf6-434d70cd87c5" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,424</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e89f42e8-7fe3-4d6b-8f45-a406536c4a4d" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,410</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca02d4f-951b-4e8d-b8d5-173656992351" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,630</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b3f2b61-5eea-4044-b188-e24350ca7eb4" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:IncomeTaxReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,614</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daf5cb5b-c3e8-49b9-b5dc-3f106438b528" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,678</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c643bbfb-f13b-49dc-8595-10fb6d168b1d" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,087</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdfd1dd2-b949-4058-9be2-f82ca26f8e48" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">613,050</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa4977b6-9668-4c3d-8485-f3454d5324d0" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">639,607</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_188ff67a-4046-432a-b0be-218d88af6ff9" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,944</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ef50e3-562e-44e8-99e7-386adb73acec" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73db4808-1e6d-430d-8444-c2b37ec85139" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,242,606</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc7f7bb4-012a-4baf-b4b3-f08ff1509d37" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,242,606</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_813181af-fa93-490c-9920-c2240145db99" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,296</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30686430-96be-47b1-b4ab-4d7f5b6aa3b1" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,595</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating and finance lease right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556031f3-2d03-4940-8c76-ea426b0951fc" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6f68803-a6cb-4ac5-b4f5-f4c2c0106ecf" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="md:OperatingAndFinanceLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,267</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5075da2-71cd-4b12-8355-014b4376422a" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,729</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9389f297-b11b-4779-8061-e33bc3863c34" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,855</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_810a4a2f-900e-4206-8fba-a67d94da81d4" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,785</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd246ea8-e336-488c-9c62-c2d7efb4c996" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,598</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba008c7e-3fb0-4a2f-9672-5e3bd9bdab81" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,102,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c15a0587-183b-472b-a171-29e6041b105a" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,152,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44e4f46c-d436-4df4-a7b6-09d8e9ffc298" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303,360</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83422c26-4378-46a3-82e0-c9c03a0efe95" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of debt and finance lease liabilities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2ade8c1-9caf-4255-bb73-461c87f425dd" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c3c35a1-b963-40b1-afdf-e0077e7ba2f2" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,545</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de1566af-97a8-40e4-8637-1634bc7cca38" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,049</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7095324-d083-4a84-acec-76e8325de055" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4ab6e8c-0e5e-4377-942b-64076308bd59" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,949</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_944feadd-3cb5-49f6-a59c-7b8547364a02" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,171</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01cf1015-d182-47a8-9817-1c7a397cc360" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,043</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3163b69d-6d93-4f11-91d9-86ae14161097" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">434,110</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term debt and finance lease liabilities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbfe387c-fdc8-4552-8580-f77549f7e2ee" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">583,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7165c4d1-4bc7-4dde-bb80-58269083a7c1" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">597,119</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term operating lease liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e82527-d6e5-4697-9dce-272788cde12d" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,963</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77f4faf-5056-414a-9ec1-e759d972ff2b" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,945</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term professional liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c15dd9db-2b55-441b-ad7d-8d421310c7f8" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244,162</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3dede1c-69c4-4607-acae-db81816ee4e1" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,455</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income tax liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_642c02b5-d486-4b77-a7cf-d55845a2037c" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,019</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3548799-3474-4241-87a6-af6729e0f408" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,246</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eee748c-83d8-4c0d-831e-ece8b826f35f" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,297</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a3361b5-64b8-4b86-906d-d6ffce57404e" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8efed8d-3d87-4d57-a4ef-ed751399d521" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,268,347</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eed0ce15-4281-4bb1-b70c-6800421bfb2b" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_3875a626-bb1e-4615-91b4-f05288577949;"><span style="-sec-ix-hidden:F_c39704f4-3c98-4511-894d-c36f242d9d7a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Preferred stock; $</span><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_cf86f0f4-bac9-4424-900d-398a72ffa700;"><span style="-sec-ix-hidden:F_41f9c648-83e8-464a-88ca-8ef3d8d63694;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.01</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4eb4221-c20e-48dd-ad14-ad11f6f9de18" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_191a8c01-699e-4c8e-9de4-c61de295bd91" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7140ff90-0caf-42ad-b1af-e0e450880509" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_73bb1848-95fe-4806-9715-52a8cdd4a5df" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;issued</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d3f78d5-69d0-401b-9d77-21079dcb5826" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b76f78-9e91-4d3a-88bf-5327668a1e85" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Common stock; $</span><span style="font-size:9pt;"><span style="-sec-ix-hidden:F_df98536b-e39d-432d-8681-2c87691c7474;"><span style="-sec-ix-hidden:F_4970b6ac-9f7d-44b0-99a6-3cbfbe49de9b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.01</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4cc69d1-974e-4c53-bf37-ef2cc63a3633" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ed5ef2f6-bd6a-48b2-896b-53a3fbc6a143" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caec2010-ca10-4677-b168-46b0e039e766" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ac4588f6-4962-4a44-b1b9-ef0bea783520" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">86,854,234</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b9229a-8646-4b12-a2de-8b70805547a0" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d0d9c747-7ed6-415d-a813-ec1efda0826e" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">85,866,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd3800ff-1d21-4794-b054-d2b05c38af9f" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">869</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fc819ed-7e5a-49b2-9300-27f7b2e0aa72" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2902647-1de1-4cec-a18f-09604165955f" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,021,290</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05e1f230-3f8d-4472-8fe1-0a1c2283fd58" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,013,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ffa1b0d-25ac-4ea8-adbb-f6880ad3412e" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df033513-e2d1-4b22-ae66-b7df65f94de6" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,071</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retained deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3906484a-ef5c-4133-9781-3543ff08dc16" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74b99739-abf0-4c53-a915-a04dff8bf792" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">248,540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41c2e264-8a0d-4743-88cd-c2f0e0cc9d98" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">833,753</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78659757-1e93-4bca-9103-41a7714d4c62" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764,938</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8468fa-4500-4c68-b83f-97abdc70e93b" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,102,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675d258b-cc12-4369-8be6-60b35bf2c6a6" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,152,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tements of Income and Comprehensive Income</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.81%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.162%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.48%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.542%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.922%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.22%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.082%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e571057-85ae-4609-93af-133dee95a3da" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,844</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b4df4e-05a7-4f17-8fbc-a1682f92e2b3" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">504,296</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8295238b-fb43-4010-a4d9-1ef2b2c90f47" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927,203</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9301f02-923e-46e3-899a-a9495778c313" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,397</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Practice salaries and benefits</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce708d24-27c7-4c6c-bd89-6204751279ed" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">323,502</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c06aaa-524e-4d93-a985-9a54088ba5b3" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,808</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e86e31c4-3239-47f8-a0db-45e0df05f666" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">660,533</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4393e47-4297-41d0-bcec-8c747c23309a" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:PracticeSalariesAndBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">726,946</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Practice supplies and other operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d510b01d-c9c0-4eb1-8f1a-ae505272f94f" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,614</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a3c09e9-851a-447c-ba6e-4eea76410359" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,369</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbd1fe3f-7f85-42a9-8423-7b20f181e2d8" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,300</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_005d691e-e645-4a06-a008-68b4fe96d00f" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:PracticeSuppliesAndOtherOperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,454</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d22f1b5-83d4-4101-96ae-e18e20a3b99c" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba88165-9a19-45e6-a4cf-e3ffc9250883" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,565</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91810236-3d39-404e-8e60-14f61e23ec9a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,318</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c56475c-bbfd-44d5-a0c0-ba6b6cbe112a" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,763</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e630b75-6302-4ca8-be0a-248ab9d37aa0" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,313</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ab3dcf1-1d03-4402-84fe-ed774c03fdcc" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,791</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d2709c4-8855-4832-beb0-9ed9f73ed297" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,645</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abc08bf6-e201-4cf2-9ab6-d8a2ae297d39" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,099</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19bb1abd-bebb-4ba5-8403-89a39b1dc49a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1d04839-3a57-47f0-a958-5b4a94913281" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffdaa0ce-1c24-4972-8f16-3986a3e26e26" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,439</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8f5aa6-ceb6-4de9-926d-97aaccb1f407" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:RestructuringCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,059</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill impairment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02be2454-30ff-4058-8577-daf8f9d5b365" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8521d97-8b7a-44d7-bd34-d97612963509" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e563612-e04b-4efb-8761-04d0789ba708" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd6f3aff-2570-4e03-907d-8a71053d8239" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,243</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-lived asset impairments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b2f40d-1106-4373-b5c3-931f718dd3d9" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac871fd-8bcb-4ce4-951f-0ecdf8bb0eaf" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,791</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a3838ac-ef65-46f4-bfb5-9f834fef6985" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bac50bbb-9b52-4f5a-b80c-43c32e2094e5" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,791</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfc802c0-6091-4ec2-a650-4f670a0291b6" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b2ea7bb-b7d9-4e17-a655-188b7a288fd0" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30fcb3c2-1c86-4ec8-aee2-3c3652e49d45" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca28706a-b31a-4fae-9cf8-b30e12ae4ce2" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b6bdf01-0ac6-4095-9339-01426716b6ed" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408,977</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cb84481-bb95-4dd0-b20c-9f43757ddf31" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">662,019</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eafe3caf-6b5c-447e-9ff3-ba78cb96a034" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">835,235</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb8459cf-225e-46f1-8806-a1accdea7dc0" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141,228</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income (loss) from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fd6d081-7e01-4c7b-b822-8a8ef8b5e0be" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c48eb14c-fad1-4c44-a24c-60c2f69cb87d" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">157,723</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfbfc197-20e9-47a4-b83b-44e452eef408" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,968</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54a3cf6e-76be-45e1-9661-5b2ce50bd581" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,831</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investment and other income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a319d5-78ae-4a1b-966d-9570814cbd5d" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c271740f-4314-4989-bb5f-876a21605f10" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d756f6dd-a377-4e33-959c-a4841451e845" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,464</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92ee2f28-9792-41a7-81c3-2384adfd9858" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:InvestmentIncomeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,852</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25e750ac-1d92-4d1d-876f-1ddc4507f21a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,130</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d57733c-0e16-40c6-b772-674e7dfb4fa5" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,308</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b9f36f-22c9-4dea-9d63-d213f3775746" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,284</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff2d535-f8e7-4187-baee-057491bb7936" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:InterestExpenseNonoperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,907</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity in earnings of unconsolidated affiliate</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad977f5b-a605-4e5a-ae53-b693150d09dd" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">505</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_195f7a03-4126-403a-b742-59a28b65a7aa" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96dda3c1-ccf6-4172-9cd6-04d1568258f6" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">911</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1d1ea08-339d-429a-b5d2-eaa258477b3a" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">982</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total non-operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d62276fe-8921-44ce-88fa-ecdd9d86137c" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,898</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17382351-f569-4cac-9116-5113e85ef0c7" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29247cc0-eed8-4454-9a7e-1e273faea469" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,909</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_097891bb-f2ba-4e87-b633-d5df49bbfadb" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,073</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income (loss) before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d257e0ca-2d36-49e3-89ba-3f200d15ece4" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,969</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d497192-c068-4141-9d4e-725475111068" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,728</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16be757f-4ffa-42c4-a6ed-5393ed15f83e" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,059</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca8501f1-20d2-4228-9456-6d5261d04cbe" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">159,904</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax (provision) benefit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e00206e0-446b-41b0-81fd-090abd61b9cf" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,709</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c670f8a9-096f-4ab1-a027-a5e9550d75ab" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_843be130-9e31-469b-8183-f1f000628c07" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,062</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0575faf8-29f2-4a33-aa2f-761dd7bff009" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,914</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb2adb53-bb04-404a-98a1-6c3a5af9c153" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,260</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b66dd6f7-8f63-4e0a-b2b8-6090d55f7dd1" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3ca73b-fbac-4daf-b35b-d50eeb67123b" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60cd3fec-e1ae-405a-90b0-22c5803f8b94" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,990</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income, net of tax</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">Unrealized holding gain on investments, net of tax of $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3b3d793-74e9-49c4-8592-b111568ef03b" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e24fa24-3002-4abf-a80f-27e4dedf77f9" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2f0b36a-c739-4f82-a7ef-61565f867cd6" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;and $</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d49a68c-34fb-4d38-b0ef-4726aea30ded" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:NetOfTaxUnrealizedHoldingGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31615c8f-1cb8-45e7-b315-a1e13ee5925b" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4946e24f-73a5-4702-8334-2ce49ee663c2" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6b82e8-a045-4bd3-9bec-a2091d6c93a1" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,208</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67ca8e2d-b306-4fd5-a458-9450af737b12" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bc8e8de-c742-4df3-84bd-910d4076f05a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,689</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f56e17f-47e1-42d7-bd23-8d203180a14b" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">152,825</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bbb8c68-0ccc-453c-a936-23c97f8ba0dd" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,205</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e815c40-9c3a-4fcd-bea9-b36589ffb77e" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,730</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Per common and common equivalent share data:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c856db6-8fc8-413b-a739-8237ef22c0ee" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.46</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f4d1094-bf65-442e-af23-a701d5f6f20f" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.84</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a62f0338-cad0-41b7-9df8-3c82a7a5f04a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.71</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8eb54a-c723-4f03-8ced-e4d45d547ca4" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.79</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a53f5dfc-515d-44f5-9ad1-fb7cf79f0d7a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.46</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d06d43d-5c9a-4b30-b23c-1cfc7eb8d192" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.84</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee7ee5fe-2236-44d8-a7be-9dca5c8639a0" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.70</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50383a89-cdec-42d9-aa25-c9a39d1e4932" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.79</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e19dbb61-1796-4bed-9a16-0b2229928a1f" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,797</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dab46aa-2dd7-4ca8-a294-77633857b2ae" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a373e90e-98ad-4e47-ba57-a040dbec2c64" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,653</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_617d21e1-bb11-4f01-be01-e4129c1ca690" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db459843-53d3-4766-b3d1-29e05b1233b7" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,529</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7277b85f-4418-4642-bf54-f2eeabc7f542" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b6e61bb-0054-498c-9b7c-a6c042de51eb" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0d99900-a3cd-4894-9b2e-dfe6c58004a8" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Sta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tements of Shareholders</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:28.434%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.818%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.398%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.398%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.058%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.398%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.498%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Retained</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Shareholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Loss) Income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1140ab30-c7bf-491b-888a-5c2a41d6fdc3" contextRef="C_02bea4f4-754b-413e-9d98-79f2fe330f07" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,866</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ea317e0-4ef3-4ce3-9019-61dccd89c205" contextRef="C_02bea4f4-754b-413e-9d98-79f2fe330f07" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d4bca5e-d29e-4995-b84a-fcf45c887398" contextRef="C_edc12ded-37cf-49fc-92de-c7343544ab45" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,013,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86af02dc-a346-478b-b5ee-999d842ecd04" contextRef="C_3d0d3861-fcff-4c38-a557-3d670d1a3de9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,071</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bae4588e-63e2-4263-ae36-97d423bfa11f" contextRef="C_2f91671e-71e9-4083-b736-fa78c83a4f94" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">248,540</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_675e5aaa-7200-4e3f-a6b4-58df598cae08" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764,938</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_939ce938-697b-4fe9-b2dc-d38fe4afdf38" contextRef="C_e1195bd8-3f70-421d-a6ef-34e21a43644f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,737</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78dc85d9-7d47-416f-b718-7afae63338f9" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,737</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72fb37d7-9a7f-44a2-b2c0-ce84df8a4d23" contextRef="C_b93ac8f1-2c07-4a19-9bb3-1a7e4f60d143" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f9ff971-6d89-4907-99bd-6eab95375bd6" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">779</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29e4543-3edd-45ed-a18d-834d757bc9e0" contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bf361c7-8692-4939-b692-a9602fd1c2bd" contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8188ec1d-99b1-4b35-9967-8621f0a51b20" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">662</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c4c485-e26d-41da-b44b-386ff1cdeef6" contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b42b99b9-10c6-4b8f-991b-7d20599c7533" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59280251-6a07-4720-908b-126218d623d7" contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,641</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5402d302-47c7-4aeb-a2ab-4711d6c0722e" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,641</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchased common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7b5443c-770c-4370-89c3-2c8f385ab9bb" contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_258d1826-fe1d-416b-b706-34a1b4acb70e" contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20065385-5c5b-4611-8064-87249073ff55" contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,568</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17f77605-d622-49a3-adbc-b01f6435a441" contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,569</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfca6909-062d-49bd-a9d7-780191ec58e0" contextRef="C_19fe297e-98f1-459f-8107-8508db33674a" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,810</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bb05c9d-b521-4fd9-b3e8-244f805659c9" contextRef="C_19fe297e-98f1-459f-8107-8508db33674a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22fb414b-889a-4570-b1ee-65ca27fadc10" contextRef="C_7f02ccee-734a-4e9c-aed7-0eab8a75869b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,016,425</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1051f861-0867-4d5e-880e-3aa2b44cf9b5" contextRef="C_b236758c-5257-4c6e-9757-301028de1d7d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9807241-4903-4c3a-83da-95869f992ed0" contextRef="C_7d2132bf-03a8-4280-9a81-ef0cfcfa8452" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">227,803</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82f7b354-8fd0-465c-a411-0a8c5d0b1ed4" contextRef="C_b627c7d1-b301-4b96-8344-f2a1a41efccb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789,188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf5564c1-d1c1-43b3-bfd9-74d69ab2044b" contextRef="C_0a519f8a-d93b-4b46-a7c9-3139cb8a19ea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,260</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5789c647-0a09-4048-8f42-92a9f02a49b7" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,260</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fb3f71f-3cc2-49ed-a0ef-6d28ca9854dc" contextRef="C_f6087d4e-66e6-45e6-ae80-7267213024b2" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdce9ca4-6fa0-4042-80ae-91adee3e962a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3073b4e-c957-4c47-889c-148e7bb500e2" contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55efea14-67cb-42fa-b42a-c72374d121ed" contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cef0f63-f198-4b8d-82e6-c68f11c5486c" contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,175</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ccc97ce-98b5-4f58-a18e-1b3052873da7" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,176</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of restricted stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ccd182-7f55-4d8d-9d4c-79481a1a3071" contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">963</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79fac5b2-f8ec-4d3a-9247-b394d5d995fd" contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2fd31b9-fe73-487d-9614-12ffbd0bcfc0" contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_982f3198-aff1-4a03-8b72-956046c5bb90" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7736fc07-9c77-4132-8d44-f8ee40d3bd23" contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1f6c16-93b0-46db-8612-eab390852643" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchased common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56db9553-c04a-4703-acdf-5874f280f7e8" contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa4d2ff-b49b-47d3-8610-329b17d90fd2" contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70704e1d-fc98-46e4-87fe-05cb0aab4601" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d14bd2e3-a2a4-4e8c-b22e-90cf3768e821" contextRef="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7d1868e-b4c2-4705-b304-8e34a493d1e8" contextRef="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">869</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8216b86c-b063-4902-ab28-33422260df6d" contextRef="C_e2fb96e5-6737-49f7-bfc9-5420746a9a50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,021,290</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d19c015-3963-4a4b-8b32-0edf32dd80c4" contextRef="C_a732c152-f078-48ed-9981-fe2813bfd8a9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b2f7483-551a-4034-9c73-892909904d19" contextRef="C_2f6f6e25-d54c-4b0a-a12d-048947969ac0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc03ae94-5f2a-4d3f-8bcf-25ff2d007021" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">833,753</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at January 1, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb5a2ebc-83bf-4738-8464-0a60b33d3c0a" contextRef="C_6ddf4aea-8896-44ae-a2ff-471183878dfc" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,018</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc24b28a-513a-45bd-a889-240cafa6bdfc" contextRef="C_6ddf4aea-8896-44ae-a2ff-471183878dfc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95e343ab-04c8-4e56-8057-0ed1e3c7cf25" contextRef="C_0dec167a-ac7c-418a-ae69-3cbcc4fb92b2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,906</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58dcd101-e47f-4e4f-b0b5-3b6e2d9711f4" contextRef="C_4ba683c9-c1d0-4296-8d60-6b927301e2bc" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,214</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47d78f3a-84b6-43e1-9b16-931dec48eaa1" contextRef="C_0236986c-5db2-4fdd-b4fa-b8140c8d6f6d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149,471</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64cc6633-824b-4550-958e-8fe8dafa04d6" contextRef="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">849,061</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5034baeb-f75d-478f-9b8e-b1df4e0dfc9c" contextRef="C_6767043a-8ca4-4e7b-8a97-d9178cf9f8df" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca42c381-db8a-4e95-b00d-75e4a69c1bfc" contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f0badcd-21fa-4472-9928-607b3ed8b737" contextRef="C_a4e56d63-8e80-4097-be11-b3c834580fc4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61954c58-5faf-486f-8899-8c83b1982df5" contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23f0d791-9f2b-4358-a879-f01ada6f8b51" contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa1eb689-913f-42fd-bc1b-89b0b68245fe" contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c05f3e-88b7-4308-922f-b6e0f57f27ee" contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">859</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6b9619d-f3ba-48cc-9fe1-20475f93846c" contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">860</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31a19e96-cc7c-4717-8bee-62b32eab0b4b" contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b1e435-6674-408a-a24b-48d0613fda52" contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a8830ab-cef3-4bab-bbb3-1c8842d31ab7" contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,067</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchased common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_533d7864-d518-403c-a192-d8730cd66734" contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_839506af-6de8-4770-8e8c-bf03ba9dc3d9" contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f12cadb8-5673-4dc5-aa93-280c1808eb31" contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aec41817-d6ec-479c-9ed8-c1115f3a7f88" contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_996bbd9c-3ee0-43a3-b7d8-d22299629973" contextRef="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,008</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be7911a0-78a3-4061-a635-fea6437d41ba" contextRef="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b73249e-f882-4280-b4ad-4dd4f6b767ea" contextRef="C_85ae1910-2e7f-4c51-938e-e043272c5d66" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002,946</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6ac03b6-df3b-4a2a-a8bc-1c737b45445c" contextRef="C_f341ef8f-6752-4a72-9c1d-980e03786ef9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffd2a6de-5cb4-45b4-81bb-4c44ddef90ff" contextRef="C_116f6c49-cd97-47f6-a585-d9c09874db22" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,436</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d959960e-9cfa-455b-b0e7-9ca8969825f5" contextRef="C_3e05a392-a376-4596-8bcf-ca0fdc5e9ed0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,196</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08f951fa-f75c-4cb0-8dab-a76da5f94ce4" contextRef="C_15a46667-2e0c-46ce-9da6-40aaeece1d0a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd9c20f8-08ab-49ad-acd8-789b48ccdc0d" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized holding gain on investments, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_622b3d59-9260-43fc-89ae-34fd44d9698c" contextRef="C_c4b9e66b-5f53-4567-b3c0-f31b5bcc6403" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d46e26-f6d2-453e-b67e-03f75aba4bfd" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock issued under employee stock purchase plan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d2d3347-d029-4064-ad34-64d0a0f7521c" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2825cc2c-676a-4359-9a1f-8ce20deeb639" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6523f5-7638-4310-8fc6-6e05691b27d0" contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,147</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_995f8d75-34e1-4f31-afcd-469059dce2b5" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of restricted stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f20e764-e7e8-4d84-979e-454afc39bca6" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d6732b-faaf-400e-8662-af7c0c276a62" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b1246b7-cf38-4498-bab5-da4c4a7279a3" contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeitures of restricted stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9845778e-99f3-4ec8-9305-0a68e3dc0410" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddde2986-9d55-4eef-b933-4a0ecc81b817" contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8ba13b0-f1ba-4db4-be24-16ab2f3df40b" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,952</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchased common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42f11d98-80aa-48b0-94bb-1f0f4ba32717" contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f230de-e256-4103-ada5-052dceb1941b" contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3962c445-15b5-4ab3-8d9d-fa90a8deb1aa" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9afc8e2b-7063-409e-a66d-7106ca4efdd9" contextRef="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,753</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0022a12a-e957-4b7a-bdd3-76c1d059717d" contextRef="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8e8f22-11cd-48bb-888e-70d278494f70" contextRef="C_8eb88e83-6d3f-4f77-ab85-5922b2e851d2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,006,018</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f77eaba-ca3d-48db-a7c8-b85540e04b42" contextRef="C_d41e6181-d9d5-4854-bb79-fc2110b6a1b5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab262955-c966-4652-a6bc-2321a50c29ba" contextRef="C_e8fa676e-89e5-4c48-82b7-8f14961e5d15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">298,461</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d44a51c3-3778-4309-a81e-3ff2ed6ce346" contextRef="C_70926ddf-afe5-4399-bd86-e068c0af16d9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">706,461</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">atements of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.287%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da3156c-6fde-4457-aca4-e208f20210ae" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36274bbb-e7a4-4a7c-bdb2-96a2e0cc8046" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">148,990</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income (loss) to net cash from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_febc65fa-847a-46a5-8380-da7a82bd4bc0" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,645</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a88a23ab-76b7-44e8-b8cf-00c3a1d5d01b" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,099</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of premiums, discounts and issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03d19820-0cda-4442-8ce3-23726337594a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">458</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638da2c3-a44a-4132-b3fe-e0495f4433de" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment losses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fc00870-2095-4093-9ee8-4f5a2aed8591" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b56665-439e-4f5f-9170-847679274b91" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:GoodwillAndIntangibleAssetImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,034</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34432b9e-8da4-4f43-95a1-a9bafc5fe995" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb0c2426-2102-4b1c-a751-20888ecd6fdf" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,873</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4fe80b1-7ccf-46bb-a2da-5e4a6c27802d" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c394ad13-4872-4242-a9a7-2d0fbbb242fd" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,019</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9138dab6-1d67-4842-9b68-d6114a550d5e" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,504</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33d80233-74b2-4f63-8348-2d353b78e5e9" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9e89dc-b7ec-4f10-a51b-87314f886340" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,501</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51902573-8394-42e9-b814-d6a03c4c1e68" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,678</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64cc9328-8d68-4fd1-b980-8315a90e7d9a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,231</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c49d5aff-9715-410b-8035-2d6b653f9c3f" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">934</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60196fb4-6a2b-44cf-a7c9-f2b832eae919" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9eeea70-7fdc-4a45-a2f8-3d4e96825c47" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d95c79f5-85a2-4574-835d-e45d014ec247" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,601</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c62d2838-9caf-40d4-a44b-907f1becb810" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16,955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ed33255-e1d3-4611-816b-ddbcfabd1afa" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac062737-7543-4153-a2f8-054fc2ab3d58" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82,917</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df8dda61-f6c3-4fae-a9a1-325989b940ee" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,763</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778313bc-b340-462f-af42-22d6e2ac4e78" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,735</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term professional liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cfbc52c-44ee-4f87-8bfb-112974d82e10" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,166</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe962ad5-31eb-493e-a17c-d4270ef843e1" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,039</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5.56%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_046bb103-87c8-4f7c-8854-dcbc5a65b7a5" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,315</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37c69547-a386-4cba-a36c-7ed4d6792cdf" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,630</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities &#8211; continuing operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae4d79b-e695-4ec3-b3a2-24c2d5626229" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,020</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51965f1-3e50-4063-b699-c075e943dc5e" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,280</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities - discontinued operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b10ccb83-2725-4ca4-841f-8e13474f7c1e" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,316</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f048eff-4ff9-4c23-9f00-b27aa68dddbc" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,995</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5a6827-0b71-4a63-96d0-6d94add1c45d" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,704</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23a92ad0-a270-43bf-8941-c4f122c1b788" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,275</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition payments, net of cash acquired</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14015486-c962-425d-ba86-db53c9d19321" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42b759ad-86b3-4c24-9cc9-8f280755e51b" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,167</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fae8836-5de5-429d-9069-7850861ec264" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,529</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b37f6e8c-def5-4dae-836a-aa148c4193ee" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,915</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities or sales of investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10e249ce-4a2c-4482-acad-865147275275" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,380</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a45c41bd-559b-4f34-b5dc-b75978a16ff5" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,244</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e81938d9-9c72-44fc-9f76-825c0c5ed793" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,833</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_634a0f4a-8b2b-4048-a5d2-fa9140e48e06" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,292</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa67152-180d-4b70-b3fe-33d4bf4af3f2" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,636</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc042315-0e4b-4592-b3e4-614421772d5c" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb7aceb6-e2d4-44b5-a726-842c1717afad" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,618</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ae54d10-48a3-449a-aa17-a0de009fc82b" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,130</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings on line of credit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af0c7b5e-ce5a-479e-99a5-54c6a86325f8" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13ffef5d-52ad-49a3-a942-933e2f1c11f6" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on line of credit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a199763-632c-4129-90b4-54818c1f88d5" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3154e53-78e2-4e16-96da-dd9bdd013dd3" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on term loan</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bced069-52f5-4885-930a-caf0a457f5f6" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,375</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27bd7314-5bac-48bc-a857-aafabaa3a506" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:PaymentsToTermLoan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments on finance lease obligations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_befa90aa-b2d6-442c-b4c6-05ecd45f73d8" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">844</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a9ec1f4-72ac-4f63-80a1-1ea70ca84760" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:RepaymentsOfLongTermCapitalLeaseObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,391</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e574168-aca0-4d72-ae6e-5bfe11a7a6e9" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68cd6c3-70f4-4e9f-8775-1432921a48f6" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,009</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchases of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17baf9aa-610a-48ce-a2e6-f66fd4057f1d" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,778</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d600e4b9-20a8-45b5-ac12-a0828f091d51" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">898</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f488b905-384c-4dc6-bff5-62af6dd367f8" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffde505a-30bc-4e9a-a385-7482630a269f" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:3.707%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b271f67b-a48d-43ba-9cbc-f4f608801293" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,294</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d627306f-e843-4fb3-b4a9-43d6ad1325bf" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,451</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8114c4b1-0e44-4714-92f4-78cdf9d76e9e" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,208</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15f02e5a-5f5e-4d9e-bf39-cbc44effdf76" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,856</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381b3de3-3e18-4c19-8ada-c30f91e83b78" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,940</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65469169-21b4-4eab-99db-65064c149a4d" contextRef="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4dc961d-4d99-4ed4-b4f2-421b1e0f41dc" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,732</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a4608a-a8d0-4f39-821b-b601f4dfbb94" contextRef="C_70926ddf-afe5-4399-bd86-e068c0af16d9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,402</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these Consolidated Financial Statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.3in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to Consolidated </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Unaudited)</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0c6e287-d817-47e3-a1b5-84d8738cde42" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">            Basis of Presentation and New Accounting Pronouncements:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group, Inc., its subsidiaries and the affiliated professional contractors.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, the Company exited almost all of its affiliated office-based practices, including its primary and urgent care service line.  The operating results of these practices did not meet the criteria to be reported as discontinued operations in the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Statements of Income and Comprehensive Income.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_173b08e7-6442-4b1d-b0f5-1cb65f6b4669" contextRef="C_03af3506-de9e-4102-99ce-56bb360a66d4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, accounting guidance related to income tax disclosures was issued which will require additional disclosure in the Company's income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The accounting guidance will also require the Company to disaggregate its income taxes paid disclosure by federal and state jurisdictions, with further disaggregation required for significant state jurisdictions. The guidance is effective for annual periods beginning after December 15, 2024. We expect this standard to impact our disclosures with no impact to our results of operations, cash flows, or financial condition.</span></p></ix:nonNumeric></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_2440ac7d-2483-4d6d-add8-cf34a3a277d4" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024, the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36494145-3831-4c0e-a1a8-ea0d1baf513d" contextRef="C_a0b59a66-3754-4522-ac83-cb30014bf52e" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fbbf99a-fe6a-4d15-a900-73a0ad0b8d01" contextRef="C_1362b435-1b65-4eb1-a216-edd421fea37f" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2deb80fc-c5b6-4ff8-92fa-0f2be92a4d8c" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true" continuedAt="F_2deb80fc-c5b6-4ff8-92fa-0f2be92a4d8c_1"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:72.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.529%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.316%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.316%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_749f20d7-7d19-4450-ad72-ee00825a8f45" contextRef="C_f08258f9-06ee-42bc-be52-ac38a7e86703" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,232</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff9b5d9-434a-411c-84ae-f4487ce442ae" contextRef="C_a9baaa9e-b082-47b3-80b0-110bd4e5da9d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,411</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87fb8066-0ac6-4be1-be0d-363f570310c2" contextRef="C_ea8772ff-e4ea-40c9-bb6b-4db26a751f8c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,423</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ebcbe0-bc12-4174-9d3f-5ad8febcb260" contextRef="C_e76ed61f-3566-4b74-9cb3-da9368513ff8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,590</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed020a53-0957-4095-8fb2-2dc0185ecfda" contextRef="C_23133a2a-3883-4163-a76d-7a02c6deddb6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,183</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676dbb69-9dd9-4268-b5b6-5fe9a2d04101" contextRef="C_99df4261-c382-44e0-b2a9-ed7013c4e41e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,294</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal home loan securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52a1fb68-0d4f-4833-a03d-02d320e46676" contextRef="C_15ed1157-0265-4dfa-865e-1e42fe186550" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,746</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e00e76ac-9a5e-42bd-bf10-6ea73ff33b83" contextRef="C_0b40aab0-d10e-4136-8e7e-ca8504900115" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,640</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72742c4b-7f84-489d-9323-b16919a208ec" contextRef="C_d5dd1698-9ade-461a-94c5-4ad7011a957b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,010</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb95362a-bea3-4724-972e-69d7341b4a52" contextRef="C_f586607b-347a-4864-85e3-de49880ea621" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,631</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc498007-1206-4a09-a15b-289778b25431" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,594</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc5f84a5-7e05-4f0b-b112-0e04a777de98" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,566</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_2deb80fc-c5b6-4ff8-92fa-0f2be92a4d8c_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_6167c093-cb72-4488-b79d-b5431e4a6424" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_6167c093-cb72-4488-b79d-b5431e4a6424_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_6167c093-cb72-4488-b79d-b5431e4a6424_1"><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques.</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b42fe4e-54d2-46d9-abc4-309fc33fef06" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.54%;box-sizing:content-box;"/>
         <td style="width:1.32%;box-sizing:content-box;"/>
         <td style="width:13%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d5dc816-ca22-48fb-bed8-0dbf77ba4c1a" contextRef="C_990f8274-6879-4e07-9304-6c955d3df201" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c44c3ed7-c3f6-4099-85e7-dc1b3fbcb266" contextRef="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727" name="md:MoneyMarketFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,295</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20d90301-55b8-4947-a106-e982e62c4697" contextRef="C_1b31d254-d902-4fef-9793-39c5c0901157" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,594</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b21ac7e-387c-4176-b7c2-00b73c6e04ae" contextRef="C_0bcc6ee1-f926-4fb2-8414-61d8916092c3" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,566</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_616a571e-a86a-46c7-80f3-c7f6871db600" contextRef="C_990f8274-6879-4e07-9304-6c955d3df201" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,872</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead1967b-bfc1-4bde-a2f9-774c73783c13" contextRef="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727" name="md:MutualFundsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4be9b78e-df8b-458d-b760-4c8af306ae37" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.72%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.08%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.24%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45fb7154-40fb-4550-8d8d-284bc517097a" contextRef="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ee7404-28be-4c9a-9189-32767189a16c" contextRef="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9979b0ff-4a49-4aad-a217-48b167d98015" contextRef="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">400,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5bdf493-fa81-4b5e-901e-5f5a89ad16d7" contextRef="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9" name="us-gaap:NotesPayableFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">382,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_84dab71c-7bd4-4b6d-884b-ad67c9bb71ca" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" escape="true" continuedAt="F_84dab71c-7bd4-4b6d-884b-ad67c9bb71ca_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_84dab71c-7bd4-4b6d-884b-ad67c9bb71ca_1"><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dd5c8dd-a61c-4385-9dc4-a475dcbc822e" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30%;box-sizing:content-box;"/>
         <td style="width:1.822%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.667%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.111%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.244%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.111%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.333%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.111%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.600000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net patient service revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74f85f86-9fe0-4b8c-a547-3f7d6b593c8e" contextRef="C_9a921698-6494-4872-95ea-71129e633bb1" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,410</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60ef3805-6536-4f7d-bd3e-91131f31a80f" contextRef="C_849c5446-6175-47f3-9857-a3245904bf88" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">432,847</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b53fd7-7007-4649-9456-3c614df9f083" contextRef="C_f769378b-1c4e-4a71-b4e3-23dc8047aca4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">786,788</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22139b9-b353-43c6-b435-d07517ffb23d" contextRef="C_70cd78d0-0823-4309-b089-3800b415f013" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">854,678</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6beb1483-5a02-4147-86e3-b3896057f570" contextRef="C_63924c28-bea0-4566-b7e1-f16b7fb50afc" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ada6d48-8b7d-406d-abea-b2765b41bdb6" contextRef="C_be92627c-332d-4ae8-91f7-a264f6271741" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,913</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb600363-470e-412e-8a39-bd0c4b8b4c3c" contextRef="C_6b743dc4-e2d9-4c22-8237-82828c532fdd" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,408</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1bd6147-5668-426c-8d0a-cbac477bffae" contextRef="C_0d526502-108f-4746-acb3-bb517ba52829" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_100c86cb-7650-45eb-8a85-b4fc5457564f" contextRef="C_e8f5ba84-ac17-483d-b73f-e6039ec42af4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6341567-b088-4a21-bb38-d7c30fea1e93" contextRef="C_bd51850b-1d63-4d74-a72e-b7306dc264a3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">536</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8089df02-8daf-4312-85da-0392da6d5790" contextRef="C_87d0e1c2-aa54-424d-8b9f-e5b52e218d71" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,007</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9af1223a-da28-49cd-b532-0384aebb4799" contextRef="C_c4e1c5ae-2d10-47df-935e-85a1a3d8a79a" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,003</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7833d9b3-6ad3-41dd-a342-4f47ab921823" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468,844</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6909435-2418-4275-913d-deb0c7eb6720" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">504,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d190b97d-35f3-40ff-ab76-4684395ce786" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927,203</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_349df035-13bf-4a22-8775-b6ee1ff345b5" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999,397</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5d9d61d-4f4a-4ab7-a77d-b58b8d8d5172" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true" continuedAt="F_d5d9d61d-4f4a-4ab7-a77d-b58b8d8d5172_1"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.233%;box-sizing:content-box;"/>
         <td style="width:1.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.197%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.82%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.198%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.578%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.677999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted managed care</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25637459-7b82-490e-a3fe-fe22ff635157" contextRef="C_fdaffee8-484a-4258-af49-fe479aa12caf" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cf13451-f2d9-427c-8d5f-1f9d84881296" contextRef="C_398bed08-bdb8-41f7-9f6c-82ad320a2a3a" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c771e4d4-44b1-4b8d-824b-8c488a5fdf13" contextRef="C_eb7d37cd-390f-4b5f-aeef-a6cc4db6d17b" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96d1e35b-73eb-4465-85f2-d4249de7ab2d" contextRef="C_a2d739c0-705d-43b1-a3d2-dabd70774246" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_187d97d8-5319-43d2-9c5b-71ff7e382970" contextRef="C_afa0579d-26f5-4238-9a84-dde4391f4adf" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46df5fd8-31b1-4578-a084-63e9330234bd" contextRef="C_6c67057d-5918-42a2-94a9-d2f590fd5ba7" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46f457d4-eb5f-412c-8e76-da8759d0643f" contextRef="C_32069b17-a7c4-4765-a651-4f7755dcf1a1" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5394895-b117-465e-82ec-e88e8323259e" contextRef="C_4801f813-81b6-4595-8272-9e5826e33caf" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other third-parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c016db89-cfc2-4c67-bcb1-b7ad5d853089" contextRef="C_a6a93686-1eb5-408b-b60f-73f0299eb788" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac855081-6bbe-4813-9d19-c165a453831d" contextRef="C_c5c51110-c65e-4f11-aa51-b3928ddfb6df" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6acdd499-562a-4ef9-8c38-2cabd90654c2" contextRef="C_a20cd2e0-875c-4771-bf90-0ccec5055b0c" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a31091-1357-45a9-a558-598a7b16d3cf" contextRef="C_1c6b672e-7b2c-4c32-b75a-2b3216ee662e" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private-pay patients</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a6d5c93-3e9a-4c92-85f1-7bc7e046b015" contextRef="C_ab9de21c-3708-4752-bea2-ef95a1215496" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd702f92-3e2b-4d62-9c05-9a37f17d0ee3" contextRef="C_7c443208-51e1-40be-8cfa-d297ad11e687" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd3e82e0-7f20-46d2-b2fc-7b630652d2c8" contextRef="C_536d7005-510c-4f6d-8437-48a7087b29e6" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0db48f4a-85c4-41e4-9ae8-71d41ece4398" contextRef="C_cb9f2cce-17c5-4e8f-8e06-23440c974965" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d64543c6-6afa-448b-b9f6-923e513740ce" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41252a13-b0aa-4054-a4b5-16faa4855f09" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb626b8-fa46-4bfb-b253-8144e1dc6044" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b98b9a2d-ee4d-430a-b016-962f8ef544ad" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_d5d9d61d-4f4a-4ab7-a77d-b58b8d8d5172_1"></ix:continuation></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02c773d9-263c-4d62-be69-e8dcf18fb592" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.           Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s book equity value. As a result, the Company performed an interim goodwill impairment assessment.  This assessment resulted in a non-cash goodwill impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_979c4a34-9714-49be-8c97-35795e05e90b" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">154.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024, the Company recognized fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d57f3cc8-6991-4ed3-b7bf-036272017f4c" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c29ba77-4d7f-456c-9f4f-84d4acd8b3d5" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the exit of its affiliated office-based practices. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized a loss on disposal of businesses of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30f2734f-3844-4aaa-887d-1b3f00f2a742" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:GainLossOnSaleOfBusiness" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the exit of its primary and urgent care service line.</span></p></ix:nonNumeric></div><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9cc0478-d399-4d2c-b5f9-cef260a94639" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db7560d1-3384-4dd8-91fe-e7e690a55618" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.76%;box-sizing:content-box;"/>
         <td style="width:2.58%;box-sizing:content-box;"/>
         <td style="width:1.36%;box-sizing:content-box;"/>
         <td style="width:17.72%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1.36%;box-sizing:content-box;"/>
         <td style="width:17.72%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06bcfc48-b58d-4ada-9a60-666fe6338c29" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,065</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26283fc6-262b-40c1-ae7d-ccaa7aeba439" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,431</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2bee2da-5461-4ea6-8826-11d847119017" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,585</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8681474f-660f-483a-822d-258c5a33168b" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215,357</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_184e16d3-d0de-40b7-9040-eaf35791b1cc" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778438ca-05e8-4c5c-b54f-30cd4f58e8ee" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="md:AccruedPayrollTaxesAndBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,450</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193d9db7-67ac-47d8-b94d-ce87a0e5b56a" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,607</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b3ad7f8-2fd9-4a9f-931f-67ebf1fa5b44" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,430</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85e80516-7640-4035-85fb-978f95c0b3da" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7387ff70-f252-4c09-9d8e-21f2aa66c453" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,159</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7365d535-2f87-4626-a37d-0a800bf17107" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,569</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8c01cae-9427-4aa1-a90c-ac2f128f195d" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,863</ix:nonFraction></span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cec33c7e-e49a-4327-b53e-07781806be82" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">303,360</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f78bfe1-0821-47eb-b916-6b5c28c72a7b" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,690</ix:nonFraction></span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b265d8e8-e234-4566-a4b8-85fb51d751bb" contextRef="C_16252d43-9504-4f57-9f9e-531fbb28977d" name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2fa32bae-2575-477f-b283-80e738d30624" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, from December 31, 2024 to June 30, 2025, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p></ix:nonNumeric></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_18b4b868-d6a4-4023-94ab-73586250cf9d" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:LineOfCreditAndLongTermDebtTextBlock" escape="true" continuedAt="F_18b4b868-d6a4-4023-94ab-73586250cf9d_1"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Line of Credit and Long-Term Debt:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 11, 2022,</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7aafec1-6c61-4e10-8b3d-10251b6c975f" contextRef="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4" name="us-gaap:SeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35bd327e-7065-445e-821f-983b669eacd0" contextRef="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc26cfa7-8a05-4ca6-98fe-a0a606607f2f" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">5.375</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5e6daf-6157-4148-a9d2-099da96f977c" contextRef="C_8d9af789-c635-4423-848f-c01e14b9c5be" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ed98bd8-3726-44ee-bf40-3c88b0ea4ec8" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8959097d-86e0-4e15-98fb-981b9f00113c" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d421c4-fad1-420d-baa9-0d47db658a2c" contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8" name="md:PurchasePrice" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_18b4b868-d6a4-4023-94ab-73586250cf9d_1"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the issuance of the 2030 Notes, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Agreement Amendment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a540fe52-a5e1-4e4f-bc2f-afed3bb2621b" contextRef="C_c8cb11ad-5131-4dcd-b1e9-3b140f8c2c78" name="us-gaap:UnsecuredDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">450</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948fb5ad-3f1c-49af-8031-2db4adbc163a" contextRef="C_8e53119c-ac1b-4329-8f58-b7176456bb51" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63dbcb39-296d-4d10-81dc-cb72a65c570f" contextRef="C_4de6435d-c283-42d7-909b-380362f9a807" name="us-gaap:UnsecuredLongTermDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s subsidiaries and affiliated professional contractors. At the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7754b2e2-02d7-418e-b2c9-c06814b20100" contextRef="C_fda73ce3-e67d-432f-a66a-80057b60473d" name="us-gaap:DescriptionOfInterestRateRiskExposure"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a997fec6-dc54-42c5-a341-fdbe038ee856" contextRef="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">206.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, composed of the Term A Loan. There was no outstanding balance under the Revolving Credit Line at June 30, 2025. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71fff40a-84af-452b-a852-274a53aaa8c4" contextRef="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">450.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available on its Revolving Credit Line at June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_157b1bb4-a0e8-4405-8341-c97192e81dd3" contextRef="C_c1710474-b351-446a-ac79-006d3ecf6183" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f35cc01b-aa75-4675-8aef-3c18d068b3a9" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4823a2a4-ce5f-4ae6-98c5-e72b335af35b" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.98%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.3%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c9a8e29-75ae-4b8d-be29-181c8edd7c9d" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,797</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaaecf8d-af30-4661-9643-0c62dfa84a0a" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84372c94-f32f-4cee-9e9f-282cc3f23c73" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,653</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aefe22a6-ab9e-484b-8ce4-8efe3f9281a3" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_463b419e-d512-4bce-8132-330e7ab8bdc4" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">732</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b11cde0-266b-4cf1-9b24-637b61f10568" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_180e7185-f84e-43c8-b55e-85aeb2dea70a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">864</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83a323bb-bd82-4c79-9543-d7f961181814" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda89dad-1f09-487c-b207-aad3abf19e6a" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36fb3e05-4210-4755-824a-69f98106ac87" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,332</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0789c542-3fb6-4b64-adbe-8d5077f7238a" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,517</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e17fdb6-6bb4-43c3-96ee-92e7dcae6146" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,074</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Antidilutive restricted stock not included in the diluted net income per common share calculation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe2c17e-5fae-456b-a737-28a7dc58439c" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c0bb00e-0c1e-4a17-85ec-d0e5fe0967e5" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8a14018-bbaa-4c29-b6b8-1ac456f15b12" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_291e71eb-ffde-4616-86fe-580ef56a8611" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">661</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad5d929a-8ef2-4208-8085-482aa2b564af" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca027809-7760-49ca-b46c-447c11b2424b" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></p></ix:nonNumeric></div></ix:nonNumeric></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_2ec20f60-ad6f-4633-945c-a8be5135cf49" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_2ec20f60-ad6f-4633-945c-a8be5135cf49_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_2ec20f60-ad6f-4633-945c-a8be5135cf49_1" continuedAt="F_2ec20f60-ad6f-4633-945c-a8be5135cf49_2"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0b7ffa4-53cf-4eb8-a481-91e1e664de4d" contextRef="C_0c404152-671c-423e-89ad-d5d765b11984" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39347ece-a695-48e1-bc5e-0dd9907fe66d" contextRef="C_083e4a33-a175-4d28-b0bd-2e88cf498028" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f639670e-058e-4933-b343-ffc6da3c4404" contextRef="C_bc9a9da7-0be2-410f-9e41-d1f7b709a28b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6622d87e-d5e2-40fd-9712-3740abd33c82" contextRef="C_4f66fd46-91e2-44aa-ad85-e4197757b4e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of restricted stock and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_419e364b-6ed7-45cd-9a80-6edf4eac468c" contextRef="C_17f99e9d-a60a-4fc9-ac76-147b8ed76885" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of performance-based restricted stock units to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab364f57-f733-409e-bd19-cde68e605108" contextRef="C_be5ebf4b-3722-4087-8a25-4b48fa85c81e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef5f5712-6543-4685-b5ee-446459840d7f" contextRef="C_30cac922-a319-4eb7-99f1-fe21f2139c14" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_998676eb-9f8b-40f0-b65b-586ed4eb697f" contextRef="C_02338ba1-62e1-425d-a755-642941b0622b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c068a26a-c2b7-4782-ad69-8b84326660fe" contextRef="C_083e4a33-a175-4d28-b0bd-2e88cf498028" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares were issued under the ESPP. At June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14387a2d-703f-4803-b038-883d851eba2e" contextRef="C_d1c3550d-a30d-470c-81b8-b361b7723645" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At June 30, 2025, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d8b89d8-423c-4809-baba-b23762b5cc1e" contextRef="C_3d9eb462-edff-4b9a-8d90-654154da97b0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7037fb88-f5ac-4fef-9d5f-a3dcdebb03f1" contextRef="C_30cac922-a319-4eb7-99f1-fe21f2139c14" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_2ec20f60-ad6f-4633-945c-a8be5135cf49_2"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three and six months ended June 30, 2025 and 2024, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2e05d8e-c052-4adc-a562-4ee518dc2e11" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_1acf5a09-c48d-4355-8260-174ec9f42da3" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb2f17e-ccee-4c6b-a558-ab0979e82b7e" contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13027419-05d9-4438-96e3-70c1ced89ccf" contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span></ix:continuation></span><span style="font-size:9pt;font-family:Times New Roman;"></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_332bad21-b8ad-40b6-bf30-10300542e631" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="md:CommonStockRepurchasesTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8caa5e2c-f91a-4200-9882-72a5911b2c4b" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" scale="3" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_aa7ec16b-57ea-49a6-9440-57bddb3a8242" contextRef="C_a0c2cfa6-1c3d-4c86-9c0c-7cee140ba3f5" name="srt:StockRepurchaseProgramAuthorizedAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49ad0465-fd1b-44f2-91ed-06f39fc79236" contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for repurchase as of December 31, 2024. Under this share repurchase program, during the six months ended June 30, 2025, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1498c40f-3105-4afd-9232-fd7682374ac2" contextRef="C_0f263814-412a-40d2-829d-21ded60e6d59" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_274f9abd-d0e0-46b6-865d-4b24feb0f6f2" contextRef="C_1cb160af-9159-4c8c-acca-d4f2300fc206" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remaining available for repurchase under this authorization as of June 30, 2025.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f26957e8-5334-42c4-936a-57c087cc5ab7" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting:</span></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd4e2c7c-f651-471b-bc43-b734139a5218" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting. Financial results for all practices are managed on a consolidated basis. The chief operating decision maker assesses performance and decides how to allocate resources based on net income and total assets as reported in the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Financial Statements. Significant segment expenses are practice salaries and benefits and general and administrative expenses as reported on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Statements of Income and Comprehensive Income. Refer to the Consolidated Financial Statements for the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s segment revenue, significant segment expenses, other segment expenses and net income.</span></p></ix:nonNumeric></div><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_633d5ac5-7d6c-426f-9133-09e59f86eb38" contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_633d5ac5-7d6c-426f-9133-09e59f86eb38_1"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_633d5ac5-7d6c-426f-9133-09e59f86eb38_1"><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price of its securities. The Company has not included an accrual for these matters as of June 30, 2025 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s affiliated physicians. The Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Financial Condition and Results</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on February 20, 2025 (the &#8220;2024 Form 10-K&#8221;). As used in this Quarterly Report, the terms &#8220;Pediatrix&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, Pediatrix Medical Group, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;PMG&#8221;), together with PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2024 Form 10-K, including Item 1A., Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix is a leading provider of physician services including newborn, maternal-fetal, and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 36 states. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units (&#8220;NICUs&#8221;), to babies born prematurely or with medical complications and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies, primarily in areas where our affiliated neonatal physicians practice. We also provide services across multiple other pediatric subspecialties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General Economic Conditions and Other Factors</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2025, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) remained stable as compared to the three months ended June 30, 2024. However, we could experience shifts toward GHC Programs if changes occur in economic behaviors or population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, costs of managed care premiums and patient responsibility amounts continue to rise, and accordingly, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Office-Based Practice Exits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024, we formalized our physician practice optimization plans, resulting in a decision to exit almost all of our affiliated office-based practices, other than maternal-fetal medicine. Over the course of many years, we expanded our pediatric service lines and footprint to provide specialized care to more patients, including through our office-based portfolio of practices. This added complexity to our operations over time and, accordingly, increased costs that resulted in operating challenges primarily for our office-based portfolio of practices. Recognizing this and our need to adapt to the current healthcare climate, we made the decision to return to a hospital-based and maternal-fetal medicine-focused organization. As of December 31, 2024, the exits of our pediatric office-based practices were completed. Additionally, the Company exited its primary and urgent care service line during 2024 based on a review of the cost and time that would be required to build the platform to scale.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;Surprise&#8221; Billing Legislation</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In late 2020, Congress enacted the No Surprises Act (&#8220;NSA&#8221;) legislation intended to protect patients from &#8220;surprise&#8221; medical bills when certain services are furnished by providers who are not in-network with the patient&#8217;s insurer. Effective January 1, 2022, if a patient&#8217;s insurance plan or coverage is subject to the NSA, providers are not permitted to send such patient an unexpected or &#8220;surprise&#8221; medical bill that arises from out-of-network emergency care provided at certain out-of-network facilities or at certain in-network facilities by out-of-network emergency providers, as well as nonemergency care provided at certain in-network facilities by out-of-network providers without the patient&#8217;s informed consent (as defined by the NSA). Many states have legislation on this topic and will continue to modify and review their laws pertaining to surprise billing.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For claims subject to the NSA, insurers are required to calculate the patient&#8217;s total cost-sharing amount pursuant to rules set forth in the NSA and its implementing regulations which, in some cases, can be calculated by reference to the applicable qualifying payment amount for the items or services received.  The patient&#8217;s cost-sharing amount for out-of-network services covered by the NSA must be no more than the patient&#8217;s in-network cost-sharing amounts. Patient cost-sharing amounts for items and services subject to the NSA count toward the patient&#8217;s health plan deductible and out-of-pocket cost-sharing limits. For claims subject to the NSA, providers are generally not permitted to balance bill patients beyond this cost-sharing amount. An out-of-network provider is only permitted to bill a patient more than the cost-sharing amount allowed under the NSA for certain types of services if the provider satisfies all aspects of an informed consent process set forth in the NSA&#8217;s implementing regulations. Providers that violate these surprise billing prohibitions may be subject to enforcement actions by the Centers for Medicare and Medicaid Services or by states, one or both of which may be tasked with investigating potential non-compliance as a result of patient complaints, as well as any state-specific penalties enforcement action and federal civil monetary penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For claims subject to the NSA, including many emergency care services, out-of-network providers will be paid an initial amount determined by the plan; if a provider is not satisfied with the initial amount paid for the services, the provider can pursue recourse through an independent dispute resolution (&#8220;IDR&#8221;) process. The outcome of each IDR dispute is generally binding on both the provider and payor with respect to the particular claims at issue in that dispute but may not affect an insurer&#8217;s future offers of payment. Accordingly, we cannot predict how these IDR results will compare to the rates that our affiliated physicians customarily receive for their services. These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient&#8217;s insurer, and therefore could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;) has altered how health care is delivered and reimbursed in the U.S. and contains various provisions, including the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions of the ACA have expanded the scope and reach of the False Claims Act and other healthcare fraud and abuse laws. The status of the ACA may be subject to change as a result of political, legislative, regulatory, and administrative developments, as well as judicial proceedings. As a result, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. We cannot say for certain whether there will be additional future challenges to the ACA or what impact, if any, such challenges may have on our business. Changes resulting from various legal proceedings, and any legislative or administrative change to the current healthcare financing system, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the ACA, there could be changes to other government-sponsored or funded healthcare programs, such as a change to the Medicaid program design or Medicaid coverage and reimbursement rates set forth under federal or state law. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for Medicaid benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and/or make it more difficult for people to enroll.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Medicaid Reform</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level. On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act, which reforms the Medicaid program by eliminating certain financial incentives for states that have expanded their Medicaid programs under the ACA, imposing work requirements on certain adult beneficiaries, and requiring states to increase patient cost-sharing amounts for certain services. We cannot predict with any assurance the ultimate effect of these reforms on reimbursements for our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-GAAP Measures</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our analysis of our results of operations, we use various GAAP and certain non-GAAP financial measures. We have incurred certain expenses that we do not consider representative of our underlying operations, including transformational and restructuring related expenses. Accordingly, we report adjusted earnings before interest, taxes and depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), defined as net income before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Earnings per share has also been adjusted (&#8220;Adjusted EPS&#8221;) and consists of diluted net income per common and common equivalent share adjusted for amortization expense, stock-based compensation expense, transformational and restructuring related expenses and impacts from discrete tax events. For the three and six months ended June 30, 2024, both Adjusted EBITDA and Adjusted EPS are being further adjusted to exclude loss on disposal of businesses and impairment losses.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis.  These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a reconciliation of each of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and six months ended June 30, 2025 and 2024, refer to the tables below (in thousands, except per share data).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40.912%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.998%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.42%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.218%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.498000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.958%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,260</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(153,025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,997</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(148,990</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,130</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,308</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,284</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,907</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax provision (benefit)</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,709</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,703</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,062</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,914</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,313</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,791</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,645</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,099</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transformational and restructuring related expenses</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,834</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,579</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,439</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,059</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment losses</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,034</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,034</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses</span></p></td>
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,873</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,873</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted EBITDA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,246</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,857</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,427</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,068</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.54%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.184%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,529</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,332</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss) and diluted net income (loss) per share</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,260</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.46</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(153,025</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.84</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization (net of tax of $421 and $533)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,599</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation (net of tax of $503 and $500)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,508</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,501</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $959 and $3,395)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,875</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,184</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.12</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment losses (net of tax of $22,438)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,596</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses (net of tax of $2,718)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,155</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.10</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">739</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">328</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,648</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.53</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,338</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.34</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2025 and 2024, other than for impairment losses, due to a portion of the expense being non-deductible. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.72%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average diluted shares outstanding</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,517</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,074</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss) and diluted net income (loss) per share</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,997</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.70</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(148,990</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1.79</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments </span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization (net of tax of $851 and $1,396)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,556</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.03</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,188</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation (net of tax of $1,076 and $1,215)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,228</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,647</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transformational and restructuring expenses (net of tax of $2,610 and $5,515)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,829</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.09</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,544</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.20</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment losses (net of tax of $22,438)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159,596</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses (net of tax of $2,718)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,155</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.10</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net impact from discrete tax events</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">564</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.02</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjusted income and diluted EPS</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,174</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.87</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,144</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.54</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June 30, 2025 and 2024, other than for impairment losses, due to a portion of the expense being non-deductible. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Three Months Ended June 30, 2025 as Compared to Three Months Ended June 30, 2024</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net revenue was $468.8 million for the three months ended June 30, 2025, as compared to $504.3 million for the same period in 2024. The decrease in net revenue of $35.5 million, or 7.0%, was primarily attributable to non-same unit activity, primarily from practice dispositions, partially offset by an increase in same-unit revenue. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue increased by $27.9 million, or 6.4%. The increase in same-unit revenue was comprised of an increase of $15.0 million, or 3.5%, from net reimbursement-related factors and $12.9 million, or 2.9%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from increased patient acuity, primarily in neonatology, improved collection activity and an increase in administrative fees from our hospital partners. The increase in revenue from patient service volumes was primarily related to increases in our neonatology and maternal-fetal medicine services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Practice salaries and benefits decreased $34.3 million, or 9.6%, to $323.5 million for the three months ended June 30, 2025, as compared to $357.8 million for the same period in 2024. The decrease of $34.3 million was primarily attributable to non-same unit activity, primarily from practice dispositions, partially offset by an increase in clinical compensation expense, including incentive compensation based on practice results, at our existing units.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Practice supplies and other operating expenses decreased $11.8 million, or 36.3%, to $20.6 million for the three months ended June 30, 2025, as compared to $32.4 million for the same period in 2024. The decrease was primarily attributable to non-same unit activity, primarily from practice dispositions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our affiliated physician practices and services. General and administrative expenses were $55.7 million for the three months ended June 30, 2025, as compared to $56.6 million for the same period in 2024. The net decrease of $0.9 million was primarily related to net staffing reductions and lower other expenses, including professional services and legal fees, partially offset by increases in incentive compensation expense based on financial results. General and administrative expenses as a percentage of net revenue was 11.9% for the three months ended June 30, 2025, as compared to 11.2% for the same period in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $5.3 million for the three months ended June 30, 2025, as compared to $8.8 million for the same period in 2024. The net decrease of $3.5 million was primarily related to non-same unit activity, primarily practice dispositions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transformational and restructuring related expenses were $3.8 million for the three months ended June 30, 2025 as compared to $13.6 million for the same period in 2024. The expenses during 2025 and 2024 primarily related to position eliminations across various shared services departments and revenue cycle management transition activities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill impairment was $154.2 million for the three months ended June 30, 2024, resulting from the triggering event during the second quarter of 2024 based on a sustained stock price decline.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived asset impairments were $27.8 million for the three months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses was $10.9 million for the three months ended June 30, 2024, resulting from the disposals of our primary and urgent care practices.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income from operations increased $217.6 million, or 138.0%, to $59.9 million for the three months ended June 30, 2025, as compared to loss from operations of $157.7 million for the same period in 2024. Our operating margin was 12.8% for the three months ended June 30, 2025, as compared to (31.3)% for the same period in 2024.  The increase in our operating margin was primarily due to favorable same-unit results, primarily related to same-unit revenue growth, and the impact from practice disposition activity. Excluding impairment activity, transformation and restructuring related expenses and loss on disposal of businesses, our income from operations was $63.7 million and $48.8 million, and our operating margin was 13.6% and 9.7% for the three months ended June 30, 2025 and 2024, respectively.  We believe excluding the impacts from impairment activity, transformational and restructuring related activity and loss on disposal of businesses provides a more comparable view of our operating income and operating margin.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total non-operating expenses were $4.9 million for the three months ended June 30, 2025, as compared to $10.0 million for the same period in 2024. The net decrease in non-operating expenses was primarily related to an increase in interest income due to higher cash balances and a decrease in interest expense from modestly lower interest rates and borrowings.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our effective income tax rate (&#8220;tax rate&#8221;) was 28.6% for the three months ended June 30, 2025 as compared to 8.8% for the three months ended June 30, 2024.  The tax rate for the three months ended June 30, 2025 and 2024 includes net discrete tax expense of $0.7 million and $0.3 million, respectively. After excluding discrete tax impacts during the three months ended June 30, 2025 and 2024, our tax rate was 27.2% and 9.0%, respectively. We believe excluding discrete tax impacts provides a more comparable view of our tax rate. The tax rate for the three months ended June 30, 2024 reflects the effects of the non-cash goodwill impairment charge and the pre-tax loss generated excluding the impairment charge.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income was $39.3 million for the three months ended June 30, 2025, as compared to net loss of $153.0 million for the same period in 2024. Adjusted EBITDA was $73.2 million for the three months ended June 30, 2025, as compared to $57.9 million for the same period in 2024.  The increase in our Adjusted EBITDA was primarily due to net favorable impacts from our same-unit results and practice disposition activity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per common and common equivalent share was $0.46 on weighted average shares outstanding of 85.5 million for the three months ended June 30, 2025, as compared to diluted net loss per common and common equivalent share of $1.84 on weighted average shares outstanding of 83.3 million for the same period in 2024. Adjusted EPS was $0.53 for the three months ended June 30, 2025, as compared to $0.34 for the same period in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Six Months Ended June 30, 2025 as Compared to Six Months Ended June 30, 2024</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net revenue was $927.2 million for the six months ended June 30, 2025, as compared to $999.4 million for the same period in 2024. The decrease in net revenue of $72.2 million, or 7.2%, was primarily attributable to non-same unit activity, primarily from practice dispositions, partially offset by an increase in same-unit revenue. Same units are those units at which we provided services for the entire current</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period and the entire comparable period. Same-unit net revenue increased by $52.9 million, or 6.2%. The increase in same-unit net revenue was comprised of an increase of $34.9 million, or 4.1%, from net reimbursement-related factors and an increase of $18.0 million, or 2.1%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to an increase in revenue resulting from increased patient acuity, primarily in neonatology, an increase in administrative fees from our hospital partners, a favorable shift in payor mix and modest improvements in managed care contracting. The increase in revenue from patient service volumes was primarily related to increases in our neonatology and maternal-fetal medicine services.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Practice salaries and benefits decreased $66.4 million, or 9.1%, to $660.5 million for the six months ended June 30, 2025, as compared to $726.9 million for the same period in 2024. The decrease of $66.4 million was primarily attributable to non-same unit activity, primarily from practice dispositions, partially offset by an increase in clinical compensation expense, including incentive compensation based on practice results, at our existing units.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Practice supplies and other operating expenses decreased $24.2 million, or 38.1%, to $39.3 million for the six months ended June 30, 2025, as compared to $63.5 million for the same period in 2024. The decrease was primarily attributable to non-same unit activity, primarily from practice dispositions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the day-to-day operations of our physician practices and services. General and administrative expenses were $114.3 million for the six months ended June 30, 2025, as compared to $116.8 million for the same period in 2024. The net decrease of $2.5 million was primarily related to net staffing reductions, partially offset by increases in other expenses, including billing and collection fees and information technology. General and administrative expenses as a percentage of net revenue were 12.3% for the six months ended June 30, 2025, as compared to 11.7% for the same period in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and amortization expense was $10.6 million for the six months ended June 30, 2025, as compared to $19.1 million for the same period in 2024. The net decrease of $8.5 million was primarily related to non-same unit activity, primarily practice dispositions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transformational and restructuring related expenses were $10.4 million for the six months ended June 30, 2025 as compared to $22.1 million for the same period in 2024. The expenses during 2025 and 2024 primarily related to position eliminations across various shared services departments and revenue cycle management transition activities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill impairment was $154.2 million for the six months ended June 30, 2024, resulting from the triggering event during the second quarter based on a sustained stock price decline.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived asset impairments were $27.8 million for the six months ended June 30, 2024, resulting from the practice portfolio management plan.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss on disposal of businesses was $10.9 million for the six months ended June 30, 2024, resulting from the disposals of our primary and urgent care practices.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income from operations increased $233.8 million, or 164.8%, to $92.0 million for the six months ended June 30, 2025, as compared to loss from operations of $141.8 million for the same period in 2024. Our operating margin was 9.9% for the six months ended June 30, 2025, as compared to (14.2)% for the same period in 2024.  The increase in our operating margin was primarily due to the impact from practice disposition activity and favorable same-unit results, primarily related to same-unit revenue growth. Excluding impairment activity, transformation and restructuring related expenses and loss on disposal of businesses, our income from operations was $102.4 million and $73.2 million, and our operating margin was 11.0% and 7.3% for the six months ended June 30, 2025 and 2024, respectively.  We believe excluding the impacts from impairment activity, transformational and restructuring related activity and loss on disposal of businesses provides a more comparable view of our operating income and operating margin.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total non-operating expenses were $8.9 million for the six months ended June 30, 2025, as compared to $18.1 million for the same period in 2024. The net decrease in non-operating expenses was primarily related to an increase in interest income due to higher cash balances and a decrease in interest expense from modestly lower borrowings and interest rates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our tax rate was 27.8% for the six months ended June 30, 2025 as compared to 6.8% for the six months ended June 30, 2024. The tax rates for the six months ended June 30, 2025 and 2024 include net discrete tax expense of $0.6 million and $2.0 million, respectively. After excluding discrete tax impacts during the six months ended June 30, 2025 and 2024, our tax rate was 27.1% and 8.1%, respectively. We believe excluding discrete tax impacts provides a more comparable view of our tax rate. The tax rate for the six months ended June 30, 2024 reflects the effects of the non-cash goodwill impairment charge and the pre-tax loss generated excluding the impairment charge.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income was $60.0 million for the six months ended June 30, 2025, as compared to net loss of $149.0 million for the same period in 2024. Adjusted EBITDA was $122.4 million for the six months ended June 30, 2025, as compared to $95.1 million for the same period in 2024.  The increase in our Adjusted EBITDA was primarily due to net favorable impacts from our same-unit results and practice disposition activity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per common and common equivalent share was $0.70 on weighted average shares outstanding of 85.5 million for the six months ended June 30, 2025, as compared to diluted net loss per common and common equivalent share of $1.79 on weighted average shares outstanding of 83.1 million for the same period in 2024. Adjusted EPS was $0.87 for the six months ended June 30, 2025, as compared to $0.54 for the same period in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025, we had $224.7 million of cash and cash equivalents as compared to $229.9 million at December 31, 2024. Additionally, we had working capital of $272.0 million at June 30, 2025, an increase of $66.5 million from working capital of $205.5 million at December 31, 2024.  The net increase in working capital is primarily due to net favorable impacts in our same-unit results, primarily related to an increase in revenue.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by (used in) operating, investing and financing activities from continuing operations is summarized as follows (in thousands):</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:67.287%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.46%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,020</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,280</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,618</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,130</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,294</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,451</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, our net cash provided by operating activities from continuing operations was $22.0 million, compared to net cash used in operating activities from continuing operations of $13.3 million for the same period in 2024. The net increase in cash provided of $35.3 million was primarily due to higher earnings and increases in cash flow from accounts receivable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, cash inflow from accounts receivable was $21.2 million, as compared to a cash outflow of $0.9 million for the same period in 2024. The increase in cash flow from accounts receivable for the six months ended June 30, 2025 as compared to the prior year period was primarily due to a decrease in days sales outstanding (&#8220;DSO&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DSO is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO was 46.4 days at June 30, 2025 as compared to 47.6 days at December 31, 2024 and 49.5 days at June 30, 2024.  The decrease in our DSO from December 31, 2024 and June 30, 2024 was primarily related to improved cash collections at our existing units.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, our net cash used in investing activities of $14.6 million consisted of capital expenditures of $7.8 million, $3.6 million of other activity, primarily related to practice dispositions, and net purchases of investments of $3.1 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the six months ended June 30, 2025, our net cash used in financing activities of $10.3 million consisted primarily of payments on our Term A Loan (as defined below).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 11, 2022, we issued $400.0 million of 5.375% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  Concurrently with the issuance of the 2030 Notes, we amended and restated our credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment and restatement, the &#8220;Credit Agreement Amendment&#8221;). The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;), among other things, (i) refinanced the prior unsecured revolving credit facility with a $450.0 million unsecured revolving credit facility, including a $37.5 million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a new $250.0 million term A loan facility (&#8220;Term A Loan&#8221;) and  (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders under the Amended Credit Agreement.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors. At our option, borrowings under the Amended Credit Agreement bear interest at (i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if we select a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated net leverage ratio. The Amended Credit Agreement also</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line, based on our consolidated net leverage ratio.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, we may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, we are in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, we had an outstanding principal balance on the Amended Credit Agreement of $206.3 million, composed of the Term A Loan. There was no balance outstanding under the Revolving Credit Line. We had $450.0 million available on the Revolving Credit Line at June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, we had an outstanding principal balance of $400.0 million on the 2030 Notes. Our obligations under the 2030 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Amended Credit Agreement. Interest on the 2030 Notes accrues at the rate of 5.375% per annum, or $21.5 million, and is payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indenture under which the 2030 Notes are issued, among other things, limits our ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions.  Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, we may be required to repurchase the 2030 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Amended Credit Agreement and the 2030 Notes. We believe we will be in compliance with these covenants throughout 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2025 was $274.8 million, of which $30.6 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $23.8 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Amended Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form 10-Q.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Caution Concerning Forward-Looking Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, future impacts of legal, regulatory, political  and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2024 Form 10-K, including the section entitled &#8220;Risk Factors.&#8221;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Quantitative and Qual</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">itative Disclosures about Market Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt.  We borrow under our Amended Credit Agreement at various interest rate options based on the Alternate Base Rate or SOFR rate depending on certain financial ratios. At June 30, 2025, we had an outstanding principal balance of $206.3 million on our Amended Credit Agreement under our Term A Loan. Considering the total outstanding balance, a 1% change in interest rates would result in an impact to income before taxes of approximately $2.1 million per year.</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Controls a</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd Procedures</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Controls Over Financial Reporting</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No changes in our internal control over financial reporting occurred during the three months ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II - OTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ER INFORMATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1.	Legal Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ceedings	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits, including with payors or other counterparties that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot ensure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</span></p><p style="text-indent:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Factors</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no material changes to the risk factors previously disclosed in our 2024 Form 10-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Unregiste</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">red Sales of Equity Securities and Use of Proceeds</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2025, we withheld 14,631 shares of our common stock to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:40.092%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.018%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.278%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.417%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.26%;box-sizing:content-box;"/>
     <td style="width:14.837%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number<br/>of Shares<br/>Repurchased </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Price<br/>Paid per Share</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number of<br/>Shares Purchased<br/>as part of<br/>the Repurchase<br/>Program</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Approximate Dollar<br/>Value of Shares<br/>that May Yet<br/>Be Purchased<br/>Under the<br/>Repurchase<br/>Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 1 &#8211;  April 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 1 &#8211; May 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,225 (b)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.44</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 1 &#8211; June 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,406 (b)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.15</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,631</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.29</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our August 2018 repurchase program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $498.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million as of June 30, 2025.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares withheld to satisfy minimum statutory withholding obligations of $0.2 million in connection with the vesting of restricted stock.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Other Information</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of the Company&#8217;s directors or officers </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6225f98-434d-40bf-b1ee-efce7596039e" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_d3efb2ad-cda0-435e-804a-52728cbadbfe" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac3f4f0a-8371-48c8-b571-3221fdfb7ede" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b5abadc4-b5e0-4bc5-acf6-77b2cb20ee88" contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appointment of Chief Investment and Strategy Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective on August 1, 2025 (the &#8220;Effective Date&#8221;), the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) appointed Mr. Don Gregory Neeb to serve as the Company&#8217;s Chief Investment and Strategy Officer.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to his appointment, Mr. Neeb served as Managing Partner of Neeb Management LLC and Neeb Investments LLC, healthcare and real estate advisory and investment firms he founded in 2013 serving global institutional clients. From 2016 to 2018, Mr. Neeb served as President and Chief Investment Officer of Quality Care Properties, Inc. (formerly NYSE: QCP) prior to its sale to Welltower Inc. and ProMedica Health System. From 2008 to 2013, Mr. Neeb served as Chief Investment and Administrative Officer for Sunrise Senior Living, Inc. (formerly NYSE: SRZ) prior to its sale to Welltower Inc. and Kohlberg Kravis Roberts &amp; Co. LP. From 1995 to 2007, Mr. Neeb served as Chief Investment Officer for The Mills Corporation (formerly NYSE: MLS), prior to its sale to Simon Property Group and Farallon Capital Management. From 1989 to 2004, Mr. Neeb worked as a Manager at Kenneth Leventhal &amp; Company serving real estate and financial institution clients. Mr. Neeb earned a B.B.A. from the University of Michigan Ross School of Business.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with his appointment as Chief Investment and Strategy Officer, on the Effective Date, Mr. Neeb, the Company and a wholly-owned subsidiary of the Company entered into an employment agreement (the &#8220;Employment Agreement&#8221;), which has an initial term of three years, subject to automatic annual renewals thereafter. Pursuant to the Employment Agreement, Mr. Neeb is to receive, among other items and subject to certain exceptions and conditions set forth therein, (i) an annual salary of $550,000; (ii) a one-time cash retention award of $1,000,000, payable within 30 days of the Effective Date and subject to pro-rata repayment in the event that Mr. Neeb voluntary resigns (other than for &#8220;Good Reason,&#8221; as defined in the Employment Agreement) or is terminated by the Company for &#8220;Cause&#8221; (as defined in the Employment Agreement) during the three years following the Effective Date; (iii) an annual performance bonus, with a target opportunity equal to 125% of his annual base salary, with the amount payable based on performance metrics and a performance range to be set annually by the Compensation and Talent Committee of the Board; (iv) an equity transformation award (the &#8220;Equity Transformation Award&#8221;) in the form of a performance share unit award with respect to 320,000 shares of the Company&#8217;s common stock, which will vest, to the extent earned, on the three-year anniversary of the Effective Date and with the shares underlying the Equity Transformation Award being earned in one-third installments based on the Company achieving stock price hurdles equal to $16.94, $20.33 and $23.71 for at least 20 consecutive trading days before the third anniversary of the Effective Date; and (v) annual equity grants in each year during the Employment Period, with a target grant date fair value of no less than $2,762,500.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Employment Agreement, Mr. Neeb is eligible for cash severance for a termination by the Company without &#8220;Cause&#8221; or by Mr. Neeb for &#8220;Good Reason&#8221; equal to two times Mr. Neeb&#8217;s base salary, plus two times the greater of his average annual performance bonus and his target bonus, plus a pro rata bonus for the year of termination based on actual performance and the acceleration of Mr. Neeb&#8217;s then-outstanding equity awards, with any performance-based awards subject to the achievement of the underlying performance goals. In the event of Mr. Neeb&#8217;s termination by the Company without Cause or resignation due to Good Reason, in each case, within six months prior to or twelve months following a Change in Control, Mr. Neeb will receive a severance payment equal to two times his base salary plus two times the greater of his average annual performance bonus and his target bonus, plus a pro rata bonus for the year of termination based on actual performance and the acceleration of Mr. Neeb&#8217;s then-outstanding equity awards, with any performance-based awards deemed achieved at the greater of target or actual performance through the date of the change in control. Mr. Neeb is also subject to customary non-competition, non-solicitation, non-disparagement and confidentiality provisions under the terms of the Employment Agreement.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed as an exhibit to this Quarterly Report on Form 10-Q.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no arrangements or understandings between Mr. Neeb and any other person pursuant to which he was appointed as Chief Investment and Strategy Officer of the Company and no family relationships between Mr. Neeb and any director or executive officer of the Company. Since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Mr. Neeb had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. 	Exh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ibits</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit No.		    	Description								</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:90%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1+</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated as of August 1, 2025, by and between PMG Services, Inc. and Don Gregory Neeb.</span></a></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1++</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="md-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p><p style="text-indent:-11.111%;padding-left:10%;font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.1+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interactive Data File</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Schema Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Calculation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Definition Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Label Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XBRL Presentation Linkbase Document.</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104+</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></p><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:-11.111%;padding-left:10%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+  Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">++  Furnished herewith.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.3in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.8%;box-sizing:content-box;"/>
     <td style="width:42.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">Pediatrix Medical Group, Inc</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:  August 5, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;/s/ Mark S. Ordan</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">             </span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Mark S. Ordan</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Chief Executive Officer</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;(Principal Executive Officer)</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:  August 5, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;/s/ Kasandra H. Rossi</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">        </span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Kasandra H. Rossi</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;(Principal Financial Officer and</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Principal Accounting Officer)</span></p></td>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-74.419%;padding-left:42.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>md-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="page" style="flex-direction:column;overflow:hidden;display:flex;min-height:11in;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="absolute-block-container" style="margin-left:-1in;z-index:6;position:relative;"><div style="align-content:start;display:inline;padding-top:0.0035in;transform:translate(0px, 0px) rotate(0.0deg);z-index:257952768;overflow:hidden;top:10.5in;left:0;padding-left:0.0035in;width:6.4931in;padding-bottom:0.0035in;position:absolute;height:0.2931in;padding-right:0.0035in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div><div class="absolute-block-container" style="margin-left:-1in;z-index:4;position:relative;"></div><div class="absolute-block-container" style="margin-left:-1in;z-index:3;position:relative;"></div><div class="absolute-block-container" style="margin-left:-1in;z-index:1;position:relative;"></div><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.1</font></p></div></div><div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS EMPLOYMENT AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is made and entered into by and between </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PMG SERVICES, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a Florida corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DON GREGORY NEEB</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) on August 1, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RECITALS</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer is presently engaged in &#x201c;Employer&#x2019;s Business&#x201d; as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto; and</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employer desires to employ Employee and benefit from Employee&#x2019;s contributions to Employer.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the mutual covenants and premises set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Employer and Employee hereby agree as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employment and Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; commencing as of the Effective Date and continuing for a period of three (3) years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee hereunder shall automatically renew for successive one (1) year periods (each a &#x201c;Renewal Term&#x201d;) until terminated in accordance herewith, unless either party has given ninety (90) days&#x2019; prior written notice to the other party of the intention not to extend Employee&#x2019;s employment for the applicable Renewal Term.  The Initial Term and each Renewal Term shall be collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Duties of Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As of the Effective Date and thereafter during the remaining Employment Period, Employee shall serve as Chief Investment and Strategy Officer of Employer and Pediatrix Medical Group, Inc., a Florida corporation and the parent corporation of Employer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by the Chief Executive Officer of Pediatrix (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee&#x2019;s Supervisor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the Board of Directors of Pediatrix (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of Pediatrix; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that such duties as assigned shall be customary to Employee&#x2019;s role as an executive officer of Employer and Pediatrix.  Employee&#x2019;s employment shall be full-time and, as such, Employee agrees to devote substantially all of Employee&#x2019;s attention and professional time to the business and affairs of Employer and Pediatrix.  Employee shall perform Employee&#x2019;s duties honestly, diligently, competently, in good faith and in the best interest of Employer and Pediatrix.  During the Employment Period, Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar capacity for any institution other than Employer and Pediatrix, and their respective subsidiaries and affiliates in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer agrees that Employee&#x2019;s serving on the board of directors of the entity disclosed to Employer on or prior to the Effective Date has been consented to by Employer and such service </font></div></div></div></div><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="flex-grow:1;"></div><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not constitute Employee&#x2019;s breach of this Agreement.  During the Employment Period, it shall not be a violation of this Agreement to (i) serve on civic or charitable boards or committees, (ii) manage personal investments, or (iii) deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities have been approved by Employee&#x2019;s Supervisor and do not violate any code of conduct or personnel policies and procedures of Employer or Pediatrix and do not, individually or in the aggregate, interfere with the performance of Employee&#x2019;s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Place of Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee&#x2019;s principal work location shall be Pediatrix&#x2019;s corporate headquarters in Florida, subject to the Employer&#x2019;s remote work policy as in effect from time to time and subject to travel reasonably required in the performance of Employee&#x2019;s duties. </font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary and Performance Bonus.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer shall pay Employee during the Employment Period an annualized salary of Five Hundred and Fifty Thousand Dollars ($550,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), payable in accordance with Employer&#x2019;s normal business practices for senior executives (including tax withholding), but in no event less frequently than monthly.  Employee&#x2019;s Base Salary shall be reviewed at least annually by the Compensation and Talent Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Talent Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) when the Compensation and Talent Committee reviews the compensation for the other executive officers of Employer and Pediatrix and may be increased, but not decreased, in its discretion.  After any such increase in Base Salary, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall refer to the increased amount.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee shall be eligible to earn a cash bonus (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for each year during the Employment Period commencing with 2025, provided that, except as otherwise provided herein, Employee has remained employed by Employer as of the end of the applicable year and that the Performance Bonus for 2025 shall be prorated based on the number of days Employee is employed by Employer during 2025.  Employee&#x2019;s target bonus opportunity for any particular year (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be one hundred and twenty-five percent (125%) of Base Salary.  The amount of bonus payable to Employee for any particular year will be determined by the Compensation and Talent Committee based upon the achievement of reasonable performance objectives established by the Compensation and Talent Committee.  All such bonuses, if earned, shall be paid no later than March 15th of the calendar year immediately following the calendar year in which it is earned.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initial Awards.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Retention Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On the Effective Date, Employee shall be granted a cash award in the amount of One Million Dollars ($1,000,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Retention Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which will be paid to Employee in a lump sum within thirty (30) days following the Effective Date; provided, that Employee shall be required to repay, on a pro-rated basis, the Retention Award to Employer, less income taxes paid with respect to the Retention Award, in the event that Employee&#x2019;s employment is terminated for Cause by Employer or if Employee voluntarily resigns other than for Good Reason, in each case, on or prior to the three-year anniversary of the Effective </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date, with the amount subject to repayment equal to (i) 100% in the event of such termination on or prior to the one-year anniversary of the Effective Date, (ii) 66.67% in the event of such termination following the one-year anniversary of the Effective Date and on or prior to the two-year anniversary of the Effective Date, and (iii) 33.33% in the event of such termination following the two-year anniversary of the Effective Date and on or prior to the three-year anniversary of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Transformation Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, Pediatrix shall grant to Employee a performance share unit award under Pediatrix&#x2019;s Amended and Restated 2008 Incentive Compensation Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2008 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to 320,000 shares of Pediatrix common stock (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatrix Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; and such award, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Transformation Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The Equity Transformation Award shall be earned with respect to (i) one-third of the shares of Pediatrix Common Stock subject to the award on the Effective Date upon the attainment of the First Stock Price Hurdle (as defined below), (ii) one-third of the number of shares of Pediatrix Common Stock subject to the award on the Effective Date upon the attainment of the Second Stock Price Hurdle (as defined below), and (iii) one-third of the number of shares of Pediatrix Common Stock subject to the award on the Effective Date upon the attainment of the Third Stock Price Hurdle (as defined below), and which shall vest, to the extent earned, on the three-year anniversary of the Effective Date, subject to Employee&#x2019;s continued employment with Employer through such date (except as otherwise provided by Section 4 of this Agreement).  For purposes of the Equity Transformation Award, the &#x201c;First Stock Price Hurdle,&#x201d; &#x201c;Second Stock Price Hurdle&#x201d; and &#x201c;Third Stock Price Hurdle&#x201d; shall be attained upon the closing price of a share of Pediatrix Common Stock equaling or exceeding $16.94, $20.33 and $23.71, respectively, for twenty (20) consecutive trading days on the primary national securities exchange on which such Pediatrix Common Stock is listed for trading.  For the avoidance of doubt, in the event the applicable Stock Price Hurdle is not achieved on or before the three-year anniversary of the Effective Date, then the portion of the Equity Transformation Award attributed to such Stock Price Hurdle shall be forfeited for no consideration.  Notwithstanding anything in this Agreement to the contrary, in the event of a Change in Control (as defined in the 2008 Plan), the Stock Price Hurdles shall be deemed earned to the extent the applicable Stock Price Hurdles have been achieved either (i) as of (including prior to) the consummation of such Change in Control using the measurement methodology specified above or (ii) based on the Change in Control Price, and thereafter the Equity Transformation Award shall convert to a time-based award that shall vest on the three-year anniversary of the Effective Date, subject to Employee&#x2019;s continued employment with Employer through such date (except as otherwise provided by Section 4 of this Agreement). The Transformation Award shall also be subject to the terms and conditions of the 2008 Plan and an award agreement, provided that such award agreement shall not be inconsistent with the terms of this Agreement and shall be in a form reasonably acceptable to Employee.  For the purposes of this paragraph, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the value of the consideration per share of Pediatrix Common Stock received by holders of Pediatrix Common Stock in the Change in Control transaction, with the value of any non-cash consideration determined prior to the Change in Control by the Compensation and Talent Committee in its discretion.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expense Reimbursement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer shall promptly reimburse Employee for all out-of-pocket expenses reasonably incurred by Employee during the Employment Period </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on behalf of or in connection with Employer&#x2019;s Business pursuant to the reimbursement standards and guidelines of Employer in effect from time to time, and no less favorable than provided for other senior executive officers of Employer or Pediatrix</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including reimbursement for appropriate professional organizations.  Employee shall account for such expenses and submit reasonable supporting documentation in accordance with Employer&#x2019;s policies in effect from time to time.  Employee shall be permitted to travel first-class for all business air travel.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Employment Period, Employee shall be entitled to participate in such health, welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and programs are applicable to other similarly situated employees of Employer. Notwithstanding the foregoing, Employee may choose to waive participation in Employer&#x2019;s health and welfare plans pursuant to the standard waiver provisions thereof and remain on Employee&#x2019;s existing health and welfare plans, in which case Employee shall be reimbursed a monthly amount equal to the cost of such Employee health and welfare plans, up to the amount of Employer&#x2019;s monthly COBRA rate, subject to applicable taxes and withholdings and subject to Employee&#x2019;s continued employment on each monthly reimbursement date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leave Time</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Employment Period, Employee shall be entitled to paid vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by Employer policy.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Plans.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Employment Period, the Compensation and Talent Committee shall grant to the Employee on an annual basis following the Effective Date, and at the same time as other executive officers of Employer, awards (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) pursuant to the 2008 Plan or any other similar plan adopted by Pediatrix (together with the 2008 Plan, each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), with a target grant date fair value determined by the Compensation and Talent Committee in the same manner as for other executive officers of Employer, but in no event less than Two Million Seven Hundred and Sixty-Two Thousand and Five Hundred Dollars ($2,762,500); provided, however, on the Effective Date, Employee shall receive pro-rated annual equity grants for the 2025 calendar year in the form of a restricted stock award with respect to 81,346 shares and a performance share award with respect to 81,346 shares, with such grants to  vest in accordance with the vesting schedules and vesting commencement dates applicable to the 2025 grants awarded to the Company&#x2019;s other executive officers, subject to the achievement of the performance measures applicable to the 2025 performance share awards granted to the Company&#x2019;s other executive officers with respect to the performance share award.  Each Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and the terms of the applicable Equity Plan and shall be made subject to an award agreement that is consistent with terms applicable to other executive officers of Employer.  In the event of a Change in Control, all performance conditions applicable to all performance-based share awards then outstanding and held by Employee (other than the Transformation Award) shall be deemed achieved based on the greater of (x) the target level of performance, if applicable, and (y) the actual level of achievement of the applicable performance goals as determined by the Compensation and Talent Committee prior to the Change in Control.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination; Compensation and Benefits Upon Termination.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement for Cause (as defined below). Employee shall be provided written notice of any action or inaction alleged to constitute Cause and not less than thirty (30) days to cure, to the extent curable. The termination date for a termination of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be the date specified by Employer in a written notice to Employee of finding of Cause.  If Employee&#x2019;s employment is terminated for Cause, Employer shall pay (i) Employee&#x2019;s Base Salary through the termination date at the rate in effect at the termination date, (ii) reimbursement for reasonable business expenses properly incurred prior to the termination date, subject to Employer policy and the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, and (iii) vacation payout and any other vested benefits, subject, in each case, to applicable Employer benefit plans or applicable law (the foregoing clauses (i)-(iii), the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement upon the Disability (as defined below) of Employee.  The termination date for a termination of this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be the date specified by Employer in a notice to Employee.  In the event of Employee&#x2019;s Disability, (i) Employee shall continue to receive the Base Salary for ninety (90) days (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Disability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under the Employer&#x2019;s short term disability policy, which may be amended or modified in the Employer&#x2019;s discretion upon written notice to Employee, and (ii) following such Initial Disability Period, if Employee&#x2019;s Disability continues, the Employer may terminate Employee&#x2019;s employment immediately upon written notice.  If Employee&#x2019;s employment is terminated in connection with Employee&#x2019;s Disability, in addition to the Accrued Obligations and subject to and conditioned on Employee&#x2019;s compliance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, Employee shall be eligible to receive (A) a bonus with respect to Employer&#x2019;s fiscal year in which the termination date occurs, determined based on actual performance, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pro-Rated Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which shall be paid in the calendar year immediately following the calendar year in which it is earned, as soon as practicable after the audited financial statements for Employer for the year for which the bonus is earned have been released, but in no event later than March 15th following the year for which the Performance Bonus is earned; and (B) all time-based Equity Awards granted to Employee by Pediatrix prior to termination of Employee&#x2019;s employment shall immediately become fully vested, non-forfeitable and, if applicable, exercisable, and all performance-based shares awards, if any, including without limitation the Transformation Award, shall remain outstanding and shall vest based upon actual performance determined at the end of the applicable performance period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Any shares delivered pursuant to the Equity Acceleration shall be delivered to Employee within sixty (60) days following such termination of employment, subject to any delay required to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or as otherwise required by the underlying award agreement. Employee shall also receive any earned and unpaid Performance Bonus with respect to the year prior to the year of termination, which shall be paid in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without regard to its continued employment requirement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Death</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee&#x2019;s employment under this Agreement shall terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employee&#x2019;s estate.  The date of Employee&#x2019;s death shall be the termination date for a termination </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon Employee&#x2019;s death during the Employment Period, Employer shall pay or provide to the person or entity designated by Employee in a notice filed with Employer or, if no person is designated, to Employee&#x2019;s estate (i) the Accrued Obligations; (ii) a Pro-Rated Bonus; and (iii) the Equity Acceleration.  Any shares delivered pursuant to the Equity Acceleration shall be delivered to Employee within sixty (60) days following such termination of employment, subject to any delay required to comply with Section 409A of the Code or as otherwise required by the underlying award agreement.  Employee shall also receive any earned and unpaid Performance Bonus with respect to the year prior to the year of termination, which shall be paid in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without regard to its continued employment requirement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Employer Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer may terminate Employee&#x2019;s employment under this Agreement without Cause by giving Employee written notice of such termination.  The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90) days from the date of such notice.  The non-renewal of this Agreement pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be considered a termination of Employee&#x2019;s employment by Employer without Cause.  Upon any termination of Employee&#x2019;s employment without Cause pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that is not a termination following a Change in Control that is covered by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in addition to the Accrued Obligations and subject to and conditioned on Employee&#x2019;s compliance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, Employee shall be eligible to receive: (i) a Pro-Rated Bonus; (ii) any earned and unpaid Performance Bonus with respect to the year prior to the year of termination, which shall be paid in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without regard to its continued employment requirement; (iii) within sixty (60) days of the termination date, Employer shall pay Employee a lump sum payment equal to the product of (A) two and (B) Employee&#x2019;s Base Salary; (iv) within sixty (60) days of the termination date, Employer shall pay Employee a lump sum payment equal to the product of (A) two and (B) the greater of (x) Employee&#x2019;s Average Annual Performance Bonus (as defined below) or (y) Employee&#x2019;s Target Bonus; and (v) the Equity Acceleration, with any shares delivered pursuant to the Equity Acceleration to be delivered to Employee within sixty (60) days following such termination of employment, subject to any delay required to comply with Section 409A of the Code or as otherwise required by the underlying award agreement;.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Employee without Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee may terminate Employee&#x2019;s employment under this Agreement without Good Reason (as defined below) upon not less than ninety (90) days prior written notice to Employer.  Upon receipt of such notice from Employee, Employer may, at its option, accelerate the effective date of Employee&#x2019;s termination of employment at any time in advance of the expiration of such ninety (90) day period (which acceleration shall not constitute Good Reason or a termination by Employer without Cause).  The termination date under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be the date specified by Employer, but in no event more than ninety (90) days after Employer&#x2019;s receipt of notice from Employee as contemplated by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon any termination of Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employee shall be entitled to the Accrued Obligations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination by Employee for Good Reason.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Employee may terminate Employee&#x2019;s employment hereunder for Good Reason.  If Employee desires to terminate Employee&#x2019;s employment under this Agreement pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employee must, within one hundred eighty (180) days after the occurrence of events giving rise to the Good </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reason, provide Employer with a written notice describing the Good Reason in reasonable detail.  If Employer fails to cure the matter cited within thirty (30) days after the date of Employee&#x2019;s notice, then this Agreement shall terminate as of the end of such thirty (30) day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30) day cure period.  If Employee&#x2019;s employment under this Agreement is terminated pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and such termination is not a termination following a Change in Control that is covered by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, then Employee shall be eligible to receive the same payments and benefits, subject to the same conditions, for a termination without Cause as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Termination in Connection with a Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If Employee&#x2019;s employment under this Agreement is terminated by Employer without Cause or by Employee for Good Reason, in each case, within six (6) months prior to or twelve (12) months following a Change in Control, then, in addition to the Accrued Obligations, Employee shall be eligible to receive: (i) a Pro-Rated Bonus; (ii) Employee shall also receive any earned and unpaid Performance Bonus with respect to the year prior to the year of termination, which shall be paid in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without regard to its continued employment requirement; (iii) within sixty (60) days of the termination date, Employer shall pay Employee a lump sum payment equal to the product of (A) two and (B) Employee&#x2019;s Base Salary; (iv) within sixty (60) days of the termination date, Employer shall pay Employee an amount equal to the product of (A) two and (B) the greater of (x) Employee&#x2019;s Average Annual Performance Bonus or (y) Employee&#x2019;s Target Bonus; and (v) the Equity Acceleration, with any shares delivered pursuant to the Equity Acceleration to be delivered to Employee within sixty (60) days following such termination of employment, subject to any delay required to comply with Section 409A of the Code or as otherwise required by the underlying award agreement.  For the avoidance of doubt, and any reductions in Base Salary or Target Bonus opportunity resulting in Good Reason shall be disregarded in calculating severance under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Further, in the event of a termination within six (6) months prior to a Change in Control under this Section 4.7, any amounts due under this Section 4.7 shall be reduced by the amounts previously paid under Section 4.4 or Section 4.5, as applicable, and the additional amounts due under clauses (iii) and (iv) of this Section 4.7 in the event of a termination within six (6) months prior to a Change in Control shall be paid within sixty (60) days following the consummation of the Change in Control.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuation of Benefit Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Following any termination that results in the expiration of Employee&#x2019;s continued benefit plan coverage, Employee and each of Employee&#x2019;s eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to COBRA. In addition, upon Employee&#x2019;s termination of employment by the Employer without Cause, or resignation by Employee with Good Reason, in each case, subject to applicable law and the limitations imposed by Employer&#x2019;s stop-loss insurance policy, Employee and his eligible dependents will be entitled to elect, for a period of two years following the date of Employee&#x2019;s termination of employment, to continue to participate in any self-insured group health plan sponsored by Employer for its employees on the same basis as regular, full-time employees of Employer and their eligible dependents.  Employee will pay the full cost of such continued group health coverage, which is understood to be the Employer&#x2019;s monthly COBRA rate.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The obligations imposed on Employee with respect to non-competition, non-solicitation, confidentiality, non-disclosure and assignment of </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights to inventions or developments in this Agreement or any other agreement executed by the parties shall continue, notwithstanding the termination of the employment relationship between the parties and regardless of the reason for such termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conditions to Severance; Certain Definitions.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Release.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer shall provide Employee with a general release in the form attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (subject to such modifications as Employer may reasonably request) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) within seven (7) days after Employee&#x2019;s termination date.  Payments or benefits to which Employee may be entitled pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof (other than the Accrued Obligations and Employee&#x2019;s right to elect for continuation of coverage provided pursuant to COBRA) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Amounts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be conditioned upon (i) Employee executing the Release within twenty one (21) days after receiving it from Employer (or such longer period as may be set forth in the Release not to exceed forty-five (45) days) and the Release becoming irrevocable upon the expiration of seven (7) days following Employee&#x2019;s execution of it, (ii) Employee agreeing to submit to a reasonable exit interview if requested by Employer, and (iii) Employee&#x2019;s compliance with all post-termination obligations to Employer and its subsidiaries and affiliates and surrendering to Employer all proprietary or confidential information and articles belonging to Employer or its subsidiaries or affiliates.  Payment of the Severance Amounts shall be suspended during the period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that begins on Employee&#x2019;s termination date and ends on the date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is at least forty-five (45) days after Employee&#x2019;s termination date; provided, however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage (or COBRA reimbursement) that would be required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof during the Suspension Period.  If Employee executes the Release and the Release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As used in this Agreement:  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Average Annual Performance Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean an amount equal to the average of the percentage of Employee&#x2019;s Target Bonus achieved for the three (3) full calendar years prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on Employee&#x2019;s Base Salary and Target Bonus in Employee&#x2019;s current position.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#x2019;s Target Bonus in each of the three full calendar years prior to termination, and Employee&#x2019;s current Target Bonus was 100% of Base Salary, and Base Salary was $1,000,000.00, then Employee&#x2019;s Average Annual Performance Bonus would equal $315,000.00. ((40%+ 100% + 70%) / 3 x 100% x $1,000,000.00 = $700,000.00).</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the occurrence of any of: (i) Employee&#x2019;s engagement in (A) willful misconduct resulting in material harm to Pediatrix or Employer, or (B) gross negligence resulting in material harm to Pediatrix or Employer; (ii) Employee&#x2019;s conviction of, or pleading nolo contendere to, a felony or any other crime involving fraud, financial misconduct, or misappropriation of Employer&#x2019;s assets; (iii) Employee&#x2019;s willful and continual failure, after written notice from Employee&#x2019;s Supervisor or the Board to (A) perform substantially </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee&#x2019;s employment duties consistent with Employee&#x2019;s position and authority, or (B) follow, consistent with Employee&#x2019;s position, duties, and authorities, the reasonable lawful mandates of Employee&#x2019;s Supervisor or the Board; (iv) Employee&#x2019;s failure or refusal to comply with a reasonable policy, standard or regulation of Employer in any material respect, including but not limited to Employer&#x2019;s sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies; or (v) Employee&#x2019;s breach of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof resulting in material harm to Pediatrix or Employer.  No act or omission shall be deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Employee in a good faith belief that such act or omission to act was in the best interests of Employer or Pediatrix or if done at the express direction of the Board or upon the advice of counsel to Employer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the requirements of applicable law, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean (i) Employee&#x2019;s inability to perform Employee&#x2019;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii) a determination by an independent qualified physician selected by Employer and acceptable to Employee (which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional one hundred eighty (180) days.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean:  (i) a decrease in Employee&#x2019;s Base Salary; (ii) a decrease in Employee&#x2019;s Target Bonus opportunity or a failure of the Compensation and Talent Committee to approve an equity grant pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof; (iii) Employee is assigned any position, duties, responsibilities or compensation that is materially inconsistent with the position, duties, or responsibilities of Employee contemplated herein as of the Effective Date, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice; (iv) Employee experiences a material diminution in Employee&#x2019;s authorities, duties or responsibilities, excluding for this purpose any isolated and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice, provided that, if following a Change in Control, (A) neither the Pediatrix Common Stock nor the common equity of its successor is listed for trading on a national securities exchange, (B) the successor company in such Change in Control does not have a similar credit profile to that of the Company immediately prior to the occurrent of such Change in Control (as determined by the Board in its reasonable discretion), or (C) if Employee is not Chief Investment and Strategy Officer (or similar title), Employee shall have Good Reason to terminate employment; (v) Employee is required to report to any person other than the Chief Executive Officer; (vi) the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Pediatrix&#x2019;s headquarters are located as of the Effective Date, except for travel reasonably required in the performance of Employee&#x2019;s duties; or (vii) any other action or inaction that constitutes a material breach of this Agreement by Employer.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors; Binding Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) acquiring a majority of Employer&#x2019;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the same extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment.  In such event, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean Employer as previously defined and any successor to its business and/or assets which executes and delivers the agreement provided for in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law.  This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not limit Employee&#x2019;s ability to terminate this Agreement in the circumstances described in Section 4.6 hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benefit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by Employee&#x2019;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  If Employee should die after the termination date and amounts would have been payable to Employee under this Agreement if Employee had continued to live, including under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, then such amounts shall be paid to Employee&#x2019;s devisee, legatee, or other designee or, if there is no such designee, Employee&#x2019;s estate.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise provided in this Agreement, this Agreement constitutes the entire agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely determinative of the subject matter hereof. Any conflict between this Agreement and any plan document or award agreement or policy shall be resolved in favor of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Material Competition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employer and Employee acknowledge and agree that a strong relationship and connection exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services.  Employer and Employee further acknowledge and agree that the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following:  (1) the use and disclosure of the Confidential Information as described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof; (2) the professional development activities described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof; and (3) the goodwill of Employer, as promoted by Employee as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.  The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such interests.  Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement.  Employee further acknowledges that the goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section.</font></div></div><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an interest in, directly or indirectly, any individual proprietorship, partnership,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee, consultant, independent contractor, stockholder, or lender, if such entity is engaged in, directly or indirectly, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer&#x2019;s Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; as defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto.  Employee acknowledges that, as of the date hereof, Employee&#x2019;s responsibilities will include matters affecting the businesses of Employer listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding the foregoing and except as otherwise set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employee shall not violate this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by providing services to an entity which has a unit, division, subsidiary, or affiliate engaged in the Employer&#x2019;s Business so long as Employee does not directly or indirectly provide services to such unit, division, subsidiary, or affiliate. For purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the Employment Period plus (i) eighteen (18) months in the event this Agreement is terminated pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, and (ii) twenty-four (24) months in the event the Agreement is terminated for any other reason.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Hire</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Employee further agrees that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at any time during the Employment Period (other than on behalf of Employer or its affiliates) and for a period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly employ, or intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a) employ or otherwise hire (i) any person who is a then current employee or exclusive independent contractor of Employer or one of its affiliates, or (ii) any person who was an employee or exclusive independent contractor of Employer or one of its affiliates in the prior six (6) month period, or (b) take any action that would reasonably be expected to induce an employee or independent contractor of Employer or one of its affiliates to leave his or her employment or engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer of Employee). Employee shall not violate this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by (x) soliciting employees or consultants through a general advertisement not directed specifically at employees or exclusive independent contractors of Employer or one of its affiliates or (y) providing a personal reference.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Solicitation.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee further agrees that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee shall not</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at any time during the Employment Period (other than on behalf of Employer or its affiliates) and for a period of eighteen (18) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly solicit or accept business from (but solely in competition with Employer&#x2019;s Business) or take any action that would reasonably be expected to materially interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with (i) hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships, (ii) patients, (iii) referral sources, (iv) vendors, (v) any other clients of Employer or its affiliates, or (vi) prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of soliciting at the time of Employee&#x2019;s termination (including potential acquisition targets).</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  At all times during the term of this Agreement, Employer shall provide Employee with access to &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;  As used in this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly, verbally, in writing or by any </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to:  (i) patients with whom Employer has a physician/patient relationship; (ii) the present or future business of Employer; or (iii) the research and development of Employer.  Without limiting the generality of the foregoing, Confidential Information includes:  (a) the development and operation of Employer&#x2019;s medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b) contractual arrangements between Employer and insurers or managed care associations or other payors; (c) the databases of Employer; (d) the clinical and research protocols of Employer, including coding guidelines; (e) the referral sources of Employer; or (f) other confidential information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in Employer&#x2019;s business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and projections, and computer programs.  The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer&#x2019;s business and its goodwill.  Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might otherwise obtain.</font></div></div><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, Confidential Information shall not include any information that (i) was known by Employee from a third party source before disclosure by or on behalf of Employer, (ii) becomes available to Employee from a source other than Employer that is not, to Employee&#x2019;s knowledge, bound by a duty of confidentiality to Employer, (iii) becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv) has been independently developed by Employee and may be disclosed by Employee without breach of this Agreement, provided, in each case, that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions.  Pursuant to the Defend Trade Secrets Act of 2016, Employee acknowledges that Employee shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition, if Employee files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee&#x2019;s attorney and may use the trade secret information in the court proceeding, if Employee (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.</font></p><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government law enforcement or regulatory agency having jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">over Employer or its operations, and cooperating in any investigation by any such federal government agency.</font></p><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as provided herein, Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employee&#x2019;s employment with Employer, in any fashion, form or manner, unless specifically consented to in writing by Employer (or as reasonably appropriate in connection with Employee&#x2019;s performance of his duties), either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information of any kind, nature, or description, subject to applicable law.  The parties agree that any breach by Employee of any term of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> resulting in material harm to Pediatrix or Employer is a material breach of this Agreement and shall constitute &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; for the termination of Employee&#x2019;s employment hereunder pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.  In the event that Employee is ordered to disclose any Confidential Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement.  In the case of any disclosure required by law, Employee shall disclose only that portion of the Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding. Employee may also disclose Confidential Information as necessary in any litigation or arbitration between Employee and Employer or any of its affiliates, subject to a mutually agreeable protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement.</font></p><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or control shall be and remain Employer&#x2019;s sole property (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Upon termination or expiration of this Agreement, or earlier upon Employer&#x2019;s request, Employee shall promptly deliver to Employer all Employer Property, retaining none other than Employee&#x2019;s personal contacts, calendar and personal correspondence and any of Employee&#x2019;s compensation-related information.</font></p><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ownership of Work Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee agrees and acknowledges that (i) all copyrights, patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#x2019;s Business (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Work Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code.  To the extent the Work Product may not be considered a work made for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration.  Upon request of Employer (and at Employer&#x2019;s cost), Employee shall take </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#x2019;s successors and assigns, as fully and as entirely as the same might be held by Employee had this assignment not been made.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clearance Procedure for Proprietary Rights Not Claimed by Employer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In the event that Employee wishes to create or develop, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">other than</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on Employer&#x2019;s time or using Employer&#x2019;s resources, anything that may be considered Work Product but to which Employee believes Employee should be entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section.  Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently detailed written description of the work under consideration for Employer to make a determination regarding the work.  Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with respect to such request or description.  Employer will determine in its sole discretion, within thirty (30) days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer.  If Employer determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer.  If Employer fails to so notify Employee within such thirty (30) day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement.  Employee agrees to submit for further review any significant improvement, modification, or adaptation that could reasonably be related to Employer&#x2019;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer.  Clearance under this procedure does not relieve Employee of the restrictive covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Disparagement.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the Employment Period and for a period of ten (10) years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or willingly make any comment that would reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employee&#x2019;s work conditions or circumstances surrounding Employee&#x2019;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing. Upon termination of this Agreement, Employer and Pediatrix will instruct directors and executive officers of Employer and Pediatrix, respectively, that they shall not make any comment that would reasonably be expected to be materially disparaging or negative to Employee, Employee&#x2019;s work performance or circumstances surrounding Employee&#x2019;s separation from Employer or otherwise impugn or criticize the name or reputation of Employee. This Section 8.7 shall not be violated by truthful testimony or statements made in the normal course of Employee&#x2019;s employment or permitted competitive activities.</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review by Employee.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Employee has carefully read and considered the terms and provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and having done so, agrees that the restrictions set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are fair and reasonably required for the protection of the interests of Employer.  In the event that any term or provision set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed from this Agreement without, in any manner, affecting the remaining portions hereof.  Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such relief to be without the necessity of posting a bond.  In the event that, notwithstanding the foregoing, any part of the covenants set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be held to be invalid, overbroad, or unenforceable by an arbitrator or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in any manner, affecting the remaining portions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (all of which shall remain in full force and effect).  In the event that any provision of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to time period or areas of restriction shall be declared by an arbitrator or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitrator or court deems reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Survival; Notice of Breach and Right to Cure.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Employer reasonably believes that Employee has breached a provision of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employer shall provide prompt written notice thereof to Employee that explains such reasonably believed breach (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alleged Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Employer agrees to work in good faith with Employee to provide Employee a reasonable opportunity to promptly cure such Alleged Breach.  In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a comment made by Employee that Employer reasonably believes is in breach of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to the Alleged Breach.  Employer and Employee further agree that Employee shall not be deemed to be in breach of any term of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof unless such breach results in material harm to Pediatrix or Employer.</font></div></div><p style="text-indent:72pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall survive the termination of this Agreement and Employee&#x2019;s employment with Employer.  In the event of a breach of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Employee, as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, Employer retains the right to terminate any continuing payments to Employee provided for in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.  In the event of a breach of any provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Employee, as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities constituting such breach shall have been finally terminated (unless Employer was aware of such breach and did not commence actions to cause Employee to cease his actions), in each case as finally determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.  The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are expressly intended to benefit and be enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof.  Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants.</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Matters</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In General.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).  For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.  Employer makes no representation or warranty and shall have no liability to Employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Six-Month Delay.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, if at the time of Employee&#x2019;s separation from service within the meaning of Section 409A of the Code, Employer determines that Employee is a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that Employee becomes entitled to under this Agreement on account of Employee&#x2019;s &#x201c;separation from service&#x201d; (within the meaning of Section 409A) that would be considered &#x201c;non-qualified deferred compensation&#x201d;, such payment shall not be payable and such benefit shall not be provided until the date that is within fifteen (15) days after the end of the six-month period beginning on the date of such &#x201c;separation from service&#x201d; or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Employee&#x2019;s estate following Employee&#x2019;s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reimbursements.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by Employer or incurred by Employee during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Separation from Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon Employee&#x2019;s termination of employment, then such payments or benefits shall be payable only upon </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee&#x2019;s &#x201c;separation from service&#x201d; as defined under Section 409A.  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Later Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and not otherwise exempt from the application of Section 409A, then, if the period during which Employee may consider and sign the Release or the period in which the Employer can make a severance payment spans two calendar years, any payment or benefit described in this Agreement will not be made or begin until the later calendar year.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 280G</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#x2019;s benefit pursuant to the terms of this Agreement or otherwise (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covered Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) constitute parachute payments (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parachute Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) within the meaning of Section 280G of the Code and, but for this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, would be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then prior to making the Covered Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the Excise Tax to (ii) the Net Benefit to Employee if the Covered Payments are limited to the extent necessary to avoid being subject to the Excise Tax.  Only if the amount calculated under (i) above is less than the amount under (ii) above will the Covered Payments be reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Benefit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the present value of the Covered Payments net of all federal, state, local, foreign income, employment and excise taxes.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such reduction shall be made in accordance with Section 409A and the following:  (i) the Covered Payments consisting of cash severance benefits that do not constitute nonqualified deferred compensation subject to Section 409A shall be reduced first, in reverse chronological order; (ii) all other Covered Payments consisting of cash payments, and Covered Payments consisting of accelerated vesting of equity based awards to which Treas. Reg. &#167; 1.280G-1 Q/A-24(c) does not apply, and that in either case do not constitute nonqualified deferred compensation subject to Section 409A, shall be reduced second, in reverse chronological order; (iii) all Covered Payments consisting of cash payments that constitute nonqualified deferred compensation subject to Section 409A shall be reduced third, in reverse chronological order; and (iv) all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg. &#167; 1.280G-1 Q/A-24(c) applies shall be the last Covered Payments to be reduced.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any determination required under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be made in writing in good faith by an independent accounting firm selected by Employer prior to the applicable Section 280G change in control (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accountants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Employer and Employee shall provide the Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes of making the calculations and determinations required by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Accountants may rely on reasonable, good-faith assumptions and approximations concerning the application of Section </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G and Section 4999 of the Code.  The Accountants&#x2019; determinations shall be final and binding on Employer and Employee.  Employer shall be responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Employer shall cooperate with the Employee in good faith in valuing, and the Accountants shall take into account the value of, services to be provided by the Employee (including the Employee agreeing to refrain from performing services pursuant to a covenant not to compete) before, on or after the date of the transaction which causes the application of Section 280G of the Code such that payments in respect of such services may be considered to be &#x201c;reasonable compensation&#x201d; within the meaning of Q&amp;A-9 and Q&amp;A-40 to Q&amp;A-44 of the final regulations under Section 280G of the Code and/or exempt from the definition of the term &#x201c;parachute payment&#x201d; within the meaning of Q&amp;A-2(a) of such final regulations in accordance with Q&amp;A-5(a) of such final regulations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.077%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that after the determinations and selections made pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overpayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or less than the amount intended or required to be provided after application of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Underpayment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33314555618148%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that:  (A) the Accountants determine, based upon the assertion of a deficiency by the Internal Revenue Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B) it is established pursuant to a final determination of a court or an Internal Revenue Service proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date of Employee&#x2019;s receipt of the Overpayment until the date of repayment.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;text-indent:108pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33314555618148%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that:  (A) the Accountants, based upon controlling precedent or substantial authority, determine that an Underpayment has occurred or (B) a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by Employer to or for the benefit of Employee together with interest at the applicable federal rate (as defined in Section 7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee until the payment date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:72pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.538%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Withholding.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All amounts payable under this Agreement shall be subject to applicable income and employment tax withholding.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution; Injunctive Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any controversy or claim arises out of or relating to this Agreement, or any alleged breach hereof, Employee and Employer shall first try to resolve such controversy or claim through mediation using the services of the American Arbitration Association.  If any such controversy or claim cannot be resolved by mediation pursuant to the foregoing, Employee and Employer agree that such controversy or claim shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that if Employee and Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association.  </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer shall bear all costs associated with such mediation and, if necessary, arbitration, including but not limited to all costs of the mediator and arbitrator, and shall reimburse Employee on a monthly basis for Employee&#x2019;s reasonable legal and other expenses, including all fees, incurred in connection with any such mediation and, if necessary, arbitration, provided, however, that if Employer ultimately prevails in any arbitration (as determined by the arbitrator), the arbitrator shall have the power to require Employee to reimburse Employer for all or a portion of the advanced legal fees and other expenses as determined by the arbitrator (and, if the arbitrator finds that Employer prevailed on certain claims and Employee prevailed on others, the arbitrator shall have the power to require Employee to reimburse Employer for a portion of the advanced legal fees and other expenses determined by the arbitrator based on those claims on which Employer prevailed).  The mediation and, if necessary, arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually agreed by the parties, and shall be conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect.  Judgment on any award rendered by the arbitrator may be entered and enforced by any court having jurisdiction thereof.  Any such mediation and, if necessary, arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrator.</font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the party shall be entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable service of process.  Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i) they are not subject to the jurisdiction of such courts, (ii) they are immune from any legal process issued by such courts and (iii) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum.  In the event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all of Employee&#x2019;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided, however, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer all such advanced legal fees and other expenses.</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given when (i) delivered by hand, (ii) delivered by electronic mail that is confirmed by non-automated means, or (iii) when delivered or delivery is refused if sent by registered or certified U.S. mail, return receipt requested, postage prepaid, or via reputable overnight courier, addressed as follows:</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"></td>
      <td style="width:50%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;text-indent:38.8pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If to Employer or Pediatrix:</font></p><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">PMG Services, Inc.</font></p></td>
      <td style="padding-top:0in;text-indent:18pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">If to Employee:</font></p><p style="text-indent:-18pt;padding-left:18pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-18pt;padding-left:18pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Don Gregory Neeb</font></p></td>
     </tr>
    </table></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"></td>
      <td style="width:50%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;text-indent:38.8pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1301 Concord Terrace</font></p><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sunrise, FL 33323</font></p><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: General Counsel</font></p><p style="margin-left:11.8pt;text-indent:-27pt;padding-left:27pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Email: maryann.moore@pediatrix.com</font></p></td>
      <td style="padding-top:0in;text-indent:18pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At address provided to Employer.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.</font></p><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits; Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns.  Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer. This Agreement may be assigned by Employer to an affiliate of Employer (with a sufficient net worth to perform the obligations hereunder) in connection with a corporate reorganization, restructuring, or similar corporate transaction, or to a successor to Employer in connection with a Change in Control, upon notice to Employee.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The invalidity of any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or clauses, or section or sections had not been inserted.  If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">16.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Nothing contained herein shall be construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:36pt;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.769%;">17.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Third Party Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#x2019;s heirs, personal representative(s) and/or legal representative) any rights or remedies under or by reason of this Agreement.  No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or representations are not set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee.</font></div></div><p style="margin-left:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The remainder of this page has been left blank intentionally.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the undersigned have executed this Agreement effective as of the Effective Date.</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EMPLOYER:</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PMG SERVICES, INC.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">EMPLOYEE:</font></p></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Mary Ann E. Moore</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mary Ann E. Moore</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Administrative Officer, General Counsel &amp; Secretary</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;text-indent:21.6pt;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="text-indent:-4.167%;padding-left:4%;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;/s/ Don Gregory Neeb</font></p><p style="margin-left:4%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Don Gregory Neeb</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PEDIATRIX MEDICAL GROUP, INC.</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:-4.167%;padding-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 	/s/ Shirley A. Weis	</font></p><p style="margin-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shirley A. Weis</font></p><p style="margin-left:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chair, Compensation and Talent</font></p><p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Committee</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature Page to Employment Agreement</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BUSINESS OF EMPLOYER</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively referred to herein as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer&#x2019;s Business</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;):</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Neonatology, including hospital well baby care;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Maternal&#x2011;Fetal Medicine, including general obstetrics services;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Pediatric Intensive Care, including Pediatric Hospitalist Care;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4) Newborn hearing screening services;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(5) Pediatric Surgery; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(6) Pediatric Emergency Medicine.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References to Employer&#x2019;s Business in this Agreement shall include such other medical service lines, practice management services and other businesses in which Employer is engaged during the Employment Period; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that to be considered a part of Employer&#x2019;s Business, Employer must have engaged in such other service line, practice management service or other business at least six (6) months prior to the termination of Employee&#x2019;s employment.  For purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, businesses of Employer shall include the businesses conducted by Employer&#x2019;s subsidiaries, entities under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended.  Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for financial reporting purposes, provided that for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement, the term &#x201c;affiliates&#x201d; shall only mean the foregoing affiliates and subsidiaries. As used in the Agreement, the term &#x201c;affiliate&#x201d; shall exclude unrelated entities owned by an acquirer of Employer or Pediatrix.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and clarifications regarding the scope of Employer&#x2019;s Business.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hospital Services.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer and Employee acknowledge that, as of the date hereof, Employer does not currently operate hospitals, hospital systems or universities.  Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employer&#x2019;s Business where such hospitals, hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#x2019;s Business.  Therefore, the parties desire to clarify their intent with respect to the limitations on Employee&#x2019;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not be deemed to restrict Employee&#x2019;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employer&#x2019;s Business.  Furthermore, even if a hospital, hospital system or university provides medical services that are included in Employer&#x2019;s Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the hospital&#x2019;s, hospital system&#x2019;s or university&#x2019;s provision of medical services that are Employer&#x2019;s Business.  For the avoidance of doubt, Employer and Employee agree that if</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A&#x2011;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee becomes the Chief Investment and Strategy Officer (or similar position), a hospital system or health system, or other executive officer of similar level to the foregoing, that Employee shall not be in breach of the provisions of this Agreement.  Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or university that are included in Employer&#x2019;s Business so long as such hospital, hospital system or university is located at least ten (10) miles from a medical practice owned or operated by Employer or its affiliate.  Subject to paragraph B below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">De Minimus Exception.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer agrees that a medical service line (other than those listed in items (1) through (8) above), practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#x2019;s Business if such medical service line, practice management service or other business constitutes less than three percent (3%) of Employer&#x2019;s annual revenues.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Divested Lines of Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer agrees that any medical service line (including those listed in items (1) through (8) above), practice management, or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity, or otherwise after the Effective Date shall not be considered to be a part of Employer&#x2019;s Business effective as of the effective date of such divestiture.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D.	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Certain Ownership Interests.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It shall not be deemed to be a violation of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for Employee to:  (i) own, directly or indirectly, one percent (1%) or less of a publicly&#x2011;traded entity that has a market capitalization of $1 billion or more; (ii) own, directly or indirectly, five percent (5%) or less of a publicly&#x2011;traded entity that has a market capitalization of less than $1 billion; or (iii) own, directly or indirectly, less than ten percent (10%) of a privately&#x2011;held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A&#x2011;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM OF RELEASE</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GENERAL RELEASE OF CLAIMS</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[NAME] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), for himself or herself and his or her family, heirs, executors, administrators, legal representatives and their respective successors and assigns, in exchange for the consideration received pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.[&#x25cf;] of that certain Employment Agreement, dated as of [_____ __], 2025, by and between Employee and Employer, to which this release is attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), does hereby release and forever discharge PMG Services, Inc. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), its subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Released Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown arising as a result of events occurring through the date hereof, including, but not limited to, all claims under any laws applicable to Employee&#x2019;s employment, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment.  Employee acknowledges that Employer encouraged Employee to consult with an attorney of Employee&#x2019;s choosing, and through this General Release of Claims encourages Employee to consult with Employee&#x2019;s attorney with respect to possible claims under the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and that Employee understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans.  Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that Employee may have as of the date hereof.  Employee further understands that by signing this General Release of Claims Employee is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof.  Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any actions to enforce rights to receive any payments or benefits which may be due Employee pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Employment Agreement, or under any of Employer&#x2019;s employee benefit plans, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv) any claims for benefits under any directors&#x2019; and officers&#x2019; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, (v) any rights as a holder of equity securities of Employer, (vi) any claims that cannot be waived as a matter of law, (vii) any claims Employee may have to government&#x2011;sponsored and administered benefits such as unemployment insurance, workers&#x2019; compensation insurance (excluding claims for retaliation under workers&#x2019; compensation laws), state disability insurance, and paid family leave benefits, and (viii) any benefits that vested on or prior to the termination date pursuant to a written benefit plan sponsored by Employer and governed by the federal law known as &#x201c;ERISA&#x201d;.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee represents that Employee has not filed against the Released Parties any complaints, charges, or lawsuits arising out of Employee&#x2019;s employment, or any other matter arising </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on or prior to the date of this General Release of Claims, and covenants and agrees that Employee will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), provided, however, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived Employee&#x2019;s rights under ADEA.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any investigation by any such federal government agency; however, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other individual remedies, provided that, for purposes of clarity, this limitation on monetary recovery does not apply to whistleblower proceedings before the United States Securities and Exchange Commission.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee hereby acknowledges that Employer has informed Employee that Employee has up to twenty&#x2011;one (21) days to sign this General Release of Claims and Employee may knowingly and voluntarily waive that twenty&#x2011;one (21) day period by signing this General Release of Claims earlier.  Employee also understands that Employee shall have seven (7) days following the date on which Employee signs this General Release of Claims within which to revoke it by providing a written notice of Employee&#x2019;s revocation to Employer.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of Florida applicable to contracts made and to be performed entirely within such State.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee acknowledges that Employee has read this General Release of Claims, that Employee has been advised that Employee should consult with an attorney before Employee executes this general release of claims, and that Employee understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This General Release of Claims shall take effect on the eighth day following Employee&#x2019;s execution of this General Release of Claims unless Employee&#x2019;s written revocation is delivered to Employer within seven (7) days after such execution.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:50%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0.08in;vertical-align:top;padding-bottom:0in;padding-right:0.08in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[DO NOT SIGN]</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">, 20</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>md-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Mark S. Ordan, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: August 5, 2025</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark S. Ordan	</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Mark S. Ordan</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Chief Executive Officer</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(Principal Executive Officer)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>md-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Kasandra H. Rossi, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.	I have reviewed this quarterly report on Form 10-Q of Pediatrix Medical Group, Inc.;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: August 5, 2025</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kasandra H. Rossi	</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Kasandra H. Rossi</font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">          Principal Accounting Officer)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>md-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification Pursuant to 18 U.S.C Section 1350</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Quarterly Report of Pediatrix Medical Group, Inc. on Form 10-Q for the quarter ended June 30, 2025 (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pediatrix Medical Group, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Pediatrix Medical Group, Inc. and will be retained by Pediatrix Medical Group, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 5, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Mark S. Ordan 	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark S. Ordan</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: /</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s/</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kasandra H. Rossi	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kasandra H. Rossi</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Principal Accounting Officer)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img261193434_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img261193434_0.jpg
M_]C_X1FB17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    A    <@$R  (    4
M    DX=I  0    !    J    -0 +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D ,C R,CHP-SHR-R Q-3HS.#HS-
M  .@ 0 #     0 !  "@ @ $     0  !D"@ P $     0   ^D
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   8:         !(     0   $@
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MR@)R@ 8R&27'*7%_C<*?NQ.,QD8B5\0,(\(C6SQ.9_C-P[.F6-HQ;J\^RLM
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  $!+     $  3A"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-!         (  3A"24T$ @      !      X0DE-!#
M  (! 3A"24T$+0      !@ !     CA"24T$"       $     $   )    "
M0      X0DE-!$0      !     "   "0    D      .$))300>       $
M     #A"24T$&@     #20    8              ^D   9     "@!5 &X
M= !I '0 ; !E &0 +0 Q     0                         !
M      9    #Z0                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #Z0    !29VAT;&]N9P  !D     &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^D
M4F=H=&QO;F<   9      W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3004       $     SA"
M24T$#      8A     $   "@    9    >   +N    8:  8  '_V/_M  Q!
M9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1
M%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ 9 "@ P$B  (1 0,1 ?_=
M  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$!
M 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A
M$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$
MDU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%1
M87$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4
MHQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G
M-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*224+;:J:G
MW7/%=5;2^Q[C#6M:-SGN<?HM:U)34ZSUC$Z/A.R\DDB=M=;?I/<?S&K%H?\
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MO_0JHW#RLKHMF6ZJW)ZGC]4JS.MX): YYHVL?C8M+?T5]'H-IOQ/?9]J_?\
M6_1*3[OCH7+73BH_O2/]7Y?Z_&M]R6NG>GI\'ZS=(SLEF)3997?<TV4,OIMH
M]5@U<_&^TUU>O[?=^C5S#ZAB9WV@8S]_V6YV-=+2V+6;38SWAN[Z?TV>Q<WU
M+JN)]8[^G8?2&6WVX^;3E7Y#JK*V8[*3OL]1][*_T]K=U%=";"ZQC?5W,ZOB
M=29>V[)S;,O#%=-E@O9:VO8S&?4Q['7->STGL<FGE['IC(9*OVCK/YOF^5/N
M:ZD&/[W1UW_6KHC<?#R?5L?7U!KWXOITW6.>VN/5/I55/M;LW_GL5SIO5,'J
MF.<C!M]6MKS6_1S7->WZ==M5K66U6-_<L8N0QNG]7PO^:>+2&4Y]6-E[_78^
MRMA<VA[J[FTOI]_NV?SOTUO=*I9TOJ-E.=D?:.J]9<[)>]E1KIBEM5/HTB;&
ML]&OT_YRWUK?IO2RX<<8^DDR]1CKQ7&.2<?W?\W#BXN-49R)U%;#[8Q=1^?B
MLSJL!SXR;ZWVUL@ZLK+&V.WQL]KK6*MC_6#I&5TJWK&/D"S!H:]]M@:Z6BH;
MK0^DM]9KVM]VS8JF6UW_ #QZ<Z#M&%E F#$FS$[KD:>G9V%]2AU/ J<]N;@6
MXW5,3:02"+:J.HULC?\ :,;=^L?Z?&_XK>ECP0E&-R(E+@KMZSDL?^-^E4LA
M!VT'%?\ @\/_ 'SW6=U[IF!7CNOL<7Y?]&IKK?;;9IO_ $>-2Q]SMK?I^SV(
MG3.K8/5:7W85A>VIYJM:YKJWLL;!=5;5<VNRM[=WYS5SQR&]&ZU1U;J%=GV#
M)Z;3C-RVL=8*'UN=:^FYM37V5UY/J5_I-O\ .UK7Q_K)TZ^FO(8R]M.1DMQ,
M>Q]+VBU[V[F6L:6^I]F_,^T6LKK]B;/#408QE*_T[]%_N5P_-%,9V=2!_5Z^
M;__5]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G
MZJ27RJDDI^JE5=]@_:;-\?;_ $7>ENF?2W-]7T=WZ/Z?I>OZ?O\ YCU?\"OE
M]).CUWV/R_R^5!Z;;]7ZJ27RJDFI?JI)?*J22G__V3A"24T$(0      5P
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M0R0T5%8)XF/"@Z/41(2D)97#Q$;PX62%)K4G_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M                              __T+_
M
M
M
M
M
M        #__1O\
M
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M;;:%?S^V[3'S3X]SFSS+<5W*Y:<ER/IT_8]Z[/:3X?Z+5H1?Y>@]"TUIU?\
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MI2I*B4E1$I*DF1I4DRZDI)E[2/Y#&LD?&G%X/8T?Z!_
M
M
M                  #_TK_
M
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MY#6@
M
M                                   /_]._P
M
M
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MF^=PP;S"[A&4X3Z[6CY5*U2>/#*'%7P;C*O-$;HW E4
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M[6O.VN82IU*<G&<))QE&47A*,HO!QDFFFFDTU@SR1_#Y
M
M
M            !__4O\
M
M                                            #\I$AB*P]*E/-1HT
M9IR1(D2'$,L,,,H-QYYYYPR2A"$D:E*49$1%U/P']2<FHQ6+9^Z=.I6J1HT8
MN<YM*,4FVVW@DDMK;>Q);6RN'ZA'K70\<>N]/<-K&!<7+?O-9DN]C:9L*6K>
M3U9D0]91)"5,SGDGU2=R^A49/0SB-R"4W);[!I/EO*LHYAJ*+C'?&AN;\-1[
MXKZ1>5ZYK;%VG=V7N"5\TA;ZYYZTIT*#X:E#*,7"K46^,K^2:E1B]_O6#55X
M^W3I82I2K$9!D-]EEW:9+E%U:Y'D5Y-?LKF]O+"5:W%M82E^9)G6-E.6MYYU
M:CZK<<6:C/VF.U4J5*A2C1H14(16"C%)));DDMB1;AEN69=DV7T<IRBWIVMK
M;P4*5&E"-.E3A%81A"$$HQBEL2BDD>H'T/<      !_J4J4HDI(U*49)2E)&
M:E*,^A$1%[3/Y" _C:2Q>Q(V'P7B+REV8AE_ ^.^YLFA/I2IJUKM<Y4=(I*_
M%!G>/Q40T]Q>)=SY=2\2\"&(NL_R.RV75W1@UT.I'B_JXX_0.8:BYV\GM)RE
M3U'JC*[2I'?3G?6_:[-_M*J.J\.G"&PV=H/2(]0W(4(>C\>)]:PLB/S;_/=7
M42T$KQ+OA6=VW)Z_1(F>I?+T&%JZ_P!)47@[M-_2PJR^BH8?1.29EWV^[%ED
MG"KJ>%62Z*-GF%9/Q3IVLH?VMO0??M>B=Z@3B#6O7&',*))*)IW9^$FLS/\
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M!1JTY=:PE!XPJ1A4C*"SL,6<Z
M
M                                                    _]6_P
M
M
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M"
M
M                          '_UK_
M
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MWW-_G1.KE]W=O*<GGBEE]E*5.G*#Z+FMBJMTVL.)3:HN2XH4(,D<&GD60
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MK8TRRJTN[6_M:=[8U85J-:,9TZE.2G"<)+&,X2BW&49)IQDFTT\4\#PA^CT
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M46J=U03PQZ5"O3QC&O1Q;IR:DG*E.G.>Y UTX4
M
M
M '__U[_
M
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MH]C>V,W%X8N%6#VTZU*32XZ56#4Z<L$\'A)1DI167ACS2
M
M
M       /_]"_P
M
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M[7BI12[>4E=7(R41*29&DR(R,CZD9'XD9&0C>4&M-/!G^@?P
M
M
M        _]&_P
M
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M61\G^7N6Z R!)T[*FNTJ\*C*XN)^57N)[_*JU&Y)-O@APTXOAA%+ 0RITH
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MCG) X
M
M                         __2O\
M
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M6,E*C%2N;D1$1$1$1$70B+P(B+V$1".A0]OVL_T
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MH^9XP
M
M                       __]._P
M
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M:-6A/LZT7"2Z))I^<S)TZM.K'CI24EUIIKST>8/F?L
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MU/7.6T^"QU/3=:6"PC&^H<$+I>#M(RHW#;>,JE6K@L(DU8YN0&
M
M
M        #__4O\
M
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M(;K0[N^9:_LO>V:YDK"UISBZBI4^VJ5&EQ=GQ2G"-/AQC-OAJ)MQP6QE&?\
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M+F]_57RKE9Q_R[1'(/3."V3ETB#8XOGV!S[G&K##\NI'RE4N2G07:K9N4?\
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M72QW\/O2=:;6YSIP;W)J\2(SG^>\
M
M                                              /_U;_
M
M
M         "F;ZYNXE[%YFEKN#(4]4:2P7'<4*.VHW&%91E#)9M?2VNG4O,-B
M;70W2+V*C=I_.(Q(KECEWO33OOMKRKJ<I>'ACY$5YZDU]47M?\>^BZ&C^04]
M7W_#2GGMU<74JDVH\-M;8VU)3;P2A&5&O53>SAJ\6.! ?EVX,.Q/S8Q2COK=
MLE)^IE.XTZVT\DNI-V%IXLL>)*0M*/->;471;)#O>3:$SC-$JUPO>U)],UY3
M7TL-C_K.*?0V8OG=_P B_)SEK.KDN@T]69I#&+][5%3R^E);/+OG&:K8;))6
ME.O3FL8NO2D:UY-O#.+Y;C=?,+&(!K(VV*-3C$_M;?4XPMZY4?O'F$E1(=..
MIEMPB(S:+V#J65:*R'*TINEV]1>JJX2\Z/I5X-C:]<5,\WN^?S_YQNK9YQG$
MLLRVIBO>&6\5I;N$DE*%6<9RN;F,DL7"YKU:>.+C"*>!B>/'EV4QB+';=ESI
M\IJ.PTGJX_)ERG2;:;3U\5+6M1$77VF8VMN,(XO8DO.2(J2DHIRD\$MK;,LR
M4QFG"C0S0N%";:A1'6XYQ"D,1&R81-7&-2NQR0:3D/%W>+BUG\H[/DUB\NRR
ME:R].EC/;CY<O*DD]F*4FU'Z5)=!6YK;4,M5:JO<];\BM4?9[,,*4,(4DUT/
MLXQXNN6+PVGX#)FJ@            !^K#[\5]F3&>=CR8[K;\>0PXME]A]E9
M.-/,NMF2DK2HB4E23(R,NI>(_,HQG%PFDXM8-/:FGO372F?J,I0DIP>#6U-;
M&FMS3)=.*'K<<[.+KE;33-A*WQKJ$;++F#;K=G93)CP4&2%,T.>>:F\AJ0V7
MEQFW)K\1KHG_ '11%VG'[7O=GY6ZX4[FG9_DJ\EB^WLU&DG+KG0P=">+VR:A
M"I+;[8GM.SZ.Y]<PM).-"=S^4;6."[*Z;J-+JA6Q[6."V13E*"]8]Q9UXX^O
M]PJW+A$FVV3_ "PT/GM=&_9<%OZ:RRZ%D]JGRTJJ==YAC<8X]B\:GF4I8GL5
M[_S^_P GR4+>*NCG;R=S3DG4C6S.]M[ZVJ[:78R2NG';A*=EC*LHXQ:=2GVM
M&+P4ZL6TB5N0=XS1N::?N,ZS&WN[6I:PXIT:=O5NG-[/)H2H0EVDMJV3C2:6
M,Y)4XRFM,.2OKH[2RY<_'N,^'1-74*_-8:SK,8]?DV?2FSZDW*@4BO-IZU1D
M?13;R;$_ E)=0?@(4YUS0OKANCDM-4(^OGA*H_%';"/F\?C1!KFAW^M6YQ*I
MEO*ZQCE-OM2NKE0KW<ET2C2\JWH/KC)7+Z5.+V$)^QMJ;*V]D#N5;1SO*\_R
M%WO+ZJY9>6%W)8:6OO.+"]^<6F.P1_2,,)0VDB(DI(B(AS6\O[W,*O;WU6=6
M?7.3D_$L=R\"V$%M2ZMU1K+,7FVK,PN,QN7C[9<59U9)/;PQXFU"*Z(02BEL
M22/@!Y#7@              "//DEB18_GOU:BQ_*KLMB%9$IMA#$9-Q%,HMP
MRV:3,UN*_89CZS(NJY!_]HD+H;,WF.GZ2F\9T/:I>**7!_8<5CTM,O?[F?,2
M6O\ D;E]"[GQ7>22>6U>C&-",';22Q;:]ZSHP<GZ:I3J,Q1C>=Y;B7S:&\FP
MXW<ZM5>M2)=6MQ]!-NO*K)A.,>::2(B>)OS$]"[5$9#H>69SFN35>VRRO.C+
M9CPOR7AZZ/I9+P231.70W,O7_+3,?RIH/-[G+*N,7)4:C5.KP[8JM0EQ4:\5
MZRM3G#KB;'XIR(JYJFXN85OU&>6LD_56I3(EU1=[OTTFO<-R4RAMOVJ:7)4M
M7L0@O9UK(>;M2/#0U#1XEN[6DL'XY4V\'UMQ<<%N@RQ+E)_R-WUNZ64\Y<L5
MQ#9%YA814*JV8<5>SG)4YMORISH5**C'TEM-X(V6Q;*%1I5)E^)V[2I%98P;
M>EN:R0T^46TK'VY\1YIYHU)2\PX3:E(/YR%%T41&1D.Q6&9Y5GUFZN7U8UZ4
MTXRP>U8K!J47A*+:Z))/#H+*=):ZY><X-,U;W2.86^;Y?<0E2K*G)\48U8RC
M*E<49J-:A*4&_:ZT*<W%XI8-,Z/&C]FP-SZ;U9MJL2VW#V/@&*9DF.VKN*$]
MD%*S8S*Y74SZ+C/..1W",S,E(,C]@BEF=E/+LQKV$]]&I*'CX6TGYJVG^:'F
M#I*YT'KK.-%7;;GE5Y<6O$_5JC5E",_%4BE-/I4DS*0\)IX
M
M
M   '_]:_P
M
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M?TLN'@?U1SGFQG;R+0&8W,&E4K0["&W!XUVJ<G%[^*-.4YKZD^O'92O<
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M)3A-*491:<91:Q336QIK:FMC6U'[C^GT
M
M                                               /_]>_P
M
M
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M.:2<J56#\JG5ABN*$DG@U)8QE&3RP/>;@
M
M                                              '_T+_
M
M
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M-K27./2E/5&E:N["%Q;S:[:UK88NE5BO/A->14CY47O2V2&9.G@
M
M
M  ?_T;_
M
M                 /\ %*2E)J49)2DC4I2C(DI21=3,S/V$0)-O!!O#:RDY
MZV?J^R=[6^1<1^,F3J:T?1S7:O:^Q*.6:?Z8+J"_VR<8H9\<_G8Q$=3VNO(5
MVV;R>Y)J@H;5+LL[M/=[AI:WH\P-;4,<SJI2M;>:_P I"2V5)Q?_ ,3-/8GM
MH1>#PJMJG [GSSJGJ&M5T9I2KAE]-\-Q6@_\S)/;3@U_<1>]K95DMGM:3G6G
M$T"+  'D.I(\9S8S+J:*"O4D_H&>952>O_H,R&FZVDXY=02]572_]*J_Y#N/
M=]I*IKV4WZBUK27]:G'T)&&QSDFZ96P/4F19L3<]?_WDQ]?F&5Q+94XJ7Y;G
MDJ150>Y"I!DKN(W#6AHNQQ/F>8DFU:OG^K,LR&+IU'VM?HIQ>WP.;VJ"\>+>
M*:BUM)-=WSNH<U.\1?JKINW]XY-3GP5\TN8RC;0P]/"BEA.[KI?W5'R82<%7
MJT(SC,W#Q/!,8PIDVZ*O)$I:%MOVTPT2KB4VM1FIMV;VI[$&7:E33"&VU=J5
M&@U]5'Q3.M49MGLFKJ?#2Z*<,5!>/ID_#)O#HP6PO2Y"=SKDYR$HT<PRFS6:
M9Y!+CS2\C&I74\,).UI[:5G#%R4>Q7;\$N"K<5DL2]1Z+->W"]/;4TE"22JW
MR/:=@\?^>XWL>RJB4?\ ^A%07^01(YCS<M6UUZV-)?\ IQ?\I5+W]KJ5QWF\
MZI2>*H4,O@O G8T*GHU&_-)5QHI#<          THYR\U,%X6ZI>RRY*+?;"
MR-,NMUE@1R/+D9%=,M%YUC8^4?F,U4#O;=GR"Z'\Y##9^<\V-:U1J6UTW8.O
M4PG6GBJ=/ID^M]48[Y/Q);6CA?/OGED'(_2,LXO>&XS*YXH6-IC@ZU5+;.>&
MV-"EBI59^&-.+XYQ*26V]M9_O+8.2;0V=D,O)LRRF<J996,H^UII!%V1*VMB
M(_8XT.*V268L9HB0TVE*4ET(1GS#,+O-+N=]?3<ZE1XMOZ"2Z$EL26Q(HHUC
MK'46O=1W6J]57,KJ]NY<4YRW);HPA'="G".$:<(X1C%))&-QXS60 /B<OU]C
M69M.+LX9,6G9VLW4+M8LD*2VAIHI+G0TR&TI;0@D/I5VHZI:4T:C4-PR'6N;
MY)A1<O?%!?W<V]B^DEM<? ML5ZW':=GT#SQUAHC@LJT_RCE\<%V%:3XH1222
MH5L)3I)))1@U.E%8X4E)\2U1RS5&48O+(DL%:U#KRT1[N*1,PVFR61(5<F^K
MM@GVJ2I:GW/)+YW8\LFUJ+ONC[W]N[JEENF:52ZO*KX8VT(.5=OP0CBY+IXH
MXQ2WM8/"<&C.9>D=<Y=*^R>Y4)4EC6HUG&G5HK%+&<6VG#%K"I"4J>+4>)33
MBOC4NUU9VG'2U;SD]BRDR&E_4J,M+AK(F($A*523(B;,U2D$UXN-JCNI[73L
M<Y2]S:WI1IYWS8J=I/9*.7T)X0CL6RYN(/&;WXT[>2BFD^WFFX+$9[S#P;ML
MA6/_ 'IKV$)+Q>5472UV>Z1ZR1)D2W/.E/.ON$VTTE;JU+-#+#9,L,HZ_2H;
M0E*$(+H24D22(B(B$Z\JRC*LBL*>59+;4K2VHK"%*C"-.G%-XOAA!**Q;;>S
M:VV]K.7W%S<7=9W%U.52<M\I-R;PV+:]NQ;%U+8C\!D3X  6SO0Z]7Y^+)Q+
MA-RDR@W8,@X6.<?-I7\O]D@/GTBU6I,NLY*OG,.?-8QZ8ZKJVOMKUJ-M40F8
M#]YWN]QG"XYEZ&H826-2_MJ:],M\KNE%>J6UW$%L:QK))JIQ3(Y \ZI0E1T'
MJVMC%X0L[B;W/=&WJ2?0]U&3W/"D]CAPV[A7V30            YTW+^AKF^
M3G)W&I<*)-JXN_\ <=:J!,CM2HBVZ_8]BRP2V'TFDS0:"4A7;U2HB4GH9$92
MJL\MR_.]-6=#-*,:T)4*3PDMS=..V+WQ>WTT6GX3_2KH[16CN:G(/2V5:\RZ
MAF=K<9-EE1PK1Q<)SL*.-2E4356C5PDTJM&<*D4WA)8D<V=<?D*)ZRP1SM5]
M.O&YTCJD^YU74JFTE*\"2DT=&9:S,R2M7O!J-#0Y%JCE7=6:E>Z=;KTUBW1?
MV2*^D>ZHM^S9/<EQO:5U<^_^/_4&F(5M3\F)U,VL8\4YY=4P=]1BEB_>\THQ
MO(KRL*?#"Y2X(05U-RDM7)425!DOPIT:1#F175L2HDIER/)C/M*['67V'B)2
M%I,C)25$1D?@8Y!*,H2<)IIIX-/8TUO370T5O5Z%>UK3MKF$J=2G)QG"2<91
ME%X2C*+P<9)IIII--8,V2XJN=FP+Q/\ [;"K!O\ ]%_6O?\ ] TO7T5+3%=]
M4J;_ /4BOY2(??@H1K=W3-ZDM]*O8R7C=Y1AZ$V;[B/A16 !LCQ8Y1[,XD[6
MJMH:WG=_9Y<#*\5F/.HH<VQI;Q.3*"Z:;Z].O3OC24I-R.\274=>BDJS.19Y
M>Z?OXWUF_!*+]+./3%_R/>GM1T[E+S8U3R=U=1U7IBICAA"XMY-JE=4&\94J
MJ7GPFDY4YX3CN:=X+C;R,UQREU/C^V]9V/O-3;(]UMZ>2MHKK$LCC-(5:XOD
M$9LS\N5&-:3(R^8\TIM]I2V76UJDWDV<6>>V$,PLGC&6QI[X26^,O"O.:P:V
M-%\7+#F7IGFSI"VUCI:KQ4:RX:E.6':V]:*7:4*T5Z6<&U]+.#C4@W"<6\\C
M*G00
M
M             #__TK_
M
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MR6O&YM+NG"K1JP>,9TYQ4HR7C3W/!I[&DTT?1C[&3
M
M                                                 #__T[_
M
M
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MEVO(Q?!;K3^JWD.Q).#8W.V52*LLOSV*X1*^J\NM4][C6*Z%7M+\Z01SS2U
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M<RQE.UQ>Q0N-LZ2V)7'%%*4KC9:''<"UL
M
M                                         /_4O\
M
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M_IN   "T1\/%GZ9&*<E-6O.DE=3D."9_6L&KYSZ<AK9N.W;J$_0:.LKR4?\
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MWKN_\PY:,U='*K^>&7YHXTJF+\FG5QPHU>I+B?9S>Q<$N*6/ CH"BILL>
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M&O**S*V_PU_!8+"YIQ6-11Z(5X.-:."X8N4J:;=-F[XV8[N
M
M                                                     !__U;_
M
M
M      @?]?SF:YQQXCGIG$+;W+9_)]RUPALXSQHG4^JX##:ME6Z3;/J@YK<B
M+1H)9%WMS9"VS[XY])3=T_EPM8\P/VCS"GQ6.2<-;:O)G=2;][0\/ XRK/#<
MZ<$UA,CUWC=<O2^C/R'93X;O-N*EL>V-NDNWEX.).-)=:J2:VQ*$8M6*[
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M<-63I2DVE&G7J2?I47/Q) N^
M
M                               __]:_P
M
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M':X1KI=$:L3<0;$=I
M
M                      /_U[_
M
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M;GU,M5RV'3^E:9D0FRZ%T(<!YH9*[3-89O27M=RL)>"I!8?VHX-=;4F4D?\
M(OREGI?F1:\T,MI866H::IUVELA?VT%!XX;(]O;JG./3.=*O)[<2> <N*YP
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MURJ4ITI/Z6W;+.X[:6I@
M
M                        '__0O\
M
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MB7VQ*L_T)
M
M              '_T;_
M
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M(+M;^JT!#$]OK\YV0W/</V"0/+'/??V52RBM+VVU]+UNE)[/ZDL8^!.*+O\
M_CQYQQUARWK<L,VJ\68:<>-!2?E5,OK2;IX8[7[VK.=&71"E*VCTD%PZ<6(
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MKS\%2I1A*HGX8U.*+\*,SC)&[@
M
M                            !__2O\
M
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MLM+S"^7NFZ>6G.0&GJ#CA.ZHU+N;]=[ZK5*T&_%2E3BO!%$@@VTD8
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M.;XIV4[NVD_J+JK."\RE4IKS"3,;J2E
M
M                                  #_T[_
M
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M3\,:5O7V?UIQ?F(D_P!U6R5;7-]>R6/8V4DO!*I6H[?ZL9+S67@A603Y
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M5J3]17EYSA3_ )<2X3_C[OW<<H,RL)/%V^;5FO!&I:V;2_K*;\TFY'3"=H
M
M
M ?_4O\
M
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M<9O25(0[)<247]6:DKZES-W+QC1IXQI0ZH];^FEOEYD<6HH_SI]Y?G[F_/\
MYA5,_J<=#*;/BHY=;2?V*AQ8NK42;C[XN&E4K-8X)0I*4H4H,WJ&KD=@
M    U/YW1$S>&'*-E:242-&;(ED1].G= QB1.0KQ^@ILC(8#5,>+3=\G]HJ/
MSHMG(.\!15?DAJR$MN&57LOZE"<E]&)0C$53_/:   %I/T!9*EZ;W[#-1&AC
M9N.R4H^5*I>+$TM1_P#:3*2+_L'<N5$O_MUW'JJ1?GQ__D6Q?\=]5O1.HJ..
MR-]1EA]50P^CPKSB?D=7+#P
M
M                          __U;_
M
M                                  #X':T,['5VR:]*36J?@.80R02>
M\UG*QZ2P223X=>O=TZ=1E<AJ=CGEE6>S@KT7YU2+,=G$.URFZI[^*C47GPDC
ME B^<IX   "T[\+Q8M-;4Y;U)K(GINOM7V+;?0NJFJO([6,\LC]OS3F(+_*(
M+]^"C*61:?N,-D:]S'S94Z37L'YQ+KNEU4LWSFCTRHT)?U9U$_9(N/BNLF\
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MBK*GI>PJ8N:QB\RKP>RO-/!JVIO_ "U*2QD_;ZBXW3A1F7'.B"0
M!J7SSFHK^%W*%]Q78ES2&PH1&?0NJ[/'GJUM/CU^F4Z2?\HP&JI*&F[YO[34
M7GQ:_E./=X.O&VY'ZKJ2>&.5WD?-G1E!>>Y8%"<15/\ />   %IGT!XIHTGO
MB;VGVR-ITL4E>/0SB8DTZI)>'R>>77Q^7Y/E[GRHC_\ ;+J7752\Z"_G+9?^
M/"DUH74%?UU_2C_5MXO_ ,1/F.K%A@
M
M                                 ?_6O\
M
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MNWTR4(K^E4BG]#$C;WNLTCE/=YU%4Q\JM"WH176ZUW0IR\Z#D_$BD&(RE$
M  6X/0CHEUW$/-K=ULTKR+?&528[AET)V!787CU8UT^CVR&Y)=1W_E;2X-/U
M:C]77EYRA37HXEQ?_'_E[MN35_>S6#N<VKM/KA"VLX+SIJ9-8.E$Y@
M
M                                                         __7
MO\
M
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MH
M
M    /__0O\
M
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MA:#T['2&B,GTK'#_ .W65M;/#IE1HPIR?A<I1;;Z6\3*(]QM@
M
M                                                    ?__1O\
M
M
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MN9QEU*IV2I>.:6]E[L2E/] (
M
M                            !__2O\
M
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MV<A-:K1^O:%.ZGPVF8I6U7%[(RDUV-1]"X:F$6WLC"<V=#D5$EE@
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M**\$$U&/4DD6YZ=R:WT[D-GD-I]CLZ-.DGNQX(J+D_#)IR?6VV99& ,R
M           0U^M/R71J/C<SIR@L$LYMOR6]22FF72*77ZWIEMRLNF*)/4TE
M.<5%JDI6DB=9?E=A]S1].<\R<Z67Y,LNI/VV[?"^M4UMF_Z6R/A3EU$)N_'S
M1CH[EC'1675.&_U#)TI)/RH65/"5Q+P=JW3MTFL)PJ5<'C!E0<1\*9P   L>
M>@AHU3DS<O(RUA'Y<=B%J/#93C?5"WI"F,ISEUDUEX*;0BE:0XCY''D=2^<1
M]CY4Y7C*YSBHMV%*#\Z4_P#P+S6BS/\ X]=!.5?.^9EW#9%1R^VDUL;?#7NF
ML>E)6T4UT2G''>G90'9BSX
M
M                           __]._P
M
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M4P]*R1_=HT<\]UK+45S'&WRJ'&L5L=Q43C27]&/:5-GI91AUE[@5:EA(
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M;45*Y:P?%=5FZMP\?5)59RA!O^[C!;DD;/#-G50
M
M                                           #_]2_P
M
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MFEKOF:M89E3XLNT[P5]J\FI>2Q]ZP6._LW&5Q)KTLJ5-26%1%PL2'+H@
M
M
M  /_U;_
M
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ML>3O+BQTA;\,KE+MKRK'^^NZJ3JRQV8QAA&C2Q2?94X8^5B;9#/G7P
M
M
M/__6O\
M
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M-NU+1^E<LT5IVVTYE2]JMXX.37E5)O;.I/Z:<L6^A+"*\E)+8D:@;,
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M-)27.G5-'#T]/*Z<UUXPJWN#Z,.*C;M[\:M3#[%,LCCLI9R
M
M                                                       '_]>_
MP
M
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M*7"N;7/#-^8$YY1E*E9Y2G]CQPJ5\'LE7:>'#TQI1;BGMDYR47&$L27.#
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MC1H4(1ITZ<(J,(4X1480A%8*,8Q244MB221[(?L]0
M
M                                                 ?_0O\
M
M
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MT_"GK35E+"^FL;:A-?Y>+7V2HGNKR7I8O[%%[?;'A3LS"%9*H
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MZD'A;0:WTZ$G/>I5Y0DX$,)F:C-2C-2E&9F9F9F9F?4S,S'-R$#;;Q9_@
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ML%QU:DL93DTL6\$E%**RJ/>;<
M
M                                   ?_]&_P
M
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M\NM*\KM+T-):0MU0MJ.V4G@ZM:HTN.M7G@G4JSP6+P2BDH0C&G&,8YI&2-X
M
M
M           __]*_P
M
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ME)MO[8>DSH
M
M                       ?_]._P
M
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MED7F>7QQ?:4HOM:<?^[16,L$M\Z?'#!<4N#' A-]@DL<&
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MVD(]6ZTU'K?,GF>HKF5:2QX(>EI4HO#R:5->3!8)8O;*>"E4E.6,G[ 8PU8
M                   V$X^<6=Z<H<G3C&F<"M<E-EYIJYR)U'U.P_&FW.BC
M?R+)Y9)BQ^B#-Q#'>I]TB,F&75?-/+Y1D6:9Y7[#+:3GAOENA'ZJ3V+Q;WT)
MG1^7'*;7W-?-?R5HC+ZEUPM*I6:X+>@GTUJ\L*<-FU0Q=2:3[.$WL+0/"[T@
M--\>7*K/-Q.5NZ]MQ#9F1$S8!GKC#Y[9DXAS'Z">GNL)+*_]7862/ R0XS%C
M.I[C[?IOE[EV4.-UF.%S<+:L5[7!_2Q?IFO72\#48LM8Y']S'1/+>5'4&M7#
M/<XAA*/%#_!6TUM3HT9K&M.+W5JZWJ,H4:4UB3#CH9-(
M
M
M#__4O\
M
M                          BEYF^C?POYENVF47&&.ZCVU8>?(<VGJ9NO
MQ^SM;!SYY2LRQQ;2ZNX-:^TWY$B,B:M)=B)K9>)=WY<=XKF1RYC"QMKG\H9?
M#!>];IRJ1C%=%&IBJM'!>EC&3I)[73D<?USR0T+KB4[NO0]Y7LL7[XM\(2D^
MNK#!TZN+WMQ51K8IHJU<J_0 YNZ!=M+S5M76<G=?Q#=>8LM:MK@["9@HZ]BK
M75UHXJ6X^KV$Q1R;,_$C,R\2*<NA.]CRRU9&%MGE2627<L$XW/E6[E]+<Q7
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M
M
M                  ?_U;_
M
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M6HW3MJC\2ACX#57)N"_,C$%N)NN,>Z^QGKYLFGU]D.306R+VJ588TS+8)/\
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M$1%["(;,=T226"/] _H
M
M                                        '__6O\
M
M
M
M
M
M                   /_]>_P
M
M
M
M
M                                                          __
MT+_
M
M
M
M
M                                    #__1O\
M
M
M
M
M
M               /_]*_P
M
M
M
M
M                                                      __T[_
M
M
M
M
M
M                                #__4O\
M
M
M
M
M
M           /_]6_P
M
M
M
M
M                                                  __UK_
M
M
M
M
M
M                            #__7O\
M
M
M
M
M
M       /_]"_P
M
M
M
M
M                                              __T;_
M
M
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M:POLNK0KT*BQA4IRC.$EUQE%M->)GTP\1Z@
M
M                        #T63Y3C.$X_;99F614>)8M00W;&\R3);:!14
M--7L>+TZUM[1QJ/'93U+N<=<2DOE,>JRL;W,[NG89=1G<5ZK484Z<)3J3D]T
M8PBG*3?4DV>>[N[2PMIWE]5A1HTUQ3G.2A"*6]RE)I)>%M(@MY'?$0\(=.3Y
M^/:LB9QR/R*"XXPN;A$.-C6O2D,_-<9/-<I\MY]/=T)$BMJI;"RZJ2Z9=O=*
M'1W="YFZBI0N\]E1R:C))\-9NI<8/<^QI8J/AC4JTYK<X[\(^ZG[R^@<CJ2M
MLHC5S2K'9C22A1Q71VM3!OP.%.<7O3ZXQ,I^*$W'+E.*PKBEK.AA'W>2QE.P
MLIRZ4DNOS#<E5,*D0KH7M(F2Z_J#MMCW(-.TZ:699]<U9=+I6]*DO,4YUG]$
MY1=][/.YS;L,GH4X]"J5JE1^?&-)?0/(Q+XH7;$26V>=<3M=WT'N03S>);'R
M7$I9)Z_/4V]<5]V@SZ>Q)H_R_*7XO^Y!D%2F_P EY_<4I=':V].JO-4*E%_1
M/U9][/.837Y0R:C4CT]G7G3?GRA57T"4OC9\0?P6W?/@8[L63E_&_*)SC4=M
MS9D*)/P)Z4[]*VUG^-K?:C-EX]\FXB0&4_*OQ'#=9]TCFAIFE.\R>-+.:$$V
M_>S<:Z2ZZ%11<GU1HSJR?4=<TMWDN7V?U(VN9NIE=:6SV])T6_NT&U%=<JD:
M<?"3AT=Y29-3UF0XW<5>04%U"CV5/>4=A$MJ>VKI;9/19]99P%N,OLNH,E-N
MM+4E1&1D9D(QW-K<V5Q.TO*<J-6FW&<)Q<9PDMCC*,DG%I[&FDT=]M[BA=T(
M7-K.-2G42E&<&I1E%[4XR3::?0T\&>T'P/L
M                                        ?__2O\
M
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MB-:Y+K[(*>?Y++R9>34IRPXZ-1).5.:72L4T]THM26QFU(T4V\
M
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MJ=I;UUBNB4)+9*G..WAG![)+S4W%IO.0U@V
M                                       /_]._P
M
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M*HM[6'10%0)9D
M                                                           !
M0F]?3FY9\C.5]GH7%KE;FGN,MA-Q)J%$D&<#(-MD@H^PLBFMH,DN.5SQ'012
M<)7E>[2G&C(ICA':KW4N6='1^@X:JOJ>&8YW&-5MKRJ=KOMZ:ZE47M\L,.+C
M@I8]G$KN[Q>O:NI]8ST[:5,;+*FZ>">R=QNK3?6X/VF./I>&;7IV0."4Y'@
M       )Y_0-YRV7'#E-7: RVX6C37)BU@8NJ)+D**#C.W74>Y8%DD)M9FEM
M5F[V4,TD$GS?/B.NJ-,)!"*_>LY84=8Z&GJS+Z?_ -QR6,JN*7E5+1;:].77
MV:QKPQQX>&I&*QJ,D1W=>8%72^KHZ<O)_P"!S62IX-[(7.ZC-=7:/"C+##'B
M@V_(1?5%598@
M               '_]2_P
M
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MG.:SXJE6WIJI)[Y5*:[*I+S9PD_--S!S@WD
M
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M-=,V
M     !__U;_
M
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M&SXO'[RM_P"3 LM[O+F^4F5\6Y2NL/%[[K_RXDP CT=K
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ME=5XWE6FIRC"+4(TJ$E'"$8K8YR>[';O)G1' [F
M                 $??JL3),#TYN8;\0UDZO2F30U^6HTJ]VL?*KYI&9?K?
M)=<[B^4NI'[1UKD13A5YPZ=C4W*\IOS8XR7T4CF_."<Z?+'.Y0W^]:B\R6"?
MT&SFCBZ(JO            Z6_I2N2G?3EX>JF=3>+2N-MHZ]?W*RIUJ#[?\
M[!+?04N\^%"/.'42I[O?E3SW@Y?VL2T_D^YOECDCGO\ >L/.VX?0P)!1R4Z2
M
M !__UK_
M
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MM9<=*M"-2$ENE&<5*+7C33*?+FWK6=S4M+B/#4I2E"2?1*+<9+S&FCTX]!\
M         #I>^E?K"7I_T\>)6$SXYQ)YZDJ<SGQ%-FT[$G;/FR-FS(LEI7BE
MYMRX4AY)^)+)77Q%+?/3.Z>H>;N?YG2?%#WU.C%[TXVT8VR:?4U237@P+4>4
M64SR3EIDUA47#+WO&JUU.NY5VGX4ZF#\.)O^.3G1P
M                              ",GUE/T9?+7[!L?_"%3#M?=S^>O(/N
M]3\7K'*>>'S4YS]RA[M3.;R+D2KT        +UGPU7X@>=?G0["_!SAXJZ[Y
M_P Z]K^K+?\ &+LL%[K/S<W'P^M[A;%A 1())@
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M+<M&93/(M(Y9DU183M;6A3E]7"E%3\^2;-A1J)LH
M                                         '__U[_
M
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MLPA"G!4Z:48Q222V));$DNA(\@?@_0
M                   !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ?B]8Y3SP
M^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^=>U_5EO^
M,798+W6?FYN/A];W"V+" B023
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MMM3AAAOX..2]*SHWBG8L[
M                        #__0O\
M
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M-O;V<,7B]CJ3;D\$H1C*R.$'8
M                 (R?64_1E\M?L&Q_\(5,.U]W/YZ\@^[U/Q>L<IYX?-3G
M/W*'NU,YO(N1*O0        O6?#5?B!YU^=#L+\'.'BKKOG_ #KVOZLM_P 8
MNRP7NL_-S<?#ZWN%L6$!$@DF
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MVG(Y7;M5;JLU.YK88=I4PP2CCM5.FFXTXOPR:4IR)!1R4Z2
M                                                  '_T;_
M
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MJ*>TW.'.#>0
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M6PVB&CFV@
M             '__TK_
M
M              *VWQ.'XGFBOSE:S\%V2B9?<G^</-/U=+\9MR+O>M^1.7_#
MH^X5RD8+,2!(        =4GB_P#BT\>/N&:D^T&O%%>M_EIF_P -NO=ZA;QI
M/Y*Y9\$M_<8&<QJYL
M                           !&3ZRGZ,OEK]@V/\ X0J8=K[N?SUY!]WJ
M?B]8Y3SP^:G.?N4/=J9S>1<B5>@       !>L^&J_$#SK\Z'87X.</%77?/^
M=>U_5EO^,798+W6?FYN/A];W"V+" B023
M
M                               #_]._P
M
M                               "MM\3A^)YHK\Y6L_!=DHF7W)_G#S3
M]72_&;<B[WK?D3E_PZ/N%<I&"S$@2        '5)XO\ XM/'C[AFI/M!KQ17
MK?Y:9O\ #;KW>H6\:3^2N6?!+?W&!G,:N;
M                                             1D^LI^C+Y:_8-C_
M .$*F':^[G\]>0?=ZGXO6.4\\/FISG[E#W:F<WD7(E7H        7K/AJOQ
M\Z_.AV%^#G#Q5UWS_G7M?U9;_C%V6"]UGYN;CX?6]PMBP@(D$DP
M
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M=I'M=OW5N-#?OPJMKJ(9-P?$_P"?S')430?%_$,?80;B(=[MW,+G+GY*3/\
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M-:%.SPFDU_B5N:Q7J"/]3O+<LJ525*4[G&+:?M'2GAZ\\7_$4>G)_P 6W/\
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M:IG WWE>5J6/;W#_ /EYGC?XA_TWO^\NW/O56G^W'[_A#YR?:+3XU'ZT_/\
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MW^FMOC5,?Q*<K?M]?XO,?XA;TU_^^VT/O3Y&'\(W.;_36WQJF/XE.5OV^O\
M%YC_ !"WIK_]]MH?>GR,/X1N<W^FMOC5,?Q*<K?M]?XO,?XA;TU_^^VT/O3Y
M&'\(W.;_ $UM\:IC^)3E;]OK_%YC_$+>FO\ ]]MH?>GR,/X1N<W^FMOC5,?Q
M*<K?M]?XO,?XA;TU_P#OMM#[T^1A_"-SF_TUM\:IC^)3E;]OK_%YFRW%/U9^
M&',O:1Z;TKF>3R<]7CEME$*KRK#;;%F;2OHW&4V<>KF6'S'I3;;WO'NZ3[S9
M;><(NUI732]><@^9'+G(_P!H]2VU*-HJD*3E2K1JN,IX\+DH[5%M</%NXG%;
MY(VG1_.30NN,W_(>15ZCN."511J4I4U)0PXE%O8Y)/BX=_"I/<F25#C!U,
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M<@             __]6_P *-/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0
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M&,H22E&2?2I)II]*951<4*UK7G:W,7"I3DXRBU@XRB\)1:Z&FFFNL]8/N?$
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ME<Y.95;F+J>56VDUEUIQ4[6#Q6*Q\JM)>OJM)X/;&"A%[4VXKQW0Y"
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M09%EFF<FM\BR>FJ5M;04(1Z>MRD^F<Y-RG+?*3;>\RL,"9@
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MX(LU$P^Y3\YN8_JNK^-V9&/O6?("Q_6%/\6NBCJ+.2 8
M  9GXX?C#Z&^[/J[[>((UO6/R0S7X'<^XS,[ICY2Y=\)H>ZP.JJ*)RWL
M \.P_<$[]YR?VE0^E'[-#QKT3\5/L<O$_0.2>+^"FH        .IOQ'=\_BE
MQC>[>WSN/6EW>WKU[?,UO6K[>OR].HHQY@1X=>9W'JO[Q?\ U%0MST9+BT?E
M,NNSM7_Z$#84:B;*?%;$V1@.H\-O=A[/S''<"P?&H:IU[E.56L2FIJZ.1]J/
M.F3%)2;CBS2VRRCJXZXI+;:5+4E)Y/)\FS;4&8TLHR2WJ7=U6?#"E2BYSD_
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M#B=G'*'EK:\N--1M:BC/,+GAG=5%MQGAY-*+^UTDVEZZ3G/9Q8*3D<3.K@
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MTL=W:32V.K-;9/:HK"$6TL91ICM!RL
M #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<V
M   Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
M  M,?"\_UM\L_N=:T^V:R$&>_!^8,@^$7/N=,ESW3/SSG/W&A[.9<D%=)-\
M     "LQZY_JR2]&UMMPXXX9*J'N#(JI#>Y,_II1HFZOQBYA$\QA^/S&#[F;
M^TC.I=D2D*)<"&M!M=)4EMV)-7NO\A*>IZU/F+K*CQ9=1EC9T)KR;FK!X.M4
M3]-0I2348O95J)\7M<'&I%3O \XYZ?I3T1I>KPWM6/\ B:T7MH4Y+%4X-;JU
M2+Q<M].#6'ER3A2J,S,^I^)GXF9^TS%DY!(
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MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M2S?-7H/**G^%LY)W+B]E6X6ZF\-\:'2NFMCBL:<65FQ-0BJ
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M5>WEW=9A=U;Z]J2JUJTI3G.3QE*<FW*4GTMMML]"/4>8
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M6VWM;;VMO:V620A"E!4Z:48Q2226"26Q));$DMB2/)'X/T
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ML(QBEL22222V);"K"K5JUZLJ]>3G.;<I2;Q<I-XMMO:VWM;>]GA#ZGS
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M[3GYUF(_@BS43#[E/SFYC^JZOXW9D8^]9\@+']84_P 6NBCJ+.2 8
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MS#YC?9=ICZS9&*\N_%^=-._<KSV=N39[I7YOSS[I:^QKEK$00)?@
M &A_J3\0J_FUQ"VAI=$6*O.&X'\M=26$DVV_J7M#%6'9>-D4IWYK+5@E<BFE
MO&1]D:8\HB[B29=3Y,\P:O+3F#8ZD<FK5R[&ZBO56U5I5-BWNFU&M!=,Z<5N
MQ.><TM%4]>Z+N\B27OA+M;>3]37IIN&U[E/%TI/HA.3WG,_LJZPI[&?46T*5
M6VE7-E5UE73F'(LV!807U1ID*9&>(EMNM.)4VXVLB-*B,C(C(72T:U*XHPN+
M>2G3J)2C*+3C*,EBI)K8TTTTUL:*KJM*I0JRHUHN$X-QE%K!IIX--/:FGL:Z
M&>&/H?,        )A?0_Y=?V6.<6%U606?N.LM_HCZ;S@GWO+@0;.]GH7KW)
M7R69-I.'<^1&=D.*)+,.7,69].HCQWF^7_[=<L;FO:0XKW*<;RC@O*E&$7[X
MIKI?'1XI**VRJ4Z:.V<@]:?LCK^A1N9\-IF6%M5Q>Q2FUV,WT>35PBV_2PG-
MG0W%1198 !29]?WU)OZ:=@/\,-.W_G:HU3>D]M^[JY76)GNTZETT)Q<G63Z/
M5N-NDI#B3/L=L_,4:#]QC.JLM[I_)G]F\I7,C45+"_OX86D)+;0M9K[+@]U2
MX6U/?&A@L?;9Q4#>\=S1_+N9/0N25,;.SGC<RB]E:XC_ '>S?"@]CZ'5Q>'M
M<).M2)GD60        V,XH<8=E\PM[X-H354#S\AS"P+ZHW$AEURGP[%X1D[
MD699"ZU_JX5?',W%EU)3KAMQV24^\TA6GZ]UODO+S2UUJO/984;>/DP37'6J
MO93HTT]\ZDMBZ(K&<L(QDUL^CM)YKK;4-OIW)XXU:[\J33X:=->GJSZHP6WK
MD\(QQE))]*_BYQJUIQ&T;@FA=45ON>+X56)8?L)#;16^4Y!*_P!XR#+\A?:(
MB=G6,DUOO&7S&R-++*4,---HI@UQK/.N8&I[K56?3XJ]S+%16/!2IK93I4T]
MT*<<(KI>V4FY2DW:;I+2V5:,T_;Z=R>/#1H1P<GZ:I-[9U)OIG.6+?0MD8X1
M22V!&I&R                  !__]*_P *-/Q,_X^&IOS1\#_#'GHL^[E7S
M67_ZUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,           !N1Q3X!<L>:-FJ-H
M+4EWD=#%EE#N-@6ZF<9US1O%T4\U/S&Z-J*X^VDR6N##4_+-)D:6%=2'.M=\
MV-!<MZ''JO,(4:LEC"A#&I<370XT88R47N4Y\-/'?-&\:/Y<ZQUU5X-.64ZM
M-/"5:6$*,'TXU981;6_@CQ3PW198#TQ\+_;OQ(D_D)RB@5LU24'-Q;3N%OV[
M#9GXK)C.<S>AF9E]+T/'^GR]?D.)NI.^[;PJ2I:1R.4X]%6[K*#\VA14_=R1
M^1]TVM*"J:ES90ETT[:DY+S*M5Q]Q-UZCX:;@;!C)19[#Y/7<HTI\V0]G6N(
M+7>1=%''C0,20:$G[22MQ9E_G&.:7'?0YJ59XT+/+:4>A*A<2?FN5T\?,2\1
MOE#NL<O*<,*MS?U'TMU:*\Y*W6'FM^,]'E/PS/"NQCN'B>W^2>,3U),FEV.0
M:WR:K;5T^:I<#^34*0KQ\3+WTNOR=/:/58]]3F31FO?^7Y=7AT\-.XIR_K>^
M9Q_L'GN^ZKH2K%^\[V^I2^FG0G'SNPB_[1'7O;X93?>+1)EKQ\WQ@.VVV$N/
MMXQG5'8:MR1Y!$9H@UMA&D759)?]A$Y+D0&S\3,T="(^OZ6[ZVE+ZI&AJ[*J
M^7M['5H3C<TU]-*+C1J1CX(QJR\9S+4/=3U%:0E6TWF-&]2V]G5A*WF_!&2=
M6$GX9.FO$0!;\XQ[_P"+F6_R)W_JC,-7Y YYQP$9%7=*F\9CJ)#\O&<D@J>K
M;2.A1DE4BNEO-DKYIJZ^ EAI36VD]<6'Y3TG?TKZBL.+LY>7!O<JE.6%2E)[
MU&I"+PVX8$<M1Z4U'I*\]X:CLZEI4VX<<?)FEO=.:QA47AA*2\)@H;2:\
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M%K%2C)8IIK:FG@UN.!5:56A5E0KQ<)P;4HR34HM;&FGM33V-/:CP1]3Y@
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MW0YCSAU:]&<O[_-*$N&XJQ["@T\&JM;&*E'PTX\=5?4'-<]HN;*M0
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M:OQ'M.?G68C^"+-1,/N4_.;F/ZKJ_C=F1C[UGR L?UA3_%KHHZBSD@&
M             &9^.'XP^AONSZN^WB"-;UC\D,U^!W/N,S.Z8^4N7?":'NL#
MJJBB<M[     /#L/W!._><G]I4/I1^S0\:]$_%3['+Q/T#DGB_@IJ
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MLY3J3D^F4Y-R;\;)NV5C99;:0L<NI0H4*2X84Z<5"$4NB,8I)+Q(^E'B/4
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MR:N^75VLURIRKY37EA&;VSH3>U4JK6]/^[J8+BP<9)22<H5Q),X2
M  6Z?A:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_P!CS_QV7H79;3$!29(
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M*49)IIIK%--;&FMJ:V-%6%2G.E4E2JIQE%M--8--;&FGM33V-'C#]GX
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M&Y69\F>6-MR[TW&5U!/,[R,9W,]C<>F-"+]93Q\K#T]3BEBUP*,L8X(=B
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MX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M6RZ&TK:Z+TI9:;MDO\/32G)>KJR\JK/K\JHY-8[HX1W)&T T@VP
M  "J5\3=QNC3L0T+RPI:Y!6>/W,W2.>366B4_*I+QB3EV /RE)+JEJ%+CW3'
M>KJ1KG-HZD?:1SP[E&LITLQS705S/R*T%>T$WL4X.-*NEX9QE1EAU4I/K(?=
MZW2\*EEEVL:$?+IR=K6:WN,U*I1;\$91JK'KJ)%/@6&$*         MT_"T_
MN'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?^.R]"[+:8@*3)       C)]9
M3]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
M "_C\/!^C>QK[KFU?KHP*HN]Y\\E?X):^QD6,]VCYKZ7PBX]DB<L1@._@
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M?(#^H;=OW(]D?:;-&P:3^5.6?"[?W:!AM1_)Z_\ @]?W*1RGQ>X5
M !<+^%R_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M            "/3U0N'47FYP\V3JB##8>V+1QRV'IZ6X2$N1MDXG$>>JZY#[
MG@VBWC.2Z5]:NI(1+-WH:FT].N<D.8E3EGS$LL^JR:LZK][W:Z[>JTI2PZ72
MDH5HKI=/AW-G->;6B(:]T3=9/3BG=4UVUL^JO33<8X]"J1<J3?0IX[TCFJRH
MLF#)D0IL=^',AOO19<24RY'DQ9,=PVGX\AATB6AQ"R-*T*(C(R,C(C(7/0G"
MK!5*;4HR2::>*:>U--;&FMJ:WE6<X3IS=.HG&46TTU@TUO370UTH_ ?H_(
M              &7M":,V-R4V]@FD-3TB[[.]A7D>EIXO[(B'#;-)R+*[N)3
M:5^[P*^*AZ;.DFDR:8:<7T/IT/7M5:HR?1FGKK4V?U>RM;2#G-]+Z(P@MG%.
MI)J$(^JE)(S>G=/YIJG.K?(,FI]I<7,U&*Z%TRG)]$(13E.71%-G2HX1\/\
M7/![CUAVB==M-RU537U7S?+G(J(UGGV?63#99%EMFE)J-/FJ;0Q#84XOW>(U
M'C$M9-=QTQ\S.86<<SM77&J<W?#VCX*-+'&-"A%OLZ4?$FY3E@N.I*<\%Q8*
MTO06BLKT#IJAI[+%Q<'E5:F&$JU:27'4EX\$HK%\,%&.+PQ-MAH!N0
M                 ?_6O\ "C3\3/^/AJ;\T? _PQYZ+/NY5\UE_^M:_XI8D
M .]7\X=G^KJ/XS=E=D2^(S        !U2^,NLF-+\<]$:DCQ2AEK?4.N\,?9
M(NBCG8]BD6MLGWO NKKLAMUUU1EU4M2E'XF**M:YW+4FL,US^<N+WY=W%9/Z
M6I5E**7@46DET))%O.E,JCD6F,OR:*X?>MM1I->&%.,9-^%R3;\+,XC6#/@
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MD4Y5JLZ]:5>H\93;DWUMO%_1/ 'U/F
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MEFLPUAE.7R6*KWEK3?\ 3KPC_*8+5-R[+3.8WD=CHVMQ/^K2G+^0Y5HO7*A
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M_F'S&^R[3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_
M       *"WKY\,/[-?+V5MW$JCW+5?)TK3/8!Q6>R!3[.BOMELZB+L+H@Y,A
M]B\;ZF1'[\ZVV7;'/I:UW4N8_P"V?+V.G[^IQ7V2<-"6+\J=LT_>T_#PQC*B
M_N47+;-%=/>*T-^RVM7G5G#AL\VXJRP6R-=-=O#^E)JJONC2V1(+!*(CZ
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M\SMYU4O,57!>#!%;?>-LHVG-6]JQ6'OBE;U/-[&--^?V?GD+PD@<+
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M:C[(^![5E)3W%VDJ9D-.RI1)^0S)@NI_+T+Z L3[C\$LDU!5Z77M5YU.L_\
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M)]93]&7RU^P;'_PA4P[7W<_GKR#[O4_%ZQRGGA\U.<_<H>[4SF\BY$J]
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M/_#0DME:O%_9,'OIT7NZ)5<%CA3G%W9Q6D3R
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M/Q,_X^&IOS1\#_#'GHL^[E7S67_ZUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
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MV>6>82>"H5Z-1OZBI&7\ACLXM7>Y3=645BZU&I#^O"4?Y3E "^<IX
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MM9K#M+J5=>%7,8W"?_J^>6E<F<QCFG*_);B+QX+=47XZ$I4,/_3)&1QXZ<
M           %$[XD;:+&9<[<8U_!E>;'T_H_$*2TBDHE>ZY1EUO8YQ-49$?S
M3<JYM,?0RZ^!'[#(6C]S;(YY=RMKYM5C@\QO:LXOKI4H4Z*\ZK"L5\]Z+-HW
MW,*EEM-XJRM:<)+JJ5)3JOSZ<J17T$M2-H        =4GB_^+3QX^X9J3[0:
M\45ZW^6F;_#;KW>H6\:3^2N6?!+?W&!G,:N;      <F3+_YV91]D5W]<G1?
MAE_^0H?<X>Q13C>_YRM]7+V3/GA[#R@      6F/A>?ZV^6?W.M:?;-9"#/?
M@_,&0?"+GW.F2Y[IGYYSG[C0]G,N2"NDF^ !BK>V*N9UH_<F$LH-Q[,=5;#Q
M5ILD]QN.9#B,RH0@D_+U-XBZ#/:6OEE>I\NS.6Q6]U;U7_Y=6$_Y##ZALWF&
M07UA':Z]O6I_UZ<H_P IRF!>\4_@       !9!^&9SZ/1\P-R:^E/I93GVA)
MMG 2I73WJWPG-JIYJ(VGY5^YV$Y[]1+2A#?OJ95.ZY>Y=FU-8^]+Z,9>"%:C
M56/BXZ<(^.2)0]U7,8V^M;[+9O#WS:.2\,J56F\/'PSF_$F7>Q663W
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M\+E_,/F-]EVF/K-D8KR[\7YTT[]RO/9VY-GNE?F_//NEK[&N6L1! E^
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MPG<3PG<U4MM6LUMPQV]G#TM-;,(KB:XI2;WT'*SH@
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M8P&;,2      !)KZ..MU[0]2GBK3G&-^+CF=3=D37#0:FH:-8XS.SN#)>/\
M6D<V!%:0?_M%H+Y1Q3O%9RLCY,9[<<6$JU"-O'K?OFI"A)+^A.3?@3.K<D<K
M>;<TLGH88JE5==^#L*<ZR;_I0BEX6CI#BFXM"  Y6?)O7R]3<C]^ZO6PJ.6O
M-S[.PMII23011L:S2;41%MD?M0MII"VU%X*29&74C(7JZ)S99_HW*<\3Q]^6
M=M6;\-2C";\U-M/J94/JO+7DVJ,QREK#WM=5Z6'@A5E%>8TDUX#!XV<U\
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M5*4)23\*DVGU--%0VJ\K>2:GS')VN'WK<UZ27@A4E%8>!I)KP&#QLY@
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M%1<6 D,         MT_"T_N'G#^^^.'[3G8K][\OV73'BS#T;$F?W1_L>?\
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MQ/-WWQ.KR]TW5\B+PO:L7Z:2_P#AHM>IB_LS6^7M6Y5%*J")YD/
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M$S_CX:F_-'P/\,>>BS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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MI/\ H3[2FO,H5:2\PK6[PV2/)N:-[52PA>PI7,/Z<.";\VK3J/S2'$2*.(
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MBG8GI7SU1,ILI:4&9MJOUH71Q4+3T=CG8J2I*V$]9;=TSE;5U9K%:WS.G_\
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M^7:T4][MZLL9)?<ZS;;Z%5@EN++XA:2I
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M\39QW=O]6Z&Y/TL#S).O,DMM49O)8;[WOY.9NT5YB,V8OI\V/"L8,R,D^O\
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MJJ^EJ1*K>;&EY:1Y@9EE$8\-%U76H]78UO;()>"'$Z;\,&:##JQSD
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ME@E6;J74>;:LSNOG^=U.TN+B6,GNC%;HP@MO#"$<(Q70EM;>+>%QLA@@
M     #JD\7_Q:>/'W#-2?:#7BBO6_P M,W^&W7N]0MXTG\E<L^"6_N,#.8U<
MV      Y,F7_ ,[,H^R*[^N3HOPR_P#R%#[G#V**<;W_ #E;ZN7LF?/#V'E
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MO*S[5NP<+2R1=3=5E.)2Z,FR+_2\_H,YI?,EDVI<NSAO#WI<T*V/5V56$_\
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M'.<XS'4&:5\YS>JZUS<S<YS?2WT);E%+",8K!1BE%)))&.QES&
M       ;L>G?RNG\+^7>HMZ)>E?R5J[LL<V97Q26XJVUEE72HS!CW5O_ %[L
M5A:;*&T?0CEQ8YF9=.HYIS>T'2YD<OLPTNTNWJ0[2VD_4W-+RZ+Q]2I279S?
MVN<S?.6>L*FA=:66H,7V,)\%=+U5"IY-18=+BGQQ7KX1.FK56E;>5E;=4TZ+
M:5%Q AVE59P7VY,*QK;".F7!G0Y+1FAQIYI:7&UI,R4DR,CZ&*4Z]"M:UYVU
MS%PJ4Y.,HR6$HRB\)1:>U----/<RUBC6I7%*->A)3A-*49)XJ46L4TUO33Q3
MZCSQ\CZ                           ?_U;_  HT_$S_CX:F_-'P/\,>>
MBS[N5?-9?_K6O^*6) #O5_.'9_JZC^,W979$OB,P           $MW!3UE^6
M7"&)5X/&L8FZ-(5ZD-,:HV)-FJ_D]")75R/KW,6"<F4Q'TZ(BJ;E0$&:UI@^
M8M2QP#FEW<M!<S:D\SG!Y;F<]KNK>*]LEUW%%X0K>&6,*KV)U>%)'9N7W/'6
M.@80R^,E?6$=UO6;\A=5&JL94O!'"=-;7V>+Q+-NA_B(. VTH4)C9\W/N/.2
MN(;;F0\UQ6RRW&/?%D1FW5Y5KUJQ6M@C/H4BPKH/L,U(270SA3JKNA\ULCJ2
MEDD:&;T5N=&K&E4P^FI7#II2^EIU*O@;9*S3W>7Y=9O3C'-I5LLJO>JM.52G
MC]+4HJ;:\,X4_"D2$8]ZDWI^Y/%1,K>9W&F,TX@EI1D.X<(Q&423^1<'*YD)
M])_Z*FR/]0<CN^3/-FRFZ=;3>8R:^UVE:JOZU*$XOSSI5MS2Y;W<..EGMBE]
M/<TJ;\ZI*+^@?Y?^I/Z?N-1UR;'F=QJDMH3W*30;APC*Y!ETZ]$1,6F3'5'X
M>Q*#/Y.G4+3DSS9O9J%'3>8IO[9:5J2\^K""^B?RYYI<M[6/'5SVQ:^DN:51
M^=3E)_0-&]R?$%^G5K&++1A^8YYO.Z82M#=7K3 ;F##.41=&T/Y!L4J.(;/7
MH:WHBY/1/4TI6HNT=/T[W2N<&=SB\PMJ&5TGZJYKPD\/!3M^WGCU1FH;=[2V
MF@9YWD>664PDK*O6S"HO4T*,DL?#.MV4<.MQ<O GN(!>8'Q#7*[?,&UP[0U1
M7\8<%L$/1'K7';1W)=N6$-PC;6G^7DAB*S5]Z>BTG45[$IE1F29RR\3E?R][
MHN@]*U:>8ZJJ2SNZA@U"I%4[2+^X*4G5PW>VU)0DMKI(CGK7O*ZPU%3G8Z=A
M'*;>6*<H2X[EK[LU%4\=_M<(SB]U1D UA83[:?-M+6=,L[.RER)]C8V$EZ;/
MGSI;QR)<V;,DJ4XZZZXI2W''%&I2C,S,S,S$KZ5&E;THT*$5"$$HQC%)1C%+
M!))8))+8DMB6XCE4J5*U25:M)SG-MRDVVVV\6VWM;;VMO:V>(/H?@
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M;[+M,?6;(Q 'OQ?G33OW*\]G;DS>Z5^;\\^Z6OL:Y:Q$$"7X   <D,7^%,X
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MUK_BEB0 [U?SAV?ZNH_C-V5V1+XC,
M  %X[X>K@B_HG15IRKV)2JA;-Y$5D1G"(LYCRYV-Z28D(L:I\B61*;7DDI#5
MHM/B2H;%:LC2I3B16)WN.:4-4ZIAH3)ZO%991)NLXOR:EZTXR7A5O%NDNJI*
MLGBDF3][M?+V6GM/3UAF=/AN\SBE236V%JFI1?@=>251]<(TGO;18N$/B38
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MU/=:<S!-NC+VN>&"JTI;:=1='E1PQ2QX9*4'MBS5X;P:D
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MGYS&^Q'3/UYR(01[\7YJT[]UO/86Y+_NE?G'._N=M[*L7#!7B39
M      ,1\@/ZAMV_<CV1]ILT;!I/Y4Y9\+M_=H&&U'\GK_X/7]RD<I\7N%0
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M=G->MS#SOWCELG'*;.35&.U=M/:G<37A6*I)[80>Y2G-$-8D8<.
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M?_K6O^*6) #O5_.'9_JZC^,W979$OB,P
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M9)E6&MM'YKH74=?3N;1\ND\832PC5I-O@JP^EDEM6+X9*4'Y46:Q#=C4P
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M3'UFR,5Y=^+\Z:=^Y7GL[<FSW2OS?GGW2U]C7+6(@@2_   #DAB_PIG
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MXI8D .]7\X=G^KJ/XS=E=D2^(S                              &\7
MC@;M_GYNB#K+7,5RHQ2I7#LMH[.G0GI&.:ZQ=YXTJERC2:$R;&42'&JJK0XE
MR2ZE1FIJ,S)DL<QYJ\U-/<J--RSO.)*I7J8QMK:,DJEQ52W+?PTXXIU:K34(
MM;)3E"$M_P"77+S.^8V>QRK*UP4882KUVFX4:;>][N*<L&J=--.;ZHQG*/1E
MXV\<]5\4=-X=HW3E BBPS#H!,H6YY;MOD%N^1.7&4Y+/;2CWJQGO=7I+YI2G
MJ9-M(;9;::13SK/6.>Z\U'<ZGU%5[6YN)8[,5"G!>DI4XXOAITULC':^F3<G
M*3LYTMIC*-'Y'0T_DE/LZ%!8?33D_35)O9Q3F]LGYB2BDEG4:N;
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M316AG.39GI_,ZV39Q1E0N;>3C.$MZ?6GN<6L'&2;C*+4HMIIF.AF#&
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M3K'U7I3.M%YW5R'/J3IUJ3V/:X5(/'AJ4Y8+BA+#8]Z>,9)2C**U_&V&M@
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M^?G,;[$=,_7G(A!'OQ?FK3OW6\]A;DO^Z5^<<[^YVWLJQ<,%>)-D
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M/.6V;.A>)UK*JW[WN4O)FM_#/UE6*]-!O;@Y0<H[2.<=A.8@
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M+<91:VIIM-;B$-Q;W%I7G:W=.5*K3;C*$XN,HR3P<91:333V--8H]2/0?$
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M=I#/-$9W4R+/J79U8;8R6+A5ACY-2G+!<4)8;]C3QC)1DG%:YC<#6
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M3J)V3\DN5U/E[I[WUF,$\TO5&5>6Q]E'?&WB^J.^HULE4QVRC"#4Q CN=M
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MS@^.4N(89CU+B>*8Y7QZF@QO'*R'345+5Q$>7%KZNJKT-L,,MI+HEMM!)+Z
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MO.36MM!3G7O+=W5E'=<T$YTTNNI'#CHO=CQI0QV1G+>1BCMAR<
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M:?W#SA_??'#]ISL5^]^7[+ICQ9AZ-B3/[H_V//\ QV7H79;3$!29(
M    &J?+OA=H#F[K1[6>^,01<Q8YR).*Y;5+9K<YP*WD-DVJXP_(C;<5'6KM
M1Y\9U#L622$HDL/(222WSE]S(U9RSSI9UI6X[.3P56E+&5"O!>HK4\4I+:^&
M2<9PQ;A.+;9I^M-"Z<U[E3RK4-#C2Q=.I'R:M&3]53G@\'NQBTX2P2G&212B
MYP^A=RXXJ3+?*=:4L_DEIB.M^5'RK7M/(D9UC]>DS6E&::WBJ?FH-I!*4[-J
M_>XI(3YKRXW=Y2;*N6/>AY?Z[IT['.JL<FS)X)TKB:5"I+_LW#X8/%[H5>SJ
M8OABIX<3@AK[N_:STA.=WE5-YI8K%JI1BW5A'_NT%C)8+?*GQPP6,G#'!0GN
MM.L.N,/MN,O,N+:>9=0IMUIUM1H<;<;61&E23(R,C+J1^!B2L91E%2B\4]J:
MW-'!VG%N,E@T?P/Z?P        +A?PN7\P^8WV7:8^LV1BO+OQ?G33OW*\]G
M;DV>Z5^;\\^Z6OL:Y:Q$$"7X   <D,7^%,X        6L/A<OY^<QOL1TS]>
M<B$$>_%^:M._=;SV%N2_[I7YQSO[G;>RK%PP5XDV0              #$?(#
M^H;=OW(]D?:;-&P:3^5.6?"[?W:!AM1_)Z_^#U_<I'*?%[A4         %PO
MX7+^8?,;[+M,?6;(Q7EWXOSIIW[E>>SMR;/=*_-^>?=+7V-<M8B"!+\ #!O)
M#D1K#BKIG-MZ;?NTTN%X16+EOI:\IRUO;1X_(IL7QV$ZI'O-C82#1&BL]R4]
MRN]Q3;2''$;/HW2&=Z[U';:7T]2[6YN98+''AA%;9U:C2?#3IQQE)X-X+!)R
M:3U_5&ILITAD=QJ#.JG9T+>.+]=.3V1IP6SBG.6$8KK>+:BFUS;N;G,C:'.7
M?F4;PV7(5$;FJ.HP7#(\MV33:]P6%(6NDQ6H-PDDLT$M3\V5Y:#DRG'I"D(\
MPFT7*\L^761\L-*4-,9*N)Q\NO6:2G<5VEQU9[\,<%&$<7P048)O#%U=Z]UQ
MFW,#4=;/\U?"I>32I)XQHTDWPTX^+'&4L%QS<I8+'!:C#H!I8         !;
M!^'Y],KZKS:OGGO''_\ [UUDF0WQNQ:WB]4V%K%<5$L-ORXCY=/*B.)<BX_W
MD?<^3TY*4^1">7 OO9\Z_>]*?*O3%;RYI?E&K!^EB\'&T373-82KX;H<-)M\
M56*F)W;^5/;U(<Q,_I^1!OWE3DO326QW+3Z(O&-'Z;BJ+#AIR=OL5[DU
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M/9'IJS67Y!:4K2BO4TH*.+ZY-;9R^FDW)]+,LC &9
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MPS' _P#ZL\N/^?-.?^ @_C5YI_Z#*OO%W_[X?PJ<O/\ 69C]^MO_ &@_PS'
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M\I-.<LZUU7R&O<UG=QIQG[XG2DDJ;DX\/9T:6#?&\<>+HPPZ9)1QHZB
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MS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
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M \)ZP
M
M
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M<8U+2MC.VKX;*E/'TLFMBJT\5&I'9MPDEPSB1[CK9S4
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MI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M[<80U_5GR6S/X)<>XS,UISY0V'PBA[K$ZL(HC+?@
M
M
M
M
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M*(RWX
M
M
M
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M'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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M!_7OI3[K>M_MQA#7]6?);,_@EQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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M9\ELS^"7'N,S-:<^4-A\(H>ZQ.K"*(RWX
M
M
M
M
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MEQ[C,S6G/E#8?"*'NL3JPBB,M^
M
M
M
M
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MOX0A7HRE)VE=))5(MMMT\$DMK;V)'2K%,1:8
M
M
M
M
M                                                      '_U;_
M
M
M
M
M
M                                #__6O\
M
M
M
M
M
M           /_]>_P
M
M
M
M
M                                                  __T+_
M
M
M
M
M
M                            #__1O\
M
M
M
M
M
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ML>9&@<SO*>7Y?G%I6KUI*,(1KP<IR>Z,5CM;>Q);6]B-P!STW4
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M\<'AL,;?WFGI[?EE\=?OHXQ_MQF?W*<V_P#;F8?%JOUIBOWK<M?TY9??Z?\
M.9XTSR3T#R*8R"3HG<.O=MQ\4=K6,E>P')ZS)&Z)ZX0^Y5-6:JU:R95(3&D&
MT2^G<3:^GTIC5M1Z,U9H^5&&J<NN,O=PI.FJ].5/C4.'B<>)+'AXHXX;L5UF
MQ9%JG3FIHU9Z>O:-ZJ/"INC4C/@<L>'BX6\,>%X=>#,VC63/
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MVX?N4YM_[<S#XM5^M'[UN6OZ<LOO]/\ G']YIZ>WY9?'7[Z.,?[</W*<V_\
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MW<2ZS8,BU9IK4[JK3U]1O>PX>T[&I&?!Q\7#Q<+>'%PRPQWX/J,ZC5S8
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MWSYWLH_^:_$KDZ)HJ"+,@ *.GQ-7X\6G?S4L0_"]FPLZ[E/S8YC^M*OXI9D
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M.;%\[X<7]'C+^[_LOZS48JN[XOSO1^ 6WLZQ8?W8?FT?PRO[&D3W"*A(D
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M_K;E8KU[\?\ G]-_<[WV5J36[I/^3SWZNT]C<%KP0-)A
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M8YG_ (X?*_\ .5WK^%&U%Y/+CYO,A_5UE^+4BI'7/RVSCX==^[U#6H;F:J
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M---/!II[4T]C3VIDL83A5@JE-J49)--/%-/:FFMC36U-'DC\'Z
M     *47Q.WXTW'G[@#_ .$6V%E7<E^0V;_#U^+TB"'>O^5V6? W[M4*T FD
M16+.WPP7XP_)C[C&.?;PT(2]]SY(9+\,J>XLE?W3OE-FOP6'NJ+HPK=)T@ :
M'>J%^CPYD?<!V!]9UCJG(_YWM.?#J'LT<\YM?-IGGP.M[$YF@NH*JC_4J4A2
M5H4I*TJ)25),TJ2I)]4J2HO$C(_88-)K!G]3:>*+WWH>^J$GEKK9KCINK($N
M\C]3T315=S:22.;N#7=:E$2/D7GO'W/W56DVX]RDS-Q]!M3R-Q3DOR*L^\YR
M0>@,Y>L--4L,FOYOBA%;+2XEBW3P7I:-3;*CT0?%2V)4^*PKD%S96LLK6F,^
MJ8YI9P\F4GMN:,=BGCTU:>Q5>F2PJ;6Y\,_HB>2-       HZ?$U?CQ:=_-2
MQ#\+V;"SKN4_-CF/ZTJ_BEF0#[U?R_L?U?3_ !FZ*YPF$1C+:7PM/[OYP?O/
MCC^W9T("]^7[#ICQYAZ%D3)[H_V3/_%9>C=ENH5^DSP    #47F#SAX[\'->
M_P O]\9DBK<GIE-XA@U*AFUS_/;"(@E.P,4QPW&S<2@U-E(FR'&8D?O1[Q(:
M[T=W0.7G+'5_,_-_R3I6VXU##M:\\8T*$7NE5J8/#'!\,(J52>#X(2P>&F:V
MU]IG0&6_E'4-?@<L>SI1PE6K-=%.&*QPV8RDXPCBN*2Q6-,GFEZ]?+_DK,M\
M9T_:R.,>I7UO1HU5@%H[_27<P3,T(>R39K:&9;#BRZF;%(F$A)*\MQ4GM\Q5
MCO+;NJ\O=&4Z=[J&FL[S!8-RKQ7O:$NJG;-N$DO75G5;:XDH8X*#6NN\1K75
M,YVF23>4V3Q2C1E[?)=<Z^"DGX*79I;FY[R#^QL;"XGS+6VGS;2SL)+TRPLK
M&4_-GSI<A9N/RIDR2I3CKBU&:EK6HU&9]3,S$FZ-&C;THT+>"A""2C&*48Q2
MW))8))="6PX'5JU*U25:M)SG)MN4FVVWO;;VMOI;/#'T/F   'E09TVLF1;&
MMF2J^P@OM2H4Z#(=B3(<IA9.,28LE@TK;<0HB4A:%$9&74CZC\5:5.M3E1K1
M4X233C))II[&FGL:?2F?NG4J4IJK2DXRB\4TVFFMS36U-=9-GPN]>'F)QDFU
M..;3O)7)G4C"V(\K']CVK[NP:B 2B2XYBVSW4O3S<2DB)#%R4Y@DI\MI$?N\
MPHT<R.ZSR[UM3J7F1TEDF8/%JI;Q2H3E_P!VV34,'TRH]E+%XR<\,'WG0O>&
MUMI2<+7-ZCS6R6"<*\GVT5_VZ^V>/4JO:1PV)1WESOAOSLXZ<Z, /.-%9@F;
M/K6HI9EKZ^2Q5["P*;*3U;BY-CZ7'/V):B4F//B.O0WS2M+,A:FW$HKAYB\K
M=8<K\V_)FJ+?AA-OL;B&,K>O%;W3J8+:MG%3FHU(XIR@DTW.;0_,'3',#+?R
MAI^OQ2CAVM&>$:U%OHJ0Q>Q]$XN4)8/ADVFEN(.=F[        !__]2_P *A
M7Q2?_P >X3__ "CD#_[YAHL&[C?^5U+]78>A>$+>]O\ YC(?J;ST;8J<">Q#
MD #?WTV.<&2\"^3V)[:B*GV&O+DV\/W)BD19K+(M>VDMM4^1%BJ,D*L:MQ*+
M*M49I,W6O(4M+,AXE<HYS<LK+FIHBXR"IPPO*?MUI5?]W<13X4WO5.JL:=3?
MY,N-)RA'#HW*W7UUR[U91SF&,K:?M=S37JZ,FL6EZ^F\)PW>4N'%1E+'I.XA
MEN-9]BN-YQAMU R/$<PHJK)L9OZMXI%==4-Y!195-I!>+IW-/L.(<09D1]#\
M2(_ 4S9AE][E5_6RS,:<J-Q;SE3J4Y+"4)PDXRC)=<9)IEI-E>VN8V=+,+&H
MJM&O"-2G.+QC*$TI1DGU---'T0\9Z0   ]#E.48]A&,Y#F677$#'L5Q.DM,D
MR2^M'TQ:VEHJ2$NRMK6?)7X(9CL-N.N*/V)29CU6-C>9G>T<NR^G*M7N)QIT
MX16,ISG)1A&*Z7*322ZV>>[N[:PM:M]>S5*C1C*<YR>$8PBG*4F^A))M^ YM
M/J9<Y<AYZ\G\HVDMR?!UECOG8;I?%I:E-_4/ :V6M4:RF0R,THL;ATU65B?5
M2DK<1&)Q;,5GI<MR5Y86G*K1%#(THRO:V%:\JKU=>26,4][ITEA3I[DTG/!2
MG(JYYJ\P+GF)JRMF[;C:4L:5K3?J*,6\)-=$ZC\N>_!M0Q<81(]QUPYJ !:[
M^%O_ )V\SOL<T9]<\J$#>_'^;]-_=+WV-J3#[I/^<SWZBT]E<%P$5ZDU0 ($
M?B.OT>,3[O\ K3ZS7@E7W.OG>E\ N?9T2.W>>^;1?#*'L:I0Q%J)7@?=ZPUE
MG6YM@8GJS6= ]E6?9S;L4.*X['EUT!^WMY1&IB&U,MWH\9LU$D_G//(3]%1#
M%9WG>5Z<RFXSW.JJH6EK!SJU&I24(+>VH*4GYB;\!D<IRK,,\S*CE&54W6N;
MB2A3@G%.4GN6,FHKS6D2(_W*/J@?DH9'_P _:@_\0CD/\2G)#]/4_O%W_P"W
M.F?N(YL_H>?WZV_##^Y1]4#\E#(_^?M0?^(0_B4Y(?IZG]XN_P#VX_<1S9_0
M\_OUM^&']RCZH'Y*&1_\_:@_\0A_$IR0_3U/[Q=_^W'[B.;/Z'G]^MOPP_N4
M?5 _)0R/_G[4'_B$/XE.2'Z>I_>+O_VX_<1S9_0\_OUM^&']RCZH'Y*&1_\
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M"CZ=4MM/3,*:9-7R'WNI21^PS+Q&HT^^ERKG4X)66:1CZYT+7#QM*\;\Y-^
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M<4JLDOIHPDY1\U(U'.-+ZDT^\,]L+BSQV)UJ-2FGXG.*3\QLPN-D,$ !:9]
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M?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
M  !1T^)J_'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$PB
M,9:D^%V_K+Y>?8+J?Z_W0@KWX?S+I[[O=>YT27G=+_.N=?<K?V=4N,"NTFX
M  &!]Z\7^/7)G'G<8WUI[ ]H5BXSD6,]DU%%?O*AMTS-;F.Y1&)JSK'?$^C]
M?+9<+J?17B?7:=+ZWU=HJ[5[I7,:]C/'%JG-J$_NE)XTZB^EJ0DO :]J#2>F
MM5VSM-165&[AA@G4@G./U%185*;\,)1?A*F?J1_#ZY'J*GR#=/"B3D.Q<%JF
M9-MDND+A9V^Q,:KF4G(E3<#M64I7?1&$=W6N>;^J*$)+RW+!Q2B1/CDUWM+/
M4%Q1TWS*C3L[JHU"G>P\BWJ2>Q1KQ;PH3D_[Q/L6WM5%)8PXYH]VZZR6A4SW
M0;G=6\$Y3M9>56IQ6UNC);:T4O4-=JDMCJMO"L0I*DJ-*B-*DF:5)41DI*B/
MH9&1^PR$VTTUBB*#6&QG^ ?PNR?#^^I#8;PP9_AMN6_78;/U/CQ6.H\AM))K
MGYKJRL-$21B\J0^?5^PQWO92P?<:WJY2/F?[@^ZNM/O9<FZ.F,T7,;3E+@L;
M^IPW=.*\FC=2Q:JI+=3N,&Y=$:R>WVV,5/'NX<T*F?Y>]#YY4XKNSAQ6\Y/;
M5MXX)TVWOG1V8=,J36SVN4G98$+R4X   <TKU7?TC?,+[L^0_M3(NAY#?,[I
MWX'3]%E6'.'YSL[^%3_D(^!ULYL7SOAQ?T>,O[O^R_K-1BJ[OB_.]'X!;>SK
M%A_=A^;1_#*_L:1/<(J$B0 ,5[PW'@_'O46P]V;)LOJ7A&M,6L\JOY*/+5)>
M8KV>L:KK675))V9-?4U"@L=Q&[(=;;+Q60SNF-.YGJ[4%GIK)H=I<WM6-*FN
MA.3VRDUCA"$<9SEZF$92Z#$9_GF7Z:R6YS[-)<%O:TY5)OI:2V1BNF4GA&*Z
M9-+I.9;R\Y2;&YD[^SS?FS):SM\LL5-T="W)=D5>%8=!<4WC.%T1.="3%@L&
M2342$F^\IZ2Z1O/NJ5=7R^T-D_+K2=KI3)8^UV\?+G@E*M6EAVE:?TTY=&+X
M8J,(^3&*55&M-79GKC4=QJ/-7Y=:7D0QQC2I+['2A]+!>+BDY3?E2;-:1NAJ
MI)IZ:OID[9]0_8LF+4OOX+I+#)L5&SMLRH"I4>"MU*9*,2Q&*X:$3[R2R9+)
MHUDU%:44B2HB4PS)XISGYUY!RAR>-2X2NLSN8OWM:J6#EAL[6JUBX48O9CAQ
M5))P@MDY0ZMRLY4YSS+S-PHMV]A0:[>X:Q2Z>SIK=.K);<,<()\4]\8RON<4
M>%'&_A;A#.$Z"UU5XTIV*PSD69S6V;38.:R&2)2IN79>^@I,DU.=SJ(J#;B,
M&I11H[".B"JJUYS*UES)S-YEJN\E6P;=.C'&-O13Z*5)/ACLV.3QJ227'.3V
MEB6C]!Z7T+8*PTY:QI8I*=5X2K56NFI4:XI;=JBL(1Q\B,5L-K!H9N    1N
M\X/2PXH<Z:>QF9[AT;"=MKBJ13;NP.%"JLXBRVVNV&G)20E+%]#29)2J+9I6
MM+?<F*_%6KS2[)RQYZ:\Y77$*>57+N<O3\NRKRE*BUCM[/U5";WJ5/!-X.<:
MB7"<NU]RBT=S!H2GF-!6][AY-U12C53Z./HK1^EJ8M+%0E!O$HM<Y/3HY$<#
MMF1<(V70.9'BV4V#T76.S\5A3)>*;#:)TDL0X22);L.W22D%*II'[.VH^YHY
M$=34AVT/EASATAS3R669Y+5[&O0BG<VU5I5;=X;6]RG2>WAK1\EK9+@FI0C7
MYK_EEJ;EYFJL,UI]K1K-JA7IING6ZDNF-3UU*7E)[N*+4G;']%7TGHW$/#X7
M(O?%"P]R;SRE/ZC4=@RV\K2.'V\?Y]&PE?4D9!8,JZ7$DOG1VC^I[1I+WQ4J
M!/>3Y]3Y@YC+1^E:K626L_+G%X>_:T'Z=]="FU[3'=.2[:6/M:A,;D3R=AHN
MRCJ?4--/-KB/DP:Q]ZTY+TBZJTU]EEOBO:UAY;G8 $3B1P      %?+XB/EO
M_0KQ,JN/N,V?NV=\FK9ZHM$1GNR77ZGQ)UBSS&0HVS-3?U1EN5U225D27XSL
MY)&9MJ(2V[H6@/VEU]4U;>PXK7)(*<<5LE=55*-%>'LXJI5Q6V,XTF]Z(V]Y
MC6?Y!T;#3=I/"XS63C+![5;T\)57X..3A3V[)1=1=#** M&*^20+TZ^!.:<_
M]JY[KS%YKM)"P;4.=YU,O5(;3#3E+-.Y5ZQQV3*?(VT)LK]^$4DOI_<69JVS
M);9*3R;F_P U<MY3Y%:9O?1565U=T*"AT]DYJ5S426UNG0C/AZ.UE34MCP?2
M.6?+N^YCYO<Y9:2[.-O;5:KGT=HHN-"#;V+CK./%T]G&HUM6*T+M*RQI+.QI
MK>%*K+:HG2ZRTK9K*XTVOL8$A46;"EQW2)3;K3J%-N(41&E1&1^)#JE"O1N:
M,+FWDITZD5*,HO%2C)8QDFMC3333Z4<[K4JM"K*A7BX3@W&46L&I)X--=#3V
M-'TNN<_RG5.P,)V=A%BNHS'7N5T&:8O9HZF<*^QJT:N*N0I"3+O0EYE'>@SZ
M*3U2?@9CQ9QE-CGV4W.29G#M+>[I5*-6/KH5(N$EX'@W@^A[3U99F5WD^96^
M;6$N"O;5(5:<NJ<)*47YZ6*Z5L.HMQFWOBW)W0.I=^8:I!46T<+J<F1#2\F0
MNEM7FCBY'C<EY/@I^KL6I==(,O#S65].I"CW6NEK[1.K,PTIF/V6QK3IXX8<
M<4\:=1+UM6FXU(_2R1;5I34-IJS3EGJ.Q^QW=*,\,<>&3V3@WUTYJ4)>&+,Y
MC5S8       *#/Q$_P"D;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(
M@I$HR/A< ^%O_FGS/^R+1?UMRL5Z]^/_ #^F_N=[[*U)K=TG_)Y[]7:>QN"U
MX(&DP@                   #07U*.;%'P.XL9EN)TH,_/[-2<*T_C<T^]J
M^V->1755;LN.E25+@UK+3]I8$2D][,=3*5I=>:Z]7Y,<M+KFGKJVT['BA:0]
MNNZBWPMX-<23Z)U&XTJ>_"4U)IQC(YSS2UY;\O-(U\[>$KF?M5M!^KK33X6U
MTP@DZD]V,8\*:<D<V/-,SRK8N79-GN<7MCD^8YC>6>2Y/D5N^<FRNKRYEKG6
M5E->/VK==6I1]"(BZ]$D1$1%<QEN76.3Y?0RK+*4:%M;0C3I4X+",(02C&*7
M4DDO1*N+Z^O,SO:N8YA4E5KUYRG4G)XRE.3QE)OK;9\R/:>0GX])7T7\@YG(
MKM]<@57>$<9HLY?U JX*EUN6[IE5\DV9<>CF++N@433J%,3+9*3=>6E<>%VK
M)R5&BCS][R%IRX<]*Z3X+G.I1]LE+RJ5FI+%.:W3KM-2A2?DQ34ZN*PA.1G)
MOD7<ZY4=1:DX[?*D_(BO)J733P:@_44DUA*IOD\8T\'C.%W?46F-4:$PBKUO
MIG7^+:VPBG010L>Q.JCU<-3WEI;=L)[C1>;+F/$DE2)LMQR0\KY[KBUF9G69
MJ#4F?:KS.IG.H[NK>W53?4JR<GAO48X[(06/DP@HPBMD8I;">^2Y%D^G;"&5
MY';4[6WANA3BHK'K?3*3]5*3<I/:VV9-&$,J   $6G.STC.*/..LMKNXQF+J
MK=S[+[E9NK7]7"@W<JR4C]A5GU(UY,7(8YJ)!.G,-,PFT]D>;'(S,^Y\K>\#
MKSEA6IVUO7=_EB:4K.O)R@H]/83>,K>6&.'!C3Q>,Z4SD?,+DQH_7]*=Q7I*
MSOVGPW5&*4W+H[:"PC66['BPGALC4B57-;>@ORZM.9<+CGLRE>Q_4]8E.5Y/
MR%QYEV?@=KKB/-)AQ>&V4UM*57TQ72(Q32VTR([BCDOLG";\YR=.<]ZGE_0Y
M<RUADM55K^?M5.PJ-1KQN'''VZ*>RA#T\JT6X3BN"$NT?"HB97W>-:5=<1TQ
MFM-T[.'ME2\@L:,J">'M4FOLTO2JE)<46^*4>S7$[TNG]1:\T+K/#=0:IQJ#
MB.O\"I8]%CE% 2?9'BL=7'I4N0OJY(ERGE.2ILMY2G9#[CCSJE.+4HZO-0Z@
MS?56=7.H<^K2N+NZFYU)RZ6]R2W1C%)1A!81A%*,4DDBP/),ERS3N54,ER>D
MJ-M;Q4(070EO;>^4I/&4I/%RDW)MMMF21AC*   !RV.9_P".'RO_ #E=Z_A1
MM1>3RX^;S(?U=9?BU(J1US\MLX^'7?N]0UJ&YFJG1!]!_P#19<:OWYNO\/N4
M"H;O3?/GG7BL_P 1MBR_N]?-%E7CNOQRN2]B/AVD   /E<VP7"=E8S:87L/$
M<:SK$+MA4:XQC+J.MR*@LV%%T-J=4VS;K#I%[2[T'T/Q+H8]^69IF>2WL,RR
MBXJ6MQ2>,*M*<J=2+ZXS@U)>8SQW^7V&:6L[',Z,+BC46$J=2$9PDO#&2:?G
M%*/UK_2%QGB7#:Y0<:J^;#T3=WT6FV!K]V1*LTZGR"[>\FDM:.PEJ<?506$@
MRB$U*<6N'+6RTAUQF4TW&LI[M7>#O=?5'HC6<XRS2E!SH5TE'WU3@L9QG%81
M[>G'R\8I*I34I.*E"4IP0Y\<EK31L%JS2T7'+ZDU&M1Q<O>\Y/",H-XOL9OR
M<)-N$W%)N,THUR1,0C$9[XM[RO.-'(K3.^,?>D-SM8;!Q[)Y3,59MN6E!'FI
MCY50+4GH?E656Y,KWR(R,VWE%U+KU&J:YTO:ZTT?F6E;M)QOJ%2FF_4U&L:5
M3QTZJA4CX8HV+2.H+C2NIK'45LVI6E:%1I>J@GA4AXITW*#\$F=3:!.AVD&%
M9UTAJ97V,2-.@RV%=[,J'+9*1&D,K+VI6A25)/Y2,495:52A5E1K)QG!N,D]
MZ:>#3\*>PMSIU(5J<:M)\49)--;FFL4UXT>6/F?L\:;-AUL.78V,N- KX$9^
M;.G3'VXT2'#BM&_)ERI+QI0VVVA*EK6LR)*2,S,B(?NE2J5JD:-&+G.;48Q2
M;;;>"22VMM[$EM;/Q4J0I0E5JM1C%-MMX));6VWL22VMG.5]6?U ;KGER6N+
M:DLIB-#ZPDVF(Z3H%*=9C2:AN235OL";#7TZ3K]UE$DS4A*VHB(D91&IA2UW
M#\@^4UMRKT73M[F">:WRC5O*FQM3PQA03]903<=C:E4=2:V2258W.3F/7YAZ
MJG6H2?Y.M'*G:PZ'''RJS7KZS2ENQ4%"#VQ;<6P[D<C-LN&?#+=/.3<E7I[3
M50VY(-M%IF&86J9#6)Z^Q=#Y,RLCR:<PE1I1U/RXT9LE/2732TT@S[E)T'F-
MS'TWRPTY/46HZF"]+1HQP=6O5PQ5.G%M;>F4GA&$<92>Y/<M#:&SW7^>0R3(
MX8OTU2I+'LZ-/'!SJ->=&*\J4MD5U7Z."?I;<7N!^/5S^#XO%S?<"H26LCWC
MF=;#F9I/E/-=LYC&&U^8U05RS-24PJY1+6V2"ER);B/-.J7FESRUQS3NYQS.
MN[7+L<:=E1DU1BD_)=3<Z]1=,ZFQ/'LX4T^$L5Y>\I-)<O+:,LOHJXO</+NJ
ML4ZK;6U4]ZHP?K(;6L..4VL22(<;.H@  !J?ROX2<;.:>%O8;OW7%5DCK,1^
M/CN:P6V:G8>%O/$:DR\3S".@Y,?M<,G5Q'#<B/J2DI,9]!=A[[H/F9K/EMF2
MS'2EY*BFTZE&6,[>LET5:+?#+9L4UPU(IO@G%[33M8:"TMKNP=CJ.UC5:34*
MJPC6I-]-.HEQ1V[7%XPDUY<9+84,?4L]+_;?IXY[&.Q?D9]HK,;"0QK?;42
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M$1C+:7PM/[OYP?O/CC^W9T("]^7[#ICQYAZ%D3)[H_V3/_%9>C=ENH5^DSP
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M1?I&^'OW9\>_:GAR3GS\SNHO@=3T4=)Y/?.=DGPJ'\ITM12\6G@
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MI+PM4E1Q\ZDEYA8[W;+N=SRLMZ,GBJ%>XIKP)U.U]&HR;H1F.]@
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M@?,[3^&7/HP*ZN\S\Y\_@UOZ$B"D2C(^%P#X6_\ FGS/^R+1?UMRL5Z]^/\
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M6=OA@OQA^3'W&,<^WAH0E[[GR0R7X94]Q9*_NG?*;-?@L/=471A6Z3I
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MKM:TUA[XK7%1>)5'2_\ TWZ)-@(U'>              I1?$[?C3<>?N /\
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M5;BHWXWQKS$BPGNNVL*'+BK72VU[VM)OZFG1@EXEPOS6RP((F$CP
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M8+H2)I<CM4Y[K#0=/.M1U_?%S*M6@Y\%.GY,&E%<-*$(;.OAQ?2V2LCA!V
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M"(QEM+X6G]W\X/WGQQ_;LZ$!>_+]ATQX\P]"R)D]T?[)G_BLO1NRW4*_29X
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MGPNW]9?+S[!=3_7^Z$%>_#^9=/?=[KW.B2\[I?YUSK[E;^SJEQ@5VDW
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MD;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O_FGS/\
MLBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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ML7-?N[\H+BPJ0U_J:DX5'%^\Z,UA**DL'<3B]J;BVJ*>W!NIAMILM;B!Q,$
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M*+G57]&O4JQ?A197W>LBGDG*^RG5CPU+V52ZDO!4?#3?]*C3IR\TF)$=SMH
M'-*]5W](WS"^[/D/[4R+H>0WS.Z=^!T_195ASA^<[._A4_Y"/@=;.;%\[X<7
M]'C+^[_LOZS48JN[XOSO1^ 6WLZQ8?W8?FT?PRO[&D3W"*A(D #G+>M5J"1I
MWU).1<3W53%3L2\J=OT+YH[$V$?8U*Q=WTILOH(NSM8QG\JFC/VGT%P_=LU#
M#47)K)ZG%C4LX3M)KUKMYN$%YM'LI>*16+SVR262<T<SAAA"YG&Y@^M5XJ<W
MYE7M(^816#NIR$LR_#0\C86%<@=P\:[V>B-&W=B%=F&%MR'.B7\VU=[T_95$
M%'7_ %LREGS9CA].AHK2\2,B(X5]]+1U7,M)9=K.UAQ2RRK*C6PZ*-SPJ,Y>
M"%:$(+PUB5?=7U/3L-27NEKB6"OZ<:E+'IJT.)RBO#*E.4GX*1=7%:Y.T
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MS\1/^D;MON,:M_:9PM9[H'S.T_AESZ,"NKO,_.?/X-;^A(@I$HR/A< ^%O\
MYI\S_LBT7];<K%>O?C_S^F_N=[[*U)K=TG_)Y[]7:>QN"UX(&DP@
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M'@_1O8U]US:OUT8%47>\^>2O\$M?8R+&>[1\U]+X1<>R1.6(P'?P .6QS/\
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ME"*WX';.[]JBGIGF1:QN9<-#,(RM)M[DZCC*D_-K0IQQZ%)G0W%1198
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MGG',KZ&$HPX<+:E);G&,MM62>Z=1**V-4U)*18,$2B2(
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M7R"XEPT\THX1\-:AQ3@NK;3E62ZY.*6UEZ 5?%@0
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M%)'T(\AZ0 .:5ZKOZ1OF%]V?(?VID70\AOF=T[\#I^BRK#G#\YV=_"I_R$?
MZV<V+YWPXOZ/&7]W_9?UFHQ5=WQ?G>C\ MO9UBP_NP_-H_AE?V-(GN$5"1(
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M-*4I0X9'=WWFG^Q^=?LQG53#+;^:X92?DV]P\(QGB]BIU-D*G0GP3;2C/&^
M*LRPH   /PE18TV-(A38[$N'+8=BRXDIIN1&E1I#9M/QY##I&E:%I,TK0HC(
MR,R,N@_4)SI352FW&46FFG@TUM336U-/:FC\SA"I!PFE*,DTTUBFGO372GTH
MYU'JZ^GO;\$.25HC&JJ4KC]MB9:97IJZ2AUR'41W)!2+S6DV2KKTET;KR6V.
M]:E/05Q7S4IU3R6[@>[]S;M^:>C*;O:B_*U@HTKR&Q.;PPA<I>MKI-RP24:J
MG'!146ZRN='+:OR]U3-6L'^3;QRJ6TNB*QQG0;]=2;P6.+E3<)8XN244([R<
M>,Y\<N1^WN*.VL:W5I'*I.*9OC3JD$X1')J+^GD+2=IB^45*E$W.K9B4)3(C
M.?*2'6E-OM-.HU?6.CM/:\R"MIK4U!5[:LO%.G-8\-6E+?"I#'&,EX8R4HRE
M%[!IC5&=:/SFEGN0UG1N*7FQG%^FIU([IPEAY47X&FI)-7KN 'K6\8>8]51X
MCG=W3:$Y .MQX4[ ,QMV8.,99:&DFU2=:YA8FW'EI?69&U52UM3T*,VT-RD-
M^\KJYYL=VK6_+JO5S#*J4\URE8N->C!RJTH]5S1CC*'"M]6"E2:VN4&^!6#<
MN.>^D];T:=EF%2.79D\$Z-625.I+KH5)8*6+W4Y-5%N2FEQ.9L1Q.Y   !I+
MS!]0KBQP@QJ3;;MV-7,Y4J$N50:JQEV+?;0RE9H-4=%9BS+J5QV'#^:5A9.1
MH:3\%2"49)/I?+SE'KKF;>QM],V<G0XL*EU43A;4NOBJM-2DOM=-3J/HAAM-
M"UMS*TCH&U=;/KJ*K88PMZ>$Z]3JX::?DI^OFX0ZY8E#WU&/4MW/ZANPXUIE
M:3PG46)2Y2]::?JK!V74T)/I-A>0Y%--+7U4NWVC\MV:ME"&D&IF*TRA;OFV
MF\GN2^F^4642H6'^)S"X2]\W<HI3GAM[.G'%]G1B]J@FW)X2G*34>&O3F=S4
MSSF7F:K7G^'LJ+?86T7C&&.SCF]G:56MCDTDEY,%%-XQOCLAR\V>X><4MD\T
M=_81H764196.23"EY)D;L9V14X+A4!U!Y+FEX:#211X;2R)MLUI.1(6Q%;/S
MGVR/2.8FO,FY;Z3NM59W+R**PITTTIUZTD^SHP^FFUM>#X(*4WY,6;9HG1^:
M:ZU';Z=RI>55>,YX8QI4DUQU9^"*>Q8KBDXP7E21TQM%Z7P3CMI_7FD-9UOU
M*P?6N,5^,T4=?8J5(;B(-R;;6;S:4D[-GR5O3IS_ &D;LAUQPR(U&*6-4:DS
M36&H;S4V=3[2ZO:DJDWT+'TL(K;A"$4H0CZF$8KH+5-/Y%E^F<DML@RJ'!;V
MM-4X+I>&^4GTRG)N<WTR;?298&!,P !J=SGXV0N77$W=_']_W9NSSO#)18C,
MEF2&*W/J"0WDN!V#[OM0RW;0XGO)I,C4P;B.O11C?>5^LZG+_7N6:LCBX6M9
M=JEOE0J)TZ\4NENE.?#CNEPOH-.Y@:6AK31U_IN6"G<4GV;>Z-:#4Z+;Z$JD
M8\7TN*Z3F%9!0W6*WUWB^25DRER'&[>RH;ZFL651K"INJ>8NOM*R='7\YMYA
M]MQIU!^*5),C]@NWM+NVO[6E?6<U5HUH1J0G%XQG":4HRB^E2BTT^E,J?N;>
MO9W%2TNH.G5I2E"<9+!QE%N,HM=#33376>I'H/@6K/1A]:3$]78EC7$7E[DI
MT6(4),T^F-T6SBG*C&*=1]D/7VPY9]51J^*H^RIME]6HK)E&DFS%8:=;@EWC
M^[=?YY?UN8'+VCVMQ5QG>6</3U)]-Q;K=*I+?5I+"4Y>7#BJ2E%R^Y&<];/*
M;.EHO6M7LZ%/R;:ZEZ6G'HHUGZF$=U.INA'R)\,(IJX!4V]5?UD"[HK.ONJ:
MUB,3ZNWJ9L:QK+*#*;)Z--@3X:EM/,N(,E-N-K-*B,C(S(5[7%O7M*\[:ZA*
ME4IMQE":<91DMCC*+2::>QIK%$U:-:C<4HU[><:D)I.,HM2C)/:FFL4T^AK8
MSV ^)]0 (H/4=]6;0G [$;NAAW-+LKDA,KWFL1T_3V+<QRFL)#'6'>[/DP%F
M=37-=R'O=G%(F3"Z(C-D@W)+'>N3G(/5?-/,*5W4ISLLFC).K=SCAQQ3VPME
M)>VU'M7$DZ=/?-XX0EQWF?SCT[R\LJEO"<;K-))]G;1ECPMK9.NU]C@MCX7A
M.>Z"PQE'GQ;5VCG6[-D9KMK9E_*RC/=@9#89-E%Y,[4N3;.Q>-U:66&B)MB.
MRGM8BQF4I:890VRTE+:$I*VS(<CRO3636V09+25"TM*<:=*"Z(Q6&UO;*3>,
MI2>,I2;E)MMLK;SC-LPS[-*^<YK4=6XN9RJ5)OIE)]"W)+=&*P48I12221C\
M98QI=X^' XES=6<=,ZY.Y96+AY'R'MXE5A*)3)HDQM5X))D16;-HG");:;>W
M=FN&DT]'&(<-]"C0X0K,[X^OJ6>ZPM=$V$^*CE$'*M@]CNJZBW%]#[*DH+'>
MI5*D6L4R>_=?T;4RC3%QJR\APU<SDHTL=ZMZ3:4NM=I4<GX8PA);&61!#8E"
M !HUZFGZ/;F7^;KM'[6'QT_DI\[>G/UA;>ZQ.?\ -;YM<\^!5_<V<R@76E4X
M '6PK_W!!_><;]I2*!ZWV:?C?HERM/[''Q+T#S!\S]@       !'/S"]4OB?
MP9V%CNL=]6^<5^4Y1AL7.ZIK&,+F9)"7C\R[G8^PX_,CN()#OO-=)(VC+J22
M2KK\X=AY><C=>\S\HK9WI6G1G0H5G0DZE94Y=HH0J/!-/%<-2.WKQ70<QUMS
M<T=R_P RI93J*=6-:K25:*ITG-<#G."Q::P?%"6SJP-3/\0_Z;W_ 'EVY]ZJ
MT_VXW[^$/G)]HM/C4?K33OXE^5_VVX^+R_G,^\9/6+X6\N-R8UHC3MWL.;G^
M61,@FU$>_P !GT56MC&J&1DEH;]F^ZM*#*+%=-!&GYRNB?E&IZV[N_,GE_IR
MMJG45*WC:6[IJ;IUXSEC4G&G'"*2;\J2QZEM-BTISMT+K//*6GLDJ5I7-93<
M5.BX1PA"4Y8R;V>3%X=;V$IPX8==          *47Q.WXTW'G[@#_P"$6V%E
M7<E^0V;_  ]?B](@AWK_ )799\#?NU0K0":1%8L[?#!?C#\F/N,8Y]O#0A+W
MW/DADOPRI[BR5_=.^4V:_!8>ZHNC"MTG2 !H=ZH7Z/#F1]P'8'UG6.J<C_G>
MTY\.H>S1SSFU\VF>? ZWL3F:"Z@JJ/N-8?UE:\^SG$OK_'&,SO\ ,MW]PJ^Y
MR,AE/YUMONM/V:.L(*%BX@     @T]:KTPX_-34_],6I*1D^3FHJ22NFCQ&F
MVY.V,&B&NPG:[EK3T-<]A2G95 XLS+SU.Q%=J)?FL2?[MG.V?+;/_P!G=057
M^1,PFN-M[+6N\(QN%U4Y+"-=+U*C46+I\,N <]N4\==Y/^6\FIK\K647PI;[
MBDL6Z+ZYK;*B_7-PW3QC03D1Y$20_$EL/1945YV/)C2&ELR(\AE9MO,/LN$2
MD+0HC2I*B(R,C(RZBUN$X5(*I3:E&2333Q33VIIK>GT,KHE&4).$TTT\&GL:
M:WIKH:/R'Z/R !;2^%I_=_.#]Y\<?V[.A 7OR_8=,>/,/0LB9/='^R9_XK+T
M;LMU"OTF> !\GGF#XKLW"<MUUG-/%R'#<ZQRYQ+*:.:DU1;:@R"O<J[6 ]V]
M#(G&75I[DF2DF9*29*(C'ORK,[[)<SM\XRNHZ-S:U(5:4X[X5*<E*,EXFD\'
ML>Y[#QYCE]GFMA6RS,(*K0N(2IU(/=*$TXR3\:;_ )#FE^H)PJSC@CR1R_3&
M3-S9^*N//9%JG-)#'9'S?75A*65):$ZA*6_?8W:J#:,((B:EM.DGJRIIQ=T/
M*7F5EG-+1MOJ2R<85TE3NJ*>VC<12XXX;^"7IZ4GZ:G*./E*256/,C0E_P O
M=45\BNTY46W.WJM;*M&3?#+JXH^DJ+HG%X>2XMZ1CIAH)N1PBYQ[LX&[?B[4
MU!9M2(4]$:LS_7UPX^K$=BXTT^;QU-Y'9/N:?9-2W*^Q9Z/Q7%*-)K:<?8>Y
MUS-Y8::YJ:>ED6H8-2AC*A7@EVMO4:PXX-[XO8JE-^34BECA)1E'>- Z_P ^
MY>9VLWR6>,981K498]G6@GCPS2W-;7":\J#W8IRC*^OP<]4GBKSKHJUG LPB
M89MI41"[[2&<6$*LSF!+;;[IJL<)PT-7T%!D:D3:PUFELT'*9BN*\E-5?,[D
M;KOE==3EFMN[G+\?(O:,92H26.SM-[H3?3"IAB\>"4XKB=B.@.;>D.8-O&.7
M5U0O</+M:K4:J?3P;E6AU2IX[,..,&^$D=''#IX   1B\XO5GXE<':NUJ\HR
M^+LK<<9IUNMTGKRR@VF5)L"29,HS*Q:-R)CT<E&DW5V"O>3;,UQHDHTF@=MY
M8\@]?<SJ].O8V[LLN;7%>7$91I</3V,7A*XEAC@J?D8[)U(8XG*-?\Y-&Z I
M3HW==75\EY-K1DI5,>CM9;8T5UN?E8;8PGN*,'.7U!.0//G8O\L=O7B:_%*5
M^4G7VJL?>DL8-@5?(/L5[A#=4:I=@\@D^^VLKN?>,NQ/E1T,QVK0>6'*727*
MG)_R=IZEQUZB7;W51)UZ\EZYKTM-/TE*.$([WQ3<IRK]Y@<R-2<Q<S]_9U4X
M:--OL;>#:I44^I>JFUZ:I+&4MVR*C%;^^C_ZO>0<+,BK=%[PL;+(N*V3VYDS
M(44BQMM(7-K*[Y638['02W7J5]U:GKBI:2:DJ-<V$@Y/GL3N3]X7N^6G,FSG
MJC3$(T<]H0VK9&%["*V4ZCV)5HI84:KV-84JCX."=+H_)3G3<Z%NH:?S^4JN
M459;'ME*UE)[:D%M;I-O&I36W?4IKBXHU+X>.Y%09=04N58K=5>1XUD=7!NZ
M"_I)T:SI[JGLXR9E=:5=C#4MI]A]I:7&G6U&E23(R,R,597EG=Y?=U+&^IRH
MUJ,I0J4YQ<9PG%X2C*+P<91::::Q3+"[:YM[VWIW=I4C5I58J4)Q:E&49+&,
MHR6*::>*:V-'N1YC[D06Z?7"X'Z#VOGVF=A7^S(^;:VR2?BF3L56N;&SKFK>
MM63<I$.P;>2EYLC/YJR(B,2#TWW9.:>J\AM-1Y12MI6U[3C5IN5Q&,G"6[&+
M6Q^ XKGO/WEYIW.+G(\RJ5U<6LW3J*-"4H\4=^#QVKPF,?\ $/\ IO?]Y=N?
M>JM/]N,Y_"'SD^T6GQJ/UIBOXE^5_P!MN/B\OYS>7A?ZA_&[GM_23_9\L\NL
M?Z*?Y'?RN_E5BLK&?)_EU]5?J![A[RXOS^[ZC3?-[>G9T1UZ]Y#E_,CE#K+E
M5[R_:V%*'O\ [;LNRJJICV'9=IQ8)</V:&'7MZC?]"\R]+\Q/?7[-SJ2]Y]E
MVG:4W3P[7M.##%O'[%+'JV=9O,.8'0#_U;_  J%?%)__ ![A/_\ *.0/_OF&
MBP;N-_Y74OU=AZ%X0M[V_P#F,A^IO/1MBIP)[$.2Q[\,E^.ENO\ ->R'\*^)
M"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y          *+WQ+OX^VMO
MS4\ _"IFPM"[EWS57GZTK_BMF5^]ZCYQ+7]7T?QBZ*\@ET1I+7?PM_\ .WF=
M]CFC/KGE0@;WX_S?IO[I>^QM28?=)_SF>_46GLK@N BO4FJ ! C\1U^CQB?=
M_P!:?6:\$J^YU\[TO@%S[.B1V[SWS:+X90]C5*&(M1*\#ZO!LZS'6>78_GVO
M\DM\/S3%;%JWQO)Z&8[7W%+9L$9,SJZ:R9*;<3U/HI)]?$>#-,KR[.LOJY5F
MU&%Q;5XN%2G-*4)Q>^,D]C3ZCV9?F%[E5[3S'+:LJ%>C)2A4@\)1DMSBUN9N
M+_>@^H=^61O_ .^%<_\ KCG?[D.4/^W+#XO#^8W?][/,O].7GWZ7\X_O0?4.
M_+(W_P#?"N?_ %P_<ARA_P!N6'Q>'\P_>SS+_3EY]^E_./[T'U#ORR-__?"N
M?_7#]R'*'_;EA\7A_,/WL\R_TY>??I?SC^]!]0[\LC?_ -\*Y_\ 7#]R'*'_
M &Y8?%X?S#][/,O].7GWZ7\X_O0?4._+(W_]\*Y_]</W(<H?]N6'Q>'\P_>S
MS+_3EY]^E_./[T'U#ORR-_\ WPKG_P!</W(<H?\ ;EA\7A_,/WL\R_TY>??I
M?SFY/IY>H;SBV-SBXL8)G?*?=668;EFZL(H\EQJ\S>UGU%W43[5+,RNL8;RC
M2XTXDS2M"BZ&0YSS=Y1<L<GY8Y[FF5Y%9V]S;V=:=.I"C&,X3C%M2BTL4T]S
M-XY:<R]?YIK_ "C+LQS>ZK4*UU2A.$ZLG&<7+;&2Z4^E'0#%3A8Z !1T^)J_
M'BT[^:EB'X7LV%G7<I^;',?UI5_%+,@'WJ_E_8_J^G^,W17.$PB,9E35V]=W
MZ.DW$W2NX]JZ@F9"Q$BW\O5VPLNU_)O(T!Q;L&/</XG,B+DMLK=<4RAXU$@U
MJ-)$:CZX+/-+:9U/"G2U+EUKF,:+;IJYMZ5=0<L%)P56$U%M))M88X+'<9C*
M-0Y_D$YU,BOKBRE524W;UJE%S2Q:4G3E'B2Q>">.&+P,Q_V_^>'Y;'+C_P R
M&X_XY&N_NGY6?[:RK_\ '6GX$S?[Q^8?Z>S'X[<_A1_;_P">'Y;'+C_S(;C_
M (Y#]T_*S_;65?\ XZT_ C]X_,/]/9C\=N?PI\/E?+'E-GD5R#G');?^9PG4
MK2[#RO<FQ<BBNI<3VK2Y'M[)Y"B47@9&7B0R=AH+0V55%5RO);"VDMSI6=O3
M:\V%-,\%YK'5V8P=/,,UO*\7O52YK37G2FS !F:C,S,S,S,S,SZF9GXF9F8V
MPUL #V=+27.26]9C^.U%G?WUU.BU=-24L"5:V]M937BCPZZLK8*''GWWG%)0
MTRTA2U*,B21F?0?"YN;:RMYW=Y4C2I4HN4YSDHPA&*Q<I2DTHQ2VMMI);6?:
MA0KW5:%M:PE4J5&HQA%.4I2;P48Q6+;;V))8MEQOTB/0Y=U/:8QR@YFT4.3L
M:N<AWVKM'3/=K"#@4YM12:[+]B$CO9D73*B2[ JT*6U 627I!KFDAJ%79W@N
M\['/Z%?1'+BJXV<\87-ZL8RKQW2I6^YQHO:IU7A*JL8PPIXRJS=Y+\@7DU:E
MJS7--.ZCA.WM7A)47OC4K;TZJWPI[53?E2QJ8*G:.$'26H    !S2O5=_2-\
MPONSY#^U,BZ'D-\SNG?@=/T658<X?G.SOX5/^0CX'6SFQ?.^'%_1XR_N_P"R
M_K-1BJ[OB_.]'X!;>SK%A_=A^;1_#*_L:1/<(J$B0   CA]2GTY];>H9IO\
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M:=@7=YYI_M5E'[(YW4QS"Q@NSE)[:]O'!)XO?4I;(SZ90X9^4^-JPT(BDE@
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MW-G,H%UI5. !UL*_]P0?WG&_:4B@>M]FGXWZ)<K3^QQ\2] \P?,_8
M 4@/B;?QTM*?FO8]^%?+19MW*/FVS+]9U/Q6T(#=ZSY=V'P"'XQ<E<(3&(P$
MR'H'?I0=$_8[N7\#]V(Z=ZSYD,T^Z6?XW1.X=W7YV<O^HN?Q:J="P5'%E
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ME^.ENO\ ->R'\*^)"'/?7^;;+?UG3_%;LD_W4_EW?_ )_C%L7?Q623Y
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MY<LJTY:PMJ*VOA6,IO=Q5)O&=27TTVWAL6"P1G@:L;"   '+8YG_ (X?*_\
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M3DMO"VMJ2PC3@L$NMOIE)[Y2DW*3VR;;Q,C##F3  YG_ *I_Z17F+]W/,?\
MWI(NEY%_,_IWX%1] JMYN_.;G?PNKZ)H&.KG.2V]\+-__'5__K'_ /O"$ >_
M-_\ NO\ _P!R_P#V F9W1O\ ]X/_ )'_ /;"V\( DS#_U[_  QQGVG-1;675
MN;1U7KC9+E&F8BE7GV#XQF*Z=%B;2K!%6K(HLDXY/FPR;Q-=O?Y:.[KVIZ9G
M*=1:@R%5%D=_<62JX<?85JE'CX<>'B[.4>+AXGACCAB\-[,7F.1Y+G#@\WLZ
M%TZ>/#VU*G5X>+#'AXXRPQP6.&&."QW&//[('$O\EWCK]Y/6G\6#+_O#U_\
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MO3N:5_?69V%M<U<$N.K0I5)8+<N*<6\%T+'8?)_V0.)?Y+O'7[R>M/XL'O\
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M"#]BM&_HBR^*T/P9L21$DB2DB2E)$24D1$1$1="(B+Y!I[;;Q9L^[8C_ $
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MRF79)DV3\?Y(M*-KVF''V-*%+BX<>'BX(QXN'BEACCAB\-[,BC#F3/_0O\
M
M
M
M
M             QIN3;&(:)U7GNX\_<M&<*UMC-GEV4/TU5+N[./25#)R)\B+
M5PB-QTVT$:U$7@E)&I1I2DS+-:<R#,-4Y[::=RE1=S>U(TJ2G)0BYS>$4Y2V
M+%[%UO!+%LQ6>9S9:>RBXSS,7)4+6G*I4<8N4E&*Q;45M>"V^+:]A5%YL?$C
MS<LQB\U]PHU_D6$R+F))K9&Z]FHJ6LGJ8[[9L/R,'P>I?G1F)1D?=&L;&<Z;
M9>/N*7>U;<\N6G<UIV%]2S;F5=T[E4VI*SMN-TIM;4J]:<82E'UU.G"./VUQ
MQ3A[KSO13O+2IEN@[:=NYIQ=U7X>TBGL;I4HN<5+ULYS>'VM/!JJV9W.2W)F
M9V=_D-_9F9F9RK6YN[FUE=3,S/S'Y,J2^Y_I+<6KY5&)T_X:RML%PTJ-*/@C
M"$(KS(QC&*\"2741$]ONJ_JJE6I+PRE*4GYKE*3?A;;ZSH!>B)Z?][PGXV6>
M3;1J3J=Z[\F4^59M3/H24W"<4IXKR,%P6=[33-81+F3[)!=IMR)1Q5DHXA+5
M4YWF>;-KS+UG"RR.IVF5Y4ITJ,UZ6M5FUV]>/TDG"$*;VXPI\:P[3!6.<A.7
M%QH/2T[O-X<&89BXU*L7OI4XI]E2?TRXI3FNB4^!^DQ<TXC:=V
M
M/__1O\
M
M
M
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M!5HW]I2E=WL=UQ<82E!]=*"2A3\$DG42V<;39*L.$G7P
M                                                       /_]*_
MP
M
M
M
M
M                                  __T[_
M
M
M
M
M
M            #__4O\
M
M
M
M
I                                                   /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>md-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-04T16:52:15.3271+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.mednax.com/20250630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:md="http://www.mednax.com/20250630" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>75000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
        <link:definition>75010 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
        <link:definition>75030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical">
        <link:definition>75040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" id="StatementConsolidatedStatementsOfEquityUnaudited">
        <link:definition>75050 - Statement - Consolidated Statements of Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" id="StatementConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>75060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1" id="DisclosureBasisOfPresentationAndNewAccountingPronouncements1">
        <link:definition>995455 - Disclosure - Basis of Presentation and New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" id="DisclosureCoronavirusPandemicCovid191">
        <link:definition>995465 - Disclosure - Coronavirus Pandemic (COVID-19)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
        <link:definition>995475 - Disclosure - Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995485 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
        <link:definition>995495 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses" id="DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses">
        <link:definition>995505 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinations" id="DisclosureBusinessCombinations">
        <link:definition>995515 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
        <link:definition>995525 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" id="DisclosureLineOfCreditAndLongTermDebt">
        <link:definition>995535 - Disclosure - Line of Credit and Long Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
        <link:definition>995545 - Disclosure - Common and Common Equivalent Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
        <link:definition>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
        <link:definition>995565 - Disclosure - Common Stock Repurchase Programs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995575 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995585 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>995595 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
        <link:definition>995605 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995615 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
        <link:definition>995625 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
        <link:definition>995635 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
        <link:definition>995645 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" id="DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
        <link:definition>995655 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" id="DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
        <link:definition>995665 - Disclosure - Coronavirus Pandemic (COVID-19) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
        <link:definition>995675 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
        <link:definition>995685 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
        <link:definition>995695 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
        <link:definition>995705 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>995715 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
        <link:definition>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
        <link:definition>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" id="DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" id="DisclosureBusinessCombinationsAdditionalInformationDetail">
        <link:definition>995755 - Disclosure - Business Combinations - Additional information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
        <link:definition>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" id="DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
        <link:definition>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
        <link:definition>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" id="DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails">
        <link:definition>995805 - Disclosure - Common and Common Equivalent Shares (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" id="DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails">
        <link:definition>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
        <link:definition>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Segment Reporting (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CoverPage" xlink:href="md-20250630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:href="md-20250630.xsd#ConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="md-20250630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:href="md-20250630.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:href="md-20250630.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" xlink:href="md-20250630.xsd#StatementConsolidatedStatementsOfEquityUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="md-20250630.xsd#StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1" xlink:href="md-20250630.xsd#DisclosureBasisOfPresentationAndNewAccountingPronouncements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:href="md-20250630.xsd#DisclosureCoronavirusPandemicCovid191" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments" xlink:href="md-20250630.xsd#CashEquivalentsAndInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements" xlink:href="md-20250630.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:href="md-20250630.xsd#AccountsReceivableAndNetRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:href="md-20250630.xsd#DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinations" xlink:href="md-20250630.xsd#DisclosureBusinessCombinations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:href="md-20250630.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:href="md-20250630.xsd#DisclosureLineOfCreditAndLongTermDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares" xlink:href="md-20250630.xsd#CommonAndCommonEquivalentShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:href="md-20250630.xsd#StockIncentivePlansAndStockPurchasePlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms" xlink:href="md-20250630.xsd#CommonStockRepurchasePrograms" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting" xlink:href="md-20250630.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies" xlink:href="md-20250630.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:href="md-20250630.xsd#DisclosureBasisOfPresentationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:href="md-20250630.xsd#CashEquivalentsAndInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables" xlink:href="md-20250630.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:href="md-20250630.xsd#AccountsReceivableAndNetRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:href="md-20250630.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:href="md-20250630.xsd#CommonAndCommonEquivalentSharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" xlink:href="md-20250630.xsd#DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:href="md-20250630.xsd#DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:href="md-20250630.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:href="md-20250630.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:href="md-20250630.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:href="md-20250630.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="md-20250630.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:href="md-20250630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:href="md-20250630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:href="md-20250630.xsd#DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:href="md-20250630.xsd#DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:href="md-20250630.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:href="md-20250630.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:href="md-20250630.xsd#DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:href="md-20250630.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:href="md-20250630.xsd#DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:href="md-20250630.xsd#DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:href="md-20250630.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:href="md-20250630.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="md-20250630.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" xlink:label="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PerformanceRestrictedStockUnitsPRSUsMember" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PaymentsToTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash outflow to term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net decrease in accrued salaries and bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries and Bonuses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued salaries and bonuses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and New Accounting Pronouncements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation And New Accounting Pronouncements Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on finance lease obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Capital Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Good will Impairment Loss excluding Deferred Tax Assets Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Goodwill, Expected Tax Deductible, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, aggregate shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents and Investments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CovidNinenteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Covid Ninenteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal Home Loan Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllOtherCorporateBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Third-Parties [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third-Party Payor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition consideration paid in cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of market value of common stock at which employees are permitted to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RadiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Radiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Frequency of Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in valuation allowance deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net patient service revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCarePatientServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care, Patient Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unnamed Corporate Joint Venture Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financing Receivables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ScheduleOfFinancingReceivablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financing receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Senior Notes, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Asset, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Deferred Tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax Assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income (loss) to net cash from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes Payable Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax adjustments, sttlements and unusual provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Incentive Plans and Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from maturities or sales of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other multi location pediatric urgent care practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Multi Location Pediatric Urgent Care Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of multi location pediatric urgent care practice acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, interest rate, effective percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Seven Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Antidilutive securities not included in the diluted net income per common share calculation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit long term debt and finance lease obligations disclosure text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Long-Term Debt, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anesthesiology Services Medical Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AnesthesiologyServicesMedicalGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anesthesiology services medical group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit facility, available balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of dilutive common share equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RuralAreaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rural Area [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Repurchase Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Repurchases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockRepurchasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entire disclosure of common stock repurchases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contributions In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contributions In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unsecured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured note issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductAndServiceOtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service, Other [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financial Instruments Measured At Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Measured At Carrying Amount Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of financial instruments measured at carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of other pediatric orthopedic practice acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Pediatric Or thopedic Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of pediatric or thopedic practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retained Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings And Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retained earnings and accumulated other comprehensive income [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition total consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PediatricSubspecialtyPracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pediatric Subspecialty Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain on investments, net of tax of $140, $66, $395 and $86</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net patient service revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Patient Service Revenue By Type Of Payor</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net patient service revenue by type payor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of unsecured debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CommonStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease In Salary | %</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increase Decrease In Salary And Wage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Increase Decrease In Salary And Wage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding (loss) gain on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Of Tax, Unrealized Holding Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized holding gain (loss) on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MaternalFetalMedicinePracticeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maternal Fetal Medicine Practice [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MoneyMarketFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity in earnings of unconsolidated affiliate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Equity Method Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method ownership percentage in joint venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fixed asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased during period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Mutual funds fair value disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mutual Funds Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_MutualFundsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mutual funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Loss) income from continuing operations before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental loss on sale, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organization, Revenue Sources [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll taxes and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes And Benefits Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payroll taxes and benefits current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset impairments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice salaries and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Salaries and Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSalariesAndBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Practice salaries and benefits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued salaries and incentive compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Antidilutive Effect of Contingently Issuable Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares not included in the calculation of diluted EPS as a result of the potentially antidilutive effect of contingently issuable shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of common and common equivalent shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized holding gain (loss) on investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coronavirus Pandemic (COVID-19)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Zero Three Zero [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoZeroThreeZeroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Practice supplies and other operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Practice Supplies And Other Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2008 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended and Restated Two Thousand Eight Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated two thousand eight plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Transformational and restructuring related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable And Net Revenue Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable and net revenue disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unnamed Corporate Joint Venture One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_UnnamedCorporateJointVentureOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unnamed Corporate Joint Venture [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">1996 non-qualified employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of Pediatric Gastroenterology Practice Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GAAP Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_GaapSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GAAP Senior Notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Other Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount withheld to satisfy minimum statutory tax withholding obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition payments, net of cash acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts and Financing Receivables [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_IncrementalSharesInContinuingOperation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental Shares In Continuing operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Common Equivalent Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (loss) attributable to Pediatrix Medical Group, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities - continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Maternal Fetal Medicine Practices Acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of maternal fetal medicine practices acquired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payment for) Other Financing Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingency Recognized at Acquisition Date, Liability Assumed, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination consideration identifiable as current and long term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash used in operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net cash provided by operating activities - discontinued operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums, discounts and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash Equivalents and Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit And Long Term Debt [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit and Long Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Five point three seven five percent unsecured senior notes due two thousand thirty member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">5.375% Unsecured Senior Notes Due 2030 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Investments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CashEquivalentsAndInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Equivalents And Investments Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dissolution of and net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Investment and other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment and other income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company's Common stock repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Remaining Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_BasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis Of Presentation Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit outstanding amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized for repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Asset Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill and Intangible Asset Impairment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating and finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Lease Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance lease right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">6.25% Senior Unsecured Notes Due 2027 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Six point two five percent senior unsecured notes due two thousand twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of restricted stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number Shares issued under Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under employee stock purchase plan shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North American Partners In Anesthesia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">North American Partners In Anesthesia [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of options, maximum years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock; $.01 par value; 200,000,000 shares authorized; 86,854,234 and 85,866,000 shares issued and outstanding, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of refund of income tax at the prior period corporate tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of refund of income tax at the prior period corporate tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_TwoThousandTwentyTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty tax year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ExtraordinaryItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extraordinary Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private-Pay Patients [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SelfPayMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Self-Pay [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Malpractice Loss Contingency, Accrual, Undiscounted, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_DeferredTaxAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts payable and accrued expenses, total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax (provision) benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hospital contract administrative fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_HospitalsContractsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hospitals Contracts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US States and Political Subdivisions Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Classification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for (Proceeds from) Other Investing Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings on revolving credit line</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Borrowings on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued under employee stock purchase plan Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_CreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_ContractedManagedCareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contracted Managed Care [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt and Lease Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt and Lease Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt and finance lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments on line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accrued periodically</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Restricted Stock Units (PRSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Percentage of Net Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Interest Rate Risk Exposure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeitures of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of restricted stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grants and awards under Stock Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accounts Payable and Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PaymentsToTermLoan" xlink:to="md_PaymentsToTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CovidNinenteenMember" xlink:to="md_CovidNinenteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherCorporateBondsMember" xlink:to="us-gaap_AllOtherCorporateBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RadiologyServicesMedicalGroupMember" xlink:to="md_RadiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCarePatientServiceMember" xlink:to="us-gaap_HealthCarePatientServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyThreeMember" xlink:to="md_TwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureTwoMember" xlink:to="md_UnnamedCorporateJointVentureTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="md_ScheduleOfFinancingReceivablesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotes" xlink:to="us-gaap_SeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncreaseInDeferredTaxAssets" xlink:to="md_IncreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="srt_ShareRepurchaseProgramDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentySevenMember" xlink:to="md_TwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredLongTermDebt" xlink:to="us-gaap_UnsecuredLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AnesthesiologyServicesMedicalGroupMember" xlink:to="md_AnesthesiologyServicesMedicalGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RuralAreaMember" xlink:to="md_RuralAreaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockRepurchasesTextBlock" xlink:to="md_CommonStockRepurchasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_ExtraordinaryItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductAndServiceOtherMember" xlink:to="us-gaap_ProductAndServiceOtherMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PediatricSubspecialtyPracticeMember" xlink:to="md_PediatricSubspecialtyPracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentMember" xlink:to="us-gaap_GovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MaternalFetalMedicinePracticeMember" xlink:to="md_MaternalFetalMedicinePracticeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MoneyMarketFundsFairValueDisclosure" xlink:to="md_MoneyMarketFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_MutualFundsFairValueDisclosure" xlink:to="md_MutualFundsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSalariesAndBenefits" xlink:to="md_PracticeSalariesAndBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" xlink:to="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoZeroThreeZeroMember" xlink:to="md_TwoZeroThreeZeroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_UnnamedCorporateJointVentureOneMember" xlink:to="md_UnnamedCorporateJointVentureOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_GaapSeniorNotesMember" xlink:to="md_GaapSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_IncrementalSharesInContinuingOperation" xlink:to="md_IncrementalSharesInContinuingOperation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_ExtraordinaryItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PrimaryBeneficiaryMember" xlink:to="md_PrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_LineOfCreditAndLongTermDebtTextBlock" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PurchasePrice" xlink:to="md_PurchasePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_TwoThousandTwentyTaxYearMember" xlink:to="md_TwoThousandTwentyTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfPayMember" xlink:to="us-gaap_SelfPayMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_DeferredTaxAssetsDomain" xlink:to="md_DeferredTaxAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_HospitalsContractsMember" xlink:to="md_HospitalsContractsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReceivable" xlink:to="us-gaap_IncomeTaxReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_CreditAgreementMember" xlink:to="md_CreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_ContractedManagedCareMember" xlink:to="md_ContractedManagedCareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="md_PerformanceRestrictedStockUnitsPRSUsMember" xlink:to="md_PerformanceRestrictedStockUnitsPRSUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfInterestRateRiskExposure" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSalariesAndBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" xlink:label="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_17"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_PaymentsToTermLoan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid191" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="md_AccountsReceivableAndNetRevenueDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" xlink:label="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_LineOfCreditAndLongTermDebtTextBlock" xlink:label="md_LineOfCreditAndLongTermDebtTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="md_LineOfCreditAndLongTermDebtTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="md_CommonStockRepurchasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockRepurchasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="md_BasisOfPresentationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="md_ExtraordinaryItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="md_CashEquivalentsAndInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="md_CashEquivalentsAndInvestmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="md_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_FairValueDisclosuresTable" xlink:to="md_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="md_ScheduleOfFinancingReceivablesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" xlink:label="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncrementalSharesInContinuingOperation" xlink:label="md_IncrementalSharesInContinuingOperation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalSharesInContinuingOperation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" xlink:label="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PerformanceRestrictedStockUnitsPRSUsMember" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="md_PerformanceRestrictedStockUnitsPRSUsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="md_CommonStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="srt_ShareRepurchaseProgramAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockTable" xlink:to="md_CommonStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" xlink:label="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" xlink:label="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationLineItems" xlink:label="md_BasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="md_BasisOfPresentationAndNewAccountingPronouncementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="md_UnnamedCorporateJointVentureOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="md_UnnamedCorporateJointVentureTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PrimaryBeneficiaryMember" xlink:label="md_PrimaryBeneficiaryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_BasisOfPresentationLineItems" xlink:to="md_BasisOfPresentationAndNewAccountingPronouncementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_BasisOfPresentationLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_UnnamedCorporateJointVentureTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="md_PrimaryBeneficiaryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="md_PercentageIncreaseDecreaseInSalaryAndWage"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CovidNinenteenMember" xlink:label="md_CovidNinenteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyTaxYearMember" xlink:label="md_TwoThousandTwentyTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RuralAreaMember" xlink:label="md_RuralAreaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsAxis" xlink:label="md_ExtraordinaryItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ExtraordinaryItemsDomain" xlink:label="md_ExtraordinaryItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="md_ContributionsInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" xlink:label="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageIncreaseDecreaseInSalaryAndWage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ExtraordinaryItemsDomain" xlink:to="md_CovidNinenteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="md_TwoThousandTwentyTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="md_RuralAreaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_ExtraordinaryItemsAxis" xlink:to="md_ExtraordinaryItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_ExtraordinaryItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ContributionsInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="md_CashEquivalentsAndInvestmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="md_CashEquivalentsAndInvestmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="md_CashEquivalentsAndInvestmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CashEquivalentsAndInvestmentsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CashEquivalentsAndInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="us-gaap_AllOtherCorporateBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AllOtherCorporateBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="md_MoneyMarketFundsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="md_MutualFundsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MoneyMarketFundsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="md_MutualFundsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="md_TwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandTwentySevenMember" xlink:label="md_TwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoZeroThreeZeroMember" xlink:label="md_TwoZeroThreeZeroMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_NotesPayableFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_TwoZeroThreeZeroMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresLineItems" xlink:label="md_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FairValueDisclosuresTable" xlink:label="md_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_GaapSeniorNotesMember" xlink:label="md_GaapSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" xlink:label="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="md_FairValueDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="md_GaapSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_FairValueDisclosuresTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="md_ScheduleOfFinancingReceivablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="us-gaap_HealthCarePatientServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_HospitalsContractsMember" xlink:label="md_HospitalsContractsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="us-gaap_ProductAndServiceOtherMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_ScheduleOfFinancingReceivablesLineItems" xlink:to="us-gaap_DisaggregationOfRevenueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_HealthCarePatientServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="md_HospitalsContractsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductAndServiceOtherMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_ContractedManagedCareMember" xlink:label="md_ContractedManagedCareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentMember" xlink:label="us-gaap_GovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="md_ContractedManagedCareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_GovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsAxis" xlink:label="md_DeferredTaxAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricOrThopedicPracticesAcquired" xlink:label="md_NumberOfPediatricOrThopedicPracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" xlink:label="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="md_NorthAmericanPartnersInAnesthesiaMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_DeferredTaxAssetsDomain" xlink:label="md_DeferredTaxAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" xlink:label="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PediatricSubspecialtyPracticeMember" xlink:label="md_PediatricSubspecialtyPracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AnesthesiologyServicesMedicalGroupMember" xlink:label="md_AnesthesiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfMaternalFetalMedicinePracticesAcquired" xlink:label="md_NumberOfMaternalFetalMedicinePracticesAcquired"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_MaternalFetalMedicinePracticeMember" xlink:label="md_MaternalFetalMedicinePracticeMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RadiologyServicesMedicalGroupMember" xlink:label="md_RadiologyServicesMedicalGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NumberOfPediatricGastroenterologyPracticeAcquired" xlink:label="md_NumberOfPediatricGastroenterologyPracticeAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseInDeferredTaxAssets" xlink:label="md_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="md_DeferredTaxAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricOrThopedicPracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_NorthAmericanPartnersInAnesthesiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="md_DeferredTaxAssetsAxis" xlink:to="md_DeferredTaxAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_PediatricSubspecialtyPracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_AnesthesiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfMaternalFetalMedicinePracticesAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="md_MaternalFetalMedicinePracticeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="md_RadiologyServicesMedicalGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_NumberOfPediatricGastroenterologyPracticeAcquired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="md_IncreaseDecreaseInAccruedSalariesAndBonuses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="md_IncreaseDecreaseInAccruedSalariesAndBonuses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotes" xlink:label="us-gaap_SeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CreditAgreementMember" xlink:label="md_CreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" xlink:label="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" xlink:label="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnsecuredLongTermDebt" xlink:label="us-gaap_UnsecuredLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PurchasePrice" xlink:label="md_PurchasePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DescriptionOfInterestRateRiskExposure" xlink:label="us-gaap_DescriptionOfInterestRateRiskExposure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="md_CreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnsecuredLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="md_PurchasePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DescriptionOfInterestRateRiskExposure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PerformanceRestrictedStockUnitsPRSUsMember" xlink:label="md_PerformanceRestrictedStockUnitsPRSUsMember"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="md_AmendedAndRestatedTwoThousandEightPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="md_PerformanceRestrictedStockUnitsPRSUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_AmendedAndRestatedTwoThousandEightPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockLineItems" xlink:label="md_CommonStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_CommonStockTable" xlink:label="md_CommonStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1" xlink:label="srt_StockRepurchaseProgramAuthorizedAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="md_CommonStockLineItems" xlink:to="md_CommonStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="srt_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="srt_StockRepurchaseProgramAuthorizedAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="md_CommonStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="md_CommonStockLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_IncomeTaxReceivable" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="md_OperatingAndFinanceLeaseRightOfUseAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReceivable" xlink:label="us-gaap_IncomeTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_OperatingAndFinanceLeaseRightOfUseAssets" xlink:label="md_OperatingAndFinanceLeaseRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSalariesAndBenefits" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="md_PracticeSuppliesAndOtherOperatingExpenses" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="7" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSalariesAndBenefits" xlink:label="md_PracticeSalariesAndBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="md_PracticeSuppliesAndOtherOperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_PaymentsToTermLoan" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="md_RepaymentsOfLongTermCapitalLeaseObligation" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_PaymentsToTermLoan" xlink:label="md_PaymentsToTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_RepaymentsOfLongTermCapitalLeaseObligation" xlink:label="md_RepaymentsOfLongTermCapitalLeaseObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="md_AccruedPayrollTaxesAndBenefitsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="md-20250630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="md_AccruedPayrollTaxesAndBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_CovidNinenteenMember" name="CovidNinenteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RuralAreaMember" name="RuralAreaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncrementalSharesInContinuingOperation" name="IncrementalSharesInContinuingOperation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PracticeSalariesAndBenefits" name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" name="PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ContributionsInAidOfReimbursementOfLostRevenue" name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_CommonStockRepurchasesTextBlock" name="CommonStockRepurchasesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" name="RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" name="PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_RadiologyServicesMedicalGroupMember" name="RadiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentySevenMember" name="TwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_GaapSeniorNotesMember" name="GaapSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockTable" name="CommonStockTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_AmendedAndRestatedTwoThousandEightPlanMember" name="AmendedAndRestatedTwoThousandEightPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_BasisOfPresentationLineItems" name="BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_OperatingAndFinanceLeaseRightOfUseAssets" name="OperatingAndFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_TwoThousandTwentyTaxYearMember" name="TwoThousandTwentyTaxYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NorthAmericanPartnersInAnesthesiaMember" name="NorthAmericanPartnersInAnesthesiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_RepaymentsOfLongTermCapitalLeaseObligation" name="RepaymentsOfLongTermCapitalLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_MutualFundsFairValueDisclosure" name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_PurchasePrice" name="PurchasePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="md_MaternalFetalMedicinePracticeMember" name="MaternalFetalMedicinePracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FairValueDisclosuresLineItems" name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ExtraordinaryItemsDomain" name="ExtraordinaryItemsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ScheduleOfFinancingReceivablesLineItems" name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" name="NumberOfMultiLocationPediatricUrgentCarePracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" name="FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfPediatricOrThopedicPracticesAcquired" name="NumberOfPediatricOrThopedicPracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_UnnamedCorporateJointVentureTwoMember" name="UnnamedCorporateJointVentureTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" name="GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfPediatricGastroenterologyPracticeAcquired" name="NumberOfPediatricGastroenterologyPracticeAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_DeferredTaxAssetsDomain" name="DeferredTaxAssetsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandTwentyThreeMember" name="TwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NumberOfMaternalFetalMedicinePracticesAcquired" name="NumberOfMaternalFetalMedicinePracticesAcquired" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_HospitalsContractsMember" name="HospitalsContractsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_AccruedPayrollTaxesAndBenefitsCurrent" name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" name="IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_TwoZeroThreeZeroMember" name="TwoZeroThreeZeroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsAxis" name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsTable" name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CommonStockLineItems" name="CommonStockLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PracticeSuppliesAndOtherOperatingExpenses" name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_ExtraordinaryItemsAbstract" name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_ContractedManagedCareMember" name="ContractedManagedCareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" name="SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" name="FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_LineOfCreditAndLongTermDebtTextBlock" name="LineOfCreditAndLongTermDebtTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_FairValueDisclosuresTable" name="FairValueDisclosuresTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PercentageIncreaseDecreaseInSalaryAndWage" name="PercentageIncreaseDecreaseInSalaryAndWage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_PaymentsToTermLoan" name="PaymentsToTermLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" name="LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="md_AnesthesiologyServicesMedicalGroupMember" name="AnesthesiologyServicesMedicalGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_MoneyMarketFundsFairValueDisclosure" name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_UnnamedCorporateJointVentureOneMember" name="UnnamedCorporateJointVentureOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PerformanceRestrictedStockUnitsPRSUsMember" name="PerformanceRestrictedStockUnitsPRSUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CreditAgreementMember" name="CreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DeferredTaxAssetsAxis" name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_PrimaryBeneficiaryMember" name="PrimaryBeneficiaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_CashEquivalentsAndInvestmentsLineItems" name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" name="DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="md_NetOfTaxUnrealizedHoldingGainLossOnInvestments" name="NetOfTaxUnrealizedHoldingGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="md_PediatricSubspecialtyPracticeMember" name="PediatricSubspecialtyPracticeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pediatrix Medical Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,084,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 224,732<span></span>
</td>
<td class="nump">$ 229,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">123,594<span></span>
</td>
<td class="nump">118,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">238,992<span></span>
</td>
<td class="nump">259,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">10,424<span></span>
</td>
<td class="nump">13,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income taxes receivable</a></td>
<td class="nump">7,630<span></span>
</td>
<td class="nump">12,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,678<span></span>
</td>
<td class="nump">5,087<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">613,050<span></span>
</td>
<td class="nump">639,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">38,944<span></span>
</td>
<td class="nump">39,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,242,606<span></span>
</td>
<td class="nump">1,242,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">9,296<span></span>
</td>
<td class="nump">11,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_OperatingAndFinanceLeaseRightOfUseAssets', window );">Operating and finance lease right-of-use assets</a></td>
<td class="nump">38,690<span></span>
</td>
<td class="nump">39,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">88,729<span></span>
</td>
<td class="nump">103,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">70,785<span></span>
</td>
<td class="nump">76,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,102,100<span></span>
</td>
<td class="nump">2,152,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">303,360<span></span>
</td>
<td class="nump">398,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt and finance lease liabilities, net</a></td>
<td class="nump">23,685<span></span>
</td>
<td class="nump">20,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">12,049<span></span>
</td>
<td class="nump">12,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">341,043<span></span>
</td>
<td class="nump">434,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">583,863<span></span>
</td>
<td class="nump">597,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">29,963<span></span>
</td>
<td class="nump">31,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">244,162<span></span>
</td>
<td class="nump">257,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">36,019<span></span>
</td>
<td class="nump">34,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">33,297<span></span>
</td>
<td class="nump">32,887<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,268,347<span></span>
</td>
<td class="nump">1,387,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000,000 shares authorized; 86,854,234 and 85,866,000 shares issued and outstanding, respectively</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,021,290<span></span>
</td>
<td class="nump">1,013,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">137<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td>
<td class="num">(188,543)<span></span>
</td>
<td class="num">(248,540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">833,753<span></span>
</td>
<td class="nump">764,938<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 2,102,100<span></span>
</td>
<td class="nump">$ 2,152,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_OperatingAndFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_OperatingAndFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000,000<span></span>
</td>
<td class="nump">200,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">86,854,234<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">86,854,234<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 468,844<span></span>
</td>
<td class="nump">$ 504,296<span></span>
</td>
<td class="nump">$ 927,203<span></span>
</td>
<td class="nump">$ 999,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="nump">323,502<span></span>
</td>
<td class="nump">357,808<span></span>
</td>
<td class="nump">660,533<span></span>
</td>
<td class="nump">726,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="nump">20,614<span></span>
</td>
<td class="nump">32,369<span></span>
</td>
<td class="nump">39,300<span></span>
</td>
<td class="nump">63,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">55,714<span></span>
</td>
<td class="nump">56,565<span></span>
</td>
<td class="nump">114,318<span></span>
</td>
<td class="nump">116,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,313<span></span>
</td>
<td class="nump">8,791<span></span>
</td>
<td class="nump">10,645<span></span>
</td>
<td class="nump">19,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">3,834<span></span>
</td>
<td class="nump">13,579<span></span>
</td>
<td class="nump">10,439<span></span>
</td>
<td class="nump">22,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived asset impairments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">408,977<span></span>
</td>
<td class="nump">662,019<span></span>
</td>
<td class="nump">835,235<span></span>
</td>
<td class="nump">1,141,228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">59,867<span></span>
</td>
<td class="num">(157,723)<span></span>
</td>
<td class="nump">91,968<span></span>
</td>
<td class="num">(141,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income (loss)</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="nump">8,464<span></span>
</td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(9,130)<span></span>
</td>
<td class="num">(10,308)<span></span>
</td>
<td class="num">(18,284)<span></span>
</td>
<td class="num">(20,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliate</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="nump">911<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="num">(4,898)<span></span>
</td>
<td class="num">(10,005)<span></span>
</td>
<td class="num">(8,909)<span></span>
</td>
<td class="num">(18,073)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">54,969<span></span>
</td>
<td class="num">(167,728)<span></span>
</td>
<td class="nump">83,059<span></span>
</td>
<td class="num">(159,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (provision) benefit</a></td>
<td class="num">(15,709)<span></span>
</td>
<td class="nump">14,703<span></span>
</td>
<td class="num">(23,062)<span></span>
</td>
<td class="nump">10,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">39,260<span></span>
</td>
<td class="num">(153,025)<span></span>
</td>
<td class="nump">59,997<span></span>
</td>
<td class="num">(148,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized holding gain on investments, net of tax of $140, $66, $395 and $86</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="nump">$ 39,689<span></span>
</td>
<td class="num">$ (152,825)<span></span>
</td>
<td class="nump">$ 61,205<span></span>
</td>
<td class="num">$ (148,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="num">$ (1.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">84,797<span></span>
</td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">84,653<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">85,529<span></span>
</td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">85,517<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_NetOfTaxUnrealizedHoldingGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Of Tax, Unrealized Holding Gain (Loss) on Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_NetOfTaxUnrealizedHoldingGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 999,906<span></span>
</td>
<td class="num">$ (2,214)<span></span>
</td>
<td class="num">$ (149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">4,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">849,061<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">999,906<span></span>
</td>
<td class="num">(2,214)<span></span>
</td>
<td class="num">(149,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,018,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(148,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">706,461<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,006,018<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
<td class="num">(298,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">856,196<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">1,002,946<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
<td class="num">(145,436)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(153,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">706,461<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,006,018<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
<td class="num">(298,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">764,938<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,013,690<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(248,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">20,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(1,569)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(1,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">789,188<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,016,425<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(227,803)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">764,938<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,013,690<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(248,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 59,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 833,753<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">1,021,290<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="num">(188,543)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">789,188<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">1,016,425<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(227,803)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">39,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan Value</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of restricted stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(963,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">$ 833,753<span></span>
</td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 1,021,290<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="num">$ (188,543)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 59,997<span></span>
</td>
<td class="num">$ (148,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">10,645<span></span>
</td>
<td class="nump">19,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,550<span></span>
</td>
<td class="nump">5,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">16,504<span></span>
</td>
<td class="num">(25,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(1,501)<span></span>
</td>
<td class="num">(1,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">21,231<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">9,601<span></span>
</td>
<td class="nump">16,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(89,951)<span></span>
</td>
<td class="num">(82,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">4,763<span></span>
</td>
<td class="nump">11,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="num">(8,166)<span></span>
</td>
<td class="nump">8,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(9,315)<span></span>
</td>
<td class="num">(11,630)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities - continuing operations</a></td>
<td class="nump">22,020<span></span>
</td>
<td class="num">(13,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="num">(2,316)<span></span>
</td>
<td class="num">(4,995)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">19,704<span></span>
</td>
<td class="num">(18,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(21,529)<span></span>
</td>
<td class="num">(39,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">18,380<span></span>
</td>
<td class="nump">31,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,833)<span></span>
</td>
<td class="num">(12,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(3,636)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,618)<span></span>
</td>
<td class="num">(29,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">235,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(235,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PaymentsToTermLoan', window );">Payments on term loan</a></td>
<td class="num">(9,375)<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_RepaymentsOfLongTermCapitalLeaseObligation', window );">Payment on finance lease obligation</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(1,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(1,778)<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(10,294)<span></span>
</td>
<td class="num">(6,451)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(5,208)<span></span>
</td>
<td class="num">(53,856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">229,940<span></span>
</td>
<td class="nump">73,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 224,732<span></span>
</td>
<td class="nump">$ 19,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PaymentsToTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PaymentsToTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_RepaymentsOfLongTermCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Capital Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_RepaymentsOfLongTermCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity attributable to discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity attributable to continuing operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 39,260<span></span>
</td>
<td class="nump">$ 20,737<span></span>
</td>
<td class="num">$ (153,025)<span></span>
</td>
<td class="nump">$ 4,035<span></span>
</td>
<td class="nump">$ 59,997<span></span>
</td>
<td class="num">$ (148,990)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">            Basis of Presentation and New Accounting Pronouncements:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#8220;PMG&#8221;) together with the accounts of PMG&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#8220;Pediatrix&#8221; and the &#8220;Company&#8221; refer collectively to Pediatrix Medical Group, Inc., its subsidiaries and the affiliated professional contractors.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During 2024, the Company exited almost all of its affiliated office-based practices, including its primary and urgent care service line.  The operating results of these practices did not meet the criteria to be reported as discontinued operations in the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Statements of Income and Comprehensive Income.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is a party to a joint venture in which it owns a </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form 10-K (the &#8220;Form 10-K&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, accounting guidance related to income tax disclosures was issued which will require additional disclosure in the Company's income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The accounting guidance will also require the Company to disaggregate its income taxes paid disclosure by federal and state jurisdictions, with further disaggregation required for significant state jurisdictions. The guidance is effective for annual periods beginning after December 15, 2024. We expect this standard to impact our disclosures with no impact to our results of operations, cash flows, or financial condition.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.            Cash Equivalents and Investments:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 and December 31, 2024, the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s cash equivalents consisted entirely of money market funds totaling $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:72.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.529%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.316%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.316%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,411</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,590</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal home loan securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,640</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.            Fair Value Measurements:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques.</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.54%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:13%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,872</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.72%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">392,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">382,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Receivable and Net Revenue:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30%;box-sizing:content-box;"></td>
         <td style="width:1.822%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.667%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.244%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.333%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.600000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net patient service revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,410</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">432,847</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">786,788</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854,678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,913</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,408</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">536</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,007</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,844</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927,203</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999,397</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.233%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.197%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.198%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.578%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.677999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted managed care</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other third-parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private-pay patients</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.           Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s book equity value. As a result, the Company performed an interim goodwill impairment assessment.  This assessment resulted in a non-cash goodwill impairment charge of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">154.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the second quarter of 2024, the Company recognized fixed asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and intangible asset impairments of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the exit of its affiliated office-based practices. </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized a loss on disposal of businesses of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million associated with the exit of its primary and urgent care service line.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.            Accounts Payable and Accrued Expenses:	</span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.76%;box-sizing:content-box;"></td>
         <td style="width:2.58%;box-sizing:content-box;"></td>
         <td style="width:1.36%;box-sizing:content-box;"></td>
         <td style="width:17.72%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1.36%;box-sizing:content-box;"></td>
         <td style="width:17.72%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,065</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,431</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,585</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215,357</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,377</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,450</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,607</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,430</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,159</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,569</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,863</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,360</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398,690</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net decrease in accrued salaries and incentive compensation of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, from December 31, 2024 to June 30, 2025, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_LineOfCreditAndLongTermDebtTextBlock', window );">Line of Credit and Long Term Debt</a></td>
<td class="text"><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Line of Credit and Long-Term Debt:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 11, 2022,</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company issued $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% unsecured senior notes due 2030 (the &#8220;2030 Notes&#8221;).  Interest on the 2030 Notes accrues at the rate of </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.375</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, or $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s obligations under the 2030 </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrently with the issuance of the 2030 Notes, the Company amended its credit agreement (the &#8220;Credit Agreement&#8221;, and such amendment, the </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Agreement Amendment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million unsecured revolving credit facility, including a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million sub-facility for the issuance of letters of credit (the &#8220;Revolving Credit Line&#8221;), and a $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million term A loan facility (&#8220;Term A Loan&#8221;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Agreement, as amended by the Credit Agreement Amendment (the &#8220;Amended Credit Agreement&#8221;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s subsidiaries and affiliated professional contractors. At the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s option, borrowings under the Amended Credit Agreement bear interest at </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, based on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s consolidated net leverage ratio.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, the Company had an outstanding principal balance on the Amended Credit Agreement of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">206.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, composed of the Term A Loan. There was no outstanding balance under the Revolving Credit Line at June 30, 2025. The Company had $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">450.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million available on its Revolving Credit Line at June 30, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At June 30, 2025, the Company had an outstanding principal balance of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the 2030 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LineOfCreditAndLongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit And Long Term Debt [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LineOfCreditAndLongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common and Common Equivalent Shares:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and is calculated using the treasury stock method.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:9pt;font-family:Times New Roman;"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,517</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Antidilutive restricted stock not included in the diluted net income per common share calculation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">916</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">661</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Incentive Plans and Stock Purchase Plans:</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;Amended and Restated 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant and generally become exercisable on a pro rata basis over a </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of </span><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of restricted stock and </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of performance-based restricted stock units to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Company&#8217;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 Non-Qualified Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible non-employee service providers are permitted to purchase the Company&#8217;s common stock at </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of market value on January 1st, April 1st, July 1st and October 1st of each year.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares were issued under the ESPP. At June 30, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares reserved for issuance under the ESPP. At June 30, 2025, the Company had approximately </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,000</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the aggregate reserved for issuance under the SPP. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares have been issued under the SPP since 2020.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three and six months ended June 30, 2025 and 2024, the Company recognized stock-based compensation expense of $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. </span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Repurchase Programs:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were purchased under this program during the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months ended June 30, 2025.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $</span><span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remained available for repurchase as of December 31, 2024. Under this share repurchase program, during the six months ended June 30, 2025, the Company purchased a nominal number of shares of its common stock for $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million remaining available for repurchase under this authorization as of June 30, 2025.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Reporting:</span></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting. Financial results for all practices are managed on a consolidated basis. The chief operating decision maker assesses performance and decides how to allocate resources based on net income and total assets as reported in the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Financial Statements. Significant segment expenses are practice salaries and benefits and general and administrative expenses as reported on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s Consolidated Statements of Income and Comprehensive Income. Refer to the Consolidated Financial Statements for the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s segment revenue, significant segment expenses, other segment expenses and net income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">            </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies:	</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price of its securities. The Company has not included an accrual for these matters as of June 30, 2025 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s affiliated physicians. The Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading price of its securities.</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company</span><a href="#mda"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span></a><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s business, financial condition, results of operations, cash flows and the trading price of its securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments held are all classified as current and at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 are summarized as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:72.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.529%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.316%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.316%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,232</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,411</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,590</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Municipal debt securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,183</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal home loan securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,640</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificates of deposit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,010</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.54%;box-sizing:content-box;"></td>
         <td style="width:1.32%;box-sizing:content-box;"></td>
         <td style="width:13%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value<br/>Category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,295</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mutual funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,872</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 30, 2025 and December 31, 2024 (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:50.72%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.08%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.24%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">392,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">400,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">382,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s net revenue by category (in thousands):</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:30%;box-sizing:content-box;"></td>
         <td style="width:1.822%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.667%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.244%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.333%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.111%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.600000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net patient service revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">397,410</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">432,847</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">786,788</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">854,678</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Hospital contract administrative fees</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,913</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,408</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">536</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,007</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">468,844</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">504,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927,203</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">999,397</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approximate percentage of net patient service revenue by type of payor was as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:36.233%;box-sizing:content-box;"></td>
         <td style="width:1.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.197%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.82%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.198%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.578%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.677999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted managed care</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other third-parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Private-pay patients</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts payable and accrued expenses consist of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.76%;box-sizing:content-box;"></td>
         <td style="width:2.58%;box-sizing:content-box;"></td>
         <td style="width:1.36%;box-sizing:content-box;"></td>
         <td style="width:17.72%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1.36%;box-sizing:content-box;"></td>
         <td style="width:17.72%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">June 30, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,065</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,431</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued salaries and incentive compensation</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,585</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215,357</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll taxes and benefits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,377</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,450</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,607</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,430</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,157</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,159</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued expenses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,569</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,863</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,360</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398,690</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text"><p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The calculation of shares used in the basic and diluted net income per common share calculation for the </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three and six months ended June 30, 2025 and 2024 is as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.98%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.3%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of dilutive common share<br/>&#160;&#160;&#160;equivalents</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of common and common<br/>&#160;&#160;&#160;equivalent shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,529</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,332</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,517</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,074</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Antidilutive restricted stock not included in the diluted net income per common share calculation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">325</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">916</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">661</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Due to a loss for the three and six months ended June 30, 2024, </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million incremental shares, respectively, are not included because the effect would be antidilutive.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Investments Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 123,594<span></span>
</td>
<td class="nump">$ 118,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">50,232<span></span>
</td>
<td class="nump">46,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">44,423<span></span>
</td>
<td class="nump">40,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">20,183<span></span>
</td>
<td class="nump">22,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 2,010<span></span>
</td>
<td class="nump">$ 2,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 5,290<span></span>
</td>
<td class="nump">$ 9,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual funds</a></td>
<td class="nump">18,872<span></span>
</td>
<td class="nump">18,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">$ 123,594<span></span>
</td>
<td class="nump">$ 118,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - 2030 Notes [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="nump">$ 382,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoZeroThreeZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 468,844<span></span>
</td>
<td class="nump">$ 504,296<span></span>
</td>
<td class="nump">$ 927,203<span></span>
</td>
<td class="nump">$ 999,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">397,410<span></span>
</td>
<td class="nump">432,847<span></span>
</td>
<td class="nump">786,788<span></span>
</td>
<td class="nump">854,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">68,224<span></span>
</td>
<td class="nump">70,913<span></span>
</td>
<td class="nump">133,408<span></span>
</td>
<td class="nump">142,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,210<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 7,007<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Fixed asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment, Long-Lived Asset, Held-for-Use</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,791<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on disposal of businesses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(10,873)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (10,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge', window );">Non-cash impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Good will Impairment Loss excluding Deferred Tax Assets Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 42,065<span></span>
</td>
<td class="nump">$ 46,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and incentive compensation</a></td>
<td class="nump">133,585<span></span>
</td>
<td class="nump">215,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">31,377<span></span>
</td>
<td class="nump">35,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">30,607<span></span>
</td>
<td class="nump">30,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">8,157<span></span>
</td>
<td class="nump">8,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">57,569<span></span>
</td>
<td class="nump">62,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 303,360<span></span>
</td>
<td class="nump">$ 398,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 81.8<span></span>
</td>
<td class="nump">$ 81.8<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Line of Credit and Long Term Debt (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt Instrument, Frequency of Periodic Payment</a></td>
<td class="text">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company&#8217;s ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_PurchasePrice', window );">Purchase price</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit facility, available balance</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="nump">206.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredLongTermDebt', window );">Proceeds from issuance of unsecured debt</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured note issued</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfInterestRateRiskExposure', window );">Interest Rate, description</a></td>
<td class="text">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company&#8217;s consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company&#8217;s consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding amount</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember', window );">5.375% Unsecured Senior Notes Due 2030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest accrued periodically</a></td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfInterestRateRiskExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the sources of interest rate risk exposure faced by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfInterestRateRiskExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">84,797<span></span>
</td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">84,653<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">864<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="nump">85,529<span></span>
</td>
<td class="nump">83,332<span></span>
</td>
<td class="nump">85,517<span></span>
</td>
<td class="nump">83,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the diluted net income per common share calculation</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares', window );">Incremental shares</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares not included in the calculation of diluted EPS as a result of the potentially antidilutive effect of contingently issuable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Performance Restricted Stock Units (PRSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=md_PerformanceRestrictedStockUnitsPRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=md_PerformanceRestrictedStockUnitsPRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,778<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(109,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>206</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Consolidated Statements of Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Basis of Presentation and New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses</Role>
      <ShortName>Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Line of Credit and Long Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</Role>
      <ShortName>Line of Credit and Long Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails</Role>
      <ShortName>Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Line of Credit and Long Term Debt (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="md-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Segment Reporting (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="md-20250630.htm">md-20250630.htm</File>
    <File>md-20250630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img261193434_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="449">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "md-20250630.htm": {
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "md-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "md-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 188,
   "keyCustom": 18,
   "axisStandard": 13,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 11,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 6
   },
   "contextCount": 122,
   "entityCount": 1,
   "segmentCount": 34,
   "elementCount": 499,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 449,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CoverPage",
     "longName": "75000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited",
     "longName": "75010 - Statement - Consolidated Balance Sheets (Unaudited)",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "longName": "75020 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited",
     "longName": "75030 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "md:PracticeSalariesAndBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical",
     "longName": "75040 - Statement - Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "shortName": "Consolidated Statements of Income and Comprehensive Income (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "md:NetOfTaxUnrealizedHoldingGainLossOnInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
     "longName": "75050 - Statement - Consolidated Statements of Equity (Unaudited)",
     "shortName": "Consolidated Statements of Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_16ceb319-42b3-45e5-aca2-e0b5ad682a53",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6767043a-8ca4-4e7b-8a97-d9178cf9f8df",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "75060 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1",
     "longName": "995455 - Disclosure - Basis of Presentation and New Accounting Pronouncements",
     "shortName": "Basis of Presentation and New Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments",
     "longName": "995475 - Disclosure - Cash Equivalents and Investments",
     "shortName": "Cash Equivalents and Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements",
     "longName": "995485 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue",
     "longName": "995495 - Disclosure - Accounts Receivable and Net Revenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses",
     "longName": "995505 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses",
     "shortName": "Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses",
     "longName": "995525 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt",
     "longName": "995535 - Disclosure - Line of Credit and Long Term Debt",
     "shortName": "Line of Credit and Long Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:LineOfCreditAndLongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares",
     "longName": "995545 - Disclosure - Common and Common Equivalent Shares",
     "shortName": "Common and Common Equivalent Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans",
     "longName": "995555 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms",
     "longName": "995565 - Disclosure - Common Stock Repurchase Programs",
     "shortName": "Common Stock Repurchase Programs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:CommonStockRepurchasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995575 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995585 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables",
     "longName": "995605 - Disclosure - Cash Equivalents and Investments (Tables)",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995615 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables",
     "longName": "995625 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables",
     "longName": "995635 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables",
     "longName": "995645 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail",
     "longName": "995655 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "shortName": "Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_03af3506-de9e-4102-99ce-56bb360a66d4",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_03af3506-de9e-4102-99ce-56bb360a66d4",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "longName": "995675 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_a0b59a66-3754-4522-ac83-cb30014bf52e",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0b59a66-3754-4522-ac83-cb30014bf52e",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "longName": "995685 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "longName": "995695 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_990f8274-6879-4e07-9304-6c955d3df201",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_990f8274-6879-4e07-9304-6c955d3df201",
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "longName": "995705 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_acc92b1b-1d33-4ded-92dd-bd2ae778529a",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_acc92b1b-1d33-4ded-92dd-bd2ae778529a",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "longName": "995725 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9a921698-6494-4872-95ea-71129e633bb1",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "longName": "995735 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)",
     "shortName": "Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_08f4d25d-4559-4691-80b0-687c52c265b4",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_08f4d25d-4559-4691-80b0-687c52c265b4",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "longName": "995765 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails",
     "longName": "995785 - Disclosure - Line of Credit and Long Term Debt (Additional Information) (Details)",
     "shortName": "Line of Credit and Long Term Debt (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "md:LineOfCreditAndLongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "longName": "995795 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails",
     "longName": "995815 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_08f4d25d-4559-4691-80b0-687c52c265b4",
      "name": "md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_08f4d25d-4559-4691-80b0-687c52c265b4",
      "name": "md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b46b7d38-353d-4da0-915e-fea75ff40a63",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "longName": "995835 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a0c2cfa6-1c3d-4c86-9c0c-7cee140ba3f5",
      "name": "srt:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Segment Reporting (Additional Information) (Details)",
     "shortName": "Segment Reporting (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04755f25-aca6-47b4-a390-81102d0c243b",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "md-20250630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts payable and accrued expenses, total",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r42",
      "r47",
      "r1128"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r854"
     ]
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Net Revenue",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "documentation": "Accounts receivable and net revenue disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r88"
     ]
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll taxes and benefits",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "documentation": "Accrued payroll taxes and benefits current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and incentive compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r773"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r59",
      "r158",
      "r632",
      "r660",
      "r661",
      "r1142"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r11",
      "r527",
      "r530",
      "r579",
      "r656",
      "r657",
      "r981",
      "r982",
      "r983",
      "r1039",
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1143",
      "r1207"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r895",
      "r905",
      "r937"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r888",
      "r898",
      "r908",
      "r940"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941",
      "r945",
      "r953"
     ]
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllOtherCorporateBondsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Corporate Bonds [Member]",
        "terseLabel": "Corporate securities",
        "documentation": "Investments in corporate fixed maturity debt securities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r435",
      "r436"
     ]
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2008 Plan [Member]",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "documentation": "Amended and restated two thousand eight plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premiums, discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r802",
      "r803",
      "r1029",
      "r1158"
     ]
    },
    "md_AnesthesiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "AnesthesiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anesthesiology Services Medical Group [Member]",
        "documentation": "Anesthesiology services medical group."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r99",
      "r154",
      "r180",
      "r182",
      "r183",
      "r219",
      "r228",
      "r239",
      "r242",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r518",
      "r523",
      "r564",
      "r619",
      "r620",
      "r626",
      "r712",
      "r788",
      "r789",
      "r804",
      "r854",
      "r860",
      "r862",
      "r876",
      "r1091",
      "r1092",
      "r1162"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r161",
      "r180",
      "r182",
      "r183",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r518",
      "r523",
      "r564",
      "r854",
      "r1091",
      "r1092",
      "r1162"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r297",
      "r541",
      "r559",
      "r560",
      "r561",
      "r562",
      "r616",
      "r769",
      "r840",
      "r845",
      "r852",
      "r1056",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r297"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]",
        "documentation": "Basis Of Presentation And New Accounting Pronouncements Table"
       }
      }
     },
     "auth_ref": []
    },
    "md_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation [Line Items]",
        "documentation": "Basis Of Presentation Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r663",
      "r819",
      "r820",
      "r1135",
      "r1136",
      "r1138"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r663",
      "r819",
      "r820",
      "r1135",
      "r1136",
      "r1138"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Business Combination, Goodwill, Expected Tax Deductible, Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r509",
      "r825",
      "r830"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Business Combination, Consideration Transferred, Total",
        "terseLabel": "Business acquisition total consideration",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r509",
      "r825",
      "r831"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Text Block]",
        "terseLabel": "Business Combinations",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r457",
      "r466",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r484",
      "r487",
      "r488",
      "r494",
      "r495",
      "r496",
      "r504",
      "r508",
      "r509",
      "r510",
      "r512",
      "r514",
      "r825",
      "r826",
      "r827",
      "r828",
      "r832",
      "r833",
      "r834"
     ]
    },
    "us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingency Recognized at Acquisition Date, Liability Assumed, Fair Value",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "Amount of liability arising from contingency in business combination, measured at acquisition-date fair value and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r487",
      "r825",
      "r831",
      "r834"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Asset Acquired, Asset, Current",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Total",
        "terseLabel": "Business combination consideration identifiable as current and long term liabilities",
        "documentation": "Amount of asset acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1139"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangible assets",
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived",
        "documentation": "Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1137",
      "r1139"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total",
        "documentation": "Amount of property, plant, and equipment acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r831",
      "r1137",
      "r1139"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r151",
      "r771"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r72",
      "r179"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]",
        "documentation": "Cash Equivalents And Investments Line Items"
       }
      }
     },
     "auth_ref": []
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CashEquivalentsAndInvestmentsTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]",
        "documentation": "Cash Equivalents And Investments Table"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activity, Discontinued Operation",
        "verboseLabel": "Net cash provided by operating activities - discontinued operations",
        "totalLabel": "Cash Provided by (Used in) Operating Activities, Discontinued Operations, Total",
        "documentation": "Amount of cash inflow (outflow) from operating activity attributable to discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r72"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Certificates of Deposit [Member]",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r870",
      "r871",
      "r872",
      "r873"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r155",
      "r156",
      "r157",
      "r180",
      "r183",
      "r206",
      "r210",
      "r212",
      "r214",
      "r221",
      "r222",
      "r289",
      "r334",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r364",
      "r365",
      "r367",
      "r368",
      "r370",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r564",
      "r665",
      "r666",
      "r667",
      "r668",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r720",
      "r737",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r963",
      "r1033",
      "r1035",
      "r1043"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r90",
      "r629",
      "r699"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r327",
      "r328",
      "r766",
      "r1080",
      "r1086"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "md_CommonStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CommonStockLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "documentation": "Common Stock [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r867",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1039",
      "r1040",
      "r1042",
      "r1143",
      "r1205",
      "r1207"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "md_CommonStockRepurchasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CommonStockRepurchasesTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchasePrograms"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Repurchase Programs",
        "label": "Common Stock Repurchases [Text Block]",
        "documentation": "Entire disclosure of common stock repurchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r700"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r700",
      "r718",
      "r1207",
      "r1208"
     ]
    },
    "md_CommonStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CommonStockTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "documentation": "Common Stock [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "verboseLabel": "Common stock; $.01 par value; 200,000,000 shares authorized; 86,854,234 and 85,866,000 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r365",
      "r372",
      "r631",
      "r854"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total comprehensive income (loss) attributable to Pediatrix Medical Group, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r165",
      "r167",
      "r171",
      "r617",
      "r643",
      "r644"
     ]
    },
    "md_ContractedManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ContractedManagedCareMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "documentation": "Contracted Managed Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of Lost Revenue",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (COVID-19)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "md_CovidNinenteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CovidNinenteenMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COVID-19 [Member]",
        "label": "Covid Ninenteen [Member]",
        "documentation": "Covid Ninenteen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "documentation": "Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r1090"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r1090"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r87",
      "r89",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r853",
      "r1031",
      "r1032",
      "r1034",
      "r1038",
      "r1081",
      "r1082",
      "r1083",
      "r1157",
      "r1159",
      "r1171"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r29",
      "r41",
      "r87",
      "r89",
      "r572"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt Instrument, Frequency of Periodic Payment",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Debt instrument maturity date description",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r30"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r361",
      "r572",
      "r573",
      "r853"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r344"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r525",
      "r623",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r853",
      "r1031",
      "r1032",
      "r1034",
      "r1038",
      "r1157",
      "r1159"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r853",
      "r1031",
      "r1032",
      "r1034",
      "r1038",
      "r1081",
      "r1082",
      "r1083",
      "r1157",
      "r1159",
      "r1171"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Interest",
        "terseLabel": "Interest accrued periodically",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r21",
      "r28",
      "r80",
      "r81",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r525",
      "r623",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r853",
      "r1031",
      "r1032",
      "r1034",
      "r1038",
      "r1157",
      "r1159"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Investments",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "totalLabel": "Deferred Income Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r101",
      "r1031",
      "r1037"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r627"
     ]
    },
    "md_DeferredTaxAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "DeferredTaxAssetsAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Axis",
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "md_DeferredTaxAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "DeferredTaxAssetsDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Domain]",
        "documentation": "Deferred Tax Assets Domain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r176",
      "r219",
      "r232",
      "r242",
      "r774",
      "r788",
      "r789"
     ]
    },
    "us-gaap_DescriptionOfInterestRateRiskExposure": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DescriptionOfInterestRateRiskExposure",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Interest Rate Risk Exposure",
        "terseLabel": "Interest Rate, description",
        "documentation": "Description of the sources of interest rate risk exposure faced by the entity."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r402",
      "r431",
      "r432",
      "r433",
      "r822"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "md_DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "label": "Dissolution Of And Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Dissolution of and net loss attributable to noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r172",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r204",
      "r206",
      "r212",
      "r213",
      "r214",
      "r218",
      "r363",
      "r434",
      "r450",
      "r516",
      "r538",
      "r539",
      "r618",
      "r645",
      "r782"
     ]
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r172",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r206",
      "r212",
      "r213",
      "r214",
      "r218",
      "r363",
      "r434",
      "r450",
      "r516",
      "r538",
      "r539",
      "r618",
      "r645",
      "r782"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Common Equivalent Shares",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r215",
      "r216",
      "r217"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r141",
      "r143",
      "r144",
      "r168",
      "r169",
      "r170",
      "r186",
      "r187",
      "r188",
      "r190",
      "r197",
      "r199",
      "r201",
      "r220",
      "r290",
      "r291",
      "r324",
      "r362",
      "r381",
      "r434",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r451",
      "r515",
      "r516",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r576",
      "r579",
      "r641",
      "r656",
      "r657",
      "r658",
      "r672",
      "r737"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r446",
      "r564",
      "r965",
      "r966",
      "r967",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method ownership percentage in joint venture",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r564"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r885",
      "r895",
      "r905",
      "r937"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r892",
      "r902",
      "r934"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]",
        "documentation": "Person with designation of executive officer."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "md_ExtraordinaryItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ExtraordinaryItemsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Abstract]",
        "documentation": "Extraordinary Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ExtraordinaryItemsAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Axis]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ExtraordinaryItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ExtraordinaryItemsDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extraordinary Items [Domain]",
        "documentation": "Extraordinary Items [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r549",
      "r550",
      "r551",
      "r560",
      "r583",
      "r584",
      "r585",
      "r769",
      "r800",
      "r801",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r840",
      "r845",
      "r852"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r545",
      "r840",
      "r1148",
      "r1151"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "FairValueDisclosuresLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Line Items]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "md_FairValueDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "FairValueDisclosuresTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Table]",
        "documentation": "Fair value disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r546",
      "r547",
      "r548",
      "r549",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r614",
      "r840",
      "r846"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r386",
      "r391",
      "r392",
      "r542",
      "r550",
      "r560",
      "r583",
      "r769",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r840",
      "r852"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r386",
      "r391",
      "r392",
      "r394",
      "r542",
      "r543",
      "r550",
      "r560",
      "r584",
      "r769",
      "r800",
      "r801",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r840",
      "r852"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r545",
      "r840",
      "r1148",
      "r1151"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r540",
      "r542",
      "r543",
      "r544",
      "r545",
      "r549",
      "r550",
      "r551",
      "r560",
      "r583",
      "r584",
      "r585",
      "r769",
      "r800",
      "r801",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r840",
      "r845",
      "r852"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1151"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r359",
      "r379",
      "r525",
      "r536",
      "r556",
      "r563",
      "r565",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r625",
      "r642",
      "r797",
      "r840",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r855",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1144",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153"
     ]
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments Measured At Carrying Amount",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net, Total",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r1077"
     ]
    },
    "md_FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five point three seven five percent unsecured senior notes due two thousand thirty member.",
        "label": "Five Point Three Seven Five Percent Unsecured Senior Notes Due Two Thousand Thirty Member",
        "terseLabel": "5.375% Unsecured Senior Notes Due 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "FivePointTwoFivePercentageSeniorNotesDueTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "label": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]",
        "documentation": "Five Point Two Five Percentage Senior Notes Due Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r941"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "md_GaapSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "GaapSeniorNotesMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAAP Senior Notes [Member]",
        "label": "GAAP Senior Notes [Member]",
        "documentation": "GAAP Senior Notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Loss on disposal of businesses",
        "negatedLabel": "Loss on disposal of businesses",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1029"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r722"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r619",
      "r620",
      "r621",
      "r622",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r619",
      "r620",
      "r621",
      "r622",
      "r795",
      "r796"
     ]
    },
    "md_GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash impairment charge",
        "label": "Good will Impairment Loss excluding Deferred Tax Assets Charge",
        "documentation": "Good will Impairment Loss excluding Deferred Tax Assets Charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r303",
      "r615",
      "r789",
      "r798",
      "r825",
      "r829",
      "r831",
      "r837",
      "r842",
      "r854",
      "r1074",
      "r1075",
      "r1140"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment",
        "totalLabel": "Goodwill and Intangible Asset Impairment, Total",
        "terseLabel": "Impairment losses",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinesses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1076"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r304",
      "r310",
      "r315",
      "r317",
      "r513",
      "r798",
      "r842"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r798"
     ]
    },
    "us-gaap_GovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government [Member]",
        "label": "Government [Member]",
        "documentation": "Organization that is the governing authority of a community."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "documentation": "Information by major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "documentation": "Major payor source of revenue for health care organizations."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HealthCarePatientServiceMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net patient service revenue [Member]",
        "label": "Health Care, Patient Service [Member]",
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1097"
     ]
    },
    "md_HospitalsContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "HospitalsContractsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hospital contract administrative fees [Member]",
        "label": "Hospitals Contracts [Member]",
        "documentation": "Hospitals Contracts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairments",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r1029",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "terseLabel": "Long-lived asset impairments",
        "verboseLabel": "Fixed asset impairments",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r18",
      "r78",
      "r173",
      "r775",
      "r841"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Fixed asset impairments",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r77",
      "r843"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) income from continuing operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r93",
      "r98",
      "r619",
      "r621",
      "r637",
      "r776",
      "r778",
      "r779",
      "r784",
      "r788",
      "r1045",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental loss on sale, net",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent, Total",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r38",
      "r84"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in earnings of unconsolidated affiliate",
        "label": "Income (Loss) from Equity Method Investments",
        "totalLabel": "Income (Loss) from Equity Method Investments, Total",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r61",
      "r92",
      "r219",
      "r233",
      "r242",
      "r285",
      "r636"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "negatedLabel": "Income tax provision",
        "negatedTerseLabel": "Income tax (provision) benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r180",
      "r200",
      "r201",
      "r219",
      "r234",
      "r242",
      "r440",
      "r441",
      "r445",
      "r646",
      "r776",
      "r778",
      "r779",
      "r824"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net decrease in accrued salaries and bonuses",
        "label": "Increase (Decrease) in Accrued Salaries and Bonuses",
        "documentation": "Increase (decrease) in accrued salaries and bonuses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes payable",
        "terseLabel": "Income taxes receivable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "md_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in deferred tax assets",
        "label": "Increase In Deferred Tax assets",
        "documentation": "Increase in deferred tax Assets."
       }
      }
     },
     "auth_ref": []
    },
    "md_IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Antidilutive Effect of Contingently Issuable Shares",
        "documentation": "Additional shares not included in the calculation of diluted EPS as a result of the potentially antidilutive effect of contingently issuable shares.",
        "terseLabel": "Incremental shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of dilutive common share equivalents",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r214",
      "r401"
     ]
    },
    "md_IncrementalSharesInContinuingOperation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "IncrementalSharesInContinuingOperation",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCommonAndCommonEquivalentSharesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Shares In Continuing operation",
        "documentation": "Incremental Shares In Continuing operation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941",
      "r945",
      "r953"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r957"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r776",
      "r779",
      "r984"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment and other income (expense)",
        "label": "Investment Income, Net",
        "totalLabel": "Investment Income, Net, Total",
        "terseLabel": "Investment and other income (loss)",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r67"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r740",
      "r742",
      "r744",
      "r747",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r868"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r740",
      "r742",
      "r744",
      "r747",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r868"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "terseLabel": "Short-term investments",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1146",
      "r1150",
      "r1152",
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents and Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r116",
      "r251",
      "r253",
      "r557",
      "r558",
      "r1170"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit outstanding amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r863"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r43",
      "r46",
      "r47",
      "r48",
      "r49",
      "r180",
      "r182",
      "r183",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r519",
      "r523",
      "r524",
      "r564",
      "r698",
      "r783",
      "r804",
      "r876",
      "r1091",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r91",
      "r634",
      "r854",
      "r860",
      "r862",
      "r1031",
      "r1036",
      "r1072",
      "r1156"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r150",
      "r180",
      "r182",
      "r183",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r519",
      "r523",
      "r524",
      "r564",
      "r854",
      "r1091",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "md_LineOfCreditAndLongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "LineOfCreditAndLongTermDebtTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit And Long Term Debt [Text Block]",
        "label": "Line Of Credit And Long Term Debt [Text Block]",
        "terseLabel": "Line of Credit and Long Term Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of Credit facility, available balance",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r45",
      "r333"
     ]
    },
    "md_LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "LineOfCreditLongTermDebtAndFinanceLeaseObligationsDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit and Long Term Debt",
        "label": "Line Of Credit Long Term Debt And Finance Lease Obligations Disclosure Text Block",
        "documentation": "Line of credit long term debt and finance lease obligations disclosure text block."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Debt, Total",
        "label": "Long-Term Debt",
        "terseLabel": "Long term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r181",
      "r185",
      "r350",
      "r360",
      "r623",
      "r800",
      "r801",
      "r853",
      "r1173"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation",
        "totalLabel": "Long-Term Debt and Lease Obligation, Total",
        "terseLabel": "Long-term debt and finance lease liabilities, net",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r628"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt and finance lease liabilities, net",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "totalLabel": "Long-Term Debt and Lease Obligation, Current, Total",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-Term Debt",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Term A loan",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r19",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term professional liabilities",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability)."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "md_MaternalFetalMedicinePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "MaternalFetalMedicinePracticeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maternal Fetal Medicine Practice [Member]",
        "documentation": "Maternal Fetal Medicine Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r223",
      "r329",
      "r330",
      "r331",
      "r332",
      "r395",
      "r426",
      "r427",
      "r428",
      "r437",
      "r545",
      "r611",
      "r654",
      "r655",
      "r662",
      "r690",
      "r691",
      "r741",
      "r743",
      "r745",
      "r746",
      "r750",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r793",
      "r805",
      "r821",
      "r825",
      "r832",
      "r835",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r1093",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r223",
      "r329",
      "r330",
      "r331",
      "r332",
      "r395",
      "r426",
      "r427",
      "r428",
      "r437",
      "r545",
      "r611",
      "r654",
      "r655",
      "r662",
      "r690",
      "r691",
      "r741",
      "r743",
      "r745",
      "r746",
      "r750",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r793",
      "r805",
      "r821",
      "r825",
      "r832",
      "r835",
      "r845",
      "r846",
      "r850",
      "r857",
      "r1093",
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "md_MutualFundsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "MutualFundsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Continuing Operation",
        "totalLabel": "Net cash provided by (used in) operating activities - continuing operations",
        "documentation": "Amount of cash inflow (outflow) from operating activity attributable to continuing operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net Income (loss) attributable to Pediatrix Medical Group, Inc.",
        "verboseLabel": "Net income (loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r74",
      "r94",
      "r144",
      "r148",
      "r164",
      "r166",
      "r170",
      "r180",
      "r182",
      "r183",
      "r184",
      "r189",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r211",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r366",
      "r369",
      "r374",
      "r434",
      "r450",
      "r516",
      "r539",
      "r564",
      "r640",
      "r719",
      "r735",
      "r736",
      "r776",
      "r778",
      "r779",
      "r874",
      "r1091"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dissolution of and net loss attributable to noncontrolling interest",
        "negatedTerseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r85",
      "r164",
      "r166",
      "r197",
      "r200",
      "r201",
      "r639",
      "r983"
     ]
    },
    "md_NetOfTaxUnrealizedHoldingGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NetOfTaxUnrealizedHoldingGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding (loss) gain on investments, net of tax",
        "label": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "documentation": "Net Of Tax, Unrealized Holding Gain (Loss) on Investments",
        "verboseLabel": "Unrealized holding gain (loss) on investments, net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "documentation": "1996 non-qualified employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899",
      "r909",
      "r933",
      "r941"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating expenses",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North American Partners In Anesthesia [Member]",
        "documentation": "North American Partners In Anesthesia [member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "terseLabel": "Notes Payable",
        "totalLabel": "Notes Payable, Total",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r1173",
      "r1174"
     ]
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Payable Fair Value Disclosure",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r1146",
      "r1150",
      "r1152",
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "md_NumberOfMaternalFetalMedicinePracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NumberOfMaternalFetalMedicinePracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Maternal Fetal Medicine Practices Acquired",
        "documentation": "Number of maternal fetal medicine practices acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfMultiLocationPediatricUrgentCarePracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NumberOfMultiLocationPediatricUrgentCarePracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other multi location pediatric urgent care practice acquired",
        "label": "Number Of Multi Location Pediatric Urgent Care Practice Acquired",
        "documentation": "Number of multi location pediatric urgent care practice acquired."
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricGastroenterologyPracticeAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NumberOfPediatricGastroenterologyPracticeAcquired",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Pediatric Gastroenterology Practice Acquired",
        "label": "Number of Pediatric Gastroenterology Practice Acquired",
        "documentation": "Number of Pediatric Gastroenterology Practice Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "md_NumberOfPediatricOrThopedicPracticesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "NumberOfPediatricOrThopedicPracticesAcquired",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other pediatric orthopedic practice acquired",
        "label": "Number Of Pediatric Or thopedic Practices Acquired",
        "documentation": "Number of pediatric or thopedic practices acquired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r792",
      "r1048"
     ]
    },
    "md_OperatingAndFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "OperatingAndFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and finance lease right-of-use assets",
        "label": "Operating And Finance Lease Right Of Use Assets",
        "documentation": "Operating and finance lease right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r776",
      "r779",
      "r784",
      "r1045",
      "r1049",
      "r1050",
      "r1051",
      "r1052"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureGoodwillLongLivedAssetImpairmentsAndLossOnDisposalOfBusinessesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Right-of-use asset impairments",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and New Accounting Pronouncements",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r83",
      "r1030"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r854"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) on investments, net of tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r284"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "terseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887",
      "r897",
      "r907",
      "r939"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r900",
      "r910",
      "r942"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r900",
      "r910",
      "r942"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for (Proceeds from) Other Investing Activity",
        "negatedLabel": "Other",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1026"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payments for repurchase of common stock",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations",
        "negatedLabel": "Repurchases of common stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition consideration paid in cash",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r498",
      "r825",
      "r831",
      "r836"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition payments, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "totalLabel": "Payments to Acquire Investments, Total",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "md_PaymentsToTermLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PaymentsToTermLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on term loan",
        "label": "Payments to Term Loan",
        "documentation": "Cash outflow to term loan."
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PediatricGastroenterologyAndGynecologyPracticeAndMultiLocationPediatricUrgentCarePracticeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]",
        "documentation": "Pediatric Gastroenterology And Gynecology practice And Multi Location Pediatric Urgent Care Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_PediatricSubspecialtyPracticeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PediatricSubspecialtyPracticeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pediatric Subspecialty Practice [Member]",
        "label": "Pediatric Subspecialty Practice [Member]",
        "terseLabel": "Pediatric Subspecialty Practice [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease In Salary | %",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "documentation": "Percentage Increase Decrease In Salary And Wage."
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net patient service revenue",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "documentation": "Percentage of net patient service revenue by type payor."
       }
      }
     },
     "auth_ref": []
    },
    "md_PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PercentageOfRefundOfIncomeTaxAtThePriorPeriodCorporateTaxRate",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of refund of income tax at the prior period corporate tax rate",
        "label": "Percentage Of Refund Of Income Tax At The Prior Period Corporate Tax Rate",
        "documentation": "Percentage of refund of income tax at the prior period corporate tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "md_PerformanceRestrictedStockUnitsPRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PerformanceRestrictedStockUnitsPRSUsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Restricted Stock Units (PRSUs) [Member]",
        "documentation": "Performance Restricted Stock Units (PRSUs) [Member]",
        "terseLabel": "Performance Restricted Stock Units (PRSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "md_PracticeSalariesAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PracticeSalariesAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice salaries and benefits",
        "label": "Practice Salaries and Benefits",
        "documentation": "Practice salaries and benefits."
       }
      }
     },
     "auth_ref": []
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Practice supplies and other operating expenses",
        "label": "Practice Supplies And Other Operating Expenses",
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r375"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r700"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r375"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "terseLabel": "Preferred stock; $.01 par value; 1,000,000 shares authorized; none issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r365",
      "r371",
      "r630",
      "r854"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r301",
      "r302",
      "r772"
     ]
    },
    "md_PrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PrimaryBeneficiaryMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Primary beneficiary [Member]",
        "documentation": "Primary beneficiary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Unsecured Debt",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Lines of Credit",
        "totalLabel": "Proceeds from Lines of Credit, Total",
        "terseLabel": "Borrowings on revolving credit line",
        "verboseLabel": "Borrowings on line of credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1031",
      "r1034"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payment for) Other Financing Activity",
        "terseLabel": "Other",
        "documentation": "Amount of cash inflow (outflow) from financing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1027"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from maturities or sales of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other revenue [Member]",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1097"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r137",
      "r245",
      "r612",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r770",
      "r775",
      "r778",
      "r779",
      "r806",
      "r807",
      "r856",
      "r857",
      "r858",
      "r859",
      "r865",
      "r971",
      "r979",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1088",
      "r1089",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1203",
      "r1204"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r137",
      "r245",
      "r612",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r770",
      "r775",
      "r778",
      "r779",
      "r806",
      "r807",
      "r856",
      "r857",
      "r858",
      "r859",
      "r865",
      "r971",
      "r979",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1088",
      "r1089",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r148",
      "r164",
      "r166",
      "r177",
      "r180",
      "r182",
      "r183",
      "r184",
      "r189",
      "r197",
      "r200",
      "r201",
      "r289",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r363",
      "r434",
      "r450",
      "r516",
      "r517",
      "r520",
      "r521",
      "r539",
      "r564",
      "r619",
      "r621",
      "r638",
      "r671",
      "r719",
      "r735",
      "r736",
      "r838",
      "r839",
      "r875",
      "r983",
      "r1091"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r578",
      "r624",
      "r635",
      "r854"
     ]
    },
    "md_PurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "PurchasePrice",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price",
        "label": "Purchase price",
        "terseLabel": "Purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "md_RadiologyServicesMedicalGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "RadiologyServicesMedicalGroupMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Radiology Services Medical Group [Member]",
        "label": "Radiology Services Medical Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r223",
      "r329",
      "r330",
      "r331",
      "r332",
      "r385",
      "r395",
      "r426",
      "r427",
      "r428",
      "r433",
      "r437",
      "r545",
      "r586",
      "r595",
      "r611",
      "r654",
      "r655",
      "r662",
      "r690",
      "r691",
      "r741",
      "r743",
      "r745",
      "r746",
      "r750",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r793",
      "r805",
      "r821",
      "r825",
      "r832",
      "r835",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r868",
      "r1084",
      "r1093",
      "r1148",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r135",
      "r136",
      "r139",
      "r140",
      "r223",
      "r329",
      "r330",
      "r331",
      "r332",
      "r385",
      "r395",
      "r426",
      "r427",
      "r428",
      "r433",
      "r437",
      "r545",
      "r586",
      "r595",
      "r611",
      "r654",
      "r655",
      "r662",
      "r690",
      "r691",
      "r741",
      "r743",
      "r745",
      "r746",
      "r750",
      "r762",
      "r763",
      "r764",
      "r765",
      "r767",
      "r768",
      "r793",
      "r805",
      "r821",
      "r825",
      "r832",
      "r835",
      "r845",
      "r846",
      "r850",
      "r851",
      "r857",
      "r868",
      "r1084",
      "r1093",
      "r1148",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r892",
      "r902",
      "r934"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on line of credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1031",
      "r1034"
     ]
    },
    "md_RepaymentsOfLongTermCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "RepaymentsOfLongTermCapitalLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment on finance lease obligation",
        "documentation": "Repayments Of Long Term Capital Lease Obligation",
        "label": "Repayments Of Long Term Capital Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r893",
      "r903",
      "r935"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r894",
      "r904",
      "r936"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r901",
      "r911",
      "r943"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transformational and restructuring related expenses",
        "label": "Restructuring Charges",
        "totalLabel": "Restructuring Charges, Total",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r174",
      "r175",
      "r325",
      "r326",
      "r777",
      "r1085"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r82",
      "r633",
      "r659",
      "r661",
      "r669",
      "r701",
      "r854"
     ]
    },
    "md_RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained Deficit [Member]",
        "label": "Retained Earnings And Accumulated Other Comprehensive Income [Member]",
        "documentation": "Retained earnings and accumulated other comprehensive income [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "totalLabel": "Net revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r219",
      "r229",
      "r230",
      "r238",
      "r242",
      "r245",
      "r247",
      "r248",
      "r382",
      "r383",
      "r384",
      "r612"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "md_RuralAreaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "RuralAreaMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "documentation": "Rural Area [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145",
      "r146",
      "r202",
      "r396",
      "r964"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r58",
      "r250",
      "r1055"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable, Net",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r58"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r446",
      "r564",
      "r965",
      "r966",
      "r967",
      "r1131",
      "r1132",
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1145",
      "r1146"
     ]
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Financing Receivables [Line Items]",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "documentation": "Schedule of financing receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r433"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Net Revenue",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1047"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r219",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r785",
      "r786",
      "r787",
      "r788",
      "r790",
      "r791",
      "r792"
     ]
    },
    "us-gaap_SelfPayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SelfPayMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private-Pay Patients [Member]",
        "label": "Self-Pay [Member]",
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes",
        "totalLabel": "Senior Notes, Total",
        "label": "Senior Notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r1173"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r400",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ]
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of options, maximum years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "SixPointTwoFivePercentSeniorUnsecuredNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027 Notes",
        "terseLabel": "6.25% Senior Unsecured Notes Due 2027 [Member]",
        "label": "Six Point Two Five Percent Senior Unsecured Notes Due Two Thousand Twenty Seven [Member]",
        "documentation": "Six point two five percent senior unsecured notes due two thousand twenty seven."
       }
      }
     },
     "auth_ref": []
    },
    "md_SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "SixPointTwoFivePercentageSeniorNotesDueTwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "label": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]",
        "terseLabel": "Six Point Two Five Percentage Senior Notes Due Two Thousand Twenty Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r155",
      "r156",
      "r157",
      "r180",
      "r183",
      "r206",
      "r210",
      "r212",
      "r214",
      "r221",
      "r222",
      "r289",
      "r334",
      "r336",
      "r337",
      "r338",
      "r341",
      "r342",
      "r364",
      "r365",
      "r367",
      "r368",
      "r370",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r564",
      "r665",
      "r666",
      "r667",
      "r668",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r700",
      "r720",
      "r737",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r963",
      "r1033",
      "r1035",
      "r1043"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51",
      "r55",
      "r56",
      "r141",
      "r143",
      "r144",
      "r168",
      "r169",
      "r170",
      "r186",
      "r187",
      "r188",
      "r190",
      "r197",
      "r199",
      "r201",
      "r220",
      "r290",
      "r291",
      "r324",
      "r362",
      "r381",
      "r434",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r451",
      "r515",
      "r516",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r576",
      "r579",
      "r641",
      "r656",
      "r657",
      "r658",
      "r672",
      "r737"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r220",
      "r364",
      "r365",
      "r367",
      "r370",
      "r576",
      "r612",
      "r664",
      "r673",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r737",
      "r778",
      "r779",
      "r869",
      "r1206"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145",
      "r146",
      "r202",
      "r396",
      "r964",
      "r968"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r220",
      "r249",
      "r364",
      "r365",
      "r367",
      "r370",
      "r576",
      "r612",
      "r664",
      "r673",
      "r684",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r700",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r737",
      "r778",
      "r779",
      "r869",
      "r1206"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r886",
      "r896",
      "r906",
      "r938"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited",
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Common stock issued under employee stock purchase plan shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeitures of restricted stock, shares",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Issuance of restricted stock, shares",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares",
        "terseLabel": "Issuance of restricted stock, shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan Value",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "terseLabel": "Forfeitures of restricted stock",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for repurchase",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Common stock repurchased",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchased common stock, shares",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during period, shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82",
      "r668",
      "r737",
      "r759"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased common stock",
        "negatedLabel": "Repurchased common stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r51",
      "r82",
      "r672",
      "r737",
      "r759",
      "r875"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r55",
      "r56",
      "r76",
      "r702",
      "r718",
      "r738",
      "r739",
      "r854",
      "r876",
      "r1031",
      "r1035",
      "r1036",
      "r1072",
      "r1156",
      "r1207"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r141",
      "r142",
      "r143",
      "r144",
      "r169",
      "r186",
      "r187",
      "r188",
      "r190",
      "r197",
      "r199",
      "r290",
      "r291",
      "r324",
      "r362",
      "r381",
      "r434",
      "r443",
      "r444",
      "r447",
      "r448",
      "r449",
      "r451",
      "r515",
      "r516",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r537",
      "r566",
      "r567",
      "r571",
      "r575",
      "r579",
      "r657",
      "r658",
      "r670",
      "r702",
      "r718",
      "r738",
      "r739",
      "r761",
      "r860",
      "r862",
      "r875",
      "r1031",
      "r1035",
      "r1036",
      "r1072",
      "r1156",
      "r1207"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax adjustments, sttlements and unusual provisions",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ThirdPartyPayorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ThirdPartyPayorMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Third-Parties [Member]",
        "label": "Third-Party Payor [Member]",
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1053",
      "r1161"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r359",
      "r379",
      "r525",
      "r536",
      "r556",
      "r563",
      "r565",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r625",
      "r642",
      "r840",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r855",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1144",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "TwoThousandTwentySevenMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027 Notes [Member]",
        "label": "Two Thousand Twenty Seven [Member]",
        "documentation": "Two Thousand Twenty Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "TwoThousandTwentyTaxYearMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureCoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Tax Year [Member]",
        "label": "Two Thousand Twenty Tax Year [Member]",
        "documentation": "Two thousand twenty tax year."
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "TwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Notes [Member]",
        "documentation": "Two Thousand Twenty Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "md_TwoZeroThreeZeroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "TwoZeroThreeZeroMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Zero Three Zero [Member]",
        "label": "Two Zero Three Zero [Member]",
        "terseLabel": "2030 Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal Home Loan Securities [Member]",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r1098",
      "r1099",
      "r1172"
     ]
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Municipal Debt Securities [Member]",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r816",
      "r855",
      "r864",
      "r1202"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r814",
      "r816",
      "r818",
      "r840",
      "r1172"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "UnnamedCorporateJointVentureOneMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture One [Member]",
        "documentation": "Unnamed Corporate Joint Venture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.mednax.com/20250630",
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]",
        "verboseLabel": "Unnamed Corporate Joint Venture Two [Member]",
        "documentation": "Unnamed Corporate Joint Venture Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized holding gain on investments, net of tax of $140, $66, $395 and $86",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_UnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnsecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unsecured Debt, Total",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured note issued",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r89",
      "r1173"
     ]
    },
    "us-gaap_UnsecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnsecuredLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureLineOfCreditAndLongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Long-Term Debt, Noncurrent",
        "terseLabel": "Proceeds from issuance of unsecured debt",
        "documentation": "Carrying value as of the balance sheet date of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding",
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r214"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.mednax.com/20250630/taxonomy/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/20250630/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of common shares outstanding",
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r214"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-40"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-15"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0000950170-25-102382-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-102382-xbrl.zip
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M-AWB@TP$W=)(:"]-N()GK8T!B@:,1X]BMIL61X+ZCXJW[:(_*J-FQ5-8V,?
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M:"J>_RRG G,R,84@-#B-/!' +Z#BZ<3^=W0CN"?BA'[%W_,B[,4/,HDO&(2
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M>6<HS,L!ZR\W+P<7L(B[-]B%@_UG,\B?;&=B:\86(_$K75M5]0H,ZNSFB67
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MQ(!F9&=49_1@?,18Q3C)A,\DP&3(Y,>4QM3*M,I,PZS #&*^QUS&/,:"RR+
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MNSLFM&9^5?%7W);</!:LQL<M.QW)O6S!UY"ZZ0X.TCK1X^?%^^GFBJLSL4O
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MV'WQ0'M?;_B^L.A-X0@!GM@$BH5<6%_?._>Y_\7+>X6UF37=@G2W$[8Q;6S
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M;+@]():K8J39)6^8Q CU>IQ%R^M<6R^U"FJ2JWCPPL3:'XADZ)?G3-,J?VE
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MM&,MC!AOZY72XI/ !TH2]XW4&Q:;$_9'IM?(!47P_<GU6F<+^9+8^AV_/)A
MI0MQ%U^"7E0V1+J.Z#5R=X_0,;Y 8Q?]NAC\;\YX ^/=YX0.;'?2E^#B_GK
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M-USU*C*$VRQ[^DGXI1[+T4"#]I:V0\W)V=$,1Z2^[$(-+S/S*M^7O-$BFX5
M0LNRDGJR@N JS6)39_R,[G8%L9[63L@-O-E+X5CRVDHQL)<NM40;Y*,=FBQ9
MK!E;:H3>BXNA7-=/S+P631F'^X3!??#L;<V%A<E 0OFROK5[?-3AD.XD*KA_
MQPVQ7.RG(.K_DQZ[@H$ 88:0:+6XMJWQH&IFBV3(?*3N9;^W=\+ *K^L(5K6
M\H-.V(&%F5_LT+0\TWCW,P81_':J=-9^<RNSJ/.L=XEIANL]%*M!4@)Q3?!I
M0"Y?/,N:7'?'=Q]8.]<B)[90;?+RM07DU+S./=D*9$%B;/5*W'NFHQ!:8)!'
M9_\S6I3&3G3GY3S((O!I:JE;[NP")$;]R73^)N,-OX"$V^#.VJY#!5&XS4AF
M,/. )>;-WGG^@ZCV9G&)!WP5;XLBVG7G"CF=>:K.4C>310[&@P5'S2I26$)F
M-(@IXI';C\LRBVW48#%;I_>6=C:_5CW(VS'(VWY,?GLY&[H ,U%) LWZ!8PH
M*G]-I4E#$\.W:M!UKCH>BV!CQPJ4S2HD9-'RF0*]CW'DGJ#1]\Z.Q2+U*M^N
M86VDEMO6/2E:W("RN57*;?? /R:8T&ERK_WMWZ&P8?WYIH?NC\=L[<.TM=T_
MF7MD)^$9NBR)@"(WD,2#"2V3S&\GY_I>)8'TO6 *YP\ZW<.G+S=O)*3WO!W+
M^T%7@QJBG.(CF26M$6)^>G]S',W\3D=W=G_N]6O\8*2V08F,*NQF^YMCP5WI
MS0U: *7B!!]1%%3AG=OK]#*0$A<-TOB95VJUNK:B-&=S%AHM)&&B)%2D5FY7
M-J-#/*JW%1V#V!H64\/.*YGMM/%[[E"LJ42F8-3:2_,=-\M9KDWO[L)&ZQY?
MQRG.[=_V-NP)K5T@-4IG9VES.$'AX-$>-_CY!<3)AE>KQQ]'+)@*+>+L22PP
MU^'*3WCV'OJ%Z;@AR%47'J$_]9NOTK;?0F(=Z02JF/B2/.V#*LHE@,IMM84P
M8IF;[1V8:(@]HLZ>4I&&KFOIJ25,;7'$2065Z.G[>^.N@B*4H*7G7.0<6T]C
M!0K&1<CXKYKE:*"$0F?LB06SM^WE!T]!&0]"3BE9M#!E1KB0L.SW/7?FKGH@
M+?I^7]VKL_;BX?U9CQ=VIK+[Y)/[/% &CR%4QI^R$]^,-LTFM>9'P')<FYA^
M4K3II@4"W8.&=7UI'Y4SF!Y^=9%QFKHZFN-Q>DVDY1 &D$(6?#6)==Q:\XNH
M^H1>TTZJ37NOZ6)RPM^]I6//9!3,XAW-*KN]^B==A4=.]:R#H:_)L[-6-%>D
M?JYZ#20Q:Z)31L^(5-:IY.P?/;*8<&JS0#&]#,Q9CMCG[7G]QR]7O-+2TC*\
M_[$U!\<%;>W?'\$7,-F1;@PC'P"$^:?HMW9=#AT3JK;J76NJ91+.SL,DE->S
M#;9T1^2UY0)%50T%U/GZ=DHZ&EWH=0'I\$S9%.2<"9UIY5 _A0A,OU;/5]T>
MZW)\J-#:9W0SVR#9-L/8/CG+D?]9BQK2_V$W$^^9'BE/YDS7A06_"9VT:_9:
MJ<D7ZN>2!W;WO=VR]*TKTCA:Q+S=N%OI-?K=>BC;L_6;M_ 0SO&*O23HD;A;
ML,E[,BXUN+M<Y[>COGL.RX._C2^<G=Q67V4O;C[8T.DR$0=YL2*HKD8_Z JB
MI!+XM0YYU<]_S?%]^ "7=3:7M'ZY$7I\52[\7)T]+95P'][M4&)0WDI8YB_K
M GZG7Y[1N38_+N(]*\,BQ>R^P*PGA_+R;&J51RA66V2[>S'"GM&3)"&=NU\Q
M5JPH_=2XB:9O-I7.\RQ,MG]<=7N9EG#@A\\QR;>UY.O6I!_(#! T)+NXZZ:U
M7W9+I]K^F:B?\\9MV:IWL#KC/L($5TX(NYO?),%%C,(R[77^@W,VM+K=N9E3
MZWQHX>[&DC?YW;N")GPH6[6H7[:WILEVMIX7M @2!B"]ILY_OA^M1O_2P0F;
M%][1G6\:9_G8.NC%/^X\ [>X89$#U3GDJ3XY;K%\(X01\N]1P%G(/SCF4J1:
M3, O5<H6B2'%A;WSH*&6)KRU3Z"YR_2BQN:MY<$?-QSHM8_>S[F^O48A)]>'
MZL8>3_<"A]D>N2H-A.IU6J$N 0<HG8D5W"+S?F?S&AQ^&AZ[RO;L2P\'R2D
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MDH4!U;P!;9I2$8THLYV?WN@RF-US__-MQZ"]7O0S!Z7[X BQL)Q6'-OH7+2
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M)RX0RXHKY#&EV:X.%E0<7)(#](-.DGJ%O8#)%+4O=GB%]\1FXI7]GK0ZG>T
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ML]GAZ '.^<N*,V":<#2-6.,P_MYG).C%_^9-R?EC6DWUU4' 6DXW*+EK=P$
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M#P1*KVK79:8\$&(NHT!J K65BE(.=RU&"0PZ!7]&J2AS%NYQSPV%]%>@-L?
MFLC946*R'[V86_S6\]P9V6Z'CK61O53@,/Y^I*VZ"RPR,4IV\%YZ1QR4146N
M0^V_EO+_/^P?_I22U:A9>/VOJ9#9CL?DGZT.UCVQH9MJAN:98\2UD25 N^G4
MZ^WYVAY=M?5!^3O55GVO7:HX*C*GO-EZ>HL<'.P-A)="0AIIBH&%J2):)[&^
M\>!!XN)(?7Z2J/J;-9FI-9HF_@J,VK Y3\_42&7N3QW=!IF$<S)(;\;K(_-P
M-[6UTP1K;TX$RLJ@R!)AB;1.AH^GJR)7:$?H^ >VCM8L=OCXN+K=VIT:CR-<
M[.7MDB.^EI24]^R\7ZU!< ]7507;C6+O!IL_X'C6P9.IS!ZK-YF8:! R9W2U
MA<0;WH;^@ 8]V!7> STAS#A>'&[+_$OR4E@N9,GVNY+IZ*N[8:(QV?,:.%G9
M*B[AFK]H>Q(=NMH/C KE\^=?E[)_GYK=C7^#YVV2#5^D:L3W%FK-+^L7A9B.
M7&_><>OG^SM(9G:?W"%/%,YLO+'9X?$6)S$WQQ5>"!-9#P%2!"+H+WWP.V7&
MK\YR5G6__R)9VHY-AL=XRW+E7\0XD.TM><J=EQ?>Y1Y)K'>R=3:L8"]!Q+\?
M20.Z0K7LP)"*9JVH/[ZQ;'\E(2%'7U*M1,T=P!$@MP8OCY7!P_.WMDO#O9\,
M$EC9S?[N&:R.V4C^^0>3=Z;RR-ALH&.VNJD;*O  )?^+Y&6-=MG-0?YA <V9
M@:V!7"/]K-$ODLMGWFW]C]P5_F?R;914;/P?U*L-3BF?J/T!#=1]Y"S=_;-C
MK:89WO^3-<]Q;5*3GW$M3[+(9M*=?&?.9OI,ID7.#QARJDGMZG(V9OJC@MIM
MLC9YW3NF?M<ZJK#.7L(I]1P<0+-E_KV]6*T'NN\[Z.VF9]@@_%5WJ<O5KH<Z
MU2P6X5H:8H0-[5: 8YS.B@;#<PQW5U#0J >?;]OCI$'F95[JG5%AV.IBX1I#
MGJ4-NF)YUQ6.Q;L 5=-$,G.?V*"ZRQ+>N- <@*R< $ 7FU &[S%''P?HO#UD
M%?ZZ&_.<"9SD&!R8H#'6B?5MYIQT7+%E%Q60/K7H=D5MZ,\<#)P==CXS&G%V
MG<6:YE)H8L)O6Z4NLBBILGW)J.C ++9M#S7 '9Z]+\WWZ.Y^S-/KL\Q:A<C)
M"E!%&G  M&M&H*3B)II4,"0$RDHP@E> C/' LNZ";$OS1P]4!^,V41EJ&9!C
M6E+V8OG$V8:1^I)1:I&$KP3=LPI:OAT$C[8=8*)8YBE.UXL?($,%4B1[%6GY
MO$N(<R<P'*P==\M'\908D.;M3VC#RBI@Y!44&TYA68JZ/L6<F$=]Z>RI^=0F
MHREXF/!4X,4<VH@YA#@@-NP)JI@B'A4!W)5= ]PF3GFQ!%9/<"0R7+V2H>6*
M<!Z3=KWA>IPD>EAT@+7VUMS-.U>97]+P5ZV-USW$E3WUQS[$DDEN=W5-=Q J
MA]T_Y)2FC1?0=KGW-#PKUAR%H4]2;.\VAX=HMAVR'I"0T+.\W4T]5]K98?O@
M0+XI,>!;[/I DE/4Y5G?]9>AQ.-EB"6.XT>9H5:LC;(;WKED.;(:#+=G:[5_
M_@DX+LDQD3X( $XDNJ^JY["HF8$#<C6]P%1&EB(Y)7;" .2Z9'1Z?^%Q?6XV
MQ@TN*@%R%QV:5+,JC<PZ _.U[SANPIM-W[V[7EIV(F_\L.#YC]B$%$[X&EIS
M]Z4*1:G=-%Q23H!5];B_@J]C50'1 DX/OK;M!XA+@Q-KLGMG!Q.D>K;!:Q(#
M(@M,9-7O\#/]C0/Y&^TYRR*EFCCZ3KK6B(H;,P<CBD#,[BE--"5JDL+>:VE3
M-]P$(_Z=B+EWUI.:S4LKP1@@N5G[\3=N'MM^^4'IJ_9'?Y7]"GQ-^K65=;_D
MNFB\;4VHRFCC@FA=7Z@R^OGV3:R4"B=?%)VSM<K<Y6=%^?%PLZ[ _ :F>,C+
M$7I=D&@KC[2T/05"2ML<6BP<_(-U2^QO$N0"9(]M*;5[QM?3<'74%B9L\JW,
MJ,\66*1H&A^Y9IUF&0O@+ *.H;JC*X"*UFV&2 T1%9"1.@:+7C(^[^(5O8?$
MVKE6V]<.O\U+C'_\$OYCB1A#;=I9NF,G"F,Y9NEA8AU@WCEC<)8)SP[4$\]F
M-.I2]IBX%JN*MQXGOHT'N_O:4]D+MPBIT["2??W7.'CYK&>9<[AI; :<L>6D
M *YH>N0>*$HT1D<KCNDD\TM*MF7/LX+!-%.-8X7DX&EOBL;1PJR:8[_<<_;&
MM) 3+UNFP;$>6:J(38T-&:WFW)B#X;X XZUH7?O>*!8\]YF>"+,@RL4=/P(_
MT,L62V0"Y!QX<=$#%.U%6;D+V 5#PTE([O[C3^O=N,8:)]X&CW,*[#9N<<<1
MG7K\/AWE"=.#M?$R+U*]+E^*UIR_"0H20=IZ$E"%W>TS$]YPW%Q#X/35M*^)
MRASM3[7YR<?4YYV;I48K^E4N WX0SGXZSE-9YX/$<M31=/].MANOM;2Q:3MY
M5'D.@<.EG1K#$Y40QO1O9<E_K+XD_[WQR&-FX^J2E]UI4I GBXK1)S5Q'#*S
M7J46G8[SL9QJ86I?0X>"1/GLA=ACZ9-CG_QO0WR4,883";*8\:4"P>$-7_C6
MU]Q")*3B&2(M4N#U5! '>$.W>WDJ'9Y%<MT-FT"O8@8U9^T7+](3-[.3&M7*
MBUSC,1$UTQ;FZ#!3!$C>J<CW&<OA:.LX?S. .-=.JIY7=&U,Y*F@>=BX1FHC
MGBJZSU'./*%Y]'YY^[WRF9W%:(:=:!@CSU^I?O_B^I@L#<^"4THK.Z(*?*0E
MFH!%S+45]57E-(\>R+_YW,54LGK;0T.-(=N1?+F.#-# H]>6G^."WD[SJ_S3
MS)_U-/;X872N9D5#AN<CD$<1@0"Q=TJ+I[QJZQCG4$JP%-Y_Z]R@*HN-&\'W
M\K$9A6X5?&@JOD^(DBSPW[U7I8VCB[)IX!#[5HI:G>X-V'_^+=H6EMXX5E%:
MA>5UW 0YXB2:RKME#X(3J"?ST6Y>*I3+%2P2'U;79Z57YGE[5:YK+E4M>HK,
M 7OBA;C29+KXA[&!&* P8,MTH$'IKU%QYM,Q,9WY-KR61MM*ULTGZTQ/OT'=
ME/4$Y #G#W,-T;+(!1VIRD4P_A@PH+9>P)%\\_N;I@K5UO:,7!5 -]3P."=^
M;$6",]"P&;\NEQI*<)+VV'IZPB#5<Z3YB^3LRW-(BD>27GFC:;YP[B^2K&7N
MBVO8<7CP+Y*X?I'-=2DM?:UH8"5CKU0,OC0->!)W631?;@;K98N6TM'_'35_
M4)D6RS2Y1=?>.>U@LG(1RSV.L8N::*+9ZZZ>>#@*LA3L?I([V(!-AZ_H-IOU
M:_*MF]F9'*J%_M/'I'CDAYWW&&EIF!#4=XZ4-:ZG6&YE(8?[P)C.>]=%:NQZ
M!Z=3$XKO.6?DH]XM'<23:R-KBDIFZ$$@S9PS.<! #K.((>!?-ASX;Q(2VT=2
M[Q_>MCC%C6;T<HE2WCL6)#I0]C5,'?^L<PG 4],CP/P^IO<+1?:>WG:J :%5
M"9L&)^M>N8#.>R9I]19,"*40+]EH&F$''.OU5,3A1M?)1)\(-+IC5'D3[:>S
M9QV9.[JSH1G-5.A3Z(15ES93RUE6)QUPB:@_9Y!8+*HNQKGL@@J_/=49AU[-
MS:V$HJ$#YG$@.U)"CT"Z\^;*&Q@52%7K-1\'@8&]8H0*]HFCN^"(MY'>'WED
M28#YKG/=/KCI6PG$0OG"M2[!T %5*S6C:A?N!<NJSA]'FA2V>W,0]?(G+OHQ
M07,/N$=#GP3#!EMYW5_]/N24@P?\M0+SWA#*HWB;%' H#X-@&O]V]?[;U7E;
M//-8*N1,/,SV+-+#6,J8]UH=8166YW<[=T.\H.OZ&#5+;BE/V>JO-B.+'5:U
MJIU%S)HH]MBG;U>36]G@V&\5O,=UCV6M"X]^;$#UC)X31YX-X<5738:"9B("
MT$OA)S?Y&'G'&>[Q6!+O7R0]SS:E)_$GJ[Q",\E7<(G"A/&<2ZJ3"OLFR##I
M!2,UKJVH)''%^K:(@/]\>+&T3R4)O6^P1EAG5#T20_ _1?G._(R?2O>JN?^4
M9 #2+_2:#Q4V4-8_"GNB:775FEOL]CY<^#QCU0IQ$YJ 2-!:ZCOR&JCDI8O7
M#7TVF5GNX">X"R@LCGY.V5H1.U_7=/S(4%A/%=B43A_P?AF<*]"-U7O./;X%
M^7+FYDMWIQH3\Z?4G^$IO/^SVMSR/&EP-/_';OV90JU:7?"6R3^Q+9KXBMF*
M@O;5-[C(Z8SM.214).8$]9H+2?2]$J\LOX(;N@1P<40<T_)NR.2.:N@?OU;?
MU&'F7J./2B/] 1BKQC(@ QZ,+L4=<+IE4!W\(M&\Y6T#X<7Y5M09J'OWX[8*
M2G=X6TV*?"T#?52T/F-B6$%LC+ V>SAAMIGC,N!D;*[2,^R#TTZY"0\R#7QZ
M')YW&]@[1R)'A6RYF;PFAE63PB9@%!].RWFKSA[G#^'T3$_E:KW(S%M91FK]
MF?C>HE^M8KRFKN_Z,B6$H')*4]>7,V<"3;1@2"*"5(A?:K@59ZVYM1W&#>T7
M8-9[$2VBFTN;&KC+R=%6OD&\%;*=FF[^<:RW@(R(>UE//;6P@S(P@0X*QVH6
M5N2+I*8U.%+;<\20:^*?U2APO9%9)NVI))@CWQDT\/9Y\K<Y<;U=H2X?>A-G
M9FMZ6,J*85 ;J:!/=%,G8%C;&(SA8$5D=F25[OA.$9<=@HX,-1,9-X_^1?)C
MZERTTI'[DUQ7.5PPS<1NYS*XL)AW"QQOKZ4/?OJIN2BWUI)]UIH60[LT&@B4
MN\=.(D/<IC^E?<*7G]M35(%/INT@M#S=4TGYTX]KE//Y%-) R,BI8@E&F(AC
M W^.C(P,VWJ:)IF/FH%%0$5+?UM/&LJ=38K3ZHGL\W$!=>S PL%+L]:D[3@5
M32010QL'A4,M(H9\_%UK6?A_K$:LQYF%IX7$T)O7@2N#X,6>?4#+%[-5-D I
M#Y7*Z%S'9^S8TGO+D1Q@+7)!;O<$?R:%N)8]J,?0$; 8:R*! )ES#)4Z?&N2
MV_.;SQY0-R#:,QR%]Q4VM9HUORNIP=)$*3-_UOL4]?Y[M<4JT*X*FM(H9EGW
M\;]5>I;_WO[B <OI]9I#JLN2Y&:JXLPL(9!KMK*%46*0@4MKJ_JA6&&\4YSC
MY;>UJI=\#*16)KO]7PF#C9(GJ+G1BP^5,:_DWQ^3^>E*<E' \=UI8RGG%3(R
MCX0*#F8WFT6#NT[GQ8T;!++E6:<U0O?%EC"ENU&UD*K$3U\D1DSL<] S5,$6
MX^$[MURCY@^L?NP\F [56B0X0B,PIX=_]YT'*-"K=VKIU[GVT_SP=Y^X]/:@
M&R14N_0#.2I:K"$* G-0LJ7ZL[7*)J"[CEK')UA?T8^\:2TO&?O%51WD)E:1
M3]V$*@X+721:U!9S2R*,DFJ+:$6U=,6F=&K1T[M>%R)+EUP&1<].\G#]ELV?
M-E:CE\?TH^YR\D2,Z2W_F!#5,GD=,ZRM;$.A(\JGI/0W'E\8\APYPZMJ7B$R
M^OXE&(9\R1\,(!X=;;^JPP?ZPW0<=%.Q,#<G6.K:+ 8 VG6-@Q/."+TR!$)5
M&0%K:_=@% ,6#&:E1ED^R_E]D"4[$L37=<R+7YS1&\POL19Z9] 2;R8E=1/[
MPTU?VXZW^)0Z!,#UB^3]#T57K"CL\7U:]&%A9^W$6D/\N'2OW0?M;.X!*J.Q
MK+&LR2\Y TXIXJ1IA6(J_TZ*!9>5_2OLB"<O.=::6F]<FBP>[A;%MF:BIS23
MDA+T!!O*,=X4X^;TQ=19.0U/?VIM\BG \2)%!OF.!SOE/!#?///*#[.:(?J+
M:U"6)[*<+214QQLQA)F)V:7.P^21GT2\J[F!:8UGOYFC114\H5S&WX'M%\FV
M<:S6GAJ+>L.(M'^$X#<W8/.\7?)$>(?N<93&(T9S 6%2BVNEV_N^4M#PZ<WM
MK8M5A3$YAF_-7[RK+^JO,9R ;&KS2QN<F$-88!'X!_-OW]V&Y?TH(2OP#R1V
M$-G&_<I27LBQ6SWS\_!+E?>W.>[KO60."D(P.J&2GI*2/OF$I1O\*B)UGA0.
MWP.Y9P#'\V8TT]K;4(#1"!2&\W; "ZPYY]N04,(9^]OUM.<)&3T#8-LKI94N
M-VHG^U(39]*]$\XZ,\N1YS&OB:WI?)(B8Z>IN8/%CE_X8UGLZ-X4YPOCUJ?'
MC7;\BYD9'/)3718/+0D:K9R!&=$!QXK+*?5#?0C;IQ[V)B$H4YZ@@0@DIO12
M3X]>#[V!TW7PN)=)X;?\]Q\_"3,Q$J%HQ3G$.(8P P<:14M4>F0^4/1)3DZ.
MI:1$"-])\6+[_WRCG @YJ5UD=^+<5!'B;2DDG(>.A_RY+>5]UK5F44FF6C_L
ML+&MB7">HVJ2ZHH].::N0*<ZR2 X0>_]A<H>ENI6Q_S(WP3[NQ@M:_0M\-=8
M-K";"B >*<-6[X5$6Z?!('+]RV15T&+@?/IS[8+1C9W1I<*PW"*BDR86BI-C
MK '^+]IY'#[-L$T^DT1K5N#!+W\?T%Q>2\YK">C<>>L08:OA0*^)$;('(6<^
M?+Z:]L=P=*2"C>$@%U)-JS+'9:'1B\)&S[B)>'*\82P.G./9X>*%'9M\'=$.
M$J?G3%'])-++ZU902]!*'M4IW&,%(ECY1B(3*!#8$70S]A-4)+G?=DPXQ-OS
MCJ1PTB:D7:V\;5;O"*N]>F3(3FM>Q+=2BY:^KTN$Q?B'Y\X5E2M2@=0(3")T
MR%P4/G653LCUQFX##X<X!//359K -';$GT"B>;!!^K?:TE[K%BT'0^HX]#60
M^O;VZYFQ5G>XFQ&,QAQV4.P+?VTM13^BH9J3J)=)2!E>'(TB(;ECHSI6_[#^
M32]1A62C?V.UK\H[OF6'\YB+<(DEG$H-X\[*5F37]*>-EH=2=*43>_?E3M/Z
M84O=L2]&0,9C?8KRXRQ@[_VGO4E'Z\ET8@21'T)7OT@.=:L%.%_AN(B:)N2E
M^9AGG3ZYFU6;$9(KT=4^RXI#U7493+L9/WPCS>(!"OQD,9BSBEFK^76M*+XV
M_",JQ._# 1Y\/*V;@6\7/5ZP$%R]H&-,$6D[X(XB-"(;,7K]-T8K5%09SDC'
M\9>,/6?N2-1-?:3[(T-]Z7XH>6AI5 6'^'B$,>6Q2P+/%JCI%PD+&NB#K6<B
M>,*>:PLQ&J5TB]6GCWPXQSS[J4?3BK_[B\2N"0:K?W/T>V6R>O_;?(TI5ZM1
MZCSDWA=I+<=5\;<K#+Y^6P]-J=6$&.WD)Y^Z+1JRF#9(Y?6NR)6NH_72&K.B
M*DQ[J+,RQD$U33O5**-?)&P^&%OCLTSL)N29U32B :":7]FV90+Z(9BMNV +
MT\A)8>W_?.?OIH)?) \8II*TZ@LG3A_<F#CT5 A7OE.PS+[0;0H*@DA*#0T'
M= M]D=^>R-HS"73!^9>@%8X:K>Q"O.$7/@-R,\J^]J;YZ%-3"?>?7&,Y>H/^
M-Z\[82O.*;46,;](/O3:80(?\%7N+!'TO)QQ]@W"OB:-$KUD3R+RIQ:5P;<5
M$Z Q]CK;C-E;&1J^H'^56SUO7SQY(67F6<84H+(33_M7;,VL%2KE:;HVG;'A
M%XK.I*OP[:GTE$&!XTZ4;6RFKKYF;4MJ+:KTK,8;Z<=W A ?@LBMRTPF\ET4
MO^;N QY8)_\BN9OF9TH98LNU#Q[,_# >AP&(H>PF<5R;FFZ'[.2-_ZWTD\C_
M]]X@CUR82Y\7NB48;Q,O:'0RQBE\\6L\:MOR@ 6AITE[Y*(_".=OQ^)V7&@3
M^0WTRP[947E[)2$(SA%^@;K&3X;WXR=H$8O-GGX-%V[A+288K_:6QQ@I;1TI
MN)-6)'J^IV7=J<2G,TD\4<2V'?[^Y^YKBEGJ%!AR6P=8TR]ON%3[H):I;>7C
M'U=M7X!^>4/O.F)O=>1A6]@C-OXW\?S:8:1)A]FJ5E%.$DM]R&#VR#$;)24;
MRT-8#D!1Q[Y;11!*F"?EJ"3<:@=Q9C8@DW0,C85*@J'LR/9;*;G]SS=V1'@D
M(UCGFGY)ES'(4$_%ULF63V5*NJB;?0:IAYYM54QN[X'YG*MD?EG5%4'Q$K7R
M8CGN@%&-%3.# 38Z:P%--?W<T/K&\3I?B1./5\X,U3Y;1QW9[2[<U0H[07Q/
MXR[),@1.X \;"V -U2V58[6^!AR[7I=$P19TJR42-8FU0D6_0KP@R9XL",@R
MQ:U[]*+;+*,@E=LN<\708VG84MD#52UDW;PI&6P/OY,FE\X.X6^4X^*4]$[R
MO8(,1WCU?(KG^DD7&5C*G?WSOB?MQ/"$R9Q0BD_<<G4WUHP?7^6:+3<2U)K)
M8SC&]I,N#!:A61=WAT1NP<!V$HVW?.<KSF @_M5AIY6Q'Q %AC'J)(@Z];>I
M9(AXI3@8L8=I+8$5DNGIZ;\>FQ)'&LOQUD8C.L'?KF%0>57S8OLY\<1M/KYD
M.]YI2WCRC%XE?N0'SV@\0#0F'ZS??B*")KI;3TK.W1N>_*'>W6[E.R&>89%T
M8Z[TBT0;/:D7.UX)?Y#&3A\KD3#'7IUAKZT2MV%EP6IJ.%Y:A[<U,9>"H3B6
M(^PN[U\XCTNY"8TP)+X:26[SXC^:"9\83U3$*>;@!A]5S!I%;-Z6&1DV,AUW
M;NDT[S1X16&3F7W>POUX@-^VP4; 2)LCT9=#,**!94'L+A*FH@)G"@1W/HS)
MUY.L=#\0S')[+'&=_!4\G]*"&=V9-'MT&=/>NO*+!$3)V!@C9!J\LNN7WH.]
M>Q;(9:UQ/SC^7G71^JEL3(4<UH56BUN5*O86>4D+*O/LH@V>O3,1KPH /@NO
MNXIJHOMR?1>M&/E!J9'J55E=R&5$&[$PATKMRMB)X3FHZL7EB;J)W2G:I@GE
MQ!;%:,P\-X+;H@L+&Y4G"_>E%_6-._*0^D62)&"XKEU]U"^WJ D0X*S<*?4X
MF"D#1S]:\G)"O>\ =60Z'[)"4O\W1O]\+NOXX]6@H$0< FFAW2[NZ7(CV]@^
MJ:YLV5?>E&WSTG3PX)[O@XGU\6>"HT!&;A#.+4L)SHFJ7C>@F<.BJ5;GFS"V
M2=J+O<*VY+Z1II18,6*FR0G_@*M+BB\-,)ZQ/<?ED=_1C=2"REAM61C-C2'&
M,)J\)Y6JHY)FY,=2=5;").R)T5-;658G98=;TI4R>[S/0_/-N\HL?[\@FO.O
M;F)N9?U$NF]O"(N%7NUJ;G&YH=3U>AH*Y^[(_OD&D:%UH &+F-NI>#GN5Y[N
MZ_"(IQZIOL0G )CIYI[M;,MN-C0EDZ-2\/PPP5*./I-4;OL!+W]_]IBN5%>_
M)[C>R5@[,107D*D=$O%[)+2%)XO]V:170FFRMVPXMJ*8/J?V$HAN:UBIJ:X8
M-\DP9 RZ^&6NK"3!_E QW5N6''>Z?UW0T[ =-]:W)0#<\A+(PX:;^J5>KY@,
M7G]P73+TC/>\;FD(H_!_[=8*JOQ%TJ)?,_))?]?84[BFDP+Y-O=LI^5!YUM>
M?9([*K^YQ\9*2<E$K>_ZP>?/CY?M> V&]L,,HPRY(GS8M.59YG@/F>#1@E\[
M=W>.CGKU0WP3KP?C"G-P]K>8EI.350*-B?\BB1?NQ9\<1H&1BY>H'^8_43''
MCP=E'6LB!BA4"S9[H^-W3SV5]SN(J76,SE+S::+CXR73"J&2H&6U,*H.]OR+
M0\O^3U+"!VLM";VN+WN_<&1;J!D(SK.]CJH. 9 K?NY6LE%149%'1MK2D19H
M38W.CLXG'Q6J1/73S\PJ:&-A_$*12)0U/2\'/5>X7>ZHAJ41O8J&YB.@?%LZ
MV%H?:J4Z,VF@:KR@V_MA%E'>ML=>K:J$(]^>/57+D3=M/$T)AQ/,S#1D7PIL
M78>LT/=#W@O8X59' M\L8 Z;EYGKJ?PY'G@B5Y]?2/==U8=/4%@G!BX5L!\Z
MS)^R_\33->J>4N?5&\5%FL/,K%0BHHR__\ZZER.KPPP-B0@,IN-_G751'>+)
M^M[0YY:6*&-C3]GN$+VRK^C!5%J?[+#A#I90)[O3Q/;O>JR0N%3]\3HQQS9P
M[U/-Z[@I)FJ5(^%4+0QT%O= (^B1-P=>97CLRA U[:N$':EI6JT/#]E)%WWU
M'7?Z89KK)Q_R$,2RP5*W(/B+Q,</TX. >A_. P/.Z[;/QYLJQ^-,F(HHBQ*5
M[-MF%4J9<OY3^?WK/W=M$7$>2XG-7\*22MZM_J[.30^UH>2A_]?L=5J9T> Q
M=CC,0OBEF K8Y2VF7SGBLT9,/%,[XB4HV?U&;6.UZ"(9M4DL7<Z4ZL$@AJ?>
MJE=J7U8OWH?*FXC40O]"2Z5M_+R;;(M:;36D3N5N3"?BM7&5DZT 0.4X[8#5
MFLW_??G?(D:MK\_$3ONVI]#U;QF4]"M84?LS6DVC?>)R9,DWN'1PXV#*O599
M[>4(//>"\)925NKH.8B#$F-78&1_H!_9L%7SB8^^UV"55GBQ?F"51__= >K]
MAV6$Z/?O+MD3:>X3RXV>'L,NXU)[]/&S$H6N.44<X5/;EB'U+">C^$5MM._
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MXGU%P@Z;+I.U>%@E"#&0D[IV/0TJ6^#E+3SJ99!$Y'C9&8V&2/#G*0(%32U
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MM?BPXWKJGDEG6U:Q%L\Q:FV*C-?'M,,]Y1<P#F4?ZQB7H!'B8\V*YMFKJ9=
M:<8T*F[T[7JW?UL)EV\U[MB0S2#Q!WRE_-EK&U8V$P%W<I/RVC=LE4I577OD
M/XOM?A:;^1B)^PH[BY31J.OV'X-DC10'(D5K<!1MV5['_<XHJO>&*+K#EY7'
MA:6N_W=]?X0<;8:.L*$I)KIIXQX=%2UNGT/&*F?B*04,>=>=<CO$3_) %]/^
M_*]2K*?)6L>D67.[-E9+36"/F(33LOTCB5^$6XM:'JW:V2+.3CW&4HEU;A/?
MQO$8A=8^<\?5B^ %;,F/V97A[$-HNBE5H8*T[7RO'+[Z-1)K*S @E.BO.%8K
M-N'),J<4N1!U=T&K9*1JWSBZ1#-E[J5W[.2Q?::^I(2J&TOI7WCZRLU$[\JN
M2)7][^3JD"[]4:$NHZ!AZBS6W711_'#J<9>[A8Y4PX 1E_Q25M5>!@&>(B\-
M6DR[*^:\P+-F:N3DS%O5B=YV2S?A92DVRP1+"S:!-;PWWOR1-_G-N5.%^JA]
M;@QB=P5P>IG_.T'/Y[D;Y&Q# A J-1ZUJQA5+&[FA"]38,^/I_!(FQ_/,!>U
M,1?8PU)!:UY)F]G[ ?A"L(3#Y87)5PXWJ9Q!%GT1_%S[V\%R$;X7,/"KR)CF
M2#=Y#<F(R'C!==BF4Z.1LB^]:([N^"(-03?+W(&*5Z!3PA@D$=$"$I%)@F63
M)-\=M/'IC_?HMC[#J4_&EWZCT='21W%KF1LTZX$E1*\ 8QF/3\^;D]G]IE1L
M<WQ\U!8ZM[CAZ&F1P<"O%\\/'@2V17KQ_OW5@NUHDSUN::^ 4"4-]$%-5N*5
MJC.1Y7G\"ZJ^0^,;;P^W!V,Q92[BGXAXQNBI?Q5_@M%$4'>4"+_I "6P.%,)
M=WT^??VKG"C)IX .IC7$\)Q! ^@U-&<UY-DWHA8M+":L(!C!PC!A):;"D%16
MEA:5$(/"_('J/#4'::G#XN*"!$OPC&XY&VNT*/!= HZ@JROVL4 >A-UNI76"
M#?*5.GD:$ ^%<^*[C\7YRDM%@T@+3Q/Z,\2^O\T0%[/FE1,L1*>EOL\R,]VI
M(N'=;X43F#I4K\<Z#2C].E7Y^9_:^D.C(2RZI4IIA?*0U<IG>,?J#O^@A:KM
M5TDG>]>DN]6HM04ZT.'9W>#4(^&,7YUKIZ5C;8G#3<T%SB.9,=A_<1P8T)]\
M<@ I>KN=&A]/M9#WGPH5J!@$<*&3O=B@)$K_BHW@#=O)T"%R@:X/#/R$V<=)
M*XY@UB&I5C>E4U2;%0++0XC$X1*L+?&%;>-S9;8MO@%K;SD>W,3.\7[(=0S4
M7!71%+!<RC5!)?\X03;.9K1Y"'8-\B7@<^.9"!H,7+833F,C-P<Y94;#V(:1
M>;.T$Z'LN@)#<UFA],2"%K][2_$5]WC07IY/J/14JFNJZ@LW71:79 =/&:'@
M,8:?6C8[KLPRD_5D7RON01_?+@D@=93RKM\2V+(Z:P8C[WVH[B.N'Z[E,_KJ
MO6_W#E.61< 2__<8<EM;+Q%6G\JA*M!JU?>QM?:4T',R8#^1 $;M4=-S$WNS
MN&K'>+0>AN//[@$>2)!(C;.M-]1?4,7'D^*X1@P-C=1]$<%102-D%GJFIW.\
MNDI[O8(BY628M*"&EA9SXL/SWG?X6__^4@E!5'S40B#J@ZI-EJJKB25$@I\?
M6,IQ(!(/SII/OZU&U0G!9@W9,K7\;T\KTK:HR8K>2AY=.%.98HRK87-R>V0G
MOLOE3E8S"24J^V9 <-*E:I_E2QY,0$((5L <>^>B)YCUQ5EI9GWU,+C/Z5*W
M:YZ"DVWP<N)=31LL>IU&4:X4&!#S3SV@5/5@M=66PTOQN'6@S6))1'?>C_4B
MJ6WX>/(50 2DS:SJFE,Y):>?B.S]_/_^,KF)V^N%"QU;=#).&MF8#[)2TS#O
MB^:5M:46(%24 Q-U8]]W/F7)!;&XG#24#UGZFUY"8KP^%;&Z:*Y6QWK;8J8U
M>U*8G_EL&M/STT"O ,J_$];4H9]#,%-K*ZP./\$-&VSA]=Z7# N36HVUY.1/
MM? /M(I;V/3/^4W[G:L3+*"URV)+(@F72H+2Z:@;[RW>@U0I%1%7@&:];ZLM
M(?\D5OWQ3^M%SZ?M"/<4FMJU(^O'QU!$1F@E.4Q*+IBQ7T*2FW.T\W4LUO(>
MPE+J/0\Z+I*4[>;0Y<@SFVBI$_$*-"#&TNZ2P_ND<;E<"U_J5K6?7Q\F6,;-
M^"MAJO&R,?A N:1 EX$Q' FV>H:>\T,(*7:2XO:'\ *J;&]G+ZXMM>7O 6Z$
M7[*P_:"?G!B7BPRENF>/=>\PHE'VMR"U[DWZ-BJ^2$NX&.CHDCP\GZ&(/SA;
ML>M=BO>4#WHD.O$4'_.10<!<O6$M1TPJSH*R97#/S\M.A+*.#Z6H$1\UE"Z>
M-^YR%7><_T\<"\]3YV[F+!3FD2B*]LDS3C@OG>\-03J27W\ETCD3<N3YI-_,
M&BR\=*H<+!= DS>2$@/N2Q%Y=D_XO-Y_F=$X;326+M4/C$>N1":  GW](#KL
MJFC_J6%_S+ 4*CZB:(P2&F<:6>(AFB.#73;ZZ!1.VT0_3(>7RH6@'>@I'/*8
MQH*ZQKHOFXPECX%]3$1/R/']]OS/9]Z]KJ\[NPY?=ID433D48Q[CAQ5^53=&
M1@%1P:5GI;:ZJZ\:P"9GBP/;O7)(LFOGI^V#EM-$D9B_R=H7MW;YTZJYTY(,
MY0^_$4:G!O2-XJ5Y4OQ 42ZQQIYH>_*Z4XL 5"L[_=^XJM?ZMQ>=B8_P4()0
M<5M88?&OGG86Y.PAGT[R0W07Z JPPL<=8G7(](MMX7LFTMJMHE/:Y@J0L4)<
M'P.K[L(P:O'N69*5I_!]=VK:;2!=.8%3>5*O5_HI4J(0<&U-_-624./;0D-)
ME&A%CP3T&T%*U4JX@RB%T2Z,U;9NX14RD2$^'HK.=@0;S"H9C:&B'32GC_8S
M#=G!9D8A8OY6(2*J5/@U2ZOE>EN[!US#)XB[G6-S0? F9DB<N:@'O"VD@/J;
MLX% +P/M:)9%S6>5!JEUFV\N8ATB9N+5E<<7] IU47E7@&E."R=4C[@%-_>/
MK1E0;1_/EWG":V>]*HO6(:[MEYO0*ENAVECRTPZA[-77.%G=(K,@,WVLD64S
MCI,M0B[S"L!..6 $[F^6+MQW9]8] A97ID2_.10<*L<I?,GT 3WPF B"#6<D
M-5$GW)OM6!\X;YECY,Y4=]?=C.06*4&/R1DW4%X,VN<SNKK5K5$U")!RN';$
MGLYZ,G\])+RPT(A)7%E?XX\SB2I?P:T6SX8FRLUQ9H;=\_G4WHO8+<V?*RQE
MK0&^]O:;*]M 6!G=HS""IRJ&<I'"GEG.Q4UL_T\S^B"V1W*=T6Q0-79=J8_A
MA_CH5,#LT=-V.#(WY%7<),RM=6'1A'O9XF7-:8PZL8"R8* QB,WM.?VFWG'2
M(6-?RBZ;0S2T9LM[96QN+PN9TAB/ AU8A=-G"EK_^OMSX O?N9WG4%EK?8)Q
MP_Q-"S8L+*[-U(OI;Y/XF"3'Y,3ILL7JZ+I[HH:&73"[H;"A,XTK -JM2[D!
MCCN+PLFNU1)^_0RRO',*CK!X,;D0>N[GGFS2B=DLQ[!+VPJS;HQ7UB(#GA(S
M19GJ*T>*-) ',4AM,<A]1V<5*S>0/;DS8^ZXY8>U\:5 ;OZSL$C-G+R\.&N^
MZI+D.XQ9VIM0V&(57+M=>Q6ED3TX8^N8JI3:T6"_SZ 4/YVUX*I @?_BB\5F
MS3V:SXB-'W<*UN9@>\2*=&$XRI]/_;0@YNW?]VK^=<J">6YPL%C U+O>LA0S
M!2/W=_J1L &0$3C20([PSIJY%R$O-\;^=/;-'X=)/R=U_VYDAV'J<T[L545T
M'E?GC(?"A_!]^'[00YS I1JW>'B?/6$^(<[UK@#ED+9I.84.S<R_(2;C49_2
M]N#]XABJ7LS-H$B C#BFC1?[^V5.Q-(I19EXX\:B@1<DRE;JT.?F\P#K1[GQ
MT4EWDX6<G.3[Z+U1!Y3MP0I+'TK.EY )+8)&P.W0V0)3J""("!-0$ZS@V]82
MV:@HX?%V%^X2ZR@]'2,A+%.(!>6\X +3LB@%CY4?2) [-BG2EC[9#<$3\?[4
M\M3 8"=>Q')OYJ%0D<\?*LRJ,7.+V<*P_7.M?!9SN&2[-)'OI'4(T8D=(U0V
MPVV :(WYT,Q-THAD+TZX3,A%)NP$/+E*'!E,I[!O^5?39MT_2MG9/"&:5HC)
MNX,]3^'8X@(S9^"B6\3H?"HMWCZI-470&E@ Q,3NPB#)Z3V@B_\!F.@K@$%M
M(E/%'Q7[T;O\&VOB;/9"]@'W%N9-+@S,L_@/(,QMDQ*G5.(Y3IT7(>B: (G7
MX9>8E_A]<6Y7O_Q!>3VO%'4()[!<9%D=53WR>USK_12WP_7%1@+]+P#@1J7R
M[>4$BV:E\:GA'J'VBE8#/L40"ZI1AE%+9>,1O<R))U6\0UZ7AH,_R0=P52-+
M2[=@Z>59<ZOS]PN;$W%&1V7&BMCQ&KW"AZ2RCWO9V3IO5EXL_I-@^\]K0^4_
M^X;_O+_&X;6[=!\9XVG#^5@&0;1EKZLWN&\4U]XE/O0U<#N%M6TT<'!;W+,V
MK2<S9;=,;U%P1][83$VOT(.@@=';:%1_[2XKZJ/WM"SO4;%^;9% 419!?RCT
MD)_N5:BFU!L .D9]*F.8<" TQYY5I<Y2)M:Q>1#PD;ZP6=O=SB:NA/IV[N_I
M"&->GM"9E15Z?^O)URZ5^58O-:PWWE6747S;;SP?./3>-TI]UGG-/Z(G7J]'
M*3M_^F$1&,H96H%7>&?EC^:,8F>_H?#(]S_[LDFA9*%"GZ VI@LG*E,"K4(M
M21KGS 2(6]Z2%(:/O8<W[F;"+]UHN'X)4&%PUI>@K$,--MCJ<E><S-Z4'0O0
MU,WR-5RLAL8O,0ZF-KGU*_U-F2P9.CQM>#'=VWHZM8[U;'WGC03GW8H$#J;>
MB<:2(WXHB6OENKH?#=8@WAT&I+I_YNIS1)Z,"7F*.MWG3 X(>KI7QVVX[KNL
MM>%009"*L'^HSV'DZJ..:M:D904Y)=][?GM\TEIM*_O>B>0VV?6]U;7=!#)O
MF&_*^-GL<J'WA#YY; Z/AMO1XYP$K34V< O0$FRJ1!M9$59AF=06/!S$"_W4
M<P6X#^WQ)+;9W8$7/<XA8E?2U,L8V^-THQM7YB;WAU^>OW2J_4DTD-!VZDTR
MJ/3O:-2Y8-+LD_<ZCX.=>F$+VXD2+4,EW6?W)A@4:^#D9-?,+F)6K9)&].=M
MR&, @)8_'\%>.5+IOQ1+ANM(2L.>.VTM#ZOL[BS2+WWP  _0B#*_S^+5%'&U
M]<D2R8R6R%C2M;R9/6ETP$M[!5",AL--8VI"=)[I])),P*N=A2K9T$U^0[31
M!S.C]&4/3E]RX=,Y5XG9,1],^G *#(YHQ2(LEI'$S'2<E@0W-_>JABPISEC"
MK/<AX99N!C@R3D<Z'+:EXX$?C.JG<&1@1P=78CAOS1LV&KRUT78&V]/-.8-D
MN/%-4S8&#CTFTLQE8O>_@L<2(%*)0LU.":>:.HLZG:N]:70'KW6QM8@?+0VR
M=!_75-8F/XR48BR>X]9K8!LH1+H0L-"RVD!X00V2,,56,DDVHP+\4 [TL58C
MB[M'^66['YIN[/%SX7F;MWC\P_?>4D9KKE>?IUK ?3FM8!Y<%-$J@R\4%T.*
M$SC N%5_#PMM*-<H4+\"L+)]Z\8#Q]]+]DB,*?>C!,P'8\*E!32*TBQ.0OK[
M_5]0UK01"TK@1/:W6OQV_2Z/^'A;/$XZ7>K;V-[T6SWCY[4ZC.2UU-<+N+-_
M3HL+'3#@_.[&UG4I5F@S61K@P"SZ>;B+[=U.+^-OJCA61/.%Y3C$8RS]-P)S
MR#BY>*@,2:-GBQ[W%7T0;,&5<:WL'J9=?&H_T?XV5[J9=O#62?(*$(GPQ 4K
MZ[\9"9G^I2HONYP:/C'[Y&\3A*9ZZ]WZEJV4\0A$@C9H[/A\>LEZ2$]B[=?(
M(J<>A=/4/[/:=<+U3<+'Y,#(V;?Y#7.WP-!XYNA"$HZCVI,!WJ!@)!5 ]^>B
MZL/>7]@$;< <B=@*??NVL^QND4"O%M%C6Y;NU;3R#'F9)LM.Y$0[H>U\:D'K
MXH7M \UR!97?46,:9YDJ&K?0#_ :V7+R\WOE;Y%?].Z4[^MZGW&AOW/\P@LG
MA-J(@5O'BP7/LN9EY @KKQ^UZ'-I0L(]S[/;$Z5:%W22R[9VI0N;F#*X[M1P
M[ I!4+LO'/Z@)^RQ5!HR=6/<\'6!4KP/SM$EY:(%OG)AP 3"E)><PN^AWFBZ
M.!67;6!<:C_9+)YX^OF7@HU0B?,)S,JYL40O K^UY][FON3.RDP_8G@XGN1Q
M)J3P&G<_1UW=9T"+]OUC,HLKR#B_3'OA< Q1>KDZ'"SDZR?C"](/0F[_]/]K
MGWE0568JJ<!3Q?1T[!6JN0QH(!/,"P.7C/;TLS9G'7,F;DX[7 %PNV'BV2(!
M2_@- 8]#9-Q.7Y=3M]O?5P!!Y5\H.V7W/F6S7,2JYY#HGEF;6F#U= ILD!0H
MVDB_;7''.EK#8^ZO/[YYO#*:&9.68(W:$AYY5HMY>JYH6WRA2''N,++:>ZOU
M-@+?^59:&6DI)=73*W9+Y7;1'?=HH=/*DR#<)B0[,[=F ':WWH];;=,KZE?T
M_<9IXKKX:2[Z"?WI?)A>_[G_1&U\WQJQ,*G)N?0\'I8^!HJ.X<KD+)#5PF])
M."54:WZBRI38##A(<(L2(6FC'!'Z"5(]I>=) ]/VT@QR(E-N@20A_^152]F/
M+6G+,]\F>P:4\&0#E&5-0W 43@GJG2KM!&UB  7S+@SG"<NH4?TL06.MF;7,
MD\E[9#K#;5*VC)5G)2OK^]$?$"/6/U](GB9&R(H4=J!9-NE+M\+;8,EZHW*Q
M"8+*4]//A8Z@F@$F!:Y$=DU7;1:9L'5\])AUM0'+]"G4*([SCKENN%_74>4P
MVUE=JE8"8<$4CM[!V>,V$NZ+,0W782T9^*-I@YDJ-"*:[@]F^<% #P=?_A>C
M?[94=/]O]0?,TKWU]L^D5=]L?(N;MJUIU54-MB7SCB:X=KY,D2%8! 3_VG_I
MS@&;RC7A97UQ.)R;MF_]:.80^Y+U"O#8-%S^O9!$CSR5-42BFUNF#L4*E^95
M52@PO4LH_AG\K]_<U'-&RUF^6_&#J3JMR:[]?,^B263&"KG;]7'/.F>.7UOS
M61[Y[ND58'E[F:?^ \ESW' B[,U2F^R%8->#]9^6#>Z3L2;\7K5A!N;2HIB>
M[EH@D>*@<U)N(*'9.J_U_9^<-E3_<6FM@.P.S:H1ZB@'17*9#.R\F,D]V/2=
M6-9THB[[_M=B<5FXAB4'7/\YR_,L*^X5_>,<TSX/X4OY"@'"0M2<4NGJ; B[
MDC1/H<VY\0C::(C8;V3E$YFX4-N5<FJI<U'',KJ/?*9 :ZDDT-*0JY?U$2G0
M?@C@-/JP:&2Z)-\D\TAF1[.]^%41>W>.E<HLGVA)1(C+ZK3DLZ_[VNLR1=>X
MM[?%?_:XK3G/_?L0Y4=2+@1HIO0(=?&[V#U;/C^)M=43>^OG$D1O@PH"=7$
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M\SBU?>1H6P+++?<]OV/'.:2DR8V!*-(,[?XD$J=/&VL?3"-208LA98 ?H0N
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M?4:09 Y!#SAR\Q[D>H>+O?C .,Z*8A0SXTYGRY:%$O$5UB4@[MHZWG>1:9Y
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M*7&X'5P)<DUY-(P/8#M<,CH5)UX":S7/<O\1T#]HODQJN/CSB@0A\FDIBGK
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M[N@[00 $4PETS1N.DD,6VA-Z ]H']'I@T_HIJ3@'!T<NF6V]@B/H7$NUP%'
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MYW%3BQ[QY XS2;/AJ!*[6W/*APB#=VD0=1Z.4*C:BM5Q3MDZZ<:,K$$2;I*
MJ&V(A.9O"I^H34)M.7\;]K56Q?ER9VG0AF0RNL2KW0]F?+^H7TBRR6@]BD[[
M]C PA"SH1Y8A8-L;:(MANYB=R/C:NT;M91^.8-0I0(#L*X2=DS!VV@SDP,22
MN:SQTB4?R,2,)Q,-9<1:7'PM]!%?377)N(+N:Z?LN1Q<16Q#I^F<HT\X[EU1
ML*&))F.&)6$*:E;H/FDOVYOE:KT:[?E[L:.4'_XDE/ZG*B!W7I\KRTQ5C-=C
MTS^EZ.$'2RLKW&OY>^UI/CYZPCS1@ %4555$58A*]5+J)H55QC<ZUL;'KOI]
MVTCC+:K=XEU>/+5'"55P!\[O\7-[]*E!I0W5;H-D 6-%=#%F4FY3D$=)@HHX
M<D-1ZM+ P.&C*PI*BU:I8]F$&H1+I+EQKJ8:%0HQ;-AN8?Q0]'/Q7P2BGE@>
MZS/AIW==H(L*?%]#5/'40HV>V5Q+O>-4^+78UK>$[2M"->LM4V[:%87O%H/Z
M1?-*;UX] I3PFV^':TN,L&0@Q"/QN$*F7*2F*MX0;RK4@6DRT<MF9,7Z.MJ)
MEXF>B;.=_&J@Z" E6)OYF&Y3E/]1@+I7)LV:.R=(Z_'E&'>$KZ';:]H?C6+_
MQ8K^0<'97-/):%<$?NA#][C6),TW$OO(Y46V4JSM3\\FK8)BOI8#,%^Z^"5-
M=YBN@=_#2;Z5* 9A0/1#8JD[O]'@X.E]AL+3S"?1GO0CT%+NC)(S'P>T+F26
M5W!^(2A)%@':W*(KM5_UMY25MM-YRHNN\^(L]WQ:I'%0(V\7+9?\">KC\?/W
MQ$6OOPAS>VF?<HDOF5%2P^R+\.3'7 W7MZ,W^ OB%[F^+$B[$WR3KL<K0&WL
MH/I.AZ][V:G]9N782@J&;U]C;?+I,]0>E6+PJ1! 75%,N1KB2P#>>GR/B?ND
ML8EBAU9&+R][91Z&R#BF:>]?#=16EU>ZNZXH?NVU0G^?^6:ZF0L<(<IP==\3
MF@]V_O;RX*5>TK,_J<:;_S.U,5GH".Y>0";Q=&0^RDC51&ZFXY=D\-OKCGH]
M*3O)W40B3>DN5555@TE]N$?E8Y$BKA:>$K =!QGK5S2*@BIXTF8^0-$!Y)"T
M$0&NDEJ;T'3O.H_-_LD)GI)Z_XJ]]6J9*G'3/9JIGL*#,Y3ELXN03WY;@$K.
M'' ($L"J^I!VTZXG?DQCY8Q)UBH>::D OS4WA%80U.K8;F_8P,X,?8'UC"[(
M]I7L%:&BU.I&>-0ZP4Z&7DD2'+4<04(%O?1?_O,AI+Q\/#>-ICY\OZ*@%VO'
MH3AGK=)BGGQ,&)=92MF(-@G[6BS.6^8>("_U$NZ'BHP\C2O*/H[-*W&VPQMK
MI4[,*#HSW]%U6I5R,:&QT_.OXBI%H\ \/7R!2:DD#=4OK@ARQ3Q:?R8-S=FH
M!RC!Y^$F6K1ZQ05AP=[_4DO\1+/EG\RB;D?964UZ?K]SQ*?ZC:-!*JR=*O=.
M.\>B+>.0LG* ;;T']:O3U"R%':',H0G>@Q?YW94'XL&-M=E.6090?=&=/8DR
MP=-08+1*K+FM#K%X8TW?H;0<!9@C;W]W+:ZOJ^KBQ^SR3/03S6:)6G6UY8DE
M)_IBV/@QJ18W^+&[RQ+")$(^L:=];=+D=0469>M >T<WEUZ!Q\V2)I>^]$=5
M=EV^=I\QO268"Z<4G)T$D-U-3'=U;IF$9G[U[__\E\?PO9-NPOW4N!MO5\X#
M72E^;CQBV/9^(OE'?!W(YI=T6L(QLB-#P50A8MQ*6<Z AFOZ=0:F1W>%$!&9
M<XA65D6_+$D<MCNFPC",0-<4YD,0G)H@[?AQ0LZ.AI>.86ZA ;.'KV_U+RNR
M'<2G[[ E^6/IE([B1-7(2\NPMF_L;1M:01K)[  DYT%^@D"LMGY)%W/JB'=F
M1M*LEYFIR<)HP4B&Z/D(S;E$TDY^A766W>2]'<<C4@/#N+M4Y8(8KF-[[UX;
M<%CLSQF.Y=]6Q_V1LL%'4J/)*Z/#7S5]9\ERPD&FZ/E,K)!)>CB^)V!P9?RL
MYOI&/;Q$)$XI90CL^K;3LY82Z?_ZY?1 3[26I_Y G0YD3;V5=V34I2%;&:]G
M<1N4IVO/O?^\/4JR>:$5P/O4P6E=\X<9%@-[62:D8^G^" '#HU>O2^+JH':Z
M'V7T?DZBR^<=JLRRPEMW=BO[0.J\N'SK1-$@\.'MV7/Q7;7]ZP*-4Y>,H5<4
M37(.EZGHHSJ6()99Q57W$R/KV=U/)9>L5'--\>9? /Z'2]L+1TN]@<- N2/%
M;<6S97_-)A[>^LO7([-MO_S=4@'G)Z6G-JB9Y8!;@?Y4Z#&2=7(@GJ'^^+/\
MITO5@ _(H\FLUIC9+. 5A3KA;)JJF>H?I+JY/=LE,$#3> 8[=CG;(S>MI&7Y
M9A\_O]B70YG#D\RN*+CLM^:?73X]X3C],7G6*?"^?(#?V(6(SI:;_#6WYP-&
ME'TF.6XE!G&:KOW/NJKX:[XY.V9 DS*^UM:U9D\8];D4="G:Z9365%/R90/8
MY,)8^4.X5?2()J337.&O%3'7&>@,:.9H([1#>#2%HOFJRP%\F$:LD1BBMM07
M52S C^P$8QIN]YG(H$&)UIP5UZNPA[SW*@5O6%$ )Y.'K0U<1!+%'OCU^__:
M"9T08XGW9SHJJ!OM/;[43EZK'S)K*A2[A Q_A/K'#1:MV*88H:+7F7I_]W=*
M6^,^MTHG*#@K/PH^;.A>2,L@:7.WEUOTOS#T4_;2E\GXY!5H)VNLO[%3IUOU
MW<(H\\VFX?Q7572*AP$]3L</"J+W5^]F&G7>.'HJ)\""PUQ1)/S8[8NK;01;
M^YDDEGS=\=ULVIU7IXA1<?BG</N3HK_F84?+(.+^HM/XB*1HL;2%14H&\)-0
M?$N$F9B>>I<DTMIRJ^+Q1.K#47N+(Y/E-6[^<!'6527K$4F.6!)#;IJWG&+6
M:X/'R4!;AL3)>!U0E"K[%*,5K@!5ANF4(3>ZI-I=0FQ2.[3T!FJS-851HCE3
M)D6:?$CV^4,Q+ J76WTT<)H1H&_D>9Y=U/3Y(^+W_=AY_,4/:EO5\J'/6+;Z
M?]]2Y=O[;X9^#_V'B<''SHO)RW?,_6O/)2Y.]LSW>[4:!LX?7)ZRZ)3BN_FO
M*!*!GCL/ O^V%LO_%O ?S^SS+6)W2%KWRZ?COE'^:E$N8G]QD?96<&M]K:"(
M72AZU()^)(^AK;,SI_7-P.0>4D)-1[E"_%Z4LE(\UT\SH2]7HF[WJ/FEJQ*5
M\40/&OLZE\3%#%7]VDADE*JF84T+S[WW$_7>(M*-J\57% ;+X1/YN;7P$:\9
MO7P45PN?@FB!JLHM91Y+1.:ZQ]8+-Y6?:C_\=WA0F2ULZQ*4E:S]=*YH)-4
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MFYX(#J07DCQ5 V96/8[O,O-[R;<W+(TJ\*[/(KMET<@>2 GY#D=56CJF^6N
M-;P$^502C=1W-8VM1FGI[C5L,6#<I3;UB $TJV_.)=(O)24'_SG31F89:0TF
M=YM_=0S<_J@N;>XIGXD+WCR0IRMVS?3R(RS)NX;6ZTCB(N*X]_]R@8#1]DC
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M\-*W)KG,J7TFV;=.T6K7<%#.0?EAWP^&+*B^H%!,P>+++C&QU_OJ,>_7Q18
MR<)394)1218&C]HTJ[3U/Y8 3=WWA4$9L97($ZV# F97F#F0/%.4!'/+>"IU
M>[BRNI,9GR11S2LF564,+N(8RKTV]9RZI]:\&U&?1'25-*O7<RH"2J>-6Q!U
M6Z_E1H]HICF)SI\+VX%<V6E<=?(^_#EB_>'?UAGU;Z9L"@J+J*W.*)XNW(V
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MB_\Z*3$W5KE,I$ME<$A)+'&PZ]3K&&D!2H/\GMH#).:J%E8@LLJ;T3;.7_Z
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MCH]NW W\<SU,L\"<JM"GM'T EXNN?M20U5MT#BS&8TXYJ*$R]* =(0;L,^M
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MYV5,K7,?KZ^OZW'F%V:*61R\OC[TKX<6]>$.\?R[NUP-"#O#F1DP-%;^<A
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M#SG^_A[.?J-@Z%&13V5[  9-W:Y "HD8[?/00S7SW\V?I:\$:W28G:7(TCO
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M@;B>1Y+[.E.D^,T0N@E&:T!\UG.H<]6*[EQT\8?17&%AMF?N58Z0FCSR2!_
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MB6@52H#*QXSZE!#'Q2^\N&+$')MY-.09W:>P1?(%+?#MA%:A3@CPN'1E@Y&
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M)P8:+U!&IU5!W%6#'?M[;!&<+4<%J!NQZ2(..L\O:?K9$*8!1Y]TA)/DN()
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M'!S1A3"#"4P4 *C;I3R$P&1WCQ6?%&D<'.CN9Y\_B4DJ=H;V3L(!_!Z/??3
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M=KY0.[KEZCS=S;6GS)2MO<725T4AT+GUY;D'>'3&J(Q\KUR$];J>2AW:><.
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M[Q<W3^8!4G(;]K9G(IK:]X3J0^<>8NHRB\6.$QT&BVI0Y8H8I6O-=P5><^O
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M_!>3:X+\!A.'*ST@,_L44V F;.PA0.7%<#X[A^A1OCJF_Y795.OPGTFW175
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MP:29FPC]A'O1'<?'7[\;E>_X_O!12E$N.:^CA"V/<$*061&^Y%%YA<^#O3K
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M'\NQPC0LK0K^?BS_+ZA82'3L0;LVR7?/'!?3,RSRF+L*)89K_#HT#@^/6WG
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M] Z83 J;&G(U!BB..!#U'9YN5;R*,,>MCB+'W+/!O[;PV%=VR+U,A/&77XZ
MC#NNR\B>3H4U:#UX8@!0#?N&S/E9;A][$:EN<8\M>8]N3-8+B0%\3,VD*U/J
MB\CE=M/XME^_8[),?,:E[FSDXBU/Z@S*#'DPX&WJ9R79T+(6 B%D$3N4_1P^
M^$LGV=06X,=+"!-,^].-2*8HSGQ# =O-Z?I5)31Q:\E9)>2J=_\ [=2SA\"O
M#;H4]88LKV.GDF45BW=8V(]Y%D\5*H8!P_[^!BZ\3_5%^ AIT8L&+EJ!%9R@
M@JXRGH<SB("']GA<15<:@(_T=;>_.LY9/JTQ;8REI-%]F.X:48 (%ZB7&9A%
M@CQ;Y<!LDQN\/?/3?GFUF4=?S/%X\W;L8D_)GGF'+6BRC!I-B<V/IWW<%"S-
MNVUN+A8D\/H.K]R?8.%GJV8N2G;Y=*<LMSXMG=*YAF$0T^BEVEJ_K]).+0ZM
MO:6R8MK=,CQBJ;0%8M\7Q^XHIT^D:>^LF+?&F^58>N[<^('Z'M1BM;>,'N:'
M&XM0F%*#OBW9WNS)Y]FC=&&C<\4R;%6$I&".M?OH35M!!9)G'@FN_4JR:EOW
M\#.=PK-_7#Q)Z[^U_'A5/'^]L>6MU)UJ$:_S(:J.LKK'U%"C],#Q!3RYSC$&
M: KZ'([@4T&.-M Y6M.0 3B*-217Z/DD>,318%:P ]+T'IFOQ)RCES9,O5@W
M6H!N1"[:>]]OS[9Z]LA(#!;R>^VV]S$ACD_!427$@BP'K-T4M[,4&K8WT?&[
MPXY\D%:]/%?4CR6)Z5:2H_0K*1.IR9L\>:MG6I%O6^QSV--[NJ6.M]DV;3\9
M:HHDMV\ND$E&>C;IVH-@1SKVZA<IHRASI$JE!;5^=!9_PCIBO/P' >_!@-(W
M&]3YQ5M.DP;3&R^=,-P79K&9_,_\Z)VN.$OF+<M#,N3IY*GPGE,FP\P]@,R@
M8Z,+O.H]Y4+HD0LO.$P]<4^2)HYGFXO16WQ!MMQWP,ONT+VN6]C)FJ!:5:?;
MUK0KES,X+W=C,9!MN.(!JAEXI?HH>MJ;:?]D*/+03PM7_M+U-E?HNZ#110CV
MQ:&\?G><>LUE<!.9F%!_N_(1@/7U2^>8I,QAS_GK]'[1:RO?R)P)ZR.MI15=
MX6&_%A'[LR"I.3;YZL]C65F;\NOH$IL7 5V)M856L@5%2\/.3*49-KW9&YKE
M[Q^%"%&J>3F\9B=J0UJ.+HZ8?0 S[9GG1#4F62XSOZ;#NF1Y&.WHDJ%'T95>
M6,YOHU6N_@<UO*')YI-9_D)#N8RC;G]DR=2*L!2DAH51F@5IUIR^%-S7870R
MVCN$1^9+8FMH^+<.[KXU80XY37 .B+0W$KL@C^JT,QGO<^F^D+T5"VCZ8;H>
M/UDJ<I[P02">A1E3O1@G/8_RD&2*%_&*D_.> ^O_OBE\3"^Y/C"H:E+/L-BT
M[]7.5T[.JX8C/4+*]L,( G>JL"F=,XQ-.SU3C&4:G[P:4_1Z&W!B&;)TV"IS
M]BW['+EG:5+MO.Q.$@X \LI)T-0+50@0Z&J7]DBW\ !G(J4*U<&/1K<]1*FI
M"Z#G:WJ:*A,[05"<-G;B097+G/B@VX9#6H?_]#38#X< R *.!2V74[H[K!E*
M:0"<"6\8]5G^@=I_&.&)^4H2H_M(:2$]<?MVHYYES3DDXTIJ<V:#;K_@!DC,
MN55SRL#8Y[3RQY]O]R2*W/C8L]D9O3;/HE](_4KR+O=4)O"A?MSN.6[.2,1N
M,/M1.^ZOCDUM%_QOL.>.IW*C.2ZC*N2G\U>M[X+85Z?7X:OUCJN9JSL2BIF]
M<+)U[F]**(/ONP CVF77=Y,!(E(NR7%00?[3^SF/TU5WP4V.%"]*F\,F^V)F
MG1&)#_+2<D+[/GZ#JA AS=?Y&,GXHEZV&N/1<.-2=Y!>B '7$8:C@S18,"UL
MN(XV&]DM(G%]<5)2KU\X>TK/M=P?+,$5MG0TI"&<55?B1<%1+7ZM^DD@63_=
MV05[2-'SA,T?&R/'M_G;X3ZK"7T&XTU;B,"Z\)B)*<NS= -UWW#D85^#OIU/
M>B1?#@0:"*1%]2(C/$" LBB-1XP:07;I@7J@N@&]P'<K8[+"]H_(3C \0.?U
MCY-06,="K.4J7?IXGX_X[>_ZDE(&>;\7!2P)M')&J??.VC]>6K*!GSR?KB9+
M[;6V8IY$'AB*=IH*3CX2!Z3368 <$C?4[11,4LQ2'>DD/?LFP^4S H864,!2
M#CFOF+4DNTS3??2EKD7<]8Z)K\Y7$F&T'.VZ$J\!DH>TX[A3#X)<M(^KS=CG
MW(WS(JMZ2#2L+YF3\+C?9[5^A_;]O9\G^KJ>T>AH-]Z>  LU1 %H0$FBIAC&
M])EWBQ=I[4W!TP1-1UJ>U[DB7,G@%)%/Q5F!#A>Y@F GS<Y-KOJG+Q+KY9L>
MY>+6VP:-)KM$D2ST4.UB,'X3WEY9= 5,#"1R]PP.-S?>9#"K2U@5!_H^'C:B
M 85>A&+V!%-0)P_SSM??OX[&>+R()^R)@W-A)ZF@3;S(ZO5(7?_[ 8L(*]VG
M2#8C9\O,Q'W]XG5#O^O>SA<L&8W* EZOA$=/?/1#\A9C%\?BO4> 5A<1BP87
ML>Z4&W+VJBNI]"90"!<-M":E]N.[YR&LM)0GG>(%KXM><;#L+"5.CV%S?M:6
M3JLY2C&BI<\A\[1Z/E-T*)\JN=1%?M(J4MB0>V=5Q^/U+T>RCJA59#8C[80O
M"VYINC,-@'[U^41=.1LGQKXCYD1'OAW3J_SQA4O?=9B%1G$[W'RFKQ UM=Y[
M5G,R%9!$G\&_D6[IK'":.4Y$Q[)LKJ9X:F[#%DS.AS.G#JD9&R/.WLDXEUGK
MA.?N9X5V!Z7Q>D@>3)4DETI>9 %\$/KE7G1DRS&H]W"3KA0@N]@A]7#LI>'[
M';<^E\4"IXWBDW,UBDS-*/.Q]G5K=8N$' OKX0$P*O#+JZ!*&B029=BW<9':
MMJ9WZ CV:8;1)YCR+_3OZM\8'G;^L0!UP<3ZFCS/3*M.=_[Q>;W6C_?Z1.I9
M-OT&ZK=*_-&IJL]+ %3^0,E,PZ4G3K]D!E4NQX<2+80)3VI@Y?8L//Y6I&/P
MP*7;\#A>I0_X6+\4%E<H]_.LX/XLZSZY3,8.>R!>A,%,KU-"WRPS11C,V033
M$'RD0,8WK^&WV27^3T/#?S&:@>2GU#N2,+-TS=2@Y!$-1CUV:[-RFQ%0=8%_
M\!FNTO^!J G [1@5@ADOYXSY(\J>4-3H:KI:HN]YR3586XOP<G3C:[G,2@*#
MKYFB-?OX=2V(5$]&T\IT(ZAS8::B%_%XG8S#7Q>O",816TY_&X%^N%1/9&>)
ML/\<O%:9+Q>9WQ.[,?ZNO;^DJ<;$/Y^+"R#& 83;V86TGF<^ 5%F/4?0?8*4
MZNOF(IO8BG OX9G,VE!M%\AQH0N%M/"Y=;R:*Z5BSXWJES;(K:F7ZS6&/271
M4W;/X:H>\Q.YMRSNQN32=TL*9%N]$L#%HV<U4D<29U<=W7A6<1D./:JFSLS&
M_#X3F&V9LK<S1M&'24-GXP>$9*DUJ>TZT6YF];YZ9A_Y#%OM9ZDZ611B+DFJ
MQQJ_K&GZ=KC!QY]="V4U!I.]NAH9-6VN;\,Z^TL>C4GFY(O36JW6#1A-^^M
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M[P*+2_DHG]"\85?/$T<WME]52_<>60_^Z&OO$.'\&%/;GTB6N\PDLR/R4N5
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MYJ?,%P =-)'E]B\1E3*'*LU$B!L%+S=O.#Z8W+JBJ 8ME"J.35; <QU2#9>
M)$4W-/\[%Y):"E]8#!!0D*QZ;.44C%J6D7:MR,M#N"L,$F0;I&+H:@4T+O\?
MN4)F7 EPXKU'N+@RPE/^E910>M$8^2(J;7G^PZA_KQ9[EO3M5-$TAR6A(:/1
M)&&X1@K76]?"<?.ORRIH>9#*[)(OK#/3QN1!+9@(@W!A4L;'S,.0DBY.+GH#
M1O'=O-6H6=R=*C<SKU\EEL73"3BH#7.4#3-6: MO)E8M0*W,+B"(5;?9!1F@
MH,N*9A\__&/M/J$+"0+1>!8P2E8(*,6+Y[4$ :4/;P85,,E]>EHG5Y'60/GV
M+@Y.]53C0=@)"OBX:D\3IZ#@")L,J+"K$Y+O-XXWX7:K=<%O\AD.BF1.LVHK
M'2V?5?--463M$[]TV)?^97Y:SIM]5&9FR?"$/[FBWK1^:)'"")O0#  ?+J<(
M2O>5^HHN#?5S:5'DDMSD36Z$.KD$<WE"5PEKRPV=9VFGYFYXZ_#IAR_/65M_
M% A;7]!C"R5<F?YC;JL4) E)(=8DG0HLF&<]<D%:&^Q[QX'$&Z\K!PBB8#L:
M47%*KST?>!<U'$SVF#,L0[H=4A0JSI)Z,6V+@S1_D;>;T\2JPC9N#P^B8)TP
MVZ,IQM_J1?)#)6::(XYD#8AD^!L:O3_R58^\L:6S/LCNYP -$UZ%'UW!_T;+
MZZ<C\_=<K["N/7Z1YC5"V+I*I19$L<!OU1,0\U?(T+NE=HE3 =<>B..IAG B
MO/"MY96!W$\J5@%($[$.=VDN)L6)C\5@8=.JI<N>*#I_%@>I6N;3FM8S(3(A
M&#L^.@Q7)YM[8.Y\P@U:<124-VZ.GFGM!$:?P+?=]8)Q2_PF7,9FA5(N3*']
M;K.O+L('%M\E39YZIQ:ZU\N.)(U)'!4=L??;IZARZDGN=:5[AN)H7AD!#VO>
MH:C=@IK(]0'P[EJ7'[>\$IKWJY@&Q39/EM-5?MMQMU9EB>*Z:B5@WED<<E2C
MTX&=:7YB9BS">%I?K?BT4_GY"D_X\OU_+M6 (X()/N+DX.>N1[T%;P6L5IV1
MO-H]5-"25V<Q0&H.N?SD=:/WQ$FE^\1@' :3]IF&PC=TD##3\RJS*P4I2[)A
M>"\^/^Q@O(SK'!^=Z@/<-3V4J1-3[',F<-H(W*WL$C=P%K>W$D8_W*I8U;E,
MA<3,C37<QO0.$UZI<;CC\F(-R[;HTZ*PD+OK0%7)/(1C>;<QH:26<^#VVP!^
MRT2U3J[RSMU3E#J[7).>+7)2!D_YB);DH=A5,02+KB)*R0*/#RY: HI$:$/K
MKK'&G=[$@DD8.$),'8?P%R-1EA2!GNC,V#6Q1TDO<=@L;<+JH:$-Y<]$6%5=
M9(CI%>JZ6F8+$*1K"6FZ_FWP:MH_G/*S1#!05;SJJ-#JRL0A<]SO[C@P^<O)
MCEO3[Y'9.KS.B=./<!I.9%^94AI>3'!;8*X:K\JJH9/8DC73$>_O+&ZP'"^#
MJ.TLY<VDY^-?M]ENO:169-I3["*O:J"=Q1+1BO(R-3HH+Q$),/$-Q4Y+S*!&
MASWB6V\1U GP?NTI55"U(G;U0<>VD+ONW<T-'KV&=V]'X[7O]"09_*9!3&NP
M>Q$9AY%2D;X/YVWY(OXEZ/!$88!6^8!B_Z UR87VR H68K.8V%=%&G03[+JH
ML%VLY6^[-DQHP(U QOB6U,%A8)^^8IF0/_H5JRJ"-=U6AZ!V8OOKVMRWU_2\
M9T^&!\_2!3MDR!_=?GEW[C_9/:<RV=X 2J5*J.6&J-;W<TJ]GL2M8;LO%&DH
M__#\@%VXLTPYB["A?<1'H,^*23\E XA#/(<+&]AY!2T(MTN-C[7Z(72'A\/]
MBXR(?!R:_M U=UL=UPP _[CV>]$NZ2O+)UEF*0:9=+I3\V7O^26A)S];,B.1
M*! %Y5H[DK^2&R+=\L; _1M04@?GJ=?A'"(96U$@]FZ+?Z'G@.]OB9;=8XN"
MP%K+2@"W?_1Z%,]R=K!OQ?'1M/F1=1%-3TMQ?'&T>K#P<YQ+2W81=&VB(3HD
M*W?"Y,*I8%^(KN==AI9O8()AX:1CFITN,Q.8W$;<)D)+"?BP,3UN98"IB@8*
M\.]^,)H92OB8*SZ8BMK5?F/H,SAQUWQY>A/$SFE0M%K9X<;9D9FT$69M[\\N
M7ESC631<,-]MD!$K]-:RIQO'';ZC#7E(T-;:$RXI,FN[!)VN<U!B]H9-NJ<
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M*'_=>?^F-VH-PG%PE^&GNL'""NS^^ZO[X0L[/\TV=UOP4V8>Y#="V6J]'I3
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M4&9Y-P]0?+7WG"W+P\V"WVY-O6HPTPQ$ B4IPD5GHIKJ)!A^J,D'Z?LZ$G@
M+)XZ!3RW9+,<37F>&+09Q/P<QSA>%=?<1("YT)(,API2GK<%Z.5R1WEH!W7S
M:CW:^AK3UM\HD]*WK8G-2#-"TX!2U!>T-IX%\]-42N375N:HDM>I7ZBK+T+,
MXQ>]?OF?6J&0+44-'?232PCZ7,8&J;_]I015',76WM_M@WB0.O*][0NTX;!4
MH(_'K3H=XO#ZM8.BP>9(33Y_1EIWEC0W+T!3521F:J;@[_4X]M1P<?2U5+;*
M$>:KDA#;%S,%<YU)QICI&1C1..B3$H7#U1P%WK&I(M&Q)\[P-%%&VM0L9F>K
MW[HLKU]F3$.C8K]:H"$I"^/6]T5T6W:.\!SY)1.WZPD7[^2S-WV@)M5JW(.9
M*EE7;!$?*Z5?TT\O),Y-4[4OM0H'U6P(W+P; ,7"3!SV0F##(?H6YL*T(]JE
M>=YFC8)U*;2D6CH?OQ<@0BAZ)/TBF:QSX41!D&I;\!(<.2CX7,O2WNB0O ^F
ME\G&II^6(/@Z2<-I"WA?V:76V,5"NTPL>C4=M>/G1SE1E_T4P>CY#JYI_?"#
M)>8!U[X'G>3,#%Y6[^?1<SNO.#DW!F>1J;UI7NSX6$:W7L8QSFVAXGV2ACRY
M_L1;Q]I3KK(1TU.VJ>D$R?SQJ5LRJAC=TDJ-<SX'?J:- ]*K:"8(^EQW2=IN
MS%B'WO-T1AR#=3&-YD['3WG+$P*:&:.TIK5V=AK;7ZR7F*V[U4;8WD=79F9:
MWT?PJG-,Q@Q5#2"T[&N\P0>+U,0Q0]',N0<@#IB0KH>=[8ME[DK>YHB?A8GA
MP;N;<M0A2B%RIU(_ORQZ;O5;5G.&>O*GA2KXZP^3(:FNW5%L='YT]%_3I ;4
M.8X.;3#YXH6:I=L71NHC$?55Q5L'&6EPX4 =0+-3885FK?3P[V=. /(+TSBW
M8/)#O(ZS;&6"X-'@D+VR8%DPP1W*1>Q.TH$$FQOD"TBU*<3N)V\R]6<K*E"'
MR85(2-X4C N]L8X5K$"[&:63QM18<?8%$ZI0*JIF?6=VCC)V8-<S.DE\S!Y+
MD1]H)!TC"N^?!0)3+3EFW-QM)\:R']&TCV5IR\[I6(C&*(FNAI;AO0QD/L/=
M7=&> *,7G%/MM$V2""H*Q880'3N"DZ+R>HOVIJE;;=YA0\C'3[/ID\XXM'L-
M'Z8+PMGGDW;G]5BM4$/03]4,(X65TWV<K*KQ7;F N/2R-QL*SS+'\!=Y1-\4
M?4P=]BZ<)OXY0GR&3P]&\:!=-[:MQ%-3:!LA(:16+%KG*!NZ*"5Y+.FI%FQ7
MV^[I#WAN7&++45"A_9C>0RS.=>BW>_^I7E;_O2F;[$?BC)Z^G8&AN,P= [=M
MIDY>"<S1^%.;28*IT5NGB90?NAN<#;%;#9_I&8%CO'SJ:3Q@< AZQUU@LWT#
M5X T*!S+E5;OUDGR1ZKJ +L0->)X;<^#,N6X03JSF78)WD'I?E& #L2R&TX3
M T3'283S3PYH1YF!+POM2^V[!Y*LZ*M,L*&V=<42._:RG[IMHU8R/#W'F1U
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M/?5O='/]%1;7$_XHME:!2R;5LP<%&G^-)B#G7B454#)+/PLD)3KVXD&=I1Q
MEX=C#(-J51->K0<7V>HZ6DM1V ]VYGW^/ZC.%[N+WV:E$J8U-WP)*Y(5J_DV
MVQ*CE(C\<90+E&'ZJ\[XP+T526([AJ90,X#RD3.,M7Y5,7EEU:Q,?'-N6N*2
M_]<6_4+"EF5X"]\>9N8-R?++D&OKJE-IEK@,4&R<[4]G&6;D2*7!)16:Q10E
M+&QI:U:U_K['W0?QMNN,)A["8E/^Z16,=F+;0ZN^O^,</>N3S,24(=<P%MY?
M]>#;+#R%1TWLEHS@,(-OLPP$XY 28Z(8CU]M3<[>C\L278@]A0V%78N)<EX
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MP!%*#9GGP29JC3R5FJX;/6-Z@8?9(G>, $1A741C&-._JGZX6X]EZBU9-)O
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MFE5(NN[-I\.Y>6-K8E53+U)Y+A@0N:F'L7A06@O65A-HF5+/&1O:O5F43)+
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M>\A973WW'3TVV*[R%?M0)Y]H03.-7(B%P9#;8,$BS*J_P<T?#G6KW8AP.U7
MYZ'+5D@.1_8&3:Y!)'=&'>=HT]\I%/Y2ZLWN\6 Q*'5U)CNG%14N6-"3LDM6
M"^92HDBHJ?OH7708">M)8=9J8WBO,?8>TFEAI_,,7!0+UI4 @:)-$WWRW?/
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MBC63W@5Y.UK%*XPJT_)!/1AA$=JAD>_<*.)4U"<@XZCPRXN"(N_4Q/H=34\
M%.J JF0.KJ(=PHVT%SI-D" ]V0DY*9/!X;9IQIO&OY@7B=^41RJ5XDR\5!KU
MQJ42>4*DM3G:(&]4:2MGR@8@"V1D%+^LI><DT%P,RXLT5GQ4S)WX$N2\(2%$
MUR<E$_/N"'DJKU9@/:WE43I]ZJ]1;2</ .=-<AN+NLM8H&<VQC$E^/ NH535
MU\XX&X.ZZ7Z+F@?+D8#F:JA3G)>SLS)#DW/QA5[6Q0='+LQTGK%9D!"<B_S
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M7!"*\<0XV.6;.B<5-31Y??QX@$T?,*\A1ZCM.=PUFVR;%ES=4T6CQU5R:3;
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MBKH)"MS9LN$6/^^Y011FF#Z?=//(:1S&Y[1IK^[D5P,7=3CWER),$R W@N]
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MKE.$8"!_K[MV*&24:R$L:)N\NR-E8 ALZ#N]$%'5$9_MCM)VI.&'[ ^FZ-\
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M;5JNW$CF-@_L42,I":J#_:\EBXF?WMK[1!1=M+XP%=O>E1BX!'@;_^:4L,4
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MRHYZMDO %_C-"V;*V>)8EF\VYQ?;EP!G>?^ST7-!^9IQ_VL!?AYY-Q>A,9>
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MW?PF5HP5A+B.=7-P/TZXO&!X%#B_:C'4TY_&+4K;7:G"0=\4#1N^:ZNJGQV
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M%.)(3?^H+04#Q-!\"51H),E?DKP4GU_4R,\8D;@TGQ#WR9YOV34ZPZ_ZKZ9
M,0*! ?$R3.5)B=15@"N1_,U+3!I/VB/,:]M<H .20+,5E79Y>^:@6#Y<1D!$
MPX24KU5! [80D^# )"-@+43_(]71Q:!4_L?\:4L41FZ9$&6ZR,NL[?-=\89"
M=87D5>V?XM-EJE7+;#TU'NRS.R@ZB'!%[W\^>9>1)[RQZS'&']6\D5MF]^L
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M7R8*;Y:(O&TMPCMN_MZOPPX[-M=)1Q8^UOFGOX&;^RGL4'BD(8\Z'=Z%44P
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MT)=X5C>+$76LY!LU,8KL444I864?"4YP:68Y*(D>?XV2> U6$H0(AALG6):
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MD!NXI<N5FEB&WFG=KQ>F*8Q1C;04$3EM VE0<KS#B(C0; _KZ+6^/%J;I)Y
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MNE7HW& WK.HD4Y:N.4'1?78D=P<=2:B_#7(QX';W?KN"D*SS[UU=FVK.]W<
M]=IT1.O;EKG6=B 79JZZHF?7---%(N^=?#3'_U+\*+>_AM>:.C;-W8-C2IM;
MX! *XS=Q)5Q&HY_H^(P<U@K.>^%^L*@=/.9K=M)7X+B'V[)P(H] RAY/:J1,
ME-Y56.SK:S)%%C43P$K.Z+X=2U7"1$>?V(N>XQ#;KG#P$5C2.'ZZ,P3^G5)F
M!RR;$//9XO#^0?UV=_:\L31172 ;\P0AT(V1$,Q,;0V++UM2YN9E(ZAR!4V<
MVQ@=Z1\A=!/\WS2=M:NL%P+T\DPE\X!M!434'?D]X Y-M,4^[J$4C!CU52EF
ME:<XK'!FF>$T.3E3J^.P 9I[Q!?@N\%S'K$1X5;$HU,P&E&14&)V\ZV$C/9[
M:R]*_A:V\BR[VPU:N'O@T]/GI?OUA@FW*+K^#(#QQR$Q7/CR=B$$(BV"N3;X
M.6DE_+CV:0.PT@W?0]3DW=AZL$A5MJ VL*B>!=9BD6=]ME996UM:$[R, ?<7
M@HERK^.#YMDK(4(1L @-5ZB(KQ/?]LZ:^LA.&F(@-\WF;NN/;V9PM"GP;_@2
M6_)_%D;M_QY .<S^[\(LAE(VA3BVG#  F)J=34%!0?'KNW>-+PFDR=94F>UW
MUV3_Z6&_Q=-;H1<[(1KK=&R;-NQ#NT%Q0U>NJK=RAS7)2#[?23YNLC!"]M?0
M9R.+N-$,-&^6]5NCD6S^/*T,#YYAQE36+!['>,':<@( !7G,SST0D7@7)3Z8
MIIUXE]>H_4;B4J22!:&,8J:LNL<1N9.G^/K/F@S*.1C46E&*G,N@)YVI^V24
M/T)+9F0;KX2J+GX($0B:ZYT_?9[_P@CBZ\.DI!4Y7V*Q$M66AX5_V*YC'EIN
MQDR,,]1WA13A_=0GZVI@?4E<0OF%8*-"GU2<41.-5R].O1,'KQ7O1'8087-I
M[EN1B3<=#]OPZM^3/TPNZ1#[JZJVUE\/!%G<'WC\,6^>GBU>5QS+EY'".RD;
M^LA$O<OKW"*50ZBW6&==;>=*;?!E*I_ATL"<!4V)3]?89O<8%'W#?TAH]2LC
MG:_)2J)YIZ=-M)GIY?(]A#2_R- FQ(QM_9,L16SUR:O.#;-#1OUU+UKW2MM9
MY<=3 $7/B;24/<6DSS26!J_^PQ3T=9+]9_IPC6"'<O2MHK$13$EO8VV7Y.AI
MAKG,C5^\8.H4@.0;X/LB?1\J:Y:?*60L,]:BA073.BME<%^(D!#P!Y/Q9N=P
MK2RS0JY. XO/PZ!6L;>J=%4WW[SK=J&($",RCE=B&H86JJVXA^!#<*OHN[U"
M<,O]3XZ?3_]9?1'ZFZ92!/RM-K7[RX"1E1XTW:8 35LR*BH:JW6KU__V;PL?
M@B;IH;4:50_="OS9T/4#>@H5I(4HMN*'_%B:E TD.&,PBFGW14U]$,MC*[,&
MHSR^ L%P(HAM;SQ\\DUL5QE3!%=:WK*H#I\-,"B=462]AN]4[$YK9?040WS;
M@RZRV[F-'[,ZB07[W=EQ6+;VHJP&<U=Y/^/["RD3-X*.50+M]%^%TOLED7]"
M2DS$9>\)":Y5U-66_/"Y*,-_^YS;TKPXV"G!AA9'6\L(QRZBD,Y><NY5;HMZ
M&(5%+O4?2:C/$)9M4 ,'?!/X/Q*;B;_G/XPG?T$AJR<>T\I57,XM0']ZQ*AF
M9^PO%2+26&5SS&)CO2@@=(C.R2GD?@[3B6=EY<<MR JOW*HGWKZ[ZG$0&0^5
M[ I)\1DTQ0^=:9U%1_;O_="I5)&1H>'"&X/&*;ZWFJ,4QO]TQU^67$T#WFSE
MF2_-M#6CF*[)F &1!C3W':(&;71P,MPZ[P8;<3-EY\RNUI7Q3M_].MAYLI*T
M&2BJ1'M<C#/]K4^ 2)Y7BQ-:1 GM>4\K9B[QKMMO6ZT"/S'S7%3Q]]C[C I7
M$5Q5'Y]R-P-9PZ=.;5-:+?<\+4L%6?Z13#[Y6[U3GORO@F=WV&_KV\IYZL-&
M=7J;Z8[Y T'ZX;^_CK2[+QE7(*9>4:CQ-.+)S#W9>MDEK^D9\P^KSNI'Z):5
MB0A-N\Z4/H$B 1]^_OLSE9 I)@/4Z^.X)"HZ"L^2%B9:R=CXKC*U),Y%+T4<
MN=G@?9DVC(2)B?C>_FLE*0/+O78F04]G6R5ZU_\<Z-.7VZ_U\-5M#*K6 /FK
M)C#09_8QY*_F#7;,NN7,PXJHAL=V4\E999:J.W!@V30EY07A&N;<H13;ID:W
M%0N4A=8NI@&1D'I6=%<YS),9L&/+*C;XG39 M:2/=\WLI9,N42[;C%^\GB7X
MU9>M'K_[EX*N<"JH3Q0*1>PC0G0B>2RV*2PE)!N5X*],,"[DR\\5A*[)^N<D
MKHQG7--KK&G$5]4K]!4=?! Q/6FYQS$]R=V[WW_IC/@N$=<Y#)!)T<T?-+/6
M-;MYJ<U0NG?F;2^T+[%"&G-YKPJ)%CYW!:IR*&2$C.?QADRM^0^NK9HUMCS?
M8R">5*ZJ89N+D0MGPS@F_TBCLUO<TI,U^@R6VPZRO]3DAWZ%7SZ2?&46>94\
ML2$OM%Z-"S'ILNY0VO'Q2]]ZM\L;4^PZ;+A<&,DJD/TV$GQ-IORYK3#E)&I5
M#W5;?56F\(?L!G$95RY@[NFLKNQ;S8M2U,5.Y76Q$>0Y<5K%5>J%;A>H0ACJ
MJO=&B 7CR4\C;HZ+$K.W6XZNQ)C.L8MC2D#5<*V2;#!K/E"$5]F"\^N[1@>;
M^3D0K5WJROCP8$.O4][TB,^&'E&BW!_4"XL_[$VR2%P>UZVMZ-Q>GX099T&H
M"3<7(A^:_^O\IQCICW]LL.@U6203HHN_X$"-$",AQOZE"%<GLW!U30:;$Q/3
M&\R0*8:65Y06HTZF#4^)?Q:B*XP<_. 62'(>IIGC*$:XTN/U:?V@9S0U2H*Y
MV,>U#\&,E[WQ U685;17HI%NOM8BH'<F$L=Q4@/11#:1>V9D_J/<3Z7\-_N?
M_YO]1_P&OU3-D\D/4*RM,W4PSY^9/_+X_E/0HH''<#'1WV.H+V^V8ZRT876Z
M844Y=M7#R]\A/5UR>)0J%?'#DV6VKLGXS4W,CDU,GC8@,-7B)0MSV^S\S/ST
M^Q8A4CQ/OW3:C'- X_>O5"JP#A,6[6,#P?S\3)Z>U:S,_,P BVAQR[V9[O 7
M*VK77YM^)_L_>OW"Z 0M?6>?KI^Q(W79I?2Z$!DYOCPN_VT8MK.U.* CY,+Y
M)4+_3E0[M(*Z4,'L+I@Q 0Y1ZP(2A"A:=%9)*1X +0^Q2E9(7%K"\U6Q(.T$
M$J]9Z\B>*FVWGE?:.'PK>U&JVP1#;N1"U&KCAVF%MU;25,Z13DD-P5I>I?NL
M/5V"$3W_UVH/]=9/3#322_)<.W'7MRRMJ).ODO?=W/"G1YY]95U)FJJD?$FV
MM.2YV:F/WVF6;\T]KQ=5;KH\L=;;[%GH7>NIOBNUK?/,O7)SO?9F'A.:4EMJ
M5=!GGUMXU*)ZO?5%OT^7ED4O>+L\[]F<V*MU<I<TW^1-U=AYU/O:N>**VK4V
M4JMNSCWG7926GEX_X?[-F3-GGMJZ<_?.K5.OG#GSY_B34Y-^SW^I>W3UT\#.
MR_^D3MUF/0SL2_Y0YG#2/M.3++&>R;-44/CVN]6_5DW-\CZLZ154ESUER?W6
M;;_.-<1US)O_?8_ZX]1YOENR_)97O3\YY6=8KL\OH>"".4'SM$\<+(B\=]GG
MFJ!>RF\5\<SM2H%'(S4>"5T-GONL<G/VF;WIW#I]RS.G/O4J67&V*NIJVO7\
M.'M/=0ZGV;=[-#^NL?81[2L2GBXNQ>_M]]Z\G2UQQHXKJ\7W3;58?C.HWF?'
M4LMUG?Z-OWQB+G?<*D\@)TG8_[\XY%/UHV]NW-Y;3.]5K_GD]N=->5)BI1MO
MS?6DF,^:FVZ9O]"5?A/?^#7)Z?3"'Q(G4VXN/><^)RH]+)_K6NG*\.97<S6/
M+:G?*E)1[+.O+7=:3&JXMU2XR:J@^5>N-+?L:TZU-[U^F'FO^KGT7U%/GBT[
MJLUYR9)]W<::PPGG"J?,#W;6/!G<LZU59X_UE2R5TM>W]LU=GEAYO/:NOM?D
M/XV38F/\>>?]6.UVS^)'M7W-MNEA9ZHN<AF=>WFK::GKSW2S[8OYYAV;ZW6>
MGUT^8?K%PRLG'SY4[QXG6S#MTG[S8X:G8Y?NT#XQG3\K5STA)CK ,\A7;V_K
MA4.)7;>F5LP*U%SQSM>+UW?.444OY6Z9T^\%S_BE!<R+K(XRLRSY?NNVII-Q
M+-=63Z]0K74[=FKY/O@-.D\UP\XSHY<UROS;E*7EU;+7Q26\ FI+%DQJM6>9
M5"IT\]CEE-5\0J4?" <W%L#__])03T04 /[_ET>T[Z^,:-_?! !02P,$%
M  @ %C@%6]=M.3FB90$ K*L9  \   !M9"TR,#(U,#8S,"YH=&WLO6MW&\F1
M)OQ]?D4M/?9TGQ=)Y?U"=?<>6A=;L]V2+$JSX_W2)Z]BV2# 00$2Z5__1A8
MBA0IB2(+0 ',GK$(H&Y9D1'Q/)$9&?G3_SX[&58?XJ2IQZ.?_X/LX_^HXLB/
M0SUZ__-_'!X]>?'B/_[W+__VT_]"J'KZ_,7+ZF7\6!WZ:?TA/JT;/QPWLTFL
M?CCZ[<?JQ6A8CV+UWW]^\VOU=.QG)W$TK5!U/)V>'CQZ]/'CQ_V0ZE$S'LZF
M\*QFWX]/'E4(+6[^9!)M_KUZ:J>Q.J"8"H0UPOPMD0>"'A"VSZ@A_Q_&!QA?
MNFQ\>CZIWQ]/JQ_\CU6^"IX]&L7A,)Y7S^N1'?G:#JNCY5,'T$R_7QT.A]6;
M?%E3O8E-G'R(87]^T^,IR -D,FI^WKO4](]L?SQY_X@88QZ=Y7/VYB<=G+G)
M,-07Y^:O[9D48_EH?O#*J=,;3Q7S4Z>73ZVO-.#RV>P1R'$*KQ:7YX/D__F5
MT_-A9YN+T\^NG7_E_?+1Y:GUV9?N2W(S<I?G'E^>/AJ/7D+/3VI_\V5A.GDT
M/3^-C^!$-)J?>=&JIKZI3? &Y-%___;KD3^.)Q9]_NHA?B;])OK]]^,/C^#
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M6M+3_;,F (-J;W[YCNW79CR;M-_:V.=@(9!6[J 6W'C!N422* %8DP!A 10
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M@05'@<(?\,,VF4Y*&%YRW?<89[J!=Y12^KMNF04@MEJ8NZ*&#Q0@=/*:F!B
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ML Z>=+)>:^E!G]FVJ<TE&O1T[E,[9SI:#^ E^L=UMFA[VF[Y4 '( I %( M
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M1W;D:SCI: H_G,!]F_TK.A;J#UFU?H*_R_?_5SN:<79 'Z=A/$.AGL36] ]
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M Q&E(\'SZ]F4=YGL>G/9-STY!K%T5Q)DH%E9I[7K]EE@8JN%N2MJ^$!A(I&
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M&UE% 9"I" I+!%=% IC*S#H?@V5?= (6)13DGL.T'*D$P9!4XOJ<Q&R*#*6
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M+N?=MYW\'&:+2;?4NGB%Z\U%?=WZ_:66[I_?-;$*'&24V7H)5J$'Y9,"I[V
MR#G7QF%A^Z70S^E;O<@/G^+F67D17K\STU^OK/27:J1N7?C9XLD[,_4UHT?]
M]KKPB6 Q;>06>Q2J!*% ,M9MF(H%@F,%A$65,1=KR_Y!L9_1E75?M]@8NL/7
MS>>BL"A-@&1EO5O%"0@6"YCJPKHX8U,V7]+/<%]W6/K?[L0[T2V^DN:PR(W<
M:I.5#\8ED*K$RKV5A2.KMUI980(&R:I'?TG5[KYNM?MM9Z:^BS'V7= 6<MI"
M?E\D*GE5QN0*\!1=#7'00I2\2B%'+A%K_*N_*.B]:7UXQZ#'I$XE:!;EF;E[
M(Y8C72*@DB[UV)?NE>F2=; RZ!K2UW3=2:E )%0>T1B91!_[ITZC2X(UWYI'
MND2Z1+ITAD E7?JL?;W%1"?006"JZE+,$GS$!$$PS[-)7H;]?;T'[)<ZC2[Q
MJ6 -'N=*RD3*1,IT]D E9?JL<HA-P:'($"6K*E-RU1NE=V?JL5"LM)'O94R'
M;&(Z4<;4_B"F\>L2'9#7X ZF%\M-F']T!Q.->3R#$(,V:=,F[2;B#1&30Y<1
MDE4"5"X27,V'P7.6%;.F,!WZJ!P^?I_IKB91W[1E]#?WT;CF"X>-[YT>8'[1
MB.5(I4BESD6EQC]*I&B#W'9=B,A!B6PA9E&E,0LFN6.!JUZ.SNM%%>\Z"%),
M'0V";&JV" DE"66[F"6A'%XZ9V.,+AD'+*54E4@F"%X:$#)Y6UP,+.]UTQ]2
MV#Q^.F>ZJB;)%:5SI%*D4J12E,Y]T891QW52#'R2 51)&2(&#U$:[7PIT5KL
MHZAZRG1.N:F5S5=7&]?'^QX5>3/:@$9%'JW0^OQJ4.1%)8-NT^OU0_QE.WM5
M_6^QF:Q?AA5.<MB$APU,_QA=I$,#:6@@#1F3_)L@V2HDR9CDW^3?XX4D&9/\
MF_Q[O) <N3'I (X&5U6>XN;#=G5:.R%N'@2=$#</UICDWP3)QB!)QB3_)O\>
M+R3)F.3?Y-_CA>3(C7DOAVWLONYLD>O5/11=X]I)9P%<&W_WL?*!9?;W'UP0
M^^8TS-/K:LNW83U+#?0YG@>KM] H1[VYU)M[/[VR(CEM<C3@2G*@N(P0ND,X
MG) 6BQ")X5ZO["$# ;X+NTM</\?5CUT'WH[C;G?)+N?S</7TVWY9]GZ_K/@/
M7;+L@>K_&(;S:I&E+20D4R13)%-GOH5$%Y4Y\PIB,1J4$@BA"%FUD?&LBRF"
ME3XF O0EBW?<1?+ *=+'AK:0D%"24+:+61+*X>5SP8C*EC4W2R&SFL]%"SZ7
MFJHE)X(-NC"U-^#MD(D )\KG+">]HGR.9(IDBF2*\KG#9;&@PZA5=\)PS>)4
M)6AP"3.@RDIGK6P*JH^1 *?.YRQ-0&TIG[N7V>M4@.V[ /OGV7R[P=R KC3B
M)10+#826*!8:8,JN9=&Y)-"\6SQ618,/F4.)-A7K"\NVEYGLMV.3:Y:C(FQS
M00DE[214)%0D5&>>M//,3%95WW3R-0&/DD$4,@%/)5F,+G/?RW'2_0DCE6$;
MIQTJPY)4#@VS))7#R^D0+:(N"$)(4W.Z["#8B.!S"CHY(WU@QRC#'BVGLS1[
MEG(Z$BH2*A(JRNF^I+&622>#\Y"JN'1';7D(H6I>S?"DSQR5E[T<>'WZG(Y*
ML4WE=#2=O<'"ZO_;V1_S)%0;A)_Q9C[[;BC[FH:*T=""'K64AA:0,<F_"9*M
M0Y*,2?Y-_CU>2)(QR;_)O\<+R9$;DWK:1]'33D/%VB"?7M=W&S'F6&J;;=2
M3M^LP'V.T7#@UAM0$3/XP VP*(3P7KC ]X:='-* ?K/Z^^AJ\??I]B+BZEG9
ME5_6S[:;]28LNINROVGN:GWXP*/EG9I:;]LKSI#S4AA&LD+('*NLL!RJ2H0
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M3I(S:&..!884HA-0!P%4XLM!&W,L,"2^)* . JC$EX,VYEA@>*Y+&HJ)+)D
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M0E?%AAD2FT:'/U!WX]&Z&Y_B9C*KGG6!K?(PQ06#-N98"@U-M)Z/\A1L NK
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M--MO\P/>')&UZ[=Y>ZI6JVQ-0<-AQHS597#U]C</].5FLE[.9WER Z1&S#W
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M8M(Y^N(57I_(/)TL<#-9ELDFO&Z5^"G^&+0QSRW^H#5% BKQ)?'EN<.0^)*
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MH#B3$'+0P+3("2/WBN^MRAY\]-5O)"N]+JMRRE0H4R%%)$4\6T6D3&7$!#U
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M=7TP6_QALKQQ[4GG<*]VKCWY/__E!.??[ AEMMAVSUZ_;KF@-8KQ!UJ-\-D
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M>1>M5HJFA"*/P":P-\@YZ1 /CDJK!$EY#]?+,@,^XO3V38#%>(_+> N6'+Q
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MV]E+A%W#/KJ]TQ,J_>KUFP(+1P"J]SU.M2MYWGB:ZI@$>I3JN&^64E2S"/0
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M]^"3=)5D&R7=^J&F_RM)18M7*5ZE>)625'1(HS/DA$&%<@[ P*H"&X>;^:W
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MXW0=8#0W7G ND21*(*X20T8+A2RC7!C,7=)Z. ##&1UIK@K %( I ',8 BT
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M;J%/?_0__@5^7&I1/_-:=_AY/OV4-UE_^&W:G,+M/W93<3_8R=]'U5]/WIV
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MRZLL!)C=.(M3T_3VYYO$>4H2A *7RR2C=J'UXU13K.E-&R<W4*D)X-$J!L#
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M"K=0&X1;?BU?X9',P^1)%J%@!5$U,CZ!>(M)^F+'29Y?).EW' J*7<R^I,[
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MY55@X>MIZ>.)*JYN5!:!QI%CN8-2+(3M+1^0;6P1%3X :SLBCW^\96:3#R,
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MBLI\&?G804W)(V2WHH)*3"K2W+;WY%,J7UWM(/9, 1T-)E3KJ8<$\$Y R8Z
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M*UU,<VS%- M=3*.+:9ZNF$;8I4;H_^D%$&KU3Z>C1OU'&)SAC% !0*$@&Q"
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M,H^$J[(_]$VP2IVH-V>R<^[+Y )[B^.+8IR+B^7RR-LJ0*YR$?,K(>VP^V/
MSI-49$^6<D@=H(3U?4FJ#J=9:=%SG*+''%F.\PQ$SW_5>PQ69VZ6"3;7MB(2
MN<E<-N/'B,2./C&4&])HHB_0C42:W'E<-%(JP\<M[U-M.IB/;0-S7KVWWM6(
MI6$F@NPDX!2.@FB@K!=VAL<<Y$91-MZ1Y7T7U%:GAH-9"1_J&=2ELMK]U+8-
M,'BCI^(UK8<&\BRNLF\4:X [!7$$EE"!92.[F]J0[-_RZ9<:2? $@DNOEBNP
M3=S-(QV(X"A4;[VDQXEXC[[ANX!XC^&T89WVVIR.&B4_71RHJK$](H?-W=WK
MW=!*GJXO<LH%@KIX#&1<Y064F0RR=R])"%56OD:E/RDRS'\LTTMERD.SQELG
M33T*^-E=QCY[9/PC3OE9F.6\R_B'V3=?6234L??_+E#[J+7"00W@'\);\EE8
M=EU&RIE&ROODC9_WS\H:B.[(^7+)03VUQH.I8XE>>:56C.GK>!Y]GF G^$0>
M5W15'EV&?30*:K5.SP&&)SNCUCQ/M$>/9<>,,C58%7S2R52BBRP>'H'OZ7[7
MY<Y*A3OOG?\V#./'7!QTT4C#H)P#RK.0.0\X)GP^S (O'T;L"HQ$<8EXE87'
MC;Q2U\,"1FR=\9.,KQE6>S;S%^B^%_1^&$"9!()9Y<*\.E$/4%?!97Y))GKA
M&-ZWL%_5$S14Z@%E:/RPZT;KL>ZQ1J8U?ZR7C1YM6N;(GCW:M![K'F<TMF:/
MME;V])#;QJ.Y<_,8?_PA3[=VEDQRF@."X#$?9VE2Q/Y0PFQ _VN'V0O8SR+/
MZD1D6^$7;9NRF69E6IA,);\2&4SPQ3E/J9^=1$&!C%NY>'!AF6FELO/6N4&]
MH0TE$]1-,A]*O+!%-6E!\?D]YQ3=D]:X7W(0E:@U\K!R_^D60W".Z;0OQ\.2
M_W;*YZ%9;@WJPMKB3W]Z8;_0;/^8;/^-6DS\1N<%_>BF/_P9%,FOI+K2IR^U
M(W!N5B=Q]D-G-)M@4N1MS;K)R)G";=L)C/M/YC5[<R0;N N,]<!;^B'HK<%0
M@^$#@N&I#$Y]QE /X=]G/.,+V]\0)FIPT>"BP46#RYTU+2,)"%Z$IF5\5CH6
M?<DR*OA7UXC#EI4:)E!)'+NAX4C#T;'#D8:@Q]1OJA9_QL_H!A8FW_]A44%1
MKIKA1\E2O[(KX__RG+[XB6_ U#]4WY(-0[&.4-D1&XVW]_9Y@(&!=R?'7NO\
M;]H)<'^' 61?EMZ3@],P,BQJ%&]9;PU#?*$B<8?@S$$DU["]#SGCI!_$?&RZ
M/10;MHJ?!Z0EO?Q!\8!PP-:,VC-&U7AYU,1L;O']J?BRJ_RH@;/G'*N!4P-G
M!XC9%S;4>*D9]2@8]9GBI=[WC^\=5+F VCOX8(N%_NK*-XB?'$L[!CL87M98
M= CM9P/;GABOW8.2W)X-R7LM8'N'%UIM/D8V[,1&OU=LM<:C\5BS:;_85*/E
M41.S+VS8/[34WK!>,NHSQ4N][W6N7#>VP[TN%O6HJ-QAC9857=TRO4.@)_&'
MW3T!NB=X-1N,S6E'/&;W43^AO6H:=3ID)QZ(,UI!UQA^*\^<=6=]Y2%9O6NM
M.HZ0V3M".8W*FE$U*A^5!U#CLL;EHR&G1@^=57=\?D1J7-&!W=,1VG8"C'3D
MK%MLV#^(%FVL-9_VBT\U7!XU,75A[1'@YLA>:'[5L*EALS/$[ L;]@\MN^)&
MU(QZY)3K!%[J?7]O#D#X X_#>1:'!?WHA^=XQFF6B</=AE&8Y4,>\16>0()O
M7_.T3!^3\R'6&H\F]OS56S_,UA&[.@DB?EDG#+9&E'-4[Z=KAEG.TOPM$6&(
M;\Q.\(3O*(SY%KFJ6<#+\)"4>SZQ:WZ',Z;&V#72FLVGXX7MS,8S>_*J[@G^
MSOD:1AJ5] ECG.*0R'0-71KLB6LCY]5\S)/-NLE-O\OC'/.+A,XB/\>CPU4O
M3CQBE_IPCHQ/16K\M8BN#-NT'/6] =3!LVX+.O6Q=M\UIY<5:[P6YLU6>-Z\
MD15!$'HAC(:.K ^"C(LSW_T0SR_'4X170(;<"-)D13^$65;0"<%X"+)X44'-
M1/%=7!S#!Z]<\SBCP\]JL[BFG:CM6(']B(1'@IX69\!&2-)Y"]5W4K<BH2_.
M(V:1\7*"QWP9,*A(GM.\>PT&^"5,U*.SM=/:&1TOQXOY:'$-E?9CSP<X^*T#
M*Z9HRXBHC7SHD5&=4 <[7OU7 W/7@-D]&F"6O=W+<R$/.O41^/2E.;)+6+C#
M*9!UONZ^4O4@Y_(^QW-,OP%[2$E-)]J'*\DH++XR@B(OTKH$07Z-(L/G('Q]
MD%,H<3B>BA*IHZ 'P(->5!"GGO&8?N+PNF05>O0&H,QWT #@*R';Q#FZ><KH
M%L6>^$/[4=%/NDA=X-('F.WFZ=&3^VH[_Q"G1X,P_@2@EAH?XR!)5X2$'3YW
M^5AYXM%@BAY\$N;P6N\6U/A21-RP3'<RM(QO$CT^1RQ^M#.X[X- EK5!H3^^
M@X>[:?C'0093&68\#8,[D:G]9.7G*.EN<6)WAPRD@8$_HT#&@;\#LQ<$,[G%
M9V\SL*%33F+72/#0(#"T>=I^J,;^8X/5"B]Q4+\5*V _C\3"AW]Z4]N>!(OY
M<.R,_>'8=(.A:W$^Y(''9Y/%U'06_(5! [_,O_#@3R_>_=,=3]V9[\R'SL2!
M>WQF#A?6!!1YSF:3(!B;;.J\,&*V@@%RSS_!/8U;VCI-TU,_68.6^B%B9R\,
M ?0@G2Y!X0\ON0^#CS*^8ZB^PP/79O[0PS>.'7CCW!RSX<2>V7//9;X;W'FH
MOR7Q :/M $,Q,=(2%AH$;/G<F9V +/X@G,T\)Q@')AO.G9DU',^]^="=P%^.
M;5N!'[@S[M\K9W]+5W%^$&.[$P;<ZXUA?!P8V_4F0^8%T^%LYMJ>:YN<S^?W
MS-C[#;8#[)'S%'YBQ\G::&S5%1IE#K$T9?$9^9.0_>$APYLN>\TR(RL\,/R!
M(&!<@?WF\R",0<:%L4$:]-B<HT#YPL^*2'A0OP[_]D:;6\>D.3ZD:GVZ7B=A
MG NN"XQWRY '8&VA%XF^0X/]*_!>SL^NC$]"Z^BP!;:M9)^N\R3;5K$[ZS^R
M\.RSSBK6[X. B\@2((D,><B^NL9KU%I17;7-M]5U/P/KT)?6VS>#5L7VIX2E
M/C+?SZ6&6W\4_:R>8##!KX!POZ8CXV<8Q5]2?H9^T]\X=\FSRE-X+2!CV[OV
MXN\&.I*7]+\-H^YD_@^M_.6)_98\TD(SQS/G8%6*5=ST]6]&]D>3,";ZRF(6
M\46KJQO,E9;S[-SD$I<5UZJL(KK<D09P;WM1)AO4 QNF^B03%#K"HK;5NGS+
MLHA(CEH&&BB<<,**/'G;_ &(+[Y>LS,NHA5#%@ 13EATP:ZRMR]^V.2+9DX(
M+FO%*8T5=S"]HQL+2R![FV6]"8'M>\^):&Q!&8-;,;A=WD3_PN=: $[1?=)"
MYA<:QC^G(:B8 );+,%.0BG X(%0E)"48]1%'?V4Q.R.7&^R4F$XL%I?0#T(3
M_>67=P2E]'T%KQG^,#"6G$7YTD/]%"^"K109'"->\-D_#S.$;_PAK' Y"%&C
M!00/L,1/*+24KH#CHH!#E+CPF# &NN:%C)Q[$28?9"/C R88P/53G"3&Y%MG
M]CGE6>@K,; E&Z0XP/G^O8!ES*^,=SB'SVFRQB0NG@W@<F]DO$9KB:<1"*'_
M^_7]B?'W=Y_?&&M%XQ#(D#'0Y.'OWWD4Y<D%>;3A1GPM/.U7[H<>,_Z7R&1\
MO<I <R_G  J\F(/3.H=6B7;J8UPQ0[F&,EA-!(9I?"WB-,RX\97'.+Y?0J3F
MCGE\_?+_]I_'WY)EY/+TS/A;RF!-@2?A$]SR/VRU?@N">&3\\EE.REHL)F)2
MYFR_2=5G@&&L7\,H@LN2=)VDPJS9'/NOOWP%?:-U\%]#3)^0JW@%"D12K&D*
M'UB*>1HQ+/,:->D:AY<CGR_DR,>UD5\DZ7<Q<B;O20V6&W_C<<QA17_AY_"(
M)3Q0$8.TDI*7&QL"Q@$F'(N]L,G>%7.7K^4L15N/&3^-?AJ=CJJTFG_$L.QI
MAAP+S/MKZ"W#,P"=+TF6&5^]99)$^/U/10:@F57!MPX@TR/[L+L-TQ^W0_P;
M@+T3 39UV@$J[,@:3<V\XN&&;DZ/8,;%,HFBJV%R@5R6%2Z 9<C2JPT/M4&J
M(4&T2&7BJW647(FAG*5<^BKJUD%UP:FZH+(11#;3$C<39CF ](:-@!X.\5YT
MYU\!YP/XPI#^!9.A#"K0U# ^B('G&, :]E3,+]C_;^]J>]NV@?#G[%<(0PJD
MF*U8MM,L63$@3=.N6-9E<0OLVT!+M"U,D3S)3I-_O[LC*5..7,>UG,CN%6C0
M1I1(W3WWRN,IHC  Y L=-Q<_6XWU9G0'$:-D(998A[I:RY= KP;NG>-^.6U(
M4D4.D<E:!- 9_1!'WOER/-OPMO:_L2 .%)6JU4AE&#><@_ EU7^I98..TA3>
M/SIJ-1!N, *'  -E<P)8<GR1C6!5"!*J8?JBXZ=]#\?37V<L[K%HED #*^JT
MG !\5L.Y(@CF7V.<)DU C\!B *&H$RKPD!YSU ?!#9%N(>8!]PL6C=9T""]Y
MH$@$PV)2V)KK[Y,D<*ZER)*XH;F-\+4R5HM8\A(38LB,/._G].\+$+2F.1?3
MS$2<E"%[U 3!_(X100R>BW5[YDJ1;,28 O/ GE#>% L:^TD\!8B2T H'Z#,$
MUB<@N>ED&J-BEO_A+4!NKWWT AE#HJT>U*?"2X)"8U;:HVLW#&O[5.:'-9'6
MM#<2:RHR+<#V%4H;XGQ]23!44X&]M$B9EUGB[9_ 7,)T\/N;<#*1^<84!>3X
M\K?T[KI*$_1-G.6;]!J4!:%7XSX5QYU]L:-[S2*\3'4IA1>@(D@'B:>?3H0!
MT(TU;CMM K]5+5F6 BA63^K22:QT0?W9,)H!3 *^O+*PN?(D:#01&D@^LK&6
M/BR1JIQW=G%K=)\#:C%-@$TX2IMX( R)_RA, W(*@'/*P<Y14%#?8/ EN1:J
M4!?<("#@:)H&$2PB1]Z^]\H] 3]FOPTA:8<6O-_NN,<>R1,(>032BC6MJ,(R
MZ:L:7I.))H72ES!4:N+@XI;2Y1>:YX# 0V#7 !H"$>!]4'W"\DG^;*FTQ/9*
M@E<7S,L6W0^+ LH/1)@ZMR*:$F;C!-XCRY0^VF\WCE^U&UAARY[&S-/X3$77
MQ$7:2C"<6VH?);Q,B-H($4.&216)H< 2B'*EC<B>T]K(P&0Z*=7<<"^,SJ<J
MMR-F<(YH+'V?$!7,G;G<%W3J.,)*['PP+@K>#["3YIH8WV(H%ZIV0C$.U/#3
M^IX>+-"$.F1"U5A</<Y!H$;:VC0Q BS\R?Q,5"Z'FM_W921UI(,>_?S+P:"X
M":0$Q1"3<&JA(D69FR$@N?7TIII9#;'MOYH1-8@T^P+X*TMWV6L<)N!EN>!_
M6AY"Z1*7XX  @)Q7GH0:&TS):MG>0ZXD '"R87R<++PS=1YYV(<_O\CH-J\
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MX?5A/PGN?_WA]>%H<A/]^C]02P,$%     @ %C@%6V-Q1N]1Y@  2;H,  \
M  !M9"TR,#(U,#8S,"YX<V3LO7MSZ[B5+_K_^12X/3,UN^O*O1^=[J23R9R2
M7[L]X[WE^-$Y,ZE3*5J$)"04J9"4;4W=#W^Q%AX$WY1(@I3;53-I;QM8P )
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MW[ML_5ZV>>]X_/O&PA&_7X5TT;PHPC\9/0&'_X_?1&R]\639A0YFQG\&P-3
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MQG$ESLK!'#>@:OW%W M19.]G]0#J0Z[ H7@9;=:EW9C65^O@N^!0:@/*8E5
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M,GW![B2&<Q#R+]D%D$XN>":'0*!F41=,.& -W,8R/",G7E2%]'=#N\,WXMH
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M9X<+'P&%0#*L!J94KSV0L6M)=#C_SWQ_#3#9LHNHN-GP'V:)REO>;CS)O*B
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M;7K?*Y.HDL*0@0E"N)0RO2Q24AZ%4-AZ>,_/Z:[(XUEA@FK2<RP17WDK4K/
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MEVNKDD,=!VZ)LTJLQF+ OX,L3>F'2M4_AILZU("0RG "<3B!SWM K=G")EM
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M>A,P/[Y_#O!G[?>\HSX+0BRE=;ZE_,_WJV ;\8?U_IDWV-VO0MJ!T@=C$IP
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MX*((\=E(J.^;B1P$509XJOBW[<K>*#BI#*Z7O:+R"AJ;?UN/7.)5A>28*Z'
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MB0^^8"('+$J*,7-]T OXE\/IK6W&G JC<2?6\[N[B_N[<<\W92FWJ <U%%K
M7"\D!NJV$%LR0#PHMDA)I4Q0<8V1+8@J@ZS+86*N.;8]0=?JPN05T)RD^RL^
M-J86L,_900SNXM-C#YP["UI^$]*-P]QSNJ#\X7%EU)%"&!7W8LOX'#%" A2:
MH(CJQPZ'.7+F&Z'7J\600^%:"%EY^HK6H %J?=U"O(X/HA ^>22?@YEIH"M5
M^LNS((K!7X<7%3C46D8UZ3%$>!Y=L^V:[ZZKR(LBO5!5SY]#C=[H>#GWBIG&
MVDU7BD,<!9G6XQPKO^9GOC?3%I-;+OF8CO=?U DO^6\.W5:=VR+($:!'D.!
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M)_9+7W?&D#RA)CV=\W-A*;@O<U,>9MZHNOM[-V]TRDG)I6\#X>>.O8C<\^?
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M'>V]X%%FQ<W0.P'(5K0)D:7'5->M3"*M.C"JH$$OT+P< 1/R&TO*>*;"XHZ
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M#T62")I$$FW RS2<IV;OA',U#?YCS4QDB_=S4-0W\8F8E.P.+A!A*I*FY/L
M](KKP/'U@@4E#7 UW@\W97X9AQ"Z>$[%?Z]\>7CN',\)&<++GP;^EG])&5[V
MZ#DTD_P69?S]O^$'5ED9^>2^TF=#IPD#G_\XIV)_X%O)\'L8D4%9-UV=\R#<
M!,+ A,"G9S#G< >87R:C#;L,O:,I7Y ,12H.U<[L8O..@[*8I+C+^!2C3H<0
MXDV^ZEL/O5^?@\#],_.\*WY;LQ#6'[+Y+EY4VFJVJNH9G_LR^P4>1F0<^\@?
M4:CD#N:EPITS_CZ*"2L,U^G\'ULFD"@U7!-7X>C4XS($?B>P*\]\5T#@ M6.
M+_\Y%T_F,0,A: UW1A''G0XPBB438.3*@%7$<[K%2)X&&:#"+\8@A$<,KOIM
M5/PF%+<=Q>KK2 PE^%=M1&GC4;!2E,_Q23C]BIBI:#X*=@">C8G -4BHPH"8
M)?7!WIL$R6F=J(C#_2B,ANE4=:WI-EX%(?N?XI>[HOG03W<V9=UWC7#'(D&Y
MOL.@+ &8,Q?4X0&9A7<T?(+')O,LE[49_,H^EY$2E_S8.YXPX5[RW^7NZ]*&
MH_@ZTB%!AO^UZ-LH;3Q"5DSO,>I,;A+*4,];5>_!CYZ0 .Y6U/.DT:581C!;
M#'YW0<SF5RYG\H6E?OX)+6DRBH.%A6SR%D0I@A5*-94]1L%4"0Q*?.:$X8X_
MZBC'%#Z033H.?=QNJ,L<\'!]=O@G'<"1XKV"Y8[/_//.IW/\QPW&A\_!0/QE
MZ\7L6NHYNO<#UUI]X(RJIH4GM^?11G%>THG;:<6_4K O:#\*AA[N/@=/-/1A
M4G>;P(^"D+H7L'6;D'%%))UZ42[T'T)G% O ]7I9T% 8%^EIX+L5C%:U'P5#
M.=&]W#Y7TG04;.AJ6#F1OKC%*"9]OV*A>^, !JBS"\+R4U38<!0L)"XAM(2%
M5!G&:/0Y++GEZOJ,@C$\X8_U?O?'K-\]909,%7&7TG#AX>QMM'$LIOKVKE5\
M6N47>IV*8AMZ\@6F7GENJ0B@:6@?3G<:B4)TR3S^./%U7P9AB4:4:C**'3&T
M RX7XFE?!9Y+PTB8J(LVI*[/T,+WK>,RE'BEO8;+")@"A)BBA0)T@QZCV*VT
MD:#R!BAI.@HV9(1*I )C'*_21E_1?!3LI)?Z,J3_V%)_OILM,AEN]=M4WG<4
MC()J+5Y3SPN>(98SZVD]6\$K>^67>_OVI3$*QG^FCA>O4#/F<P=%2]P3Y6)F
M=8]1,%49!UP<*UDJAQY*:Q0+D8]?TN!MET%XYCELC=XF\8/[MZWP8$B/X2V-
M^-86ZDF=$![%$BG/>Q&7ZF^CF"A:""3>K !RD:M9:B8M:CRT!'/)GNA-P+B"
M_1S@S]KX?T=]%H2(LG6^I?S/]ZM@&SF^>__,&^SN5UPJ+A1QNB Y]+(8<[MD
M"[#2\\W[$Y<'V(+)4">SDECA.AQ$8Q1'>^JZJ/PXWHW#W"M?!JL9>FJAU:RV
MUXAVM>X0C_EP&BM:Z O/_'GHZ3[XOK.&%UD:4_\#[H9?^)I" ,5S4+C\C?H,
M[M)'<>.6;K0Y)UB&SKK(L5_><NC=27()-*IG4L$R*E3\FO<:Q6U6DG59:G.N
M:C\*AHQGM%!"3OX\_!>BSXDPV'RA\2HP8G/ROZ6T*&:U+:U1[%NV/CU$]\^+
M=K"PX2A8J/HV*L/I&G4<^BXL -(KC#8K;3>*/5)6;"X'//++&=:;W\W!TH?(
M/H6@@-EB&+$N+=PN5P]-<RO7L.$!%G$<HF65R;SSP4:QE+>J8+@ _;ITYJA2
MEQMC*CN,@J5F83TC"^4Q4K^N_%S.1>;KK&@YBATH3&+#A,I$A&IFX\GW&P6#
MB7TIN@_@-N#RH4>_TCBIJ74?[ FC6*QP=C_.*!;0A$@O>&N*UJ*FR_""8*$"
ME'?%UK4=Q?Y459NO@+4 ,6$/DW83<J-8#KA>DT_QCL:Q1U7BQ(._C;:.AU]@
M!%5L"B-E]B$P"I;SKNBJBZJ\]2B823Q(LW#I<,E-BG$HH=]ANGU4'C31O/=(
MHB?NUH[G*;FU.'HBU604>W1+8[Z"U%6J(7_ZM^NM!_'Z7,IA<U9X\.I[C8*Y
MY)W"8"CMN+NE.-6S((JC'%Y*5*=OMB$Y^%&=\OFXZ*CWG&7VD*;^./C3+I.6
M,$)'!K44O^NE#4=Q"/GLYI2ZT27_+6#"?W%BB&3>8?:?Y]$Y%F$#L$:=6%88
M0K(_F5&P;U[>9Q#;[3$7_U& 0:%N1B,O2D3,9,#Z*K_07@<<Q9+61:]5B0Q-
M^PY^48D'<^JZ?+NB&WZM.MY_LTTYQ$=1RU'L5G-H_T+]JW'O43!K^ C+C5FY
M1D/;@!0Z6M.D(F5MS!B(#B4SBITSL+\R-5*2U)OKRH#M?0B,@N7RA-6+Q8)B
MW9-#,UX+"(SK1I7_@0WY6'FAF@U'L6O:"G6ZTS_^S/AU&,Y7.P2,* .F:=9S
M%$QF/7652"PE;4?!B JM0^2$V/&73/ML&@)F[$=A%$PG,KC"]2ZVNV=;C6+R
M*3OW-.9/U^,V1G=J (&&4)Z<ZQO\P*G[KD1LV8_(T") +B[K#@Q-S4*XC*:#
M7_(**P..5/9>-_\V^$0E"!.%2A'>E>_2E_^D)3E'F4:C^$H:E)6KMB/MT7\4
M#!MV!5E.7BB,!A,5;U3SWJ-@%E2N##Q#XC"1\ WI7Q@MA9<E[U65T'X7+W-,
M#TG$Q$(=R>H,1K'H4_ZQN\S;@MB<G L!B4A=L'N!P74;RTB?G-A3FK#3">&A
M'R@0P/__]MZTR74;213]*Q.^G[M[[%[=<?M%U'I<<^L<5==BQ\R7#I8(21Q3
MI)I+5<F__B7 G<1*D4*2K(ANNRPE(&0BD4CD6C2)JS<LOJ!1X#14DK1J?JKT
MJZ'F1,$[+T%,-Y:X=31XO, %1($"D/80QGG&)BO.7S:D$3O)E(-0H%;5+LD*
MU=[#070S%?XYO"09$L1=;;A7A^Y@%*C6<^Z=:!5EI:_84[.0)PJ3F&@8"O2^
MA@$Y?G6B7TERFP:N3K4CQ1 4:-6MXIK&<TSJ2O%$EMKG.D HEMY54EA*6U7[
MJ"(Y7Z_4'F[[ K\(0%W;D=@PL5]W&(K=%%M^F^\=KI:F.18%HG1)E2XDDQE\
M2-O,V(E@;1NI1##6[09YV'!6"_2_B1/=!.XU7)9MTX$(#@W[5(X#<<90%\PZ
M_0LCTC]3)TI(Y!^S MHB6U,+S/KR&[X-IF6M(N9<#=9RQW(+%@4;U=]O14K
M(Z%J/UQ]EV$4A>\T9< YP'>B0C@F,U@/"1*E8O'C@N30*':0&AXBLB-!#*^:
MS&+^C<!#!V2NX)D@ L>"3O&,R;.TRYY\M! $C3"^96W5BDYZBK>0WB0H4&>:
M*&O\762F9[7/&[Z/;G.VJJB;6+\]:5;;FL9C&CGP.\3AEZUJ?FM[L376J_($
M^.%F:FC[R 09EU##W5UPX;DT/=+;OZ913 I[2ISD$=4=W$P&VT;UY@.TZC!R
MO<")CNQQV[T1)& H!$BA;F=BO52Z0;[S54,1- IDLO+=V9( 6E7GNP6( @7=
M]Z@DV]%P"A1HEP9RI04=C>4\C_^NPK\94XGC#V7PMB597O:">KN+=U_\E3C4
M=N!6EM/,)27V,I\TD6T2%&&49>3D*GK>A0=J\2HB)V-%!*;.4-MH=G)H6.!Y
MD4:3UPGOJ/M\+>J$J5"<X%Z(&P]&@6IAAE?7_^=#HD"B$XK0"D#@?RHK;]!_
M/A0$X92KH+DGGDNRGJ//\""+,XWM>QX!3,;;%EQ/WD>O,GSBB+H!9D3!!<V>
MI4*/* <,Q?*'K+E2A>J.7MZE]E/6#91?O<#;I_LNEW>^M'V*2Q7I*7V-#X1J
MBLE1KT>/> 0*-N9HOL*, #XH"C3ROK]Y[2)9N1(>( H4:F>54SM$,])",A(%
MDD]D2_FF[",K+=@@@,6!2%5[L2!Y+GT;4K=X1*ZHQ :FHXXBFEFKCGD>] =0
MD.S9^<AB;<41>BT0%,M^"2+B^/2J_0)+HJ^*5:!(/U<,08%6M[B8IHC!*#NK
MEFCB9U,;!L7",P_5*DUB4,MHN#E7%+2!4"R]6_>,IE]+[+L2>!0(U7)R\Z6R
MM]1]"*_),LB[46-74X ;3X>"')+>VR)'M #<OO9>/)%7&^"Y9H>.W"EW>:2)
M7JL-ZQ+7T>4-QZ/8OWH-E,+YO]HH/18:PVSO9\V5?"\HC<T#0;$KY1F7W;8=
M(!1+!\[8>$(#;/4MBL7FW9!+CZ_<]2@"1H'*%T)++QYVWAH>=66<@>B5+H9&
M@0Q-2DGR3"(J,<5O 3XD"B1^(=YVEQ#W C1*N!4*1UI'3Q/6%C>:P+J=KNPN
M^037H //,VYA>!Z0[9NBNKF[N0]/CN]$M"+8+ZV")2;C4+!CI6GR6V_5(]SR
M;JB- #A:SE3<_'>HR6WS0A'[63W.?PI]>LB4SWKCP2BXXJOC'W)[,UU@I9$?
M\ZZ*+R!B8O8R(:X\[JCG5"C(H,IQ19?:VBBH+6CGQ&]Z_$BRCKDD?YIDIK3<
M540!A$ZVL7\3!6'UNMTBZV];JM?MSM^J"I@2>!P(-?RZ)NF_>B-1(%DJ17![
M&A:KUAB( D7ML)5)Q:/T]J_#,_A HN1(FPD6E5L.HF[ 9_EAVWK75^#D""Z3
M6P*7"$O%!9REOG.-$2CXAMN!2&82E@ZPOD^MT@.*GA=Z(U#L4S,SE)\"IX)%
M@4@M_E]BS>I"H5A\5>*.FI;YW>-$:5WJ@2A0I+)7SEY-"!2+;N:SBLR*72@4
MB^=SP^H] &5IYQWD%6FU!Z- 55+:YR?BTT3/%W[;:ZV!*%"\ @4F*\E$XM7F
MFAQ">%E*-$HQ. ITRF@6T:%J *!8,K>]6<LWDC>X$HAJW>&XBAM<P9^KZ#E\
M;TAM"1B*W6IETS8:5V6^!*&%0SH*!7*%4R2+_Z,LDP<$\DO_"Z&M,UJ>NG@L
M*DG2^[_-93P8%+O0O/?%B@T/SOJ+)DU2>$5J/F:DP"CVHJD(9U;X%(YN7L K
M#.)+L@DC4A.VW21N_;+4(_X<0G+2O<Y0)&Z%8>'W:=:0*$.2L\M!3;P3)D=!
M*MT(MB\1K6#N^^$[#1L"&$!1&HT_P+S6W>,W'R"\:;G<U0:445XNM1C*^N(?
MZ6W#7W'M*Q1,J-/C4*1IZXY%@:C2PH//N$//)GV'N?P@@9L/^B??]:@UTKH2
M5Y1HR]1D01D]+I#U(_[L)31\XRYPO3?/!26'%[[#!4+!6J4VEJ>Z,*6^VY)&
MK)H:36!;9\W?R_!(IBH34ZK@NKLD =EX7)F@.P;%7M9-4>W^-+1CQ<8+O(3X
MU$"559RG$39Y9K_*M&4ZG^V=+AQ:+)[,:VQ9:W\ED"AV->>_8GGJ0-L6) HD
M:A[W,M'U@1H4:8R;GJ=>. X7@JSR?1Y7(-*7A, H4%'4N<92Q[HT\^;U**J>
MN_05O>$5':*!SC'_*TG6Y(#SVY:*6C4<ZSU*LIXLM+]T'I28^$>6MT)-@!T;
MZ#B_@(++JK(PBHZB7$ 4* C"XJ_I1N0/!%6NI.$4UM\5F9'GUO/SI?+=#]7W
M*/9)5#E*$AU=ZUT5>3%\5?<ZR*KXCO5;M@7=51B%@?/F16G\ +Q(]M[Z:O7S
MW?4W+R )(8&Z(5&/&:RS^Q5-PN:I4YTO43 ZUY_)+):Y%S,K'D=U6N/>&SHS
M(2%"O?7F%2B&VS#*+6CB6T8]RO8)?'X/_X=$X?,N(H3^(>I?R0&R;M,IDJQ>
M E9<:.,13E4-*2 *UGIY>HZ84:;6VU#,4F)HVZQ4OM#3P\'/7NC-UCJY&5/X
MLE>-0[%;[8(\FCV)-8:A0.\+"0@ML Z"V-U[ <V>=9C^+S9>*X;89LL+H+O+
MXL6ISD^-[+6J@#=44:;QB/Q.2@9#4>Q>[LLI7-7T8/WB);NK-$Y 6XS*?I[4
M. C_<P7J9H]I4*!_RRR=++2O;0@5%$67CT"!%'NIINN$J>]7\';;\I4K'ISM
ML\>+];\75*N0PJ+8B6_D/==7Z4,*WAWPYSKSI#R$OK<^9O^4W@.F<]C>P6[!
MHBSP(!<1Z@>:^00H]EJ9YRU*\V;_^!G.8OG8YI;O'7)^VSSR$@3.GB(2@7(#
MM^1_T<J\/\."85=7 3^]26N,;<0*(P+[]_')^_@6!O],'9^](&[V!S\\$I(E
M8.9QI$)5XI2I4!R(6C$A+1ND#!X%0E7'3VJ**.P-1UE.D70$"J2NR2&B=799
M.V=R\ F3*J"9[^FS(S,\\%#3&6?=;E9$EC!7CY?%+LDZ";;AK(N3=J^)+PZH
M;"&A\:"L5VOQ$M;M5:$:;QOA+\!:M8+L7,'(A4%QEJ1V"R$0BJ5W"A\P@XI1
M6K;A%*C0O@VC*K6#^BS+JTB&J7@4"N1J,1:TBL"M'[['FC$9'7@4"&7/;,,R
MW\I!*%#K')ZBR ')XMU9=Q*.D.\S'@7"/>J\JFMM&4UE^ZZK151D^NY=P,D6
M$8=A2 :AV.&B4U116D9JY1 "V]ZE;FX.3]A( 5'L!DB!*KF&;V>J =BF^D/D
M[8&,6;PFO#*B([]=B  ,"\6IU&7=O%WB7AY?8FHS+O6_"]"\W[+:\)PD,<$6
MG3"C[3TM'B/2.C6JKGMZ@U'L?[TD=$UC9%IQ>2=56\:]U<VF0($VISI3O>Q2
M%EI4I4;FQ<ZS)I%5&2<>-8:9&061\LI42K45U16B*7OX69M<B]\I$Z(@23<^
MZ2$B!\=SB][)^2._B%#(=E4OTDEG)A1$J)O\RB#I8'L5QJRIP75>XY2+MNY8
M-*;$6UB1X_\W<:);^*2!DP0,Q3X)U(<LY*QQXF2"R7P6%,BWX@8U.JXT(5$@
M410"R&7!MS ("W')ERE"<"3HE(7([@):0@Y.?%88CQ(^JS-5BTH.7%JZR/%H
MI](BF"2)-<.IQOHM%(3D=R\0I[[(X&T_$^Y!QUMMLL(HM&1GK="T*&) 9PB*
M?>I>\NPNKVI_F^@'W*$HT*SE%#C4+%<H[EQ6%,#:9D/6))@U#*8QS*P+<*UO
M<-G81]P]>.=%"=]J,>34*/:;N3QH;E>S*A:SM_/#5OCN!]-94"#/BT*3Z4\R
M>!0(25J2Z7E<C":P?<Y;];5AP35-X5[4)TMKD&W4@-AQZ*?9TRJ+H:LLO,W$
M375YJR'F0\'>S5+%HDSN+A2.Q9?GA[F;:_TD?!ILSI[-5<>)PF0H.ZRGS8B"
M*'5]CPJ<K/$&"[E:O?K>-K,725Y\1A.@0+FK#=;*R55^3CU%DCL4!9KZMH;3
M+!76K4M%(<OO?WAE)87:9J7V]RAVI[KS,@X29$QPP% LOU70%=@$WL3[1T(?
MP90[TF1'4R^)6\%DO@1^>';OV5 0H^U_9RWTV M34ZTUFL"V9E1&3$?>NM/$
MKOZ=[86RIO2KS0/0CL9\9"XOODXJ T7!8HP9:@X[>?,T,30*9#CFF,*TFJL/
MLL.B/QH%LO<D 04^+DQLM;C\3(1Q=2K%&-LGJ^Y:9RF+N1'T+KCP7%H0V]N_
MIE%,B@8 <9%_U E!Z3D/BIWEN-0U[>EZ(U$@*>C,)\Z8EPY @1*O..-M1/Z=
MTNZ29C4=6\/LUVC@*E*5_L31P0R&6=?T<W_2TW'_&C:*,W:^1,%H@C<4)_BH
MA\]8,@L*Y+DE4!_I4XR:I\7R0V<<"@1UBNEHW@<]IT)!AJ*V*;/C-G+ZJTJI
M7-^5QC@4"):9'9F?F]KYPH#9\52%+'D#;*MN58A8$=Q/F*WND=;76&U MG3=
MJ ;#4.Q8/58C,YM(ZJD(@5&@TF(AL7;"!;3-;$_>1^:K?0]K3MK,-UNZ:GE.
MVG< .S+G+M<)/-B\*/98+ DU?89&$Z! N7@ L9CSO'"Q0)H*0%&@8>YU9UU%
MAG'@LZDPDR'+L1)66S A@VHJVX+N6Q@ENXL]K'7M! ].E-!^CG?!!3!NLB.Q
MY_"K5.B-PK''I1M37D&E[NEDQ5/@-O6RJ/-L*[F[/M3DUA_@7YT/;Y_N^=UM
M&E]:7RKKM</KRU%^@8+Q\DC^7"F3.**Y@"A0J.6V,WDNBONIP]B6:%4G6FJ'
MW:2!2]M=Y+[NB^1Y1WT\890=N[*N$'SWV&I2<^I<*':0[<LN]%T0T)FF75;E
M>Z Y&""L#$."AIT9!Y'*5')!1?3L%F?YX_+JG7TFLGU@.L\,X%^:PB(J\2L!
M1K&;($ZSW*E:4:G*(BP0P)(1*) JSHLZD84/:9O).'GRK0M<"(2"_D_$WP!%
MQ=;?!H!U?T/6">&1;%F5W2#AM='EP:"@]5?'/^2YW33&M HE/C+CLN._!&Z>
M(0AZM_@D])G']CGI5__O(JA7'+[U-FR*VL@QBP_V_7';I"Y2;*DJEYF<.C9*
M,12*@Z+C?=%/>90-1X%NJ7GG+Z6\KYL@U(8'B@*-TD]X>>0YY$7F1(UA*-!K
MN>2[1D'A8T(VR+:P^"F,631(7!0ZYU<I%(&AV)EZT!+KR04CU%7O5(-0H-:[
M3/(]+ZYRN%F1*(*Z17GU1J#8\9<GYJVF65BT%#HH>8[_E+[2CKPQS=N0=4;1
M&8D"R6LO/H2QXW^)PO3 NDN"0K5V9%XGQ1 4:(&:D>Y3EFDDZEA&%799IS/#
M*5"@7:OE5)>J;/V:R2V&4Z! N[<4+:R*9==-AN;SS@E6!Y:;]84^6^,[E7_F
M#+^-@M#B,@*(0ERRLUE&&BGBY7F@*- HGH4&;Q+%$!1H<>*[I2&>,G@4"+43
ME/+>IMQ )#ZH=7<G2_VC?B>JH;BIX],>2RQ1EU)[YQV>PTQGXS>U,QR.8M=
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MA)LEP)G3:L8'6III\\Q<L=,ZSHO(MZ$+JZWGS?%\NE6W842K8[-M4YJR3*;
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M(/\5>D'R,U"/QE$'Y"NATJ;+;GK#!EPGA[_A?!)6T%+K-%30]I)\N&RZ>@]
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M7G%?0FL+'';>&BZ*)/)>4W9IBZ609  R)*2L(1UB+^^2E;FZ==:LFZ]D%SB
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MCE@3PIITD*(A&6 1">9_HRQ%RW(FWMKQG])7&@P:TR!:!4):@RTB]R6$-W?
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MISW,&I&_.OXA-T)3W;!Z$!YS+GX)7*HK F.4+V[!%O2:RF*V!HA:$B=:1T,
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M@!>5\-A?@.<[6Y:0K[:X@N&SR0 3?B;L]"A'D@=NWH911="&M5V A\9 '$]
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M0G?R\EB!Y+?YQ;L3N9T=;H<@GSZQO0#K]8ZXJ0_7MQ*+6(2&-*MML/GMQ:P
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MKH?YDXM6GYG&. 1JLXSP2"B'VHO=5-DFN%NB&F7QL$BL#H)#(QYA,<! QZ3
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MOC[^]<U%L&W2AK"I@[UZD5;!O_WK]?'A47SZA4.C54E47)01[>0&%K]$.R4
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M\IV,U[S)X:7@7![:RAJG*RZ6('XQ? &/8#$F_"B37I\ZS1N\CI8C (66@M%
MW\ #?.]D$JQ55%9AT.09^'4PK3""DM8XS>$^"3Z!ES2:P:=VH0^"C_@Y?<JV
MAK(; Y[@B16M6U M0'D$F(!=PG+&\,L:#)0<I@*'5S5Q#$/ -X Q!'M'/#89
M=!7LJ0CM%2-2'_";LDPV;MC *V?N^$$6HQ@$*(GRF =SE=8+\\(J)6-J!9II
M'2S@9><P@#R U5#PP=[SPTF01.M*F^=@GJ4PUJLRK6N\K(#W4+A7< (*YU:R
M*BDM'MI\<"GMP&OX(.DQ^YW9P]G +\,)!*J)3#OW96&'P]0'KIAR&@KGQ[U0
M)GR*EF&6L730E,]4B?DJ& Z\\,Z&5>V$O2<1&>)>'0V/81D>QSML>+QNZE15
MKFX=DL2#5CK;=AC5YK0(DJ;$,XG]4P02X6^=[1S:(X3U&)LCH+%>+5(U _UW
MJ:K:V&$7-2@?-5\'[]#+17-EYONP[U621G697@>_PD]P^@0_ET6S"N%&\<&F
M7+.,')4Z/LC]DWO_!TX !OK+#[)R9F*&)$ZMW#1H1$2^HI&P /FAC0"2@-&+
M&'8\W+Q<ZV-8(\X<$P1<3)#-$K^RC-9X(H+V!67'AZ"YCB)R-8R9;H7_@CV,
MMV2).[]6<4-2[<B8%:N=%H*N07+1P*1?IE4Q3,Q"($;2RR(JR:1]39CTHJQ:
MJ_+P]LW#K@R]X""7 ".;<=8@DC(,IDU--FZ6+M.:]A7LW*QB+U)<E0BU)N\<
MV-0_P@HFLF@A+J?Z1Y->1AD\)<0UK)IIE<(REK39^?H(OI[!RBI_E4^_5H+M
M"X_N55E<I@F&58>TD/4BJCL:5>M%ZSNX^K6K)LHB4[*VRNC'XJ8SV$8I^ET@
M\_19DV7[I(KA^R$^" ?LV 8V7)&HRP*,#10;K(!)R;_$VS@6DWU85&O/C*/N
MQ0R=SR('N\"< * YII+QI*M ^J*TK&[U6O(*^N#J#D#F? $K5-79.H2] /8W
M)6-#=/%7JI9?P(6E8#\\O%[0 U,.Q4SAF^1BEOC#ME&]MB;7-D-+3R8*AOGP
M*H7W@*T=!N@Y%[#/Z93U'&%,/?B./QA%G&'0?^+Y0!4!R]KD8 Q6,-M36".\
M[4)E"2@48^-%1C5@W,D:9?#26N$G5N&7Y.;G:W'!*]!!650&<02[* 5OG*-1
M:[@*O(.Z8?N-+H57S3=,6ZBMO[0$.[5:B47;5DNN3O*##?A> 0%P=\FOON#*
MKL!QEH:@K-RX9I^8VHVE#QR)5_;)"WLIN/]!.,#_B[.B\FQ!DCH0&I9RT04M
MKP:C15-EA9]O,%W[XD3ZE88$$M$7#=@0&;C/N@@G3$ 7W[U,SBT&G)?%U8NC
MWH(=6Y[37S;HE0EV*LMHZ'Y93Z][K_)D*/4^5&WV.>4^7]-L:]>B[=)$?*V:
M//HOUK\NRM9>DR@3Q9)X=_A_ "GDC_FASTA\L726@UC[%/MX$657T;KJUM@.
MIPSJ.ZNW^R,W8$ODONWRNL^*>G_%(/<?&0F^E=Q8PQD-#;)?58_9@UH&3 VR
M;<#D-/53-UK_:<LVCX++M,@<I))[-S1Q]M*)&.IP19R"98.F4KP D[BF;!69
M7&268ZH2/015A? U^!Z\.JA$=(LJ\K52$\6M* 8 %\%5B<I E,L DU9-B5\&
M/W"&?@B8X=$G?!G&J](7*13$V<$Z4$D3T]CIYL;<AUM419 5'(@@HRQ"6RYE
M)RRZ5&S+@1B"KPZFG+7C>F-B9-LE!<T93Y<B#R,N$G1_*3?>Q#79D/2NN0)G
M$*SV6+L-\)P8!ELJWY^$+]C@E7T(>H$@J6G2D%O+'@\E">>P-'-X?,B>X R<
M0>UY*.U^DCO2ZP:C8X.PL2FX,"8&D(LKKI0WM$W>C1$.)R DT?T*7B-FB #<
M:1?=H&=#<H(H?UW,QJSBL+**)SN<57R?1:P;WEM5,221[XT4@EN>Q^D*5#RL
MYR=0ZZSR;=C0J% 75ZTC2$BH\X\&%@\4,RHU2?R%&-KY';:]\?<[]0^E6F*(
MD1Y*RGR-^A)NH2@TT)- XA" O6T))TT6.,&O$J/>7#U\.XW-<<.#WEC""+W]
MAJ"WQSL,O7T952JXB#),&W!0U4KURR)OJO$(&](1=KS3B%Q'V(9Y<FGHXRIR
ML+?)%J<,3? HS\'6AS'! <(;"8Z#GS#Z_%<P@/'$P(WU4SJKU\''1=%4^.OK
M(H-+JV#OSX\?'X;POI/=K9L>Z+(ZZ6]83_)W>QRCKNV0H_[+;$)Q5:(#&JN*
MT:\JQTR#2:'"$CJ^5'3-23+0U_#[A+/M*8)* W6)8D-8UAG:$ES-26FM)8QY
MD:U[+2A701NKJ527J;I"R<([1E4M0@@WU$ 8S$OFE05'?:1\/7[.?K[.K3 L
M8V=E[\;W'*1$!E<+E=]RG7BM&?X;NU=K]#'G1SLY_2W9;_I-\%4@O&CD(N1!
M(T-@#?5'(+II75'FK53X5$0/$C808R@4G=$WP&L=80U-#<).RM7 =9JH D*(
M:R_(K&00+8MFK*4:FN6VRY#FCELPI$W1!?. 7E,@4"F>^5C+$94$38FJ13#%
MT>_N>3?HA;#G&YY-%.BGRJ"M%K13)$4&&7((A8$&XA%V)(33+598'5WQ:7>5
M5LI>HLNN+8PXJ@2P#G^5"'GB SX<;$FB?W3*>&C8C"J*&$;5F7AZ1R(\,C('
M(RJIEFE*:EAP+7FSG#+$#@N4["C3JG]L,EMXZUZ+$!3*7-4BR,4*>:2;W 5/
M86%3&C<(K*+WV$G6JX_\E@.6<;/L6 6W<%R]^@HN7>_/T!B#XQ1YE(*]H^/'
M/TQ0"!S+0@K$^+C&O_&::F_%0[QO6%O"_,$8$L6E="Q+M[,L64J;E<@I;-<4
MG!1=%VA"GZU0)X5(R?%1%681TVKQ&0]%^Q&S@V@YTMMBSC"=D8I&@]/NI2A-
MT&W"A)V@_WZ-2OC6T>-ZH7=LC'=/]%RDH$C0PL7:.>8[T%JG=5TNG II39N0
M'CU:2\.REG8Y5:,K/L^N,+U^OY)U=/CL043KGC, =Q>NDX/#IT\?1+CVHLD.
M"]<'I?'P)%Y#.AL/@G=Y#P"W4R (ZGU>1@3$%:L\PE<Q2 ES'KZ#D_57..'P
M;6W$] CCI3L>,QWP*CIQ4SXFM8U!1[)KE& X-<B:Y0K.\R59[[2"*=;5[YU(
M17[K*/9%XS2P%3=^,8,3ZY2\*SRY5& ;A5QH %_<-]9V6G&\J36M+E \Y-AK
MFH/#H3!2JRI^(_(ZI&Y QU):]PFU:'(0=P.>W2F+ ;/"H39 X^U5!+:.9^<C
M-,BA7[@L,I#ZJ$PIUXS%/95;^H#W^!F+2SZ0748C(@\+]H\*^U#P1!VQ+YY,
MCC"M2I(3_CK<@'5_0/SK@\'=OSLXNW"U[D+_BF,76#LBVWL!QB.F?<2TCYCV
M;P?3OL6Y&CRJG2UX U06X]R!RI%11E8/6&I8E<O <VQ:YYM-5"H.%HNVC BW
MWK5;8#"WL%IX6 15?_+DX,G36SS+-T1O_Q@*9/496%?%K0>*MV#(_,G)P<G)
M9X_V]L_:.-I;FH-XCS%D,;20Q7270Q;GX,$A^$GW18R&Z?@>!)OB%Q8YP6XI
M12\\5SCR@N1P58FU\VDMD0WFU>L!.Y_![DDD;_ ! ^KH+QX?'CY#MB-T02];
M0?7W6903O4(DW]S9$ B]);[.D&3 @>BTP@(GQQ1SXK5M<==@#A-1[741?]K-
M=)M]EU?\+A?X+D-:F=#V,M#5^A''9G9U ^R(6K3-9SA=N678#OR"DFJ=382&
M(1I>&"0T>?>^'>5*8;O<@U5JT:>JG6QFC>Z&3F;B)S^E957+'=^7R/+PUZ9,
M,A7L.<TQI@J,KHD8EIV1VE3^5QKSA<+ZQ-L.VAJ9?_S(/]+3/V/@'&MF <)2
MTU /@)A8:Y,AUNS&GV'.>@5#_8T<TKPQ6!%Z#0\<C$\KFOE"2)CPU?>V0E*F
MZT#7)3[JUN;B3OH)[?.F!!=:63;&S3O+UW*;1-GJ2'WE1@'RM*F^>M.BM6"'
M4[W@+GP J5G06UG1]^"-(C&#-DL:^8O$ %,2PD<1B/K/1T\.GC\*@S\?'X*G
M1./[\_')P=.CT&'W0;HE L 2UB+8.SZ<,+V+@&#K,J*;409"1@@C(WJL7)<=
MX]4E5]/"XQ=1/J=*:9%$7.H- X?%1.]'0OOR+%E4V@Z719KHRK"D:*9U)X/@
MP8UZMDE:$1970!G:HYLJ>*#Z@@U0:\ QPH6<UA;;E#FL,?4WX=P+S4?/0"T#
M6%'.5*HG)2_\-A<P.V^+&G<5DG[1VD3Y&C-&<YZ:=O$ZXYUSF-QR'7;<Y2AX
MQ>L%?WB%5Q69IUGD>F-C3G@#=<=?V1=(\.&)/KI\[7/C@GFUZ7K1A+0:3SU&
MG#FU MHYG^@WK9KETA3STVQW7[&I=$!@J:*J*7FVEJI>% F8!_,UUMW'Z2Q%
MEV):(!J\Y+/,@Z1U;TRO8HBT- 'L31+"4P=C!^FC18NHF'*?'\8G!Y/7&;7^
MC>AO-(2V3 D1*DY5^RSMI>275S:BREQEN4Q?9&OV/4RD8P';:WQ^"$QUP@ZL
M:C,?=@Q=O@BRJO56H,PN\>$Y%;!1C#/6AJ8Y:L\_S[!K653"V*+5(MQ) WW#
M-AFB<2Y+!UJ!MQ?V&C(U/GY3HQ67N6T]F:D=D;!K8#&3:K.U^L?A)JU2XPZ)
M8FYS9"30C T!C?!V^P0!\0?IX!F]*&;W&;>&.W9K6<;*[&^\,OMDERNSN?O<
M6( ]*&#JR4X78)]?HXY$>%.ZG#9E1?(RI..LIQ2[!,5>$R9*QMP"Q2-O<%/O
M%[/]%9Q%J@:+G5ZR<DT7,(4::J4RO6UA]XB*&E%17U'P3T94U(B*&E%1(RKJ
M.T)%[2XF"ES,J0+S9(9>+%,\QL@<R1&C#;PB+PVA"%@Q362CG*5KC044'B5:
M3O1BYTV*')MYBWQR"Y,9!_&P<HZH1J++HN20#:+(30C)MB=N$YKT\T>X;)=W
M,1A=MPF#AMC?202@0LY.9[V>'1P^.G3^=W1_[(Q#,GE=+DY?$LB\19K358E5
MC7[OBZ*<1WGZ3XIW5-T*>*2Y:>0>%"DT5K$0W2W3VBWQA,FGS "F3(JXP>=S
M*.56E#F&+W6+7/96Z:\PR%-+AD$X]V:8W-HGO60L?-O=(RWENM$O'I9?O,OT
M%D8P==!E2 KB]EUA+/H"&V9DO*NX8CQ=H0:![4G*8*&B#'NK7JEL%I4*6]I4
M$3$+KS')6J>26*HB;-#!.H-/BQD.!--<-$\!K&YN6)+G9;2L@KU;YCQH(-WO
M3YS>;_:TZM!UFA[)2G6)CMJI.YTMZ1DMAL&=O!Y\T^M,DZWAI[HA5%[O\PXZ
M64U\,B9IYT6*[;;,XN [Q8NBJ.@I5Q&Q YBU$57;5:V\5(R0X-62UVA;$=IN
MX%N7/'D5S7;-;,1T$^;%")RN>TX!VS6H2WR'30\-;>T\EIWU5NO)"8:EG<)K
MIC'C!A[..8G*XIZ='L2;'MRL#"#%E(=V9TL_\=6[EQ_.@K*=.W17F@H Z4&6
ML,V<CI^9;"RD%D\_WC_'DWM'5(^GU5U/JUVF%_A%(=( [_A-'5-I$EQ&L4W@
M9?2:!."10M<6B4>7XU[)EXP]VJ(H,:=$CW5Z7U[-@TSNH#R6LWPM\TPSB&B#
M!A6^Q--IL69IA9U[::G<XUE.]C@J2\2H%)?DS(IFSV%7\U?\$]QZ">X:,J_W
MP;#7[7[9OT>]?U>]_VB'];X@L1 CA![_D%3"=LU_.WQ&J[3&WDL1*M,P+3/?
MPU9:"8Z!"7-;%2U%4VFLUPW!KI!A5>#*<*^:?"?!2R(MPRTGZ'@P%@$G9&=^
MD] 58>.28B4'@=LZNI@KNM;8 >9>8? -+.)@JZ0$U15I4D+>O02PQ Z\ O7Z
M$G(ZP931YH7!Y4S::,/6-VWA7N)MBH%_O"H,J= %_M'C:;](K^OU/EYCN-J9
MOMWA<[=41,?ATR?'X>/#PXG+9+,HKN"^9=A?-=&QA 5LYS#:B*)3O/HTJ97A
M>R;.R8XQ+&&')8.C=4,GY*0GB!X#1=OE.,^.PI-'3W1)"+UK3QWC+;XK<D#.
MO P7+F' [P9+'?^&VKN*P3AO,GF^_E180:T#7;7"-&8FY'$T2 O;1@$#%6+]
M]DU2TVDFTZ)!)%RK,R6"N]XXG W35QG&J\\=8"\_T8:G8(P=M9VK^V'W)#Z7
MI/&_;HU.[@"%6T!B+X;FZ"P?5$P#<:,Q'8PSQ^K2*N@ EWEH/8&Z[7H )N3-
MS94#8>!T *<Y=2; ?VCK0D&Z>PM-I19%4SMU#LA1F_G@HSV'VZG> ":?=&H3
M3&6!!^>'Z2.63"PPN.9Z M''F<*,"GSNC)GX-NU;2=G8>B+27Z/F,=_KV0W.
MA+A3-B^BC+K2?8FVWX[Q_5(?[X]+,/;[?2-^;,2//9!%]FC$CXWXL1$_-N+'
M!HL?&VMEAETK\VB':V4^6MZLTZZUJ4$=P=^P5MVY=DS*#BDX_VBG2VL^>M1M
MPO<[I)B=6UJ#63C#3[R=R9B9JUHA $MHW&7S..B#^6D@SU6)_AZ&Y6K-$I&O
M ZX092"M_ Q?5'..EF L@+K#*WDFXUO=D%Z'<QJ_UB"PR4\DPF?HMW+YMDNV
MQQ%+##O[[(1]?7UOFAP_K U_VJ6 LZEZMYMQ",)K10E7DU;+$AVX26$J7&])
MF1O[@A4%8:6P#/Q(\H0QHAO6>0.==VB?:_N&(MG#]C:.FHR@[A-"25J5 M<3
M-*U\VKY:>(JZL&$'V6N@LP8!C(AB5;I5<3Y19.<A74!4:;IJ2S#009O!O.ZB
MQ)\,3.(9L^>2.AET#(A9T=3"$Z'39!@Y)R7,QHY9M393O ^#,^OI(SH9>:XO
MRJ(KIADTN$:TD+!W#TK[/HUN=VG8SN*X1#S?NRE86(RG'Y(@./1KH[DZ*'-U
MEQ'OKPW@>TBR?I\VJB$FLZ_:8ZVZ)I[P&][.+OPVC;[C(4G#YQE]76.O)_G7
M%:/73N6#:[I9;BN">S/1.>?I\8ZN/4=T9[!$*&#/M0>RL[2\NGF9LVT8QS4D
MT; @(KWWK2ECU[9:%$A+ACVH;8&+6*ZZN9$ 4C6;,BSELDA8Q 15T;VOI1!B
M+;/9WS#FV\3!JQ%*8N,TAVY7H#XY-3(I/8^^1&.ZK1)[7N&S7:+-!; ;MAIN
MV813[-KOZ+'#VN48'C:!\]]]%1KP4>J#30Q689=VHE;+CX>T\XQ?LKWELM:5
M>V<3T,W<U[0-9.EN+!<U;BJ->MWD(@;7%3: "S;0D C!,'B0AV63U2F(A04E
MM-KR:@B5,P+C%:/8V2)=<QBA%>","Z\"2U#S!Q+!H>D+6R&L+*"6L'LG3QY/
MP!39R=/A?5GL?Z M/]S.O*''):P;U\D"WV/+6*+AKPI<>@RJ8.22_65+GAF!
MR%#("(0DCU'?$\4_:E &]-F*%$'WT>/P%RO\O'O,8QVBT1(</93Z'KAC;]M<
M_Q5['M7M<FT>RTS!>R\GA(%R:#Y=L)D'<S,:P@/KVEC39P1:>2G=U9HJZN,W
M:S+XA6,?(9$)"@TM+T2>=-!.ZEJ5,9Y$&OJT!=(EL$)N41SE:[=6'[491F&R
M=)E*K?PF'%=H@)Y<>]G"ACGDJ$Y+YJX6<Y6=! 3[NY>[WUDQG=7.FJ-:NN(8
M9)T?/$BE@XVM\[46&^3LN%046FV!W'O>QT7YZ:^YVT<::_(1LO>DVU>SVU5I
MYFP>OP(6Q@A/B=9>7TTRF=9\0!MG\/#YF9:M-XB#0M:)#ZA=&D3T)73^'3U_
M]N3;Z$:";S1(P:)8K$M2;!9.#!F>GC5I$Q].VTG%$2VQ-LU0%.1$02W4Y'1,
M=D^ /ORQ;Q^93WR+:.,YW(:#[Y*<Z.UQ/+!8B3Z.2C67QK>(>.BM5A<!(@D9
M0\J#"BGO<EGZ:Q75BR'M"8=QZ/9A8U96-HR"Z#>TY< ?T+$2<@#Q95VS-30[
M$/6JL\7P(@D,N3'+7G();@ F<6CM8W8OXX=[T=%;!*U'1/J(2/^*N^^Q"XL=
M$>DC(GU$I(^(]$$ATK^BI3I\1M/O&.EX,C"CE6#JFZR^;:3UO7C$HM3P6Z=X
MN&*X+1$P84"H GF-?((=Y:759VFFVSDZG+ 4%\T+?<>T<FX5;C-Q*=6^(>EW
MROG2*&CE&DX=*-R&2-HW'83CF-L=@D%C-&B,!HW1H!V*!NTR695;#^/&/7X3
MR?RFZV.NW)?$UY^G2*3KG":=.ICV\;$)C/@9F#BZ)3^AA79B,M4.9HU9$9W0
MDW,'&0]F6$N5JZLHNP$%N8MJ_&A@-0!FL6-ICD>TNI^3.'=%PI-*;6?BN?\Y
M-_1%^QOQ !X-:M4U"0[U__46QUJ;??UO+7D.FZ^P]KNY'$^'M!PC5O$[P2J^
MX#[-7;>3W='1/_KN_:-3B3YLB 6(G]ZMG^R)RAB)C(*L6:Y <2SQ<WJBQY._
M*HNDB2F+B%C:^JHP.+RM5:8XULO!#+6'I:P[^C,XMB(XTLZ8_;"[M_K*=TJB
M+NO>[",3H+F1H\N-<2--8_FEL:.Z^(8#1Z=C6&!888''WUQ80!F%_'-1),$'
MJEX?TH'A!D_O*SC@O&J?9B.HB4]ST7'8V:;86'Y4:B>/+)Q5W7+IV=^W !8W
M_!$BPAC/Q&+%"C+2^HXC#\I0VFZ&J6S4:7AO\CN1E)NLZTO2\J*OU/4J+<W7
M>,#^FQM4,YM,43>.CQ/G$(>X<]T!QFSTD2>;@C#.NNZB->:HD"%LKMO&M+I5
M#LNB5!NV!M=@=$N,G*W0MPOPD*21P>\Z(3:N\_VF-C\WY/0MYYX'M4 W]>C9
M$/D8[<-AV8=/OD'[$.&LSB%^IZX_]]_DYTML0XQ-L69KOYM7?$V("O1(G8JY
M+[$ZOQ%]^61("^]V=X0M&6I?'[YC"G\)O0B&R=$SWS)!74I%S*42TY=,FDJG
M"LNT,H =$HX1OCW"M[^B;)N--L*W[3R,\.T1OCW"MT?X]N#@VVPYA@;IZ\6S
MNHRH8%/&93K50&(W.I;F+GEHHD :,L\B+;&S5V8H=ND&RZA&FR8FK@LQ@CJ<
MO-;NV1PRU&@EZJ%S4V6>26,)"P(G4OS'\AA7 H_N:=%%H(FMD4_)E%A;S[/$
M[Q+5W#+66S P]9KY/BW3:/0_@+?'.(]6SFZ$ZPQD>41WW(Z=RG08E'PV@W@Z
M%+K:#Z-+#:8'_MXMLO7A<<@/I(B1&;1PFN_H^@X+'<>8GC'F.*R8X]-O).;(
M^MDC,NS1W4/:$ ?W82AL3(%BMG1+'+9-+F[!+L'>DTFPA%$N*@M]P_]>J0Q)
M\(Z.S9^W'I.LSV\+PKP7J-]8)C7" $<8X.:A@BPNB^:KH_]&J-_7J!']27@H
MH\LB3;3_FA3-M Y-PPFX5Q,SZ!U>UZ7"AB^[JP$^] ILWR;':82Y1A)6>"I\
MR0TYV,K;M.*=*(S"418W&+'"F4-OG8:S\]B;0;E+N.)-B:(2:H94IU-RV[/9
M<K3W>;C.4CFO'W+/)U(AL/L:M>$Z*Q<D;U9^]5=A9B[3HJE@0] AR;=Q_!84
M1P=JP42%K<;'=$,Q+$#M=(=E.YUP&4#"&E47O[D#OO<)](V &]4+\=;"KFR6
M2Z=/P;:&RJ/W- COZ=D.>T^OV%HR B?=%JG_^Z#XH>EP,YY&"X-&P3@^H0P7
MN!^Q[2O>TG:BVSR)XWE@R82NR92PE]0/==,.2J)6BJ2HZL=?P6:,N;]7W)IT
M_4S;:<^U95Z]>_GA[ ";86A-%S*\^',PNZ)\^]W$,*"F8\S]T8?MWN8TNE:/
MWW1**VC+L0R+LUP5E>^R.AT?0.?L9T6%:U@U;##H?@_>:J#J[IOWJW3#M.M@
MGR"/4;."A8L.7%L#?P$@.I0^AZ;5R"K"SO7I2KK D;6JLMD^O16,:EX6S2I8
MJ"B#J26IJV ]JZ)L^?(X9G1IE(RE"H2_D$*9TZB":8@0%#L'0PM, *33WJ<$
MAO,-)_4C"Y*6?9/G@N1I'M%M(%+]ACJI5!: ;K>.]R9VZPC;>L6',"QKD8CI
MW=^2@TY3, 1(U*E['HQF/.4&=<H]W_U3#O?X0/O$2:U"X50D:U7I:/I.8 H)
M'="K5+4<#/@!^D&Q:-P0-^LLQ65/(V[>@I=@#QQ0M)BQ)+>P0MVO^4Y'K-J(
M5?N*HO]TQ*J-6+41JS9BU4:LV@Y@U6@6"3^6YA@I(U,%_)1$7:JL6#$.(^W
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MNCK=&.O6TRP-OBBEE!$I6E.BHTS>;XMPS>.8M[>Z:%88=J\*"CJC!+PLA(@
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MAF,"@P%./2Z8MN1\.,0D6D9S0X=/27FGSBBG6@*X/S/"B!7F,=K0&U^FA26
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MFG!)FF"Z+9$WSCK2+"=$LAK@MZH9U4RH:[5<&9HJJGWB.CC+B38+O9O>;RG
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MVR&EW62I99.E=YLS66I$AYW!?@D;IBE4S:&%.4Z8?[RB0EHQZA(L><XKL;V
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M5?L2>/^Y5!F=:*T3K74N:2T7K9WL#F;1_>G6R>Y-.AF?_@902P,$%     @
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M@=0P]\&3'J+'/U.O8%8K=9U0(RU'0.).\4'U:H"I>!*R7.HI8.MXJ$MRY/=
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M95R)]:A_:U0%E\*:% 3>=NP T2$ X59!X&*2#KD> .LC.5V7"B6..SPZ/CV
MPU#U^%145]6EI%T 7<&4VF?$8$OHK=!$NCRXH^Q.1QEV1.-<Q31*4+P;_UU9
MT3,!V^OFZ]??KX'M^];)"P7; 3_<^QD<*H9N%V*T3V.B0>%CRDOW\"H4QR6
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M,S1?,"YJ<&=02P$"% ,4    "  6. 5;UVTY.:)E 0"LJQD #P
M    @ ' %@0 ;60M,C R-3 V,S N:'1M4$L! A0#%     @ %C@%6V-Q1N]1
MY@  2;H,  \              ( !CWP% &UD+3(P,C4P-C,P+GAS9%!+ 0(4
M Q0    ( !8X!5MWM ;B)GD  .,*!  -              "  0UC!@!M9"UE
M>#$P7S$N:'1M4$L! A0#%     @ %C@%6[O@^?@5"   ;3D   T
M     ( !7MP& &UD+65X,S%?,2YH=&U02P$"% ,4    "  6. 5;>#46)RD(
M  #H.@  #0              @ &>Y 8 ;60M97@S,5\R+FAT;5!+ 0(4 Q0
M   ( !8X!5NHM+8RL@0  / @   -              "  ?+L!@!M9"UE>#,R
<7S$N:'1M4$L%!@     '  < I@$  ,_Q!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>md-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20250630"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="md-20250630.xsd" xlink:type="simple"/>
    <context id="C_849c5446-6175-47f3-9857-a3245904bf88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_85ae1910-2e7f-4c51-938e-e043272c5d66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_87d0e1c2-aa54-424d-8b9f-e5b52e218d71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8d9af789-c635-4423-848f-c01e14b9c5be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8e53119c-ac1b-4329-8f58-b7176456bb51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_8eb88e83-6d3f-4f77-ab85-5922b2e851d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_990f8274-6879-4e07-9304-6c955d3df201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_99df4261-c382-44e0-b2a9-ed7013c4e41e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9a921698-6494-4872-95ea-71129e633bb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_9c88a547-180e-4424-b50b-a5932a2d00ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a0b59a66-3754-4522-ac83-cb30014bf52e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a0c2cfa6-1c3d-4c86-9c0c-7cee140ba3f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_a20cd2e0-875c-4771-bf90-0ccec5055b0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a2d739c0-705d-43b1-a3d2-dabd70774246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a4e56d63-8e80-4097-be11-b3c834580fc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a6a93686-1eb5-408b-b60f-73f0299eb788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_a732c152-f078-48ed-9981-fe2813bfd8a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_a9baaa9e-b082-47b3-80b0-110bd4e5da9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ab9de21c-3708-4752-bea2-ef95a1215496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_adc93a05-2575-42d8-b329-4f35de71ac68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_afa0579d-26f5-4238-9a84-dde4391f4adf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b236758c-5257-4c6e-9757-301028de1d7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b46b7d38-353d-4da0-915e-fea75ff40a63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_b627c7d1-b301-4b96-8344-f2a1a41efccb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b93ac8f1-2c07-4a19-9bb3-1a7e4f60d143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_bc9a9da7-0be2-410f-9e41-d1f7b709a28b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_bd51850b-1d63-4d74-a72e-b7306dc264a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_be5ebf4b-3722-4087-8a25-4b48fa85c81e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_be92627c-332d-4ae8-91f7-a264f6271741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c1710474-b351-446a-ac79-006d3ecf6183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_c4b9e66b-5f53-4567-b3c0-f31b5bcc6403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c4e1c5ae-2d10-47df-935e-85a1a3d8a79a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c5c51110-c65e-4f11-aa51-b3928ddfb6df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c8cb11ad-5131-4dcd-b1e9-3b140f8c2c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_cb9f2cce-17c5-4e8f-8e06-23440c974965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d1c3550d-a30d-470c-81b8-b361b7723645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d41e6181-d9d5-4854-bb79-fc2110b6a1b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d5dd1698-9ade-461a-94c5-4ad7011a957b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_d63eb551-12c7-4a81-96be-660b39fca8d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e1195bd8-3f70-421d-a6ef-34e21a43644f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e2c40e04-69e3-4727-909e-2d58b4ab1248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2025-08-01</instant>
        </period>
    </context>
    <context id="C_e2fb96e5-6737-49f7-bfc9-5420746a9a50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:FivePointThreeSevenFivePercentUnsecuredSeniorNotesDueTwoThousandThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoZeroThreeZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e76ed61f-3566-4b74-9cb3-da9368513ff8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e8f5ba84-ac17-483d-b73f-e6039ec42af4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_e8fa676e-89e5-4c48-82b7-8f14961e5d15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ea584bda-977e-42b7-b574-9d656ac33e6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ea8772ff-e4ea-40c9-bb6b-4db26a751f8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_eb7d37cd-390f-4b5f-aeef-a6cc4db6d17b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_edc12ded-37cf-49fc-92de-c7343544ab45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f08258f9-06ee-42bc-be52-ac38a7e86703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_f341ef8f-6752-4a72-9c1d-980e03786ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_f52719a9-de3b-449c-92cd-aff10e01b14e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f586607b-347a-4864-85e3-de49880ea621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6087d4e-66e6-45e6-ae80-7267213024b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f769378b-1c4e-4a71-b4e3-23dc8047aca4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_fda73ce3-e67d-432f-a66a-80057b60473d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_fdaffee8-484a-4258-af49-fe479aa12caf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_fff7438c-96ca-489b-9cad-339fddf8c81f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_02338ba1-62e1-425d-a755-642941b0622b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0236986c-5db2-4fdd-b4fa-b8140c8d6f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02bea4f4-754b-413e-9d98-79f2fe330f07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_03af3506-de9e-4102-99ce-56bb360a66d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_04755f25-aca6-47b4-a390-81102d0c243b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_070261c9-34d5-4928-b2a8-489b2db71abd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_083e4a33-a175-4d28-b0bd-2e88cf498028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_08f4d25d-4559-4691-80b0-687c52c265b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0a519f8a-d93b-4b46-a7c9-3139cb8a19ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0b40aab0-d10e-4136-8e7e-ca8504900115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0bcc6ee1-f926-4fb2-8414-61d8916092c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0c404152-671c-423e-89ad-d5d765b11984">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_0d526502-108f-4746-acb3-bb517ba52829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0dec167a-ac7c-418a-ae69-3cbcc4fb92b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0f263814-412a-40d2-829d-21ded60e6d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_116f6c49-cd97-47f6-a585-d9c09874db22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1362b435-1b65-4eb1-a216-edd421fea37f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_15a46667-2e0c-46ce-9da6-40aaeece1d0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_15ed1157-0265-4dfa-865e-1e42fe186550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_16252d43-9504-4f57-9f9e-531fbb28977d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17f99e9d-a60a-4fc9-ac76-147b8ed76885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">md:PerformanceRestrictedStockUnitsPRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_19fe297e-98f1-459f-8107-8508db33674a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1b31d254-d902-4fef-9793-39c5c0901157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_1c6b672e-7b2c-4c32-b75a-2b3216ee662e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1cb160af-9159-4c8c-acca-d4f2300fc206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_23133a2a-3883-4163-a76d-7a02c6deddb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_2f6f6e25-d54c-4b0a-a12d-048947969ac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_2f91671e-71e9-4083-b736-fa78c83a4f94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_30cac922-a319-4eb7-99f1-fe21f2139c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_32069b17-a7c4-4765-a651-4f7755dcf1a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_398bed08-bdb8-41f7-9f6c-82ad320a2a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_3d0d3861-fcff-4c38-a557-3d670d1a3de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3d9eb462-edff-4b9a-8d90-654154da97b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_3e05a392-a376-4596-8bcf-ca0fdc5e9ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_46fe409d-897a-4387-adbc-9b8a5ac4f844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_4801f813-81b6-4595-8272-9e5826e33caf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4ba683c9-c1d0-4296-8d60-6b927301e2bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4de6435d-c283-42d7-909b-380362f9a807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_4f66fd46-91e2-44aa-ad85-e4197757b4e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_536d7005-510c-4f6d-8437-48a7087b29e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_63924c28-bea0-4566-b7e1-f16b7fb50afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6767043a-8ca4-4e7b-8a97-d9178cf9f8df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6b743dc4-e2d9-4c22-8237-82828c532fdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_6c67057d-5918-42a2-94a9-d2f590fd5ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_6ddf4aea-8896-44ae-a2ff-471183878dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_70926ddf-afe5-4399-bd86-e068c0af16d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_70cd78d0-0823-4309-b089-3800b415f013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7c443208-51e1-40be-8cfa-d297ad11e687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7d2132bf-03a8-4280-9a81-ef0cfcfa8452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">md:RetainedEarningsAndAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7f02ccee-734a-4e9c-aed7-0eab8a75869b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>md:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_2452faa5-c63e-41b1-9ecb-64f47d6b6a21">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_cc16b5cc-e75e-4826-85a3-edee8f36a28d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_f19b10c0-6976-4e93-9ac6-d04367410af8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_acf8be9b-3b49-4232-8a48-f6b9be1c692e">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      id="F_3875a626-bb1e-4615-91b4-f05288577949"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      id="F_c39704f4-3c98-4511-894d-c36f242d9d7a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="2"
      id="F_cf86f0f4-bac9-4424-900d-398a72ffa700"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="INF"
      id="F_41f9c648-83e8-464a-88ca-8ef3d8d63694"
      unitRef="U_USDollarShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="2"
      id="F_df98536b-e39d-432d-8681-2c87691c7474"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="INF"
      id="F_4970b6ac-9f7d-44b0-99a6-3cbfbe49de9b"
      unitRef="U_USDollarShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentType
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_f063dc1c-161a-426e-8d75-85c2bad97413">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_c2d369ec-7d22-44ee-989a-d38f9657db11">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_4b01dd25-8c1e-45fe-822c-c61b63019569">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_afcd409c-6a6b-4383-9705-35c1078c40a9">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_55ca7aea-1e14-4a42-b2e9-0c41d32e6dff">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_d1e9e4c5-2970-45d8-b8b1-aa4a953f6d3d">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_a0ea1859-e61c-43d9-b8ec-cb85281f8d0b">Pediatrix Medical Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_5673bb80-1ea5-40e0-86c6-1f3f68a84bb0">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_d8a3d145-ac50-4383-83de-9c1cc8a871df">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_2754f939-e47a-402b-b7f0-61cef48d5691">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_64e2095d-2fbf-413f-89ec-cc5543ceffbe">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_d4839d92-db3d-41f0-87f4-96fc302ec5d2">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_6e5afba2-e074-474f-8494-15ab44a5832f">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_01108a81-f545-409d-ae3c-d8657bacc032">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_de96af33-c902-45af-afbf-ef82658aed10">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_7db6b274-ff3e-4f4b-b835-8ddda6ccd03c">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_091a6894-536b-4e71-8f0d-c4b07725f30b">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_e20eb2eb-5798-4f1e-bff8-206b517d8c47">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_c4cd852e-d36b-4567-9f4c-4d89967269c4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_7554ab12-6c57-4884-9039-c527307f7ebe">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_8671a6b7-7661-4808-87f1-a1f242610312">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_e032612f-e29a-4ddb-b762-396ed6ea0fbf">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_7354ba2f-9a35-4441-8067-12b2b9b37d11">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_7b2e386a-4d32-4b97-a43c-122eb250a863">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_e2c40e04-69e3-4727-909e-2d58b4ab1248"
      decimals="0"
      id="F_d6a4ba8e-11fa-4ba3-8d5d-c076eb7b3a81"
      unitRef="U_shares">87084187</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_bcb0cf69-dfd8-4566-8db7-a30fd2374dfa"
      unitRef="U_USD">224732000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_6847212c-d92f-465d-85eb-b29819e1c75d"
      unitRef="U_USD">229940000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_a948edb9-36a0-4ff0-8c1e-397fe2f75072"
      unitRef="U_USD">123594000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_37147dfb-5fe4-4e9a-bca4-568c75d9714d"
      unitRef="U_USD">118566000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_61fdb5df-5518-4f37-8977-89af3d55addd"
      unitRef="U_USD">238992000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_94d53a0e-f513-435f-ac8d-6b4bd71ed994"
      unitRef="U_USD">259990000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_98f06a91-0bc9-4d6e-8bf6-434d70cd87c5"
      unitRef="U_USD">10424000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_e89f42e8-7fe3-4d6b-8f45-a406536c4a4d"
      unitRef="U_USD">13410000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_eca02d4f-951b-4e8d-b8d5-173656992351"
      unitRef="U_USD">7630000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_3b3f2b61-5eea-4044-b188-e24350ca7eb4"
      unitRef="U_USD">12614000</us-gaap:IncomeTaxReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_daf5cb5b-c3e8-49b9-b5dc-3f106438b528"
      unitRef="U_USD">7678000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_c643bbfb-f13b-49dc-8595-10fb6d168b1d"
      unitRef="U_USD">5087000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_fdfd1dd2-b949-4058-9be2-f82ca26f8e48"
      unitRef="U_USD">613050000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_fa4977b6-9668-4c3d-8485-f3454d5324d0"
      unitRef="U_USD">639607000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_188ff67a-4046-432a-b0be-218d88af6ff9"
      unitRef="U_USD">38944000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_64ef50e3-562e-44e8-99e7-386adb73acec"
      unitRef="U_USD">39172000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_73db4808-1e6d-430d-8444-c2b37ec85139"
      unitRef="U_USD">1242606000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_fc7f7bb4-012a-4baf-b4b3-f08ff1509d37"
      unitRef="U_USD">1242606000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_813181af-fa93-490c-9920-c2240145db99"
      unitRef="U_USD">9296000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_30686430-96be-47b1-b4ab-4d7f5b6aa3b1"
      unitRef="U_USD">11595000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_556031f3-2d03-4940-8c76-ea426b0951fc"
      unitRef="U_USD">38690000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <md:OperatingAndFinanceLeaseRightOfUseAssets
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_b6f68803-a6cb-4ac5-b4f5-f4c2c0106ecf"
      unitRef="U_USD">39267000</md:OperatingAndFinanceLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_f5075da2-71cd-4b12-8355-014b4376422a"
      unitRef="U_USD">88729000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_9389f297-b11b-4779-8061-e33bc3863c34"
      unitRef="U_USD">103855000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_810a4a2f-900e-4206-8fba-a67d94da81d4"
      unitRef="U_USD">70785000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_fd246ea8-e336-488c-9c62-c2d7efb4c996"
      unitRef="U_USD">76598000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_ba008c7e-3fb0-4a2f-9672-5e3bd9bdab81"
      unitRef="U_USD">2102100000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_c15a0587-183b-472b-a171-29e6041b105a"
      unitRef="U_USD">2152700000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_44e4f46c-d436-4df4-a7b6-09d8e9ffc298"
      unitRef="U_USD">303360000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_83422c26-4378-46a3-82e0-c9c03a0efe95"
      unitRef="U_USD">398690000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_e2ade8c1-9caf-4255-bb73-461c87f425dd"
      unitRef="U_USD">23685000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_8c3c35a1-b963-40b1-afdf-e0077e7ba2f2"
      unitRef="U_USD">20545000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_de1566af-97a8-40e4-8637-1634bc7cca38"
      unitRef="U_USD">12049000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_f7095324-d083-4a84-acec-76e8325de055"
      unitRef="U_USD">12704000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_d4ab6e8c-0e5e-4377-942b-64076308bd59"
      unitRef="U_USD">1949000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_944feadd-3cb5-49f6-a59c-7b8547364a02"
      unitRef="U_USD">2171000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_01cf1015-d182-47a8-9817-1c7a397cc360"
      unitRef="U_USD">341043000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_3163b69d-6d93-4f11-91d9-86ae14161097"
      unitRef="U_USD">434110000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_dbfe387c-fdc8-4552-8580-f77549f7e2ee"
      unitRef="U_USD">583863000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_7165c4d1-4bc7-4dde-bb80-58269083a7c1"
      unitRef="U_USD">597119000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_84e82527-d6e5-4697-9dce-272788cde12d"
      unitRef="U_USD">29963000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_b77f4faf-5056-414a-9ec1-e759d972ff2b"
      unitRef="U_USD">31945000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_c15dd9db-2b55-441b-ad7d-8d421310c7f8"
      unitRef="U_USD">244162000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_f3dede1c-69c4-4607-acae-db81816ee4e1"
      unitRef="U_USD">257455000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_642c02b5-d486-4b77-a7cf-d55845a2037c"
      unitRef="U_USD">36019000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_d3548799-3474-4241-87a6-af6729e0f408"
      unitRef="U_USD">34246000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_1eee748c-83d8-4c0d-831e-ece8b826f35f"
      unitRef="U_USD">33297000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_5a3361b5-64b8-4b86-906d-d6ffce57404e"
      unitRef="U_USD">32887000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_d8efed8d-3d87-4d57-a4ef-ed751399d521"
      unitRef="U_USD">1268347000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_eed0ce15-4281-4bb1-b70c-6800421bfb2b"
      unitRef="U_USD">1387762000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="INF"
      id="F_c4eb4221-c20e-48dd-ad14-ad11f6f9de18"
      unitRef="U_shares">1000000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="INF"
      id="F_191a8c01-699e-4c8e-9de4-c61de295bd91"
      unitRef="U_shares">1000000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="INF"
      id="F_7140ff90-0caf-42ad-b1af-e0e450880509"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="INF"
      id="F_73bb1848-95fe-4806-9715-52a8cdd4a5df"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_2d3f78d5-69d0-401b-9d77-21079dcb5826"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_96b76f78-9e91-4d3a-88bf-5327668a1e85"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="INF"
      id="F_d4cc69d1-974e-4c53-bf37-ef2cc63a3633"
      unitRef="U_shares">200000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="INF"
      id="F_ed5ef2f6-bd6a-48b2-896b-53a3fbc6a143"
      unitRef="U_shares">200000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="0"
      id="F_caec2010-ca10-4677-b168-46b0e039e766"
      unitRef="U_shares">86854234</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="0"
      id="F_ac4588f6-4962-4a44-b1b9-ef0bea783520"
      unitRef="U_shares">86854234</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="0"
      id="F_76b9229a-8646-4b12-a2de-8b70805547a0"
      unitRef="U_shares">85866000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="0"
      id="F_d0d9c747-7ed6-415d-a813-ec1efda0826e"
      unitRef="U_shares">85866000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_bd3800ff-1d21-4794-b054-d2b05c38af9f"
      unitRef="U_USD">869000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_8fc819ed-7e5a-49b2-9300-27f7b2e0aa72"
      unitRef="U_USD">859000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_d2902647-1de1-4cec-a18f-09604165955f"
      unitRef="U_USD">1021290000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_05e1f230-3f8d-4472-8fe1-0a1c2283fd58"
      unitRef="U_USD">1013690000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_4ffa1b0d-25ac-4ea8-adbb-f6880ad3412e"
      unitRef="U_USD">137000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_df033513-e2d1-4b22-ae66-b7df65f94de6"
      unitRef="U_USD">-1071000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_3906484a-ef5c-4133-9781-3543ff08dc16"
      unitRef="U_USD">-188543000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_74b99739-abf0-4c53-a915-a04dff8bf792"
      unitRef="U_USD">-248540000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_41c2e264-8a0d-4743-88cd-c2f0e0cc9d98"
      unitRef="U_USD">833753000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_78659757-1e93-4bca-9103-41a7714d4c62"
      unitRef="U_USD">764938000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_8c8468fa-4500-4c68-b83f-97abdc70e93b"
      unitRef="U_USD">2102100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_675d258b-cc12-4369-8be6-60b35bf2c6a6"
      unitRef="U_USD">2152700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_8e571057-85ae-4609-93af-133dee95a3da"
      unitRef="U_USD">468844000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_24b4df4e-05a7-4f17-8fbc-a1682f92e2b3"
      unitRef="U_USD">504296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_8295238b-fb43-4010-a4d9-1ef2b2c90f47"
      unitRef="U_USD">927203000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_d9301f02-923e-46e3-899a-a9495778c313"
      unitRef="U_USD">999397000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_ce708d24-27c7-4c6c-bd89-6204751279ed"
      unitRef="U_USD">323502000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_85c06aaa-524e-4d93-a985-9a54088ba5b3"
      unitRef="U_USD">357808000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_e86e31c4-3239-47f8-a0db-45e0df05f666"
      unitRef="U_USD">660533000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_f4393e47-4297-41d0-bcec-8c747c23309a"
      unitRef="U_USD">726946000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_d510b01d-c9c0-4eb1-8f1a-ae505272f94f"
      unitRef="U_USD">20614000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_4a3c09e9-851a-447c-ba6e-4eea76410359"
      unitRef="U_USD">32369000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_bbd1fe3f-7f85-42a9-8423-7b20f181e2d8"
      unitRef="U_USD">39300000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_005d691e-e645-4a06-a008-68b4fe96d00f"
      unitRef="U_USD">63454000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_9d22f1b5-83d4-4101-96ae-e18e20a3b99c"
      unitRef="U_USD">55714000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_7ba88165-9a19-45e6-a4cf-e3ffc9250883"
      unitRef="U_USD">56565000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_91810236-3d39-404e-8e60-14f61e23ec9a"
      unitRef="U_USD">114318000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_0c56475c-bbfd-44d5-a0c0-ba6b6cbe112a"
      unitRef="U_USD">116763000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_9e630b75-6302-4ca8-be0a-248ab9d37aa0"
      unitRef="U_USD">5313000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_0ab3dcf1-1d03-4402-84fe-ed774c03fdcc"
      unitRef="U_USD">8791000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_1d2709c4-8855-4832-beb0-9ed9f73ed297"
      unitRef="U_USD">10645000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_abc08bf6-e201-4cf2-9ab6-d8a2ae297d39"
      unitRef="U_USD">19099000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_19bb1abd-bebb-4ba5-8403-89a39b1dc49a"
      unitRef="U_USD">3834000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_f1d04839-3a57-47f0-a958-5b4a94913281"
      unitRef="U_USD">13579000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_ffdaa0ce-1c24-4972-8f16-3986a3e26e26"
      unitRef="U_USD">10439000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_3b8f5aa6-ceb6-4de9-926d-97aaccb1f407"
      unitRef="U_USD">22059000</us-gaap:RestructuringCharges>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_02be2454-30ff-4058-8577-daf8f9d5b365"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_d8521d97-8b7a-44d7-bd34-d97612963509"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_7e563612-e04b-4efb-8761-04d0789ba708"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_bd6f3aff-2570-4e03-907d-8a71053d8239"
      unitRef="U_USD">154243000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_53b2f40d-1106-4373-b5c3-931f718dd3d9"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_6ac871fd-8bcb-4ce4-951f-0ecdf8bb0eaf"
      unitRef="U_USD">27791000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_8a3838ac-ef65-46f4-bfb5-9f834fef6985"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_bac50bbb-9b52-4f5a-b80c-43c32e2094e5"
      unitRef="U_USD">27791000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_bfc802c0-6091-4ec2-a650-4f670a0291b6"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_0b2ea7bb-b7d9-4e17-a655-188b7a288fd0"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_30fcb3c2-1c86-4ec8-aee2-3c3652e49d45"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_ca28706a-b31a-4fae-9cf8-b30e12ae4ce2"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingExpenses
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_7b6bdf01-0ac6-4095-9339-01426716b6ed"
      unitRef="U_USD">408977000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_8cb84481-bb95-4dd0-b20c-9f43757ddf31"
      unitRef="U_USD">662019000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_eafe3caf-6b5c-447e-9ff3-ba78cb96a034"
      unitRef="U_USD">835235000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_fb8459cf-225e-46f1-8806-a1accdea7dc0"
      unitRef="U_USD">1141228000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_1fd6d081-7e01-4c7b-b822-8a8ef8b5e0be"
      unitRef="U_USD">59867000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_c48eb14c-fad1-4c44-a24c-60c2f69cb87d"
      unitRef="U_USD">-157723000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_dfbfc197-20e9-47a4-b83b-44e452eef408"
      unitRef="U_USD">91968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_54a3cf6e-76be-45e1-9661-5b2ce50bd581"
      unitRef="U_USD">-141831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_12a319d5-78ae-4a1b-966d-9570814cbd5d"
      unitRef="U_USD">3727000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_c271740f-4314-4989-bb5f-876a21605f10"
      unitRef="U_USD">-161000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_d756f6dd-a377-4e33-959c-a4841451e845"
      unitRef="U_USD">8464000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_92ee2f28-9792-41a7-81c3-2384adfd9858"
      unitRef="U_USD">1852000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_25e750ac-1d92-4d1d-876f-1ddc4507f21a"
      unitRef="U_USD">9130000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_2d57733c-0e16-40c6-b772-674e7dfb4fa5"
      unitRef="U_USD">10308000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_49b9f36f-22c9-4dea-9d63-d213f3775746"
      unitRef="U_USD">18284000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_aff2d535-f8e7-4187-baee-057491bb7936"
      unitRef="U_USD">20907000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_ad977f5b-a605-4e5a-ae53-b693150d09dd"
      unitRef="U_USD">505000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_195f7a03-4126-403a-b742-59a28b65a7aa"
      unitRef="U_USD">464000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_96dda3c1-ccf6-4172-9cd6-04d1568258f6"
      unitRef="U_USD">911000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_d1d1ea08-339d-429a-b5d2-eaa258477b3a"
      unitRef="U_USD">982000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_d62276fe-8921-44ce-88fa-ecdd9d86137c"
      unitRef="U_USD">-4898000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_17382351-f569-4cac-9116-5113e85ef0c7"
      unitRef="U_USD">-10005000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_29247cc0-eed8-4454-9a7e-1e273faea469"
      unitRef="U_USD">-8909000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_097891bb-f2ba-4e87-b633-d5df49bbfadb"
      unitRef="U_USD">-18073000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_d257e0ca-2d36-49e3-89ba-3f200d15ece4"
      unitRef="U_USD">54969000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_1d497192-c068-4141-9d4e-725475111068"
      unitRef="U_USD">-167728000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_16be757f-4ffa-42c4-a6ed-5393ed15f83e"
      unitRef="U_USD">83059000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_ca8501f1-20d2-4228-9456-6d5261d04cbe"
      unitRef="U_USD">-159904000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_e00206e0-446b-41b0-81fd-090abd61b9cf"
      unitRef="U_USD">15709000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_c670f8a9-096f-4ab1-a027-a5e9550d75ab"
      unitRef="U_USD">-14703000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_843be130-9e31-469b-8183-f1f000628c07"
      unitRef="U_USD">23062000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_0575faf8-29f2-4a33-aa2f-761dd7bff009"
      unitRef="U_USD">-10914000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_cb2adb53-bb04-404a-98a1-6c3a5af9c153"
      unitRef="U_USD">39260000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_b66dd6f7-8f63-4e0a-b2b8-6090d55f7dd1"
      unitRef="U_USD">-153025000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_4b3ca73b-fbac-4daf-b35b-d50eeb67123b"
      unitRef="U_USD">59997000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_60cd3fec-e1ae-405a-90b0-22c5803f8b94"
      unitRef="U_USD">-148990000</us-gaap:ProfitLoss>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_a3b3d793-74e9-49c4-8592-b111568ef03b"
      unitRef="U_USD">140000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_9e24fa24-3002-4abf-a80f-27e4dedf77f9"
      unitRef="U_USD">66000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_c2f0b36a-c739-4f82-a7ef-61565f867cd6"
      unitRef="U_USD">395000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <md:NetOfTaxUnrealizedHoldingGainLossOnInvestments
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_6d49a68c-34fb-4d38-b0ef-4726aea30ded"
      unitRef="U_USD">86000</md:NetOfTaxUnrealizedHoldingGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_31615c8f-1cb8-45e7-b315-a1e13ee5925b"
      unitRef="U_USD">429000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_4946e24f-73a5-4702-8334-2ce49ee663c2"
      unitRef="U_USD">200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_bf6b82e8-a045-4bd3-9bec-a2091d6c93a1"
      unitRef="U_USD">1208000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_67ca8e2d-b306-4fd5-a458-9450af737b12"
      unitRef="U_USD">260000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_2bc8e8de-c742-4df3-84bd-910d4076f05a"
      unitRef="U_USD">39689000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_6f56e17f-47e1-42d7-bd23-8d203180a14b"
      unitRef="U_USD">-152825000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_7bbb8c68-0ccc-453c-a936-23c97f8ba0dd"
      unitRef="U_USD">61205000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_9e815c40-9c3a-4fcd-bea9-b36589ffb77e"
      unitRef="U_USD">-148730000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="2"
      id="F_2c856db6-8fc8-413b-a739-8237ef22c0ee"
      unitRef="U_USDollarShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="2"
      id="F_5f4d1094-bf65-442e-af23-a701d5f6f20f"
      unitRef="U_USDollarShare">-1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="2"
      id="F_a62f0338-cad0-41b7-9df8-3c82a7a5f04a"
      unitRef="U_USDollarShare">0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="2"
      id="F_fe8eb54a-c723-4f03-8ced-e4d45d547ca4"
      unitRef="U_USDollarShare">-1.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="2"
      id="F_a53f5dfc-515d-44f5-9ad1-fb7cf79f0d7a"
      unitRef="U_USDollarShare">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="2"
      id="F_1d06d43d-5c9a-4b30-b23c-1cfc7eb8d192"
      unitRef="U_USDollarShare">-1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="2"
      id="F_ee7ee5fe-2236-44d8-a7be-9dca5c8639a0"
      unitRef="U_USDollarShare">0.7</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="2"
      id="F_50383a89-cdec-42d9-aa25-c9a39d1e4932"
      unitRef="U_USDollarShare">-1.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_e19dbb61-1796-4bed-9a16-0b2229928a1f"
      unitRef="U_shares">84797000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_0dab46aa-2dd7-4ca8-a294-77633857b2ae"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_a373e90e-98ad-4e47-ba57-a040dbec2c64"
      unitRef="U_shares">84653000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_617d21e1-bb11-4f01-be01-e4129c1ca690"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_db459843-53d3-4766-b3d1-29e05b1233b7"
      unitRef="U_shares">85529000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_7277b85f-4418-4642-bf54-f2eeabc7f542"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_1b6e61bb-0054-498c-9b7c-a6c042de51eb"
      unitRef="U_shares">85517000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_a0d99900-a3cd-4894-9b2e-dfe6c58004a8"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_02bea4f4-754b-413e-9d98-79f2fe330f07"
      decimals="-3"
      id="F_1140ab30-c7bf-491b-888a-5c2a41d6fdc3"
      unitRef="U_shares">85866000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_02bea4f4-754b-413e-9d98-79f2fe330f07"
      decimals="-3"
      id="F_3ea317e0-4ef3-4ce3-9019-61dccd89c205"
      unitRef="U_USD">859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_edc12ded-37cf-49fc-92de-c7343544ab45"
      decimals="-3"
      id="F_3d4bca5e-d29e-4995-b84a-fcf45c887398"
      unitRef="U_USD">1013690000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3d0d3861-fcff-4c38-a557-3d670d1a3de9"
      decimals="-3"
      id="F_86af02dc-a346-478b-b5ee-999d842ecd04"
      unitRef="U_USD">-1071000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2f91671e-71e9-4083-b736-fa78c83a4f94"
      decimals="-3"
      id="F_bae4588e-63e2-4263-ae36-97d423bfa11f"
      unitRef="U_USD">-248540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_675e5aaa-7200-4e3f-a6b4-58df598cae08"
      unitRef="U_USD">764938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_e1195bd8-3f70-421d-a6ef-34e21a43644f"
      decimals="-3"
      id="F_939ce938-697b-4fe9-b2dc-d38fe4afdf38"
      unitRef="U_USD">20737000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_78dc85d9-7d47-416f-b718-7afae63338f9"
      unitRef="U_USD">20737000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_b93ac8f1-2c07-4a19-9bb3-1a7e4f60d143"
      decimals="-3"
      id="F_72fb37d7-9a7f-44a2-b2c0-ce84df8a4d23"
      unitRef="U_USD">779000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_8f9ff971-6d89-4907-99bd-6eab95375bd6"
      unitRef="U_USD">779000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3"
      decimals="-3"
      id="F_b29e4543-3edd-45ed-a18d-834d757bc9e0"
      unitRef="U_shares">60000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec"
      decimals="-3"
      id="F_6bf361c7-8692-4939-b692-a9602fd1c2bd"
      unitRef="U_USD">662000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_8188ec1d-99b1-4b35-9967-8621f0a51b20"
      unitRef="U_USD">662000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3"
      decimals="-3"
      id="F_36c4c485-e26d-41da-b44b-386ff1cdeef6"
      unitRef="U_shares">7000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_b42b99b9-10c6-4b8f-991b-7d20599c7533"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec"
      decimals="-3"
      id="F_59280251-6a07-4720-908b-126218d623d7"
      unitRef="U_USD">3641000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_5402d302-47c7-4aeb-a2ab-4711d6c0722e"
      unitRef="U_USD">3641000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3"
      decimals="-3"
      id="F_f7b5443c-770c-4370-89c3-2c8f385ab9bb"
      unitRef="U_shares">109000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_3fca8faf-6c55-4421-8fbb-2527bcaa65c3"
      decimals="-3"
      id="F_258d1826-fe1d-416b-b706-34a1b4acb70e"
      unitRef="U_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_9c88a547-180e-4424-b50b-a5932a2d00ec"
      decimals="-3"
      id="F_20065385-5c5b-4611-8064-87249073ff55"
      unitRef="U_USD">1568000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_46fe409d-897a-4387-adbc-9b8a5ac4f844"
      decimals="-3"
      id="F_17f77605-d622-49a3-adbc-b01f6435a441"
      unitRef="U_USD">1569000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="C_19fe297e-98f1-459f-8107-8508db33674a"
      decimals="-3"
      id="F_bfca6909-062d-49bd-a9d7-780191ec58e0"
      unitRef="U_shares">85810000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_19fe297e-98f1-459f-8107-8508db33674a"
      decimals="-3"
      id="F_2bb05c9d-b521-4fd9-b3e8-244f805659c9"
      unitRef="U_USD">858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7f02ccee-734a-4e9c-aed7-0eab8a75869b"
      decimals="-3"
      id="F_22fb414b-889a-4570-b1ee-65ca27fadc10"
      unitRef="U_USD">1016425000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b236758c-5257-4c6e-9757-301028de1d7d"
      decimals="-3"
      id="F_1051f861-0867-4d5e-880e-3aa2b44cf9b5"
      unitRef="U_USD">-292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7d2132bf-03a8-4280-9a81-ef0cfcfa8452"
      decimals="-3"
      id="F_d9807241-4903-4c3a-83da-95869f992ed0"
      unitRef="U_USD">-227803000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b627c7d1-b301-4b96-8344-f2a1a41efccb"
      decimals="-3"
      id="F_82f7b354-8fd0-465c-a411-0a8c5d0b1ed4"
      unitRef="U_USD">789188000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0a519f8a-d93b-4b46-a7c9-3139cb8a19ea"
      decimals="-3"
      id="F_bf5564c1-d1c1-43b3-bfd9-74d69ab2044b"
      unitRef="U_USD">39260000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_5789c647-0a09-4048-8f42-92a9f02a49b7"
      unitRef="U_USD">39260000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_f6087d4e-66e6-45e6-ae80-7267213024b2"
      decimals="-3"
      id="F_8fb3f71f-3cc2-49ed-a0ef-6d28ca9854dc"
      unitRef="U_USD">429000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_bdce9ca4-6fa0-4042-80ae-91adee3e962a"
      unitRef="U_USD">429000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd"
      decimals="-3"
      id="F_e3073b4e-c957-4c47-889c-148e7bb500e2"
      unitRef="U_shares">96000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd"
      decimals="-3"
      id="F_55efea14-67cb-42fa-b42a-c72374d121ed"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5"
      decimals="-3"
      id="F_2cef0f63-f198-4b8d-82e6-c68f11c5486c"
      unitRef="U_USD">1175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_7ccc97ce-98b5-4f58-a18e-1b3052873da7"
      unitRef="U_USD">1176000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd"
      decimals="-3"
      id="F_a7ccd182-7f55-4d8d-9d4c-79481a1a3071"
      unitRef="U_shares">963000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd"
      decimals="-3"
      id="F_79fac5b2-f8ec-4d3a-9247-b394d5d995fd"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5"
      decimals="-3"
      id="F_c2fd31b9-fe73-487d-9614-12ffbd0bcfc0"
      unitRef="U_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_982f3198-aff1-4a03-8b72-956046c5bb90"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5"
      decimals="-3"
      id="F_7736fc07-9c77-4132-8d44-f8ee40d3bd23"
      unitRef="U_USD">3909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_df1f6c16-93b0-46db-8612-eab390852643"
      unitRef="U_USD">3909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_070261c9-34d5-4928-b2a8-489b2db71abd"
      decimals="-3"
      id="F_56db9553-c04a-4703-acdf-5874f280f7e8"
      unitRef="U_shares">15000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_33ae31ac-2445-4e4c-acee-40d4bf6154e5"
      decimals="-3"
      id="F_5aa4d2ff-b49b-47d3-8610-329b17d90fd2"
      unitRef="U_USD">209000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_70704e1d-fc98-46e4-87fe-05cb0aab4601"
      unitRef="U_USD">209000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9"
      decimals="-3"
      id="F_d14bd2e3-a2a4-4e8c-b22e-90cf3768e821"
      unitRef="U_shares">86854000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ac074863-7830-4ef0-b3e2-96c0b99f34f9"
      decimals="-3"
      id="F_d7d1868e-b4c2-4705-b304-8e34a493d1e8"
      unitRef="U_USD">869000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e2fb96e5-6737-49f7-bfc9-5420746a9a50"
      decimals="-3"
      id="F_8216b86c-b063-4902-ab28-33422260df6d"
      unitRef="U_USD">1021290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a732c152-f078-48ed-9981-fe2813bfd8a9"
      decimals="-3"
      id="F_6d19c015-3963-4a4b-8b32-0edf32dd80c4"
      unitRef="U_USD">137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2f6f6e25-d54c-4b0a-a12d-048947969ac0"
      decimals="-3"
      id="F_3b2f7483-551a-4034-9c73-892909904d19"
      unitRef="U_USD">-188543000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_bc03ae94-5f2a-4d3f-8bcf-25ff2d007021"
      unitRef="U_USD">833753000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_6ddf4aea-8896-44ae-a2ff-471183878dfc"
      decimals="-3"
      id="F_fb5a2ebc-83bf-4738-8464-0a60b33d3c0a"
      unitRef="U_shares">84018000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6ddf4aea-8896-44ae-a2ff-471183878dfc"
      decimals="-3"
      id="F_cc24b28a-513a-45bd-a889-240cafa6bdfc"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0dec167a-ac7c-418a-ae69-3cbcc4fb92b2"
      decimals="-3"
      id="F_95e343ab-04c8-4e56-8057-0ed1e3c7cf25"
      unitRef="U_USD">999906000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4ba683c9-c1d0-4296-8d60-6b927301e2bc"
      decimals="-3"
      id="F_58dcd101-e47f-4e4f-b0b5-3b6e2d9711f4"
      unitRef="U_USD">-2214000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0236986c-5db2-4fdd-b4fa-b8140c8d6f6d"
      decimals="-3"
      id="F_47d78f3a-84b6-43e1-9b16-931dec48eaa1"
      unitRef="U_USD">-149471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53"
      decimals="-3"
      id="F_64cc6633-824b-4550-958e-8fe8dafa04d6"
      unitRef="U_USD">849061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_6767043a-8ca4-4e7b-8a97-d9178cf9f8df"
      decimals="-3"
      id="F_5034baeb-f75d-478f-9b8e-b1df4e0dfc9c"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0"
      decimals="-3"
      id="F_ca42c381-db8a-4e95-b00d-75e4a69c1bfc"
      unitRef="U_USD">4035000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_a4e56d63-8e80-4097-be11-b3c834580fc4"
      decimals="-3"
      id="F_0f0badcd-21fa-4472-9928-607b3ed8b737"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0"
      decimals="-3"
      id="F_61954c58-5faf-486f-8899-8c83b1982df5"
      unitRef="U_USD">60000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e"
      decimals="-3"
      id="F_23f0d791-9f2b-4358-a879-f01ada6f8b51"
      unitRef="U_shares">108000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e"
      decimals="-3"
      id="F_aa1eb689-913f-42fd-bc1b-89b0b68245fe"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68"
      decimals="-3"
      id="F_98c05f3e-88b7-4308-922f-b6e0f57f27ee"
      unitRef="U_USD">859000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0"
      decimals="-3"
      id="F_d6b9619d-f3ba-48cc-9fe1-20475f93846c"
      unitRef="U_USD">860000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e"
      decimals="-3"
      id="F_31a19e96-cc7c-4717-8bee-62b32eab0b4b"
      unitRef="U_shares">21000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68"
      decimals="-3"
      id="F_b8b1e435-6674-408a-a24b-48d0613fda52"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0"
      decimals="-3"
      id="F_1a8830ab-cef3-4bab-bbb3-1c8842d31ab7"
      unitRef="U_USD">3067000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e"
      decimals="-3"
      id="F_533d7864-d518-403c-a192-d8730cd66734"
      unitRef="U_shares">97000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_f52719a9-de3b-449c-92cd-aff10e01b14e"
      decimals="-3"
      id="F_839506af-6de8-4770-8e8c-bf03ba9dc3d9"
      unitRef="U_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_adc93a05-2575-42d8-b329-4f35de71ac68"
      decimals="-3"
      id="F_f12cadb8-5673-4dc5-aa93-280c1808eb31"
      unitRef="U_USD">886000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_d63eb551-12c7-4a81-96be-660b39fca8d0"
      decimals="-3"
      id="F_aec41817-d6ec-479c-9ed8-c1115f3a7f88"
      unitRef="U_USD">887000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f"
      decimals="-3"
      id="F_996bbd9c-3ee0-43a3-b7d8-d22299629973"
      unitRef="U_shares">84008000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9430bdcd-d0b0-4a01-a33f-5e169f3aa59f"
      decimals="-3"
      id="F_be7911a0-78a3-4061-a635-fea6437d41ba"
      unitRef="U_USD">840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_85ae1910-2e7f-4c51-938e-e043272c5d66"
      decimals="-3"
      id="F_7b73249e-f882-4280-b4ad-4dd4f6b767ea"
      unitRef="U_USD">1002946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f341ef8f-6752-4a72-9c1d-980e03786ef9"
      decimals="-3"
      id="F_a6ac03b6-df3b-4a2a-a8bc-1c737b45445c"
      unitRef="U_USD">-2154000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_116f6c49-cd97-47f6-a585-d9c09874db22"
      decimals="-3"
      id="F_ffd2a6de-5cb4-45b4-81bb-4c44ddef90ff"
      unitRef="U_USD">-145436000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3e05a392-a376-4596-8bcf-ca0fdc5e9ed0"
      decimals="-3"
      id="F_d959960e-9cfa-455b-b0e7-9ca8969825f5"
      unitRef="U_USD">856196000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_15a46667-2e0c-46ce-9da6-40aaeece1d0a"
      decimals="-3"
      id="F_08f951fa-f75c-4cb0-8dab-a76da5f94ce4"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_fd9c20f8-08ab-49ad-acd8-789b48ccdc0d"
      unitRef="U_USD">-153025000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_c4b9e66b-5f53-4567-b3c0-f31b5bcc6403"
      decimals="-3"
      id="F_622b3d59-9260-43fc-89ae-34fd44d9698c"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_39d46e26-f6d2-453e-b67e-03f75aba4bfd"
      unitRef="U_USD">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_7d2d3347-d029-4064-ad34-64d0a0f7521c"
      unitRef="U_shares">139000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_2825cc2c-676a-4359-9a1f-8ce20deeb639"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa"
      decimals="-3"
      id="F_7c6523f5-7638-4310-8fc6-6e05691b27d0"
      unitRef="U_USD">1147000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_995f8d75-34e1-4f31-afcd-469059dce2b5"
      unitRef="U_USD">1149000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_3f20e764-e7e8-4d84-979e-454afc39bca6"
      unitRef="U_shares">1630000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_f9d6732b-faaf-400e-8662-af7c0c276a62"
      unitRef="U_USD">16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa"
      decimals="-3"
      id="F_9b1246b7-cf38-4498-bab5-da4c4a7279a3"
      unitRef="U_USD">-16000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_9845778e-99f3-4ec8-9305-0a68e3dc0410"
      unitRef="U_shares">22000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa"
      decimals="-3"
      id="F_ddde2986-9d55-4eef-b933-4a0ecc81b817"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_e8ba13b0-f1ba-4db4-be24-16ab2f3df40b"
      unitRef="U_USD">1952000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_ea584bda-977e-42b7-b574-9d656ac33e6d"
      decimals="-3"
      id="F_42f11d98-80aa-48b0-94bb-1f0f4ba32717"
      unitRef="U_shares">2000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_f69eb5df-7c54-4913-8897-3bff94f4b6aa"
      decimals="-3"
      id="F_88f230de-e256-4103-ada5-052dceb1941b"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_3962c445-15b5-4ab3-8d9d-fa90a8deb1aa"
      unitRef="U_USD">11000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6"
      decimals="-3"
      id="F_9afc8e2b-7063-409e-a66d-7106ca4efdd9"
      unitRef="U_shares">85753000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3f3ad9a8-86fe-4cd3-a219-40a3403e0af6"
      decimals="-3"
      id="F_0022a12a-e957-4b7a-bdd3-76c1d059717d"
      unitRef="U_USD">858000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8eb88e83-6d3f-4f77-ab85-5922b2e851d2"
      decimals="-3"
      id="F_3b8e8f22-11cd-48bb-888e-70d278494f70"
      unitRef="U_USD">1006018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d41e6181-d9d5-4854-bb79-fc2110b6a1b5"
      decimals="-3"
      id="F_6f77eaba-ca3d-48db-a7c8-b85540e04b42"
      unitRef="U_USD">-1954000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e8fa676e-89e5-4c48-82b7-8f14961e5d15"
      decimals="-3"
      id="F_ab262955-c966-4652-a6bc-2321a50c29ba"
      unitRef="U_USD">-298461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_70926ddf-afe5-4399-bd86-e068c0af16d9"
      decimals="-3"
      id="F_d44a51c3-3778-4309-a81e-3ff2ed6ce346"
      unitRef="U_USD">706461000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_0da3156c-6fde-4457-aca4-e208f20210ae"
      unitRef="U_USD">59997000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_36274bbb-e7a4-4a7c-bdb2-96a2e0cc8046"
      unitRef="U_USD">-148990000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_febc65fa-847a-46a5-8380-da7a82bd4bc0"
      unitRef="U_USD">10645000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_a88a23ab-76b7-44e8-b8cf-00c3a1d5d01b"
      unitRef="U_USD">19099000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_03d19820-0cda-4442-8ce3-23726337594a"
      unitRef="U_USD">458000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_638da2c3-a44a-4132-b3fe-e0495f4433de"
      unitRef="U_USD">440000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_5fc00870-2095-4093-9ee8-4f5a2aed8591"
      unitRef="U_USD">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_d1b56665-439e-4f5f-9170-847679274b91"
      unitRef="U_USD">182034000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_34432b9e-8da4-4f43-95a1-a9bafc5fe995"
      unitRef="U_USD">-0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_cb0c2426-2102-4b1c-a751-20888ecd6fdf"
      unitRef="U_USD">-10873000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:ShareBasedCompensation
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_f4fe80b1-7ccf-46bb-a2da-5e4a6c27802d"
      unitRef="U_USD">7550000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_c394ad13-4872-4242-a9a7-2d0fbbb242fd"
      unitRef="U_USD">5019000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_9138dab6-1d67-4842-9b68-d6114a550d5e"
      unitRef="U_USD">16504000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_33d80233-74b2-4f63-8348-2d353b78e5e9"
      unitRef="U_USD">-25028000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_ba9e89dc-b7ec-4f10-a51b-87314f886340"
      unitRef="U_USD">1501000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_51902573-8394-42e9-b814-d6a03c4c1e68"
      unitRef="U_USD">1678000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_64cc9328-8d68-4fd1-b980-8315a90e7d9a"
      unitRef="U_USD">-21231000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_c49d5aff-9715-410b-8035-2d6b653f9c3f"
      unitRef="U_USD">934000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_60196fb4-6a2b-44cf-a7c9-f2b832eae919"
      unitRef="U_USD">-204000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_b9eeea70-7fdc-4a45-a2f8-3d4e96825c47"
      unitRef="U_USD">-3703000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_d95c79f5-85a2-4574-835d-e45d014ec247"
      unitRef="U_USD">-9601000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_c62d2838-9caf-40d4-a44b-907f1becb810"
      unitRef="U_USD">-16955000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_9ed33255-e1d3-4611-816b-ddbcfabd1afa"
      unitRef="U_USD">-89951000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_ac062737-7543-4153-a2f8-054fc2ab3d58"
      unitRef="U_USD">-82917000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_df8dda61-f6c3-4fae-a9a1-325989b940ee"
      unitRef="U_USD">4763000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_778313bc-b340-462f-af42-22d6e2ac4e78"
      unitRef="U_USD">11735000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_9cfbc52c-44ee-4f87-8bfb-112974d82e10"
      unitRef="U_USD">-8166000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_fe962ad5-31eb-493e-a17c-d4270ef843e1"
      unitRef="U_USD">8039000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_046bb103-87c8-4f7c-8854-dcbc5a65b7a5"
      unitRef="U_USD">-9315000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_37c69547-a386-4cba-a36c-7ed4d6792cdf"
      unitRef="U_USD">-11630000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_4ae4d79b-e695-4ec3-b3a2-24c2d5626229"
      unitRef="U_USD">22020000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_a51965f1-3e50-4063-b699-c075e943dc5e"
      unitRef="U_USD">-13280000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_b10ccb83-2725-4ca4-841f-8e13474f7c1e"
      unitRef="U_USD">-2316000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_5f048eff-4ff9-4c23-9f00-b27aa68dddbc"
      unitRef="U_USD">-4995000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_ae5a6827-0b71-4a63-96d0-6d94add1c45d"
      unitRef="U_USD">19704000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_23a92ad0-a270-43bf-8941-c4f122c1b788"
      unitRef="U_USD">-18275000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_14015486-c962-425d-ba86-db53c9d19321"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_42b759ad-86b3-4c24-9cc9-8f280755e51b"
      unitRef="U_USD">8167000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_7fae8836-5de5-429d-9069-7850861ec264"
      unitRef="U_USD">21529000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_b37f6e8c-def5-4dae-836a-aa148c4193ee"
      unitRef="U_USD">39915000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_10e249ce-4a2c-4482-acad-865147275275"
      unitRef="U_USD">18380000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_a45c41bd-559b-4f34-b5dc-b75978a16ff5"
      unitRef="U_USD">31244000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_e81938d9-9c72-44fc-9f76-825c0c5ed793"
      unitRef="U_USD">7833000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_634a0f4a-8b2b-4048-a5d2-fa9140e48e06"
      unitRef="U_USD">12292000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_9fa67152-180d-4b70-b3fe-33d4bf4af3f2"
      unitRef="U_USD">3636000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_dc042315-0e4b-4592-b3e4-614421772d5c"
      unitRef="U_USD">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_fb7aceb6-e2d4-44b5-a726-842c1717afad"
      unitRef="U_USD">-14618000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_1ae54d10-48a3-449a-aa17-a0de009fc82b"
      unitRef="U_USD">-29130000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_af0c7b5e-ce5a-479e-99a5-54c6a86325f8"
      unitRef="U_USD">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_13ffef5d-52ad-49a3-a942-933e2f1c11f6"
      unitRef="U_USD">235500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_3a199763-632c-4129-90b4-54818c1f88d5"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_f3154e53-78e2-4e16-96da-dd9bdd013dd3"
      unitRef="U_USD">235500000</us-gaap:RepaymentsOfLinesOfCredit>
    <md:PaymentsToTermLoan
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_5bced069-52f5-4885-930a-caf0a457f5f6"
      unitRef="U_USD">9375000</md:PaymentsToTermLoan>
    <md:PaymentsToTermLoan
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_27bd7314-5bac-48bc-a857-aafabaa3a506"
      unitRef="U_USD">6250000</md:PaymentsToTermLoan>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_befa90aa-b2d6-442c-b4c6-05ecd45f73d8"
      unitRef="U_USD">844000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <md:RepaymentsOfLongTermCapitalLeaseObligation
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_8a9ec1f4-72ac-4f63-80a1-1ea70ca84760"
      unitRef="U_USD">1391000</md:RepaymentsOfLongTermCapitalLeaseObligation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_1e574168-aca0-4d72-ae6e-5bfe11a7a6e9"
      unitRef="U_USD">1838000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_e68cd6c3-70f4-4e9f-8775-1432921a48f6"
      unitRef="U_USD">2009000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_17baf9aa-610a-48ce-a2e6-f66fd4057f1d"
      unitRef="U_USD">1778000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_d600e4b9-20a8-45b5-ac12-a0828f091d51"
      unitRef="U_USD">898000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_f488b905-384c-4dc6-bff5-62af6dd367f8"
      unitRef="U_USD">-135000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_ffde505a-30bc-4e9a-a385-7482630a269f"
      unitRef="U_USD">79000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_b271f67b-a48d-43ba-9cbc-f4f608801293"
      unitRef="U_USD">-10294000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_d627306f-e843-4fb3-b4a9-43d6ad1325bf"
      unitRef="U_USD">-6451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_8114c4b1-0e44-4714-92f4-78cdf9d76e9e"
      unitRef="U_USD">-5208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_15f02e5a-5f5e-4d9e-bf39-cbc44effdf76"
      unitRef="U_USD">-53856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_381b3de3-3e18-4c19-8ada-c30f91e83b78"
      unitRef="U_USD">229940000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_16ceb319-42b3-45e5-aca2-e0b5ad682a53"
      decimals="-3"
      id="F_65469169-21b4-4eab-99db-65064c149a4d"
      unitRef="U_USD">73258000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_f4dc961d-4d99-4ed4-b4f2-421b1e0f41dc"
      unitRef="U_USD">224732000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_70926ddf-afe5-4399-bd86-e068c0af16d9"
      decimals="-3"
      id="F_51a4608a-a8d0-4f39-821b-b601f4dfbb94"
      unitRef="U_USD">19402000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_d0c6e287-d817-47e3-a1b5-84d8738cde42">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;            Basis of Presentation and New Accounting Pronouncements:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, &#x201c;PMG&#x201d;) together with the accounts of PMG&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of PMG have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states. The terms &#x201c;Pediatrix&#x201d; and the &#x201c;Company&#x201d; refer collectively to Pediatrix Medical Group, Inc., its subsidiaries and the affiliated professional contractors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During 2024, the Company exited almost all of its affiliated office-based practices, including its primary and urgent care service line.  The operating results of these practices did not meet the criteria to be reported as discontinued operations in the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s Consolidated Statements of Income and Comprehensive Income.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is a party to a joint venture in which it owns a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% economic interest.  The Company accounts for this joint venture under the equity method of accounting because the Company exercises significant influence over, but does not control, this entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form 10-K (the &#x201c;Form 10-K&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, accounting guidance related to income tax disclosures was issued which will require additional disclosure in the Company's income tax rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The accounting guidance will also require the Company to disaggregate its income taxes paid disclosure by federal and state jurisdictions, with further disaggregation required for significant state jurisdictions. The guidance is effective for annual periods beginning after December 15, 2024. We expect this standard to impact our disclosures with no impact to our results of operations, cash flows, or financial condition.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_03af3506-de9e-4102-99ce-56bb360a66d4"
      decimals="3"
      id="F_173b08e7-6442-4b1d-b0f5-1cb65f6b4669"
      unitRef="U_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_2440ac7d-2483-4d6d-add8-cf34a3a277d4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.            Cash Equivalents and Investments:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of June 30, 2025 and December 31, 2024, the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s cash equivalents consisted entirely of money market funds totaling $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.529%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.316%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.316%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_a0b59a66-3754-4522-ac83-cb30014bf52e"
      decimals="-5"
      id="F_36494145-3831-4c0e-a1a8-ea0d1baf513d"
      unitRef="U_USD">5300000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_1362b435-1b65-4eb1-a216-edd421fea37f"
      decimals="-5"
      id="F_7fbbf99a-fe6a-4d15-a900-73a0ad0b8d01"
      unitRef="U_USD">9300000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_2deb80fc-c5b6-4ff8-92fa-0f2be92a4d8c">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments held are all classified as current and at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:72.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.529%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.316%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.316%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Municipal debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal home loan securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f08258f9-06ee-42bc-be52-ac38a7e86703"
      decimals="-3"
      id="F_749f20d7-7d19-4450-ad72-ee00825a8f45"
      unitRef="U_USD">50232000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a9baaa9e-b082-47b3-80b0-110bd4e5da9d"
      decimals="-3"
      id="F_dff9b5d9-434a-411c-84ae-f4487ce442ae"
      unitRef="U_USD">46411000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ea8772ff-e4ea-40c9-bb6b-4db26a751f8c"
      decimals="-3"
      id="F_87fb8066-0ac6-4be1-be0d-363f570310c2"
      unitRef="U_USD">44423000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e76ed61f-3566-4b74-9cb3-da9368513ff8"
      decimals="-3"
      id="F_74ebcbe0-bc12-4174-9d3f-5ad8febcb260"
      unitRef="U_USD">40590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_23133a2a-3883-4163-a76d-7a02c6deddb6"
      decimals="-3"
      id="F_ed020a53-0957-4095-8fb2-2dc0185ecfda"
      unitRef="U_USD">20183000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_99df4261-c382-44e0-b2a9-ed7013c4e41e"
      decimals="-3"
      id="F_676dbb69-9dd9-4268-b5b6-5fe9a2d04101"
      unitRef="U_USD">22294000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_15ed1157-0265-4dfa-865e-1e42fe186550"
      decimals="-3"
      id="F_52a1fb68-0d4f-4833-a03d-02d320e46676"
      unitRef="U_USD">6746000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0b40aab0-d10e-4136-8e7e-ca8504900115"
      decimals="-3"
      id="F_e00e76ac-9a5e-42bd-bf10-6ea73ff33b83"
      unitRef="U_USD">6640000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d5dd1698-9ade-461a-94c5-4ad7011a957b"
      decimals="-3"
      id="F_72742c4b-7f84-489d-9323-b16919a208ec"
      unitRef="U_USD">2010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f586607b-347a-4864-85e3-de49880ea621"
      decimals="-3"
      id="F_cb95362a-bea3-4724-972e-69d7341b4a52"
      unitRef="U_USD">2631000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_fc498007-1206-4a09-a15b-289778b25431"
      unitRef="U_USD">123594000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_dc5f84a5-7e05-4f0b-b112-0e04a777de98"
      unitRef="U_USD">118566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_6167c093-cb72-4488-b79d-b5431e4a6424">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.            Fair Value Measurements:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of three levels:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:13.333%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;392,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;382,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_6b42fe4e-54d2-46d9-abc4-309fc33fef06">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Mutual funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_990f8274-6879-4e07-9304-6c955d3df201"
      decimals="-3"
      id="F_4d5dc816-ca22-48fb-bed8-0dbf77ba4c1a"
      unitRef="U_USD">5290000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727"
      decimals="-3"
      id="F_c44c3ed7-c3f6-4099-85e7-dc1b3fbcb266"
      unitRef="U_USD">9295000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_1b31d254-d902-4fef-9793-39c5c0901157"
      decimals="-3"
      id="F_20d90301-55b8-4947-a106-e982e62c4697"
      unitRef="U_USD">123594000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_0bcc6ee1-f926-4fb2-8414-61d8916092c3"
      decimals="-3"
      id="F_2b21ac7e-387c-4176-b7c2-00b73c6e04ae"
      unitRef="U_USD">118566000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_990f8274-6879-4e07-9304-6c955d3df201"
      decimals="-3"
      id="F_616a571e-a86a-46c7-80f3-c7f6871db600"
      unitRef="U_USD">18872000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="C_3134cc2d-b54f-4bc4-a943-8cee5d58d727"
      decimals="-3"
      id="F_ead1967b-bfc1-4bde-a2f9-774c73783c13"
      unitRef="U_USD">18581000</md:MutualFundsFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_4be9b78e-df8b-458d-b760-4c8af306ae37">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025 and December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:50.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;392,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;382,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a"
      decimals="-3"
      id="F_45fb7154-40fb-4550-8d8d-284bc517097a"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_acc92b1b-1d33-4ded-92dd-bd2ae778529a"
      decimals="-3"
      id="F_95ee7404-28be-4c9a-9189-32767189a16c"
      unitRef="U_USD">392000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9"
      decimals="-3"
      id="F_9979b0ff-4a49-4aad-a217-48b167d98015"
      unitRef="U_USD">400000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="C_e5c84dfd-2ba1-452d-844d-fabca2b4a3d9"
      decimals="-3"
      id="F_b5bdf493-fa81-4b5e-901e-5f5a89ad16d7"
      unitRef="U_USD">382000000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_84dab71c-7bd4-4b6d-884b-ad67c9bb71ca">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable and Net Revenue:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs within 30 to 60 days of billing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.822%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.667%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.244%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.333%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.600000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;432,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;786,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.233%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.197%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.578%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.677999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_8dd5c8dd-a61c-4385-9dc4-a475dcbc822e">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:30%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.822%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.667%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.244%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.333%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.111%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.600000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net patient service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;397,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;432,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;786,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;854,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Hospital contract administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;468,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;504,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;999,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_9a921698-6494-4872-95ea-71129e633bb1"
      decimals="-3"
      id="F_74f85f86-9fe0-4b8c-a547-3f7d6b593c8e"
      unitRef="U_USD">397410000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_849c5446-6175-47f3-9857-a3245904bf88"
      decimals="-3"
      id="F_60ef3805-6536-4f7d-bd3e-91131f31a80f"
      unitRef="U_USD">432847000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_f769378b-1c4e-4a71-b4e3-23dc8047aca4"
      decimals="-3"
      id="F_b8b53fd7-7007-4649-9456-3c614df9f083"
      unitRef="U_USD">786788000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_70cd78d0-0823-4309-b089-3800b415f013"
      decimals="-3"
      id="F_f22139b9-b353-43c6-b435-d07517ffb23d"
      unitRef="U_USD">854678000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_63924c28-bea0-4566-b7e1-f16b7fb50afc"
      decimals="-3"
      id="F_6beb1483-5a02-4147-86e3-b3896057f570"
      unitRef="U_USD">68224000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_be92627c-332d-4ae8-91f7-a264f6271741"
      decimals="-3"
      id="F_2ada6d48-8b7d-406d-abea-b2765b41bdb6"
      unitRef="U_USD">70913000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_6b743dc4-e2d9-4c22-8237-82828c532fdd"
      decimals="-3"
      id="F_fb600363-470e-412e-8a39-bd0c4b8b4c3c"
      unitRef="U_USD">133408000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_0d526502-108f-4746-acb3-bb517ba52829"
      decimals="-3"
      id="F_a1bd6147-5668-426c-8d0a-cbac477bffae"
      unitRef="U_USD">142716000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_e8f5ba84-ac17-483d-b73f-e6039ec42af4"
      decimals="-3"
      id="F_100c86cb-7650-45eb-8a85-b4fc5457564f"
      unitRef="U_USD">3210000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_bd51850b-1d63-4d74-a72e-b7306dc264a3"
      decimals="-3"
      id="F_d6341567-b088-4a21-bb38-d7c30fea1e93"
      unitRef="U_USD">536000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_87d0e1c2-aa54-424d-8b9f-e5b52e218d71"
      decimals="-3"
      id="F_8089df02-8daf-4312-85da-0392da6d5790"
      unitRef="U_USD">7007000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_c4e1c5ae-2d10-47df-935e-85a1a3d8a79a"
      decimals="-3"
      id="F_9af1223a-da28-49cd-b532-0384aebb4799"
      unitRef="U_USD">2003000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_7833d9b3-6ad3-41dd-a342-4f47ab921823"
      unitRef="U_USD">468844000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_d6909435-2418-4275-913d-deb0c7eb6720"
      unitRef="U_USD">504296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_d190b97d-35f3-40ff-ab76-4684395ce786"
      unitRef="U_USD">927203000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_349df035-13bf-4a22-8775-b6ee1ff345b5"
      unitRef="U_USD">999397000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_d5d9d61d-4f4a-4ab7-a77d-b58b8d8d5172">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.233%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.197%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.82%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.198%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.578%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.677999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contracted managed care&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other third-parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Private-pay patients&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_fdaffee8-484a-4258-af49-fe479aa12caf"
      decimals="2"
      id="F_25637459-7b82-490e-a3fe-fe22ff635157"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_398bed08-bdb8-41f7-9f6c-82ad320a2a3a"
      decimals="2"
      id="F_6cf13451-f2d9-427c-8d5f-1f9d84881296"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_eb7d37cd-390f-4b5f-aeef-a6cc4db6d17b"
      decimals="2"
      id="F_c771e4d4-44b1-4b8d-824b-8c488a5fdf13"
      unitRef="U_pure">0.70</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_a2d739c0-705d-43b1-a3d2-dabd70774246"
      decimals="2"
      id="F_96d1e35b-73eb-4465-85f2-d4249de7ab2d"
      unitRef="U_pure">0.71</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_afa0579d-26f5-4238-9a84-dde4391f4adf"
      decimals="2"
      id="F_187d97d8-5319-43d2-9c5b-71ff7e382970"
      unitRef="U_pure">0.23</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_6c67057d-5918-42a2-94a9-d2f590fd5ba7"
      decimals="2"
      id="F_46df5fd8-31b1-4578-a084-63e9330234bd"
      unitRef="U_pure">0.23</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_32069b17-a7c4-4765-a651-4f7755dcf1a1"
      decimals="2"
      id="F_46f457d4-eb5f-412c-8e76-da8759d0643f"
      unitRef="U_pure">0.24</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_4801f813-81b6-4595-8272-9e5826e33caf"
      decimals="2"
      id="F_f5394895-b117-465e-82ec-e88e8323259e"
      unitRef="U_pure">0.24</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_a6a93686-1eb5-408b-b60f-73f0299eb788"
      decimals="2"
      id="F_c016db89-cfc2-4c67-bcb1-b7ad5d853089"
      unitRef="U_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_c5c51110-c65e-4f11-aa51-b3928ddfb6df"
      decimals="2"
      id="F_ac855081-6bbe-4813-9d19-c165a453831d"
      unitRef="U_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_a20cd2e0-875c-4771-bf90-0ccec5055b0c"
      decimals="2"
      id="F_6acdd499-562a-4ef9-8c38-2cabd90654c2"
      unitRef="U_pure">0.04</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_1c6b672e-7b2c-4c32-b75a-2b3216ee662e"
      decimals="2"
      id="F_68a31091-1357-45a9-a558-598a7b16d3cf"
      unitRef="U_pure">0.03</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_ab9de21c-3708-4752-bea2-ef95a1215496"
      decimals="2"
      id="F_5a6d5c93-3e9a-4c92-85f1-7bc7e046b015"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_7c443208-51e1-40be-8cfa-d297ad11e687"
      decimals="2"
      id="F_dd702f92-3e2b-4d62-9c05-9a37f17d0ee3"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_536d7005-510c-4f6d-8437-48a7087b29e6"
      decimals="2"
      id="F_bd3e82e0-7f20-46d2-b2fc-7b630652d2c8"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_cb9f2cce-17c5-4e8f-8e06-23440c974965"
      decimals="2"
      id="F_0db48f4a-85c4-41e4-9ae8-71d41ece4398"
      unitRef="U_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="INF"
      id="F_d64543c6-6afa-448b-b9f6-923e513740ce"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="INF"
      id="F_41252a13-b0aa-4054-a4b5-16faa4855f09"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="2"
      id="F_aeb626b8-fa46-4bfb-b253-8144e1dc6044"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="2"
      id="F_b98b9a2d-ee4d-430a-b016-962f8ef544ad"
      unitRef="U_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_02c773d9-263c-4d62-be69-e8dcf18fb592">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.           Goodwill, Long Lived Asset Impairments and Loss on Disposal of Businesses:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the second quarter of 2024, the Company experienced a triggering event, due to a sustained decline in its stock price and a market capitalization below the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s book equity value. As a result, the Company performed an interim goodwill impairment assessment.  This assessment resulted in a non-cash goodwill impairment charge of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;154.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the second quarter of 2024, the Company recognized fixed asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and intangible asset impairments of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the exit of its affiliated office-based practices. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized a loss on disposal of businesses of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million associated with the exit of its primary and urgent care service line.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_979c4a34-9714-49be-8c97-35795e05e90b"
      unitRef="U_USD">154200000</md:GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_d57f3cc8-6991-4ed3-b7bf-036272017f4c"
      unitRef="U_USD">20100000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_9c29ba77-4d7f-456c-9f4f-84d4acd8b3d5"
      unitRef="U_USD">7700000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_30f2734f-3844-4aaa-887d-1b3f00f2a742"
      unitRef="U_USD">-10900000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_a9cc0478-d399-4d2c-b5f9-cef260a94639">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6.            Accounts Payable and Accrued Expenses:	&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;215,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The net decrease in accrued salaries and incentive compensation of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, from December 31, 2024 to June 30, 2025, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter.&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_db7560d1-3384-4dd8-91fe-e7e690a55618">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts payable and accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued salaries and incentive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;215,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll taxes and benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_06bcfc48-b58d-4ada-9a60-666fe6338c29"
      unitRef="U_USD">42065000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_26283fc6-262b-40c1-ae7d-ccaa7aeba439"
      unitRef="U_USD">46431000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_d2bee2da-5461-4ea6-8826-11d847119017"
      unitRef="U_USD">133585000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_8681474f-660f-483a-822d-258c5a33168b"
      unitRef="U_USD">215357000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_184e16d3-d0de-40b7-9040-eaf35791b1cc"
      unitRef="U_USD">31377000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_778438ca-05e8-4c5c-b54f-30cd4f58e8ee"
      unitRef="U_USD">35450000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_193d9db7-67ac-47d8-b94d-ce87a0e5b56a"
      unitRef="U_USD">30607000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_7b3ad7f8-2fd9-4a9f-931f-67ebf1fa5b44"
      unitRef="U_USD">30430000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_85e80516-7640-4035-85fb-978f95c0b3da"
      unitRef="U_USD">8157000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_7387ff70-f252-4c09-9d8e-21f2aa66c453"
      unitRef="U_USD">8159000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_7365d535-2f87-4626-a37d-0a800bf17107"
      unitRef="U_USD">57569000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_d8c01cae-9427-4aa1-a90c-ac2f128f195d"
      unitRef="U_USD">62863000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="-3"
      id="F_cec33c7e-e49a-4327-b53e-07781806be82"
      unitRef="U_USD">303360000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-3"
      id="F_1f78bfe1-0821-47eb-b916-6b5c28c72a7b"
      unitRef="U_USD">398690000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="C_16252d43-9504-4f57-9f9e-531fbb28977d"
      decimals="-5"
      id="F_b265d8e8-e234-4566-a4b8-85fb51d751bb"
      unitRef="U_USD">81800000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-5"
      id="F_2fa32bae-2575-477f-b283-80e738d30624"
      unitRef="U_USD">81800000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <md:LineOfCreditAndLongTermDebtTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_18b4b868-d6a4-4023-94ab-73586250cf9d">&lt;p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;         &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Line of Credit and Long-Term Debt:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 11, 2022,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company issued $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% unsecured senior notes due 2030 (the &#x201c;2030 Notes&#x201d;).  Interest on the 2030 Notes accrues at the rate of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.375&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum, or $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and is &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s obligations under the 2030 &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Although the Company is not required to make mandatory redemption or sinking fund payments with respect to the 2030 Notes, upon the occurrence of a change in control, the Company may be required to repurchase the 2030 Notes at a purchase price equal to &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the aggregate principal amount of the 2030 Notes repurchased plus accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concurrently with the issuance of the 2030 Notes, the Company amended its credit agreement (the &#x201c;Credit Agreement&#x201d;, and such amendment, the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Credit Agreement Amendment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). The Credit Agreement Amendment, among other things, (i) refinanced the prior unsecured revolving credit facility with a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million unsecured revolving credit facility, including a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million sub-facility for the issuance of letters of credit (the &#x201c;Revolving Credit Line&#x201d;), and a $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million term A loan facility (&#x201c;Term A Loan&#x201d;) and (ii) removed JPMorgan Chase Bank, N.A., as the administrative agent under the Credit Agreement and appointed Bank of America, N.A. as the administrative agent for the lenders.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Credit Agreement, as amended by the Credit Agreement Amendment (the &#x201c;Amended Credit Agreement&#x201d;) matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s subsidiaries and affiliated professional contractors. At the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s option, borrowings under the Amended Credit Agreement bear interest at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, based on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s consolidated net leverage ratio.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Amended Credit Agreement contains customary covenants and restrictions, including covenants that require the Company to maintain a minimum interest coverage ratio, a maximum consolidated net leverage ratio and to comply with laws, and restrictions on the ability to pay dividends, incur indebtedness or liens and make certain other distributions subject to baskets and exceptions, in each case, as specified therein. Failure to comply with these covenants would constitute an event of default under the Amended Credit Agreement, notwithstanding the ability of the Company to meet its debt service obligations. The Amended Credit Agreement includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Amended Credit Agreement. In addition, the Company may increase the principal amount of the Revolving Credit Line or incur additional term loans under the Amended Credit Agreement in an aggregate principal amount such that on a pro forma basis after giving effect to such increase or additional term loans, the Company would be in compliance with the financial covenants, subject to the satisfaction of specified conditions and additional caps in the event that the Amended Credit Agreement is secured.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At June 30, 2025, the Company had an outstanding principal balance on the Amended Credit Agreement of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;206.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, composed of the Term A Loan. There was no outstanding balance under the Revolving Credit Line at June 30, 2025. The Company had $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;450.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million available on its Revolving Credit Line at June 30, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At June 30, 2025, the Company had an outstanding principal balance of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on the 2030 Notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:LineOfCreditAndLongTermDebtTextBlock>
    <us-gaap:SeniorNotes
      contextRef="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4"
      decimals="-5"
      id="F_c7aafec1-6c61-4e10-8b3d-10251b6c975f"
      unitRef="U_USD">400000000</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_e484d6d2-a0dc-4ac5-8cc2-c9f99369c7a4"
      decimals="5"
      id="F_35bd327e-7065-445e-821f-983b669eacd0"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="5"
      id="F_bc26cfa7-8a05-4ca6-98fe-a0a606607f2f"
      unitRef="U_pure">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="C_8d9af789-c635-4423-848f-c01e14b9c5be"
      decimals="-5"
      id="F_9d5e6daf-6157-4148-a9d2-099da96f977c"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_7ed98bd8-3726-44ee-bf40-3c88b0ea4ec8">payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_8959097d-86e0-4e15-98fb-981b9f00113c">Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company&#x2019;s ability to (1) incur liens, (2) enter into sale and lease-back transactions and (3) merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions</us-gaap:DebtInstrumentDescription>
    <md:PurchasePrice
      contextRef="C_85bed5fd-5baa-4c9d-8e27-75516ee10ea8"
      decimals="2"
      id="F_d3d421c4-fad1-420d-baa9-0d47db658a2c"
      unitRef="U_pure">1.01</md:PurchasePrice>
    <us-gaap:UnsecuredDebt
      contextRef="C_c8cb11ad-5131-4dcd-b1e9-3b140f8c2c78"
      decimals="-6"
      id="F_a540fe52-a5e1-4e4f-bc2f-afed3bb2621b"
      unitRef="U_USD">450000000</us-gaap:UnsecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt
      contextRef="C_8e53119c-ac1b-4329-8f58-b7176456bb51"
      decimals="-5"
      id="F_948fb5ad-3f1c-49af-8031-2db4adbc163a"
      unitRef="U_USD">37500000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:UnsecuredLongTermDebt
      contextRef="C_4de6435d-c283-42d7-909b-380362f9a807"
      decimals="-6"
      id="F_63dbcb39-296d-4d10-81dc-cb72a65c570f"
      unitRef="U_USD">250000000</us-gaap:UnsecuredLongTermDebt>
    <us-gaap:DescriptionOfInterestRateRiskExposure
      contextRef="C_fda73ce3-e67d-432f-a66a-80057b60473d"
      id="F_7754b2e2-02d7-418e-b2c9-c06814b20100">(i) the Alternate Base Rate (defined as the highest of (a) the prime rate as announced by Bank of America, N.A., (b) the Federal Funds Rate plus 0.50% and (c) Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) for an interest period of one month plus 1.00% with a 1.00% floor) plus an applicable margin rate of 0.50% for the first two fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 0.125% to 0.750% based on the Company&#x2019;s consolidated net leverage ratio or (ii) Term SOFR rate (calculated as the Secured Overnight Financing Rate published on the applicable Reuters screen page plus a spread adjustment of 0.10%, 0.15% or 0.25% depending on if the Company selects a one-month, three-month or six-month interest period, respectively, for the applicable loan with a 0% floor), plus an applicable margin rate of 1.50% for the first two full fiscal quarters after the date of the Credit Agreement Amendment, and thereafter at an applicable margin rate ranging from 1.125% to 1.750% based on the Company&#x2019;s consolidated net leverage ratio. The Amended Credit Agreement also provides for other customary fees and charges, including an unused commitment fee with respect to the Revolving Credit Line ranging from 0.150% to 0.200% of the unused lending commitments under the Revolving Credit Line</us-gaap:DescriptionOfInterestRateRiskExposure>
    <us-gaap:LongTermDebt
      contextRef="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23"
      decimals="-5"
      id="F_a997fec6-dc54-42c5-a341-fdbe038ee856"
      unitRef="U_USD">206300000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_93a5a2fa-6ec6-47ee-b7af-01758347ba23"
      decimals="-5"
      id="F_71fff40a-84af-452b-a852-274a53aaa8c4"
      unitRef="U_USD">450000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_c1710474-b351-446a-ac79-006d3ecf6183"
      decimals="-5"
      id="F_157b1bb4-a0e8-4405-8341-c97192e81dd3"
      unitRef="U_USD">400000000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_f35cc01b-aa75-4675-8aef-3c18d068b3a9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common and Common Equivalent Shares:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock and is calculated using the treasury stock method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Antidilutive restricted stock not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(a) Due to a loss for the three and six months ended June 30, 2024, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million incremental shares, respectively, are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_4823a2a4-ce5f-4ae6-98c5-e72b335af35b">&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three and six months ended June 30, 2025 and 2024 is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:88.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.98%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of dilutive common share&lt;br/&gt;&#160;&#160;&#160;equivalents&lt;/span&gt;&lt;span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of common and common&lt;br/&gt;&#160;&#160;&#160;equivalent shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Antidilutive restricted stock not included in the diluted net income per common share calculation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(a) Due to a loss for the three and six months ended June 30, 2024, &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million incremental shares, respectively, are not included because the effect would be antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_6c9a8e29-75ae-4b8d-be29-181c8edd7c9d"
      unitRef="U_shares">84797000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_eaaecf8d-af30-4661-9643-0c62dfa84a0a"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_84372c94-f32f-4cee-9e9f-282cc3f23c73"
      unitRef="U_shares">84653000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_aefe22a6-ab9e-484b-8ce4-8efe3f9281a3"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_463b419e-d512-4bce-8132-330e7ab8bdc4"
      unitRef="U_shares">732000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_1b11cde0-266b-4cf1-9b24-637b61f10568"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_180e7185-f84e-43c8-b55e-85aeb2dea70a"
      unitRef="U_shares">864000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_83a323bb-bd82-4c79-9543-d7f961181814"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_bda89dad-1f09-487c-b207-aad3abf19e6a"
      unitRef="U_shares">85529000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_36fb3e05-4210-4755-824a-69f98106ac87"
      unitRef="U_shares">83332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_0789c542-3fb6-4b64-adbe-8d5077f7238a"
      unitRef="U_shares">85517000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_4e17fdb6-6bb4-43c3-96ee-92e7dcae6146"
      unitRef="U_shares">83074000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-3"
      id="F_9fe2c17e-5fae-456b-a737-28a7dc58439c"
      unitRef="U_shares">325000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-3"
      id="F_6c0bb00e-0c1e-4a17-85ec-d0e5fe0967e5"
      unitRef="U_shares">916000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-3"
      id="F_d8a14018-bbaa-4c29-b6b8-1ac456f15b12"
      unitRef="U_shares">168000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-3"
      id="F_291e71eb-ffde-4616-86fe-580ef56a8611"
      unitRef="U_shares">661000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_ad5d929a-8ef2-4208-8085-482aa2b564af"
      unitRef="U_shares">100000</md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares>
    <md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-5"
      id="F_ca027809-7760-49ca-b46c-447c11b2424b"
      unitRef="U_shares">300000</md:IncrementalCommonSharesAttributableToAntidilutiveEffectOfContingentlyIssuableShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_2ec20f60-ad6f-4633-945c-a8be5135cf49">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock Incentive Plans and Stock Purchase Plans:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;Amended and Restated 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Amended and Restated 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant and generally become exercisable on a pro rata basis over a &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of restricted stock and &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of performance-based restricted stock units to its employees and non-employee directors under the Amended and Restated 2008 Incentive Plan. At &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares available for future grants and awards under the Amended and Restated 2008 Incentive Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;   &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Company&#x2019;s Amended and Restated 1996 Non-Qualified Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 Non-Qualified Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible non-employee service providers are permitted to purchase the Company&#x2019;s common stock at &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes stock-based compensation expense for the discount received by participating employees and non-employee service providers. During the six months ended June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares were issued under the ESPP. At June 30, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares reserved for issuance under the ESPP. At June 30, 2025, the Company had approximately &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares in the aggregate reserved for issuance under the SPP. &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares have been issued under the SPP since 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three and six months ended June 30, 2025 and 2024, the Company recognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0c404152-671c-423e-89ad-d5d765b11984"
      id="F_a0b7ffa4-53cf-4eb8-a481-91e1e664de4d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_083e4a33-a175-4d28-b0bd-2e88cf498028"
      id="F_39347ece-a695-48e1-bc5e-0dd9907fe66d">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_bc9a9da7-0be2-410f-9e41-d1f7b709a28b"
      id="F_f639670e-058e-4933-b343-ffc6da3c4404">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4f66fd46-91e2-44aa-ad85-e4197757b4e5"
      decimals="-5"
      id="F_6622d87e-d5e2-40fd-9712-3740abd33c82"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_17f99e9d-a60a-4fc9-ac76-147b8ed76885"
      decimals="-5"
      id="F_419e364b-6ed7-45cd-9a80-6edf4eac468c"
      unitRef="U_shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_be5ebf4b-3722-4087-8a25-4b48fa85c81e"
      decimals="-5"
      id="F_ab364f57-f733-409e-bd19-cde68e605108"
      unitRef="U_shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_30cac922-a319-4eb7-99f1-fe21f2139c14"
      decimals="2"
      id="F_ef5f5712-6543-4685-b5ee-446459840d7f"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_02338ba1-62e1-425d-a755-642941b0622b"
      decimals="2"
      id="F_998676eb-9f8b-40f0-b65b-586ed4eb697f"
      unitRef="U_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_083e4a33-a175-4d28-b0bd-2e88cf498028"
      decimals="-5"
      id="F_c068a26a-c2b7-4782-ad69-8b84326660fe"
      unitRef="U_shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d1c3550d-a30d-470c-81b8-b361b7723645"
      decimals="-5"
      id="F_14387a2d-703f-4803-b038-883d851eba2e"
      unitRef="U_shares">1400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3d9eb462-edff-4b9a-8d90-654154da97b0"
      decimals="-3"
      id="F_5d8b89d8-423c-4809-baba-b23762b5cc1e"
      unitRef="U_shares">61000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_30cac922-a319-4eb7-99f1-fe21f2139c14"
      decimals="-3"
      id="F_7037fb88-f5ac-4fef-9d5f-a3dcdebb03f1"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      decimals="-5"
      id="F_f2e05d8e-c052-4adc-a562-4ee518dc2e11"
      unitRef="U_USD">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="-5"
      id="F_1acf5a09-c48d-4355-8260-174ec9f42da3"
      unitRef="U_USD">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_08f4d25d-4559-4691-80b0-687c52c265b4"
      decimals="-5"
      id="F_2eb2f17e-ccee-4c6b-a558-ab0979e82b7e"
      unitRef="U_USD">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_fff7438c-96ca-489b-9cad-339fddf8c81f"
      decimals="-5"
      id="F_13027419-05d9-4438-96e3-70c1ced89ccf"
      unitRef="U_USD">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_332bad21-b8ad-40b6-bf30-10300542e631">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock Repurchase Programs:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were purchased under this program during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months ended June 30, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million remained available for repurchase as of December 31, 2024. Under this share repurchase program, during the six months ended June 30, 2025, the Company purchased a nominal number of shares of its common stock for $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million representing shares withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock, resulting in $&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million remaining available for repurchase under this authorization as of June 30, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="INF"
      id="F_8caa5e2c-f91a-4200-9882-72a5911b2c4b"
      unitRef="U_shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_a0c2cfa6-1c3d-4c86-9c0c-7cee140ba3f5"
      decimals="-5"
      id="F_aa7ec16b-57ea-49a6-9440-57bddb3a8242"
      unitRef="U_USD">500000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_764409ab-50d4-4ac2-b6ab-3c2fc380e568"
      decimals="-5"
      id="F_49ad0465-fd1b-44f2-91ed-06f39fc79236"
      unitRef="U_USD">2900000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0f263814-412a-40d2-829d-21ded60e6d59"
      decimals="-5"
      id="F_1498c40f-3105-4afd-9232-fd7682374ac2"
      unitRef="U_USD">1800000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_1cb160af-9159-4c8c-acca-d4f2300fc206"
      decimals="-5"
      id="F_274f9abd-d0e0-46b6-865d-4b24feb0f6f2"
      unitRef="U_USD">1100000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_f26957e8-5334-42c4-936a-57c087cc5ab7">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which is also its single reporting unit, for purposes of presenting financial information in accordance with the accounting guidance for segment reporting. Financial results for all practices are managed on a consolidated basis. The chief operating decision maker assesses performance and decides how to allocate resources based on net income and total assets as reported in the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s Consolidated Financial Statements. Significant segment expenses are practice salaries and benefits and general and administrative expenses as reported on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s Consolidated Statements of Income and Comprehensive Income. Refer to the Consolidated Financial Statements for the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s segment revenue, significant segment expenses, other segment expenses and net income.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      decimals="INF"
      id="F_cd4e2c7c-f651-471b-bc43-b734139a5218"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_04755f25-aca6-47b4-a390-81102d0c243b"
      id="F_633d5ac5-7d6c-426f-9133-09e59f86eb38">&lt;p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;            &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies:	&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s business, financial condition, results of operations, cash flows and the trading&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;price of its securities. The Company has not included an accrual for these matters as of June 30, 2025 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s affiliated physicians. The Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&lt;/span&gt;&lt;a href="#mda"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;/a&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s business, financial condition, results of operations, cash flows and the trading price of its securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      id="F_c6225f98-434d-40bf-b1ee-efce7596039e">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      id="F_d3efb2ad-cda0-435e-804a-52728cbadbfe">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      id="F_ac3f4f0a-8371-48c8-b571-3221fdfb7ede">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_b46b7d38-353d-4da0-915e-fea75ff40a63"
      id="F_b5abadc4-b5e0-4bc5-acf6-77b2cb20ee88">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
